,euctr_id,title,reg_date,other_id,field,provenance
1,2004-000957-47, Comparison of Bisoprolol and Carvedilol in elderly patients with,08-11-2007,NA,US NCT number,protocol
2,2004-000957-47, Comparison of Bisoprolol and Carvedilol in elderly patients with,08-11-2007,NA,other,protocol
3,2004-000957-47, Comparison of Bisoprolol and Carvedilol in elderly patients with,08-11-2007,NA,US NCT number,results
4,2004-000957-47, Comparison of Bisoprolol and Carvedilol in elderly patients with,08-11-2007,NA,ISRCTN number,results
5,2004-002420-18," A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",11-02-2005,NA,US NCT number,protocol
6,2004-002420-18," A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",11-02-2005,NA,other,protocol
7,2004-002420-18," A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",11-02-2005,NA,US NCT number,results
8,2004-002420-18," A prospective, non-randomized, non-controlled, open label, multicenter phase II Study: PTK 787/ ZK222584 in patients with advanced neuroendocrine tumors.",11-02-2005,NA,ISRCTN number,results
9,2004-002646-35, Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,08-05-2006,NA,US NCT number,protocol
10,2004-002646-35, Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,08-05-2006,NA,other,protocol
11,2004-002646-35, Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,08-05-2006,NCT00568542,US NCT number,results
12,2004-002646-35, Pilot study for evaluation of growth factor erythropoietin beta for improvement of left ventricular function after coronary interventions,08-05-2006,NA,ISRCTN number,results
13,2004-002754-62, Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction,08-10-2004,NA,US NCT number,protocol
14,2004-002754-62, Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction,08-10-2004,NA,other,protocol
15,2004-002754-62, Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction,08-10-2004,NA,US NCT number,results
16,2004-002754-62, Development of CYP2D6 genotype based dosage guidelines for the beta-blockers metoprolol and carvedilol based on hepatic clearance and resting and exercise heart rate reduction,08-10-2004,NA,ISRCTN number,results
17,2004-002788-25, Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy,02-06-2006,NA,US NCT number,protocol
18,2004-002788-25, Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy,02-06-2006,NA,other,protocol
19,2004-002788-25, Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy,02-06-2006,NA,US NCT number,results
20,2004-002788-25, Hippocampal volume in young adults with moderate to severe depression before and after combined antidepressant therapy,02-06-2006,NA,ISRCTN number,results
21,2004-002803-34, Phase I/II-Studie,25-11-2004,NA,US NCT number,protocol
22,2004-002803-34, Phase I/II-Studie,25-11-2004,NA,other,protocol
23,2004-002803-34, Phase I/II-Studie,25-11-2004,NA,US NCT number,results
24,2004-002803-34, Phase I/II-Studie,25-11-2004,NA,ISRCTN number,results
25,2004-002903-34, Phänotypisierung und Genotypisierung von Cytochrom P450-Enzymen,03-12-2004,NA,US NCT number,protocol
26,2004-002903-34, Phänotypisierung und Genotypisierung von Cytochrom P450-Enzymen,03-12-2004,NA,other,protocol
27,2004-002903-34, Phänotypisierung und Genotypisierung von Cytochrom P450-Enzymen,03-12-2004,NA,US NCT number,results
28,2004-002903-34, Phänotypisierung und Genotypisierung von Cytochrom P450-Enzymen,03-12-2004,NA,ISRCTN number,results
29,2004-003739-30," Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]",28-09-2005,NA,US NCT number,protocol
30,2004-003739-30," Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]",28-09-2005,NA,other,protocol
31,2004-003739-30," Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]",28-09-2005,NA,US NCT number,results
32,2004-003739-30," Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM]",28-09-2005,NA,ISRCTN number,results
33,2004-003783-30, Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer,23-02-2005,NA,US NCT number,protocol
34,2004-003783-30, Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer,23-02-2005,NA,other,protocol
35,2004-003783-30, Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer,23-02-2005,NA,US NCT number,results
36,2004-003783-30, Application of Aprepitant as salvage prophylaxis after failure of a conventional antiemetic therapy during moderately emetogenic chemotherapy in gastrointestinal cancer,23-02-2005,NA,ISRCTN number,results
37,2004-003801-26," Offene, multizentrische, nicht-randomisierte Phase II Studie:Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Behandlung von refraktären und rezidivierten aggressiven Non-Hodgkin-Lymphomen",08-11-2004,NA,US NCT number,protocol
38,2004-003801-26," Offene, multizentrische, nicht-randomisierte Phase II Studie:Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Behandlung von refraktären und rezidivierten aggressiven Non-Hodgkin-Lymphomen",08-11-2004,NA,other,protocol
39,2004-003801-26," Offene, multizentrische, nicht-randomisierte Phase II Studie:Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Behandlung von refraktären und rezidivierten aggressiven Non-Hodgkin-Lymphomen",08-11-2004,NA,US NCT number,results
40,2004-003801-26," Offene, multizentrische, nicht-randomisierte Phase II Studie:Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Behandlung von refraktären und rezidivierten aggressiven Non-Hodgkin-Lymphomen",08-11-2004,NA,ISRCTN number,results
41,2004-003816-47, Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,19-10-2005,NA,US NCT number,protocol
42,2004-003816-47, Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,19-10-2005,NA,other,protocol
43,2004-003816-47, Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,19-10-2005,NA,US NCT number,results
44,2004-003816-47, Clinical pilot study on the effect of Metformin in adipose children and adolescents with insulin-resistance,19-10-2005,NA,ISRCTN number,results
45,2004-004024-12, Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,17-02-2005,NA,US NCT number,protocol
46,2004-004024-12, Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,17-02-2005,NA,other,protocol
47,2004-004024-12, Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,17-02-2005,NA,US NCT number,results
48,2004-004024-12, Efficacy of the EGFR antibody Cetuximab in combination with weekly Oxaliplatin/5FU/Folinsäure (AIO-FUFOX) in advanced gastro-oesophageal adenocarcinoma,17-02-2005,NA,ISRCTN number,results
49,2004-004086-15," Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe heart failure",17-05-2005,NA,US NCT number,protocol
50,2004-004086-15," Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe heart failure",17-05-2005,NA,other,protocol
51,2004-004086-15," Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe heart failure",17-05-2005,NA,US NCT number,results
52,2004-004086-15," Comparison of nephrotoxic effects of the contrast dyes iodixanol (iso-osmolar, non-ionic, dimer) and ioversol (low-osmolar, non-ionic, monomer) in patients with impaired renal function and severe heart failure",17-05-2005,NA,ISRCTN number,results
53,2004-004129-89, Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation ,08-08-2005,NA,US NCT number,protocol
54,2004-004129-89, Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation ,08-08-2005,NA,other,protocol
55,2004-004129-89, Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation ,08-08-2005,NA,US NCT number,results
56,2004-004129-89, Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation ,08-08-2005,NA,ISRCTN number,results
57,2004-004320-13," RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",25-07-2005,NA,US NCT number,protocol
58,2004-004320-13," RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",25-07-2005,NA,other,protocol
59,2004-004320-13," RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",25-07-2005,NA,US NCT number,results
60,2004-004320-13," RANDOMIZED PHASE III-STUDY ON VALPROIC ACID IN COMBINATION WITH ALL-TRANS RETINOIC ACID, STANDARD INDUCTION- AND CONSOLIDATION THERAPY IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",25-07-2005,NA,ISRCTN number,results
61,2004-004321-95," RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",21-04-2005,NA,US NCT number,protocol
62,2004-004321-95," RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",21-04-2005,NA,other,protocol
63,2004-004321-95," RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",21-04-2005,NA,US NCT number,results
64,2004-004321-95," RANDOMIZED PHASE II-STUDY ON VALPROIC ACID, ALL-TRANS RETINOIC ACID AND THEIR COMBINATION IN INDUCTION AND CONSOLIDATION THERAPY AS WELL AS PEGFILGRASTIM AFTER CONSOLIDATION THERAPY IN YOUNGER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA",21-04-2005,NA,ISRCTN number,results
65,2004-004352-40, Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,30-11-2004,NA,US NCT number,protocol
66,2004-004352-40, Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,30-11-2004,NA,other,protocol
67,2004-004352-40, Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,30-11-2004,NA,US NCT number,results
68,2004-004352-40, Einfluss einer präoperativen Vakzinierung auf das Immunsystem und die postoperative Infektionsrate,30-11-2004,NA,ISRCTN number,results
69,2004-004403-37," Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie",28-10-2005,NA,US NCT number,protocol
70,2004-004403-37," Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie",28-10-2005,NA,other,protocol
71,2004-004403-37," Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie",28-10-2005,NA,US NCT number,results
72,2004-004403-37," Eine monozentrische, randomisierte, kontrollierte Studie zur Untersuchung von Interferon-beta zur Behandlung der Multiplen-Sklerose (MS)-assoziierten und primären Uveitis intermedia im Vergleich zur Standardtherapie",28-10-2005,NA,ISRCTN number,results
73,2004-004482-15, Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.,25-01-2006,NA,US NCT number,protocol
74,2004-004482-15, Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.,25-01-2006,NA,other,protocol
75,2004-004482-15, Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.,25-01-2006,NA,US NCT number,results
76,2004-004482-15, Hirnaktivierung während Gedächtnisaufgaben bei Patienten mit Schizophrenie unter Behandlung von Ziprasidon oder Risperidon. Eine FMRT-Untersuchung.,25-01-2006,NA,ISRCTN number,results
77,2004-004509-11, Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP),06-09-2005,NA,US NCT number,protocol
78,2004-004509-11, Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP),06-09-2005,NA,other,protocol
79,2004-004509-11, Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP),06-09-2005,NA,US NCT number,results
80,2004-004509-11, Efficiency and tolerability of L-Dopa in patients with Hereditary Spastic Paraplegia (HSP),06-09-2005,NA,ISRCTN number,results
81,2004-004796-11," An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy",29-01-2007,NA,US NCT number,protocol
82,2004-004796-11," An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy",29-01-2007,NA,other,protocol
83,2004-004796-11," An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy",29-01-2007,NA,US NCT number,results
84,2004-004796-11," An Open-Label, Non-Randomized, Single center Study to Evaluate the Use of Zoledronic Acid in the Prevention of Cancer Treatment-Related Bone Loss in Postmenopausal Women with ER+ and/or PgR+ Breast Cancer Receiving Letrozole as Adjuvant Therapy",29-01-2007,NA,ISRCTN number,results
85,2004-004824-11," Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks",04-10-2005,NA,US NCT number,protocol
86,2004-004824-11," Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks",04-10-2005,NA,other,protocol
87,2004-004824-11," Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks",04-10-2005,NA,US NCT number,results
88,2004-004824-11," Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1 % betamethasone cream as treatment control twice daily for 3 weeks",04-10-2005,NA,ISRCTN number,results
89,2004-004953-24, A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,US NCT number,protocol
90,2004-004953-24, A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,other,protocol
91,2004-004953-24, A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,US NCT number,results
92,2004-004953-24, A double-blind placebo-controlled two period crossover study of pregabalin and aprepitant in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,ISRCTN number,results
93,2004-005020-41, Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren,30-12-2004,NA,US NCT number,protocol
94,2004-005020-41, Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren,30-12-2004,NA,other,protocol
95,2004-005020-41, Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren,30-12-2004,NA,US NCT number,results
96,2004-005020-41, Topische Anwendung von Tacrolimus (Protopic) bei verschiedenen Formen des kutanen Lupus erythe-matodes im Rahmen einer klinischen Untersuchung an mehreren nationalen Zentren,30-12-2004,NA,ISRCTN number,results
97,2004-005078-22," Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose ",14-04-2005,NA,US NCT number,protocol
98,2004-005078-22," Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose ",14-04-2005,NA,other,protocol
99,2004-005078-22," Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose ",14-04-2005,NA,US NCT number,results
100,2004-005078-22," Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose ",14-04-2005,NA,ISRCTN number,results
101,2004-005172-17, Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,22-05-2006,NA,US NCT number,protocol
102,2004-005172-17, Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,22-05-2006,NA,other,protocol
103,2004-005172-17, Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,22-05-2006,NA,US NCT number,results
104,2004-005172-17, Renal haemodynamics during application of contrast media in patients undergoing cardiac catheterisation with high risk of acute renal failure: randomized comparison of different contrast media,22-05-2006,NA,ISRCTN number,results
105,2004-005197-23, Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.,17-05-2006,NA,US NCT number,protocol
106,2004-005197-23, Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.,17-05-2006,NA,other,protocol
107,2004-005197-23, Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.,17-05-2006,NA,US NCT number,results
108,2004-005197-23, Funktionelle Ergebnisse der intravitrealen Injektion von Triamcinolonacetonid im Vergleich zur konventionellen Lasertherapie bei diabetischem Makulaödem.,17-05-2006,NA,ISRCTN number,results
109,2004-005211-28, A double-blind placebo-controlled four period crossover study of paracetamol and tramadol in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,US NCT number,protocol
110,2004-005211-28, A double-blind placebo-controlled four period crossover study of paracetamol and tramadol in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,other,protocol
111,2004-005211-28, A double-blind placebo-controlled four period crossover study of paracetamol and tramadol in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,US NCT number,results
112,2004-005211-28, A double-blind placebo-controlled four period crossover study of paracetamol and tramadol in the electrical hyperalgesia model of central sensitisation in healthy volunteers,15-09-2005,NA,ISRCTN number,results
113,2004-005223-18," Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study ",07-03-2005,NA,US NCT number,protocol
114,2004-005223-18," Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study ",07-03-2005,NA,other,protocol
115,2004-005223-18," Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study ",07-03-2005,NA,US NCT number,results
116,2004-005223-18," Evaluation of growth response in short children suffering from a disease with growth retardation and treated with Somatropin: A prospective, longitudinal non-randomised, open, phase II study ",07-03-2005,NA,ISRCTN number,results
117,2004-005244-28, Pilotstudie zur Therapieoptimierungsstudie für den ,01-02-2005,NA,US NCT number,protocol
118,2004-005244-28, Pilotstudie zur Therapieoptimierungsstudie für den ,01-02-2005,NA,other,protocol
119,2004-005244-28, Pilotstudie zur Therapieoptimierungsstudie für den ,01-02-2005,NA,US NCT number,results
120,2004-005244-28, Pilotstudie zur Therapieoptimierungsstudie für den ,01-02-2005,NA,ISRCTN number,results
121,2005-000040-85, Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom,19-01-2005,NA,US NCT number,protocol
122,2005-000040-85, Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom,19-01-2005,NA,other,protocol
123,2005-000040-85, Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom,19-01-2005,NA,US NCT number,results
124,2005-000040-85, Erbitux Monotherapie bei Patienten mit lokoregional nicht behandelbarem Hepatozellulären Karzinom,19-01-2005,NA,ISRCTN number,results
125,2005-000223-42, Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD),03-11-2005,NA,US NCT number,protocol
126,2005-000223-42, Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD),03-11-2005,NA,other,protocol
127,2005-000223-42, Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD),03-11-2005,NA,US NCT number,results
128,2005-000223-42, Effects of ziprasidone vs. placebo during the first four weeks of eight weeks sertraline treatment in patients with posttraumatic stress disorder (PTSD),03-11-2005,NA,ISRCTN number,results
129,2005-000295-41," Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s disease.",20-12-2005,NA,US NCT number,protocol
130,2005-000295-41," Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s disease.",20-12-2005,NA,other,protocol
131,2005-000295-41," Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s disease.",20-12-2005,NA,US NCT number,results
132,2005-000295-41," Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud´s disease.",20-12-2005,NA,ISRCTN number,results
133,2005-000355-15, Phase I/II-study of hyperfractionated-accelerated radiation therapy (HART) plus cetuximab (CET) plus cisplatin (CIS) chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.,16-03-2005,NA,US NCT number,protocol
134,2005-000355-15, Phase I/II-study of hyperfractionated-accelerated radiation therapy (HART) plus cetuximab (CET) plus cisplatin (CIS) chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.,16-03-2005,NA,other,protocol
135,2005-000355-15, Phase I/II-study of hyperfractionated-accelerated radiation therapy (HART) plus cetuximab (CET) plus cisplatin (CIS) chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.,16-03-2005,NA,US NCT number,results
136,2005-000355-15, Phase I/II-study of hyperfractionated-accelerated radiation therapy (HART) plus cetuximab (CET) plus cisplatin (CIS) chemotherapy in locally advanced inoperable squamous cell cancers of head and neck.,16-03-2005,ISRCTN47339346,ISRCTN number,results
137,2005-000490-21," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",07-04-2005,NA,US NCT number,protocol
138,2005-000490-21," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",07-04-2005,NA,other,protocol
139,2005-000490-21," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",07-04-2005,NA,US NCT number,results
140,2005-000490-21," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Extended Bisphosphonate and Surveillance-Trial SUCCESS-Trial",07-04-2005,NA,ISRCTN number,results
141,2005-000570-52, Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck,28-10-2005,NA,US NCT number,protocol
142,2005-000570-52, Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck,28-10-2005,NA,other,protocol
143,2005-000570-52, Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck,28-10-2005,NA,US NCT number,results
144,2005-000570-52, Einfluss von Pioglitazon auf den 24-Stunden-Blutdruck,28-10-2005,NA,ISRCTN number,results
145,2005-000615-99, Freiburger ZNS-NHL Studie,13-10-2006,NA,US NCT number,protocol
146,2005-000615-99, Freiburger ZNS-NHL Studie,13-10-2006,NA,other,protocol
147,2005-000615-99, Freiburger ZNS-NHL Studie,13-10-2006,NCT00647049,US NCT number,results
148,2005-000615-99, Freiburger ZNS-NHL Studie,13-10-2006,NA,ISRCTN number,results
149,2005-000663-26, Immunsuppressive Therapy in Duchenne Muscular Dystrophy,21-03-2005,NA,US NCT number,protocol
150,2005-000663-26, Immunsuppressive Therapy in Duchenne Muscular Dystrophy,21-03-2005,NA,other,protocol
151,2005-000663-26, Immunsuppressive Therapy in Duchenne Muscular Dystrophy,21-03-2005,NA,US NCT number,results
152,2005-000663-26, Immunsuppressive Therapy in Duchenne Muscular Dystrophy,21-03-2005,NA,ISRCTN number,results
153,2005-000752-32, Medical treatment of Menière’s disease with betahistine:,15-06-2005,NA,US NCT number,protocol
154,2005-000752-32, Medical treatment of Menière’s disease with betahistine:,15-06-2005,NA,other,protocol
155,2005-000752-32, Medical treatment of Menière’s disease with betahistine:,15-06-2005,NA,US NCT number,results
156,2005-000752-32, Medical treatment of Menière’s disease with betahistine:,15-06-2005,NA,ISRCTN number,results
157,2005-000771-18," Prospective, doubleblind, randomized multicenter study to proof the clinical and ",17-05-2006,NA,US NCT number,protocol
158,2005-000771-18," Prospective, doubleblind, randomized multicenter study to proof the clinical and ",17-05-2006,NA,other,protocol
159,2005-000771-18," Prospective, doubleblind, randomized multicenter study to proof the clinical and ",17-05-2006,NA,US NCT number,results
160,2005-000771-18," Prospective, doubleblind, randomized multicenter study to proof the clinical and ",17-05-2006,NA,ISRCTN number,results
161,2005-000774-46, BOne marrOw transfer to enhance ST-elevation infarct regeneration-2,22-02-2005,NA,US NCT number,protocol
162,2005-000774-46, BOne marrOw transfer to enhance ST-elevation infarct regeneration-2,22-02-2005,NA,other,protocol
163,2005-000774-46, BOne marrOw transfer to enhance ST-elevation infarct regeneration-2,22-02-2005,NA,US NCT number,results
164,2005-000774-46, BOne marrOw transfer to enhance ST-elevation infarct regeneration-2,22-02-2005,ISRCTN17457407,ISRCTN number,results
165,2005-000967-24," Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II",30-08-2005,NA,US NCT number,protocol
166,2005-000967-24," Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II",30-08-2005,NA,other,protocol
167,2005-000967-24," Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II",30-08-2005,NCT00398489,US NCT number,results
168,2005-000967-24," Evaluation of Response Rate to Pre-operative Docetaxel + Herceptin study part A and Docetaxel study part B In Locally Advanced Breast Cancer Patients, Stratified by HER2-Status, Trial Phase II",30-08-2005,NA,ISRCTN number,results
169,2005-000968-33," Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK",16-03-2005,NA,US NCT number,protocol
170,2005-000968-33," Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK",16-03-2005,NA,other,protocol
171,2005-000968-33," Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK",16-03-2005,NA,US NCT number,results
172,2005-000968-33," Doppel-blinde, randomisierte, kontrollierte Studie zur intraarteriellen Transplantation von Knochenmarks-Progenitorzellen bei Patienten mit chronischer Ischämie bei pAVK",16-03-2005,NA,ISRCTN number,results
173,2005-000986-20, The CORE Study (Chemotherapy or Endocrine Treatment first?),15-08-2005,NA,US NCT number,protocol
174,2005-000986-20, The CORE Study (Chemotherapy or Endocrine Treatment first?),15-08-2005,NA,other,protocol
175,2005-000986-20, The CORE Study (Chemotherapy or Endocrine Treatment first?),15-08-2005,NA,US NCT number,results
176,2005-000986-20, The CORE Study (Chemotherapy or Endocrine Treatment first?),15-08-2005,NA,ISRCTN number,results
177,2005-001017-17, µ-Opiatrezeptorvermittelte Dopaminfreisetzung bei Alkoholabhängigkeit:,11-04-2006,NA,US NCT number,protocol
178,2005-001017-17, µ-Opiatrezeptorvermittelte Dopaminfreisetzung bei Alkoholabhängigkeit:,11-04-2006,NA,other,protocol
179,2005-001017-17, µ-Opiatrezeptorvermittelte Dopaminfreisetzung bei Alkoholabhängigkeit:,11-04-2006,NA,US NCT number,results
180,2005-001017-17, µ-Opiatrezeptorvermittelte Dopaminfreisetzung bei Alkoholabhängigkeit:,11-04-2006,NA,ISRCTN number,results
181,2005-001069-32," A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years",24-05-2005,NA,US NCT number,protocol
182,2005-001069-32," A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years",24-05-2005,NA,other,protocol
183,2005-001069-32," A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years",24-05-2005,NA,US NCT number,results
184,2005-001069-32," A prospective 8 weeks acute phase-IV study investigating efficacy, safety and tolerability of Quetiapine fumarate in 60 drug-naïve first-episode psychosis patients aged 18 to 35 years",24-05-2005,NA,ISRCTN number,results
185,2005-001113-18, Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,21-12-2005,NA,US NCT number,protocol
186,2005-001113-18, Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,21-12-2005,NA,other,protocol
187,2005-001113-18, Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,21-12-2005,NA,US NCT number,results
188,2005-001113-18, Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO,21-12-2005,NA,ISRCTN number,results
189,2005-001207-19, Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C infektion who relapsed after Interferon alfa / Ribavirin combination treatment,05-07-2005,NA,US NCT number,protocol
190,2005-001207-19, Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C infektion who relapsed after Interferon alfa / Ribavirin combination treatment,05-07-2005,NA,other,protocol
191,2005-001207-19, Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C infektion who relapsed after Interferon alfa / Ribavirin combination treatment,05-07-2005,NA,US NCT number,results
192,2005-001207-19, Randomized multicenter open label trial comparing the efficacy and safety of 48 versus 72 weeks of Peginterferon-alfa-2a plus daily Ribavirin and Amantadinsulfat in patients with chronic Hepatitis C infektion who relapsed after Interferon alfa / Ribavirin combination treatment,05-07-2005,NA,ISRCTN number,results
193,2005-001278-28, Untersuchungen über die Wirkung der gestörten Glucosetoleranz auf die renale und systemische Hämodynamik und das renin-Angiotensin-System sowie deren pharmakologische Beeinflussung mittels AT1-Rezeptorblockade,21-06-2005,NA,US NCT number,protocol
194,2005-001278-28, Untersuchungen über die Wirkung der gestörten Glucosetoleranz auf die renale und systemische Hämodynamik und das renin-Angiotensin-System sowie deren pharmakologische Beeinflussung mittels AT1-Rezeptorblockade,21-06-2005,NA,other,protocol
195,2005-001278-28, Untersuchungen über die Wirkung der gestörten Glucosetoleranz auf die renale und systemische Hämodynamik und das renin-Angiotensin-System sowie deren pharmakologische Beeinflussung mittels AT1-Rezeptorblockade,21-06-2005,NA,US NCT number,results
196,2005-001278-28, Untersuchungen über die Wirkung der gestörten Glucosetoleranz auf die renale und systemische Hämodynamik und das renin-Angiotensin-System sowie deren pharmakologische Beeinflussung mittels AT1-Rezeptorblockade,21-06-2005,NA,ISRCTN number,results
197,2005-001411-22, Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study,12-10-2005,NA,US NCT number,protocol
198,2005-001411-22, Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study,12-10-2005,NA,other,protocol
199,2005-001411-22, Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study,12-10-2005,NA,US NCT number,results
200,2005-001411-22, Serotonin-Transporter Binding in Tourette-Syndrome and Obsessive-Compulsive Disorder before and during Treatment with SRI: a I-123-ADAM-SPECT-Study,12-10-2005,NA,ISRCTN number,results
201,2005-001415-21, Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor Thrombendarteriektomie,02-12-2005,NA,US NCT number,protocol
202,2005-001415-21, Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor Thrombendarteriektomie,02-12-2005,NA,other,protocol
203,2005-001415-21, Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor Thrombendarteriektomie,02-12-2005,NA,US NCT number,results
204,2005-001415-21, Phase II Studie zur Evaluierung der SH U 555 C unterstützten Magnetresonanztomographie der arteriosklerotischen Karotisstenose bei Patienten vor Thrombendarteriektomie,02-12-2005,NA,ISRCTN number,results
205,2005-001456-20, „Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,22-11-2005,NA,US NCT number,protocol
206,2005-001456-20, „Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,22-11-2005,NA,other,protocol
207,2005-001456-20, „Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,22-11-2005,NA,US NCT number,results
208,2005-001456-20, „Pilotstudie zum Einfluss selektiver neurogener Blockaden auf die perioperative Immunreaktion bei Lungen-resezierten Patienten.“,22-11-2005,NA,ISRCTN number,results
209,2005-001481-14, LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent,02-12-2005,NA,US NCT number,protocol
210,2005-001481-14, LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent,02-12-2005,NA,other,protocol
211,2005-001481-14, LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent,02-12-2005,NA,US NCT number,results
212,2005-001481-14, LOCAL-TAX Trial: Local intracoronary administration of Paclitaxel after stent implantation for prevention of restenosis in comparison with stent implantation alone and with implantation of a Paclitaxel-eluting stent,02-12-2005,NA,ISRCTN number,results
213,2005-001486-33, Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome,15-06-2005,NA,US NCT number,protocol
214,2005-001486-33, Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome,15-06-2005,NA,other,protocol
215,2005-001486-33, Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome,15-06-2005,NA,US NCT number,results
216,2005-001486-33, Efficacy and safety of levetiracetam in the inpatient treatment of alcohol withdrawal syndrome,15-06-2005,NA,ISRCTN number,results
217,2005-001559-39, Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,02-06-2006,NA,US NCT number,protocol
218,2005-001559-39, Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,02-06-2006,NA,other,protocol
219,2005-001559-39, Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,02-06-2006,NA,US NCT number,results
220,2005-001559-39, Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epithelialem Ovarialkarzinom und Peritonealkarzinom,02-06-2006,NA,ISRCTN number,results
221,2005-001596-34, Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia,07-12-2005,NA,US NCT number,protocol
222,2005-001596-34, Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia,07-12-2005,NA,other,protocol
223,2005-001596-34, Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia,07-12-2005,NA,US NCT number,results
224,2005-001596-34, Multicentre phase II trial of Bendamustine in combination with rituximab for patients with previously untreated or relapsed chronic lymphocytic leukemia,07-12-2005,NA,ISRCTN number,results
225,2005-001602-76, Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression. ,09-01-2006,NA,US NCT number,protocol
226,2005-001602-76, Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression. ,09-01-2006,NA,other,protocol
227,2005-001602-76, Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression. ,09-01-2006,NA,US NCT number,results
228,2005-001602-76, Phase III clinical trial comparing treatments of hormone-refractory prostate cancer (HRPC) with Docetaxel: continuous treatment vs. intermittent repetition of treatment after progression. ,09-01-2006,NA,ISRCTN number,results
229,2005-001621-29, Pre-POINT (Primary Oral INsulin Trial) study ,07-12-2007,NA,US NCT number,protocol
230,2005-001621-29, Pre-POINT (Primary Oral INsulin Trial) study ,07-12-2007,NA,other,protocol
231,2005-001621-29, Pre-POINT (Primary Oral INsulin Trial) study ,07-12-2007,NA,US NCT number,results
232,2005-001621-29, Pre-POINT (Primary Oral INsulin Trial) study ,07-12-2007,NA,ISRCTN number,results
233,2005-001762-13, Energy metabolism of critically ill children treated with lipid emulsion and carnitine,05-07-2005,NA,US NCT number,protocol
234,2005-001762-13, Energy metabolism of critically ill children treated with lipid emulsion and carnitine,05-07-2005,NA,other,protocol
235,2005-001762-13, Energy metabolism of critically ill children treated with lipid emulsion and carnitine,05-07-2005,NA,US NCT number,results
236,2005-001762-13, Energy metabolism of critically ill children treated with lipid emulsion and carnitine,05-07-2005,NA,ISRCTN number,results
237,2005-001827-12, Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie,12-07-2005,NA,US NCT number,protocol
238,2005-001827-12, Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie,12-07-2005,NA,other,protocol
239,2005-001827-12, Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie,12-07-2005,NA,US NCT number,results
240,2005-001827-12, Myfortic ® zur Therapie des Bullösen Pemphigoids. Eine offene monozentrische proof-of-concept Studie,12-07-2005,NA,ISRCTN number,results
241,2005-001907-21," A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",24-06-2005,NA,US NCT number,protocol
242,2005-001907-21," A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",24-06-2005,NA,other,protocol
243,2005-001907-21," A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",24-06-2005,NA,US NCT number,results
244,2005-001907-21," A randomised, double-blinded, multicenter, parallel group study comparing a remifentanil-regimen with a fentanyl-regimen for analgesia in mechanically ventilated patients",24-06-2005,NA,ISRCTN number,results
245,2005-001919-21, Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom,13-07-2006,NA,US NCT number,protocol
246,2005-001919-21, Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom,13-07-2006,NA,other,protocol
247,2005-001919-21, Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom,13-07-2006,NA,US NCT number,results
248,2005-001919-21, Phase II-Studie: Standardchemotherapie Capecitabin in Kombination mit Bevacizumab in der Erstlinientherapie beim metastasierten kolorektalen Karzinom,13-07-2006,NA,ISRCTN number,results
249,2005-001991-11, Effekte von Escitalopram auf Aufmerksamkeit und kognitive Funktionen bei gesunden Probanden,13-10-2005,NA,US NCT number,protocol
250,2005-001991-11, Effekte von Escitalopram auf Aufmerksamkeit und kognitive Funktionen bei gesunden Probanden,13-10-2005,NA,other,protocol
251,2005-001991-11, Effekte von Escitalopram auf Aufmerksamkeit und kognitive Funktionen bei gesunden Probanden,13-10-2005,NA,US NCT number,results
252,2005-001991-11, Effekte von Escitalopram auf Aufmerksamkeit und kognitive Funktionen bei gesunden Probanden,13-10-2005,NA,ISRCTN number,results
253,2005-002180-90, Lókoregionale Tiefenhyperthermie begleitend  zu ACNU in der Rezidivtherapie von Patienten mit malignen Gliomen (WHO°III/IV)- Phase I/II-Studie,21-06-2006,NA,US NCT number,protocol
254,2005-002180-90, Lókoregionale Tiefenhyperthermie begleitend  zu ACNU in der Rezidivtherapie von Patienten mit malignen Gliomen (WHO°III/IV)- Phase I/II-Studie,21-06-2006,NA,other,protocol
255,2005-002180-90, Lókoregionale Tiefenhyperthermie begleitend  zu ACNU in der Rezidivtherapie von Patienten mit malignen Gliomen (WHO°III/IV)- Phase I/II-Studie,21-06-2006,NA,US NCT number,results
256,2005-002180-90, Lókoregionale Tiefenhyperthermie begleitend  zu ACNU in der Rezidivtherapie von Patienten mit malignen Gliomen (WHO°III/IV)- Phase I/II-Studie,21-06-2006,NA,ISRCTN number,results
257,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,protocol
258,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,other,protocol
259,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,results
260,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,ISRCTN number,results
261,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,protocol
262,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,other,protocol
263,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,results
264,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,ISRCTN number,results
265,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,protocol
266,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,other,protocol
267,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,results
268,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,ISRCTN number,results
269,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,protocol
270,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,other,protocol
271,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,US NCT number,results
272,2005-002192-32," Phase II Randomized, Parallel-Group Trial on PTK-ZK with or without DTIC in Patients with non-resectable Metastatic Malignant Melanoma",03-03-2006,NA,ISRCTN number,results
273,2005-002320-34, Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),16-05-2006,NA,US NCT number,protocol
274,2005-002320-34, Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),16-05-2006,NA,other,protocol
275,2005-002320-34, Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),16-05-2006,NCT00844142,US NCT number,results
276,2005-002320-34, Randomized controlled 12 months trial with etanercept (enbrel ®) vs. sulfasalazine followed by an open-label extension with etanercept up to week 540 in early axial spondyloarthritis with focus on improvement of acute inflammatory lesions as detected by MRI (ESTHER),16-05-2006,NA,ISRCTN number,results
277,2005-002407-17, Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy,19-12-2005,NA,US NCT number,protocol
278,2005-002407-17, Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy,19-12-2005,NA,other,protocol
279,2005-002407-17, Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy,19-12-2005,NA,US NCT number,results
280,2005-002407-17, Effects of rosiglitazone on renal hemodynamics and proteinuria of type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy,19-12-2005,NA,ISRCTN number,results
281,2005-002475-32," Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",16-05-2006,NA,US NCT number,protocol
282,2005-002475-32," Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",16-05-2006,NA,other,protocol
283,2005-002475-32," Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",16-05-2006,NA,US NCT number,results
284,2005-002475-32," Pilotstudy about endocrinilogical, peripherphysilogical and painreducing effects of Gamma-hydroxybutyrate in combination with operant-behaviour-therapeutic paintherapy with patients in Fibromyalgia-Syndrome",16-05-2006,NA,ISRCTN number,results
285,2005-002582-37," Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients ",28-10-2005,NA,US NCT number,protocol
286,2005-002582-37," Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients ",28-10-2005,NA,other,protocol
287,2005-002582-37," Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients ",28-10-2005,NA,US NCT number,results
288,2005-002582-37," Characterization of protective effects of a piperidine derivative (DPMP, 4-diphenylmethoxy-1 [3-(4-ter-butylbenzoyl)-propyl] piperidine) on cognitive impairment in urticaria patients ",28-10-2005,NA,ISRCTN number,results
289,2005-002618-40," HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas in children and adolescents",09-01-2006,NCT00749723,US NCT number,protocol
290,2005-002618-40," HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas in children and adolescents",09-01-2006,NA,other,protocol
291,2005-002618-40," HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas in children and adolescents",09-01-2006,NA,US NCT number,results
292,2005-002618-40," HIT-REZ 2005 - A multicentre clinical trial and phase II study for the treatment of refractory and relapsed primitive neuroectodermal tumours (medulloblastomas, supratentorial PNETs) and ependymomas in children and adolescents",09-01-2006,NA,ISRCTN number,results
293,2005-002634-35," Single centre, prospective, comparative, open-label, randomised study to evaluate the efficacy and tolerability of the combination of Moxifloxacin plus Metronidazole versus Piperacillin/Tazobactam for the treatment of patients with intra-abdominal abscesses (MEMO)",06-07-2005,NA,US NCT number,protocol
294,2005-002634-35," Single centre, prospective, comparative, open-label, randomised study to evaluate the efficacy and tolerability of the combination of Moxifloxacin plus Metronidazole versus Piperacillin/Tazobactam for the treatment of patients with intra-abdominal abscesses (MEMO)",06-07-2005,NA,other,protocol
295,2005-002634-35," Single centre, prospective, comparative, open-label, randomised study to evaluate the efficacy and tolerability of the combination of Moxifloxacin plus Metronidazole versus Piperacillin/Tazobactam for the treatment of patients with intra-abdominal abscesses (MEMO)",06-07-2005,NA,US NCT number,results
296,2005-002634-35," Single centre, prospective, comparative, open-label, randomised study to evaluate the efficacy and tolerability of the combination of Moxifloxacin plus Metronidazole versus Piperacillin/Tazobactam for the treatment of patients with intra-abdominal abscesses (MEMO)",06-07-2005,NA,ISRCTN number,results
297,2005-002699-13, Modafinil in der Behandlung von Müdigkeit bei Tumorpatienten - eine randomisierte doppelblinde N=1 Studie,30-09-2005,NA,US NCT number,protocol
298,2005-002699-13, Modafinil in der Behandlung von Müdigkeit bei Tumorpatienten - eine randomisierte doppelblinde N=1 Studie,30-09-2005,NA,other,protocol
299,2005-002699-13, Modafinil in der Behandlung von Müdigkeit bei Tumorpatienten - eine randomisierte doppelblinde N=1 Studie,30-09-2005,NA,US NCT number,results
300,2005-002699-13, Modafinil in der Behandlung von Müdigkeit bei Tumorpatienten - eine randomisierte doppelblinde N=1 Studie,30-09-2005,NA,ISRCTN number,results
301,2005-002983-27, Prospektive randomisierte Studie zur Untersuchung der Wirksamkeit der Photodynamischen Therapie bei aktinischen Keratosen,13-10-2005,NA,US NCT number,protocol
302,2005-002983-27, Prospektive randomisierte Studie zur Untersuchung der Wirksamkeit der Photodynamischen Therapie bei aktinischen Keratosen,13-10-2005,NA,other,protocol
303,2005-002983-27, Prospektive randomisierte Studie zur Untersuchung der Wirksamkeit der Photodynamischen Therapie bei aktinischen Keratosen,13-10-2005,NA,US NCT number,results
304,2005-002983-27, Prospektive randomisierte Studie zur Untersuchung der Wirksamkeit der Photodynamischen Therapie bei aktinischen Keratosen,13-10-2005,NA,ISRCTN number,results
305,2005-003013-32," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS ",21-09-2005,NA,US NCT number,protocol
306,2005-003013-32," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS ",21-09-2005,NA,other,protocol
307,2005-003013-32," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS ",21-09-2005,NA,US NCT number,results
308,2005-003013-32," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED; MULTICENTER TRIAL OF BIVALIRUDIN AND UN-FRACTIONATED HEPARIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS ",21-09-2005,NA,ISRCTN number,results
309,2005-003026-26, High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT,14-03-2006,NA,US NCT number,protocol
310,2005-003026-26, High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT,14-03-2006,NA,other,protocol
311,2005-003026-26, High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT,14-03-2006,NA,US NCT number,results
312,2005-003026-26, High-dose chemotherapy with transplantation of gene-modified haematopoietic stem cells for HIV-positive patients with malignant diseases indicating an HSCT,14-03-2006,NA,ISRCTN number,results
313,2005-003156-35, Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study ,23-08-2005,NA,US NCT number,protocol
314,2005-003156-35, Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study ,23-08-2005,NA,other,protocol
315,2005-003156-35, Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study ,23-08-2005,NA,US NCT number,results
316,2005-003156-35, Efficacy and tolerability of Ziprasidone vs. Clozapine in the treatment of dually diagnosed (DD-) patients with schizophrenia and cannabis use disorder: A randomised study ,23-08-2005,NA,ISRCTN number,results
317,2005-003166-42, Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.,20-09-2005,NA,US NCT number,protocol
318,2005-003166-42, Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.,20-09-2005,NA,other,protocol
319,2005-003166-42, Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.,20-09-2005,NA,US NCT number,results
320,2005-003166-42, Palliative Chemotherapy (2nd line) with Imatinib (GlivecTM) in Patients with Bile Duct Cancer.,20-09-2005,NA,ISRCTN number,results
321,2005-003195-38, Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate ,12-09-2005,NA,US NCT number,protocol
322,2005-003195-38, Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate ,12-09-2005,NA,other,protocol
323,2005-003195-38, Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate ,12-09-2005,NA,US NCT number,results
324,2005-003195-38, Randomized double-blind placebo-controlled and parallel group study to evaluate the impact of one year therapy with monthly oral ibandronate ,12-09-2005,NA,ISRCTN number,results
325,2005-003196-21, Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil -,27-04-2006,NA,US NCT number,protocol
326,2005-003196-21, Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil -,27-04-2006,NA,other,protocol
327,2005-003196-21, Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil -,27-04-2006,NA,US NCT number,results
328,2005-003196-21, Enhancing the Therapeutic Efficacy of Sleep Deprivation by Modafinil -,27-04-2006,NA,ISRCTN number,results
329,2005-003201-81," GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.",19-01-2007,NA,US NCT number,protocol
330,2005-003201-81," GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.",19-01-2007,NA,other,protocol
331,2005-003201-81," GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.",19-01-2007,NA,US NCT number,results
332,2005-003201-81," GACHE: German trial of Acyclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis. A multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial.",19-01-2007,NA,ISRCTN number,results
333,2005-003245-14, Neuronale Korrelate von dysfunktionellen Aufmerksamkeitskomponenten bei Patienten mit Schizophrenie: cholinerge Rezeptorsysteme und pharmakologische Therapie,05-09-2006,NA,US NCT number,protocol
334,2005-003245-14, Neuronale Korrelate von dysfunktionellen Aufmerksamkeitskomponenten bei Patienten mit Schizophrenie: cholinerge Rezeptorsysteme und pharmakologische Therapie,05-09-2006,NA,other,protocol
335,2005-003245-14, Neuronale Korrelate von dysfunktionellen Aufmerksamkeitskomponenten bei Patienten mit Schizophrenie: cholinerge Rezeptorsysteme und pharmakologische Therapie,05-09-2006,NA,US NCT number,results
336,2005-003245-14, Neuronale Korrelate von dysfunktionellen Aufmerksamkeitskomponenten bei Patienten mit Schizophrenie: cholinerge Rezeptorsysteme und pharmakologische Therapie,05-09-2006,NA,ISRCTN number,results
337,2005-003271-21," Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherapie und Transplantation peripherer Stammzellen",24-05-2006,NA,US NCT number,protocol
338,2005-003271-21," Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherapie und Transplantation peripherer Stammzellen",24-05-2006,NA,other,protocol
339,2005-003271-21," Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherapie und Transplantation peripherer Stammzellen",24-05-2006,NA,US NCT number,results
340,2005-003271-21," Doppelblinde, prospektive, randomisierte, monozentrische, placebo-kontrollierte Pilotstudie zur Wirksamkeit und Sicherheit von Moxifloxacin in der Prophylaxe der Bakteriämie nach Hochdosis-Chemotherapie und Transplantation peripherer Stammzellen",24-05-2006,NA,ISRCTN number,results
341,2005-003305-90, A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial.,15-03-2006,NA,US NCT number,protocol
342,2005-003305-90, A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial.,15-03-2006,NA,other,protocol
343,2005-003305-90, A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial.,15-03-2006,NCT00105001,US NCT number,results
344,2005-003305-90, A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies. A Multi-Center Trial.,15-03-2006,NA,ISRCTN number,results
345,2005-003324-19, STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: ,14-09-2006,NA,US NCT number,protocol
346,2005-003324-19, STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: ,14-09-2006,NA,other,protocol
347,2005-003324-19, STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: ,14-09-2006,NA,US NCT number,results
348,2005-003324-19, STEP ONE –trial (Study on the Treatment of Elderly Patients with Older and Newer antiepileptic drugs) - trial: ,14-09-2006,NA,ISRCTN number,results
349,2005-003327-39," Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study",22-12-2005,NA,US NCT number,protocol
350,2005-003327-39," Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study",22-12-2005,NA,other,protocol
351,2005-003327-39," Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study",22-12-2005,NA,US NCT number,results
352,2005-003327-39," Integration of 3D-conformal, local radiotherapy (3DCRT) to metastatic sites in a paclitaxel weekly chemotherapy regimen in oligometastatic breast cancer patients: a phase I- and randomised phase II-study",22-12-2005,NA,ISRCTN number,results
353,2005-003484-23, Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin,16-12-2009,NCT01126216,US NCT number,protocol
354,2005-003484-23, Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin,16-12-2009,NA,other,protocol
355,2005-003484-23, Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin,16-12-2009,NCT01126216,US NCT number,results
356,2005-003484-23, Randomised phase-III-trial of simultaneous radiochemotherapy (RCT) of locally advanced head and neck cancer in the stages III and IV A-B: Comparing dose reduced RCT (63.6 Gy) with Paclitaxel/Cisplatin to standard RCT (70.2 Gy) with 5-Fluorouracil/Cisplatin,16-12-2009,NA,ISRCTN number,results
357,2005-003488-22, Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,22-05-2006,NA,US NCT number,protocol
358,2005-003488-22, Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,22-05-2006,NA,other,protocol
359,2005-003488-22, Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,22-05-2006,NA,US NCT number,results
360,2005-003488-22, Regulation des Antidiuretisches Hormons (ADH) und der antidiuretischen Wirkung unter Glucocorticoid - Therapie,22-05-2006,NA,ISRCTN number,results
361,2005-003516-29," Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants",20-10-2006,NA,US NCT number,protocol
362,2005-003516-29," Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants",20-10-2006,NA,other,protocol
363,2005-003516-29," Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants",20-10-2006,NA,US NCT number,results
364,2005-003516-29," Prospective, randomized, double-blinded clinical trial on remifentanil for analgesia and sedation of ventilated neonates and infants",20-10-2006,NA,ISRCTN number,results
365,2005-003557-27, Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis,21-11-2005,NA,US NCT number,protocol
366,2005-003557-27, Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis,21-11-2005,NA,other,protocol
367,2005-003557-27, Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis,21-11-2005,NA,US NCT number,results
368,2005-003557-27, Covered Transjugular Intrahepatic Portosystemic Stent Shunt versus Optimized medical Treatment for the Secondary Prevention of Variceal Bleeding in Cirrhosis,21-11-2005,NA,ISRCTN number,results
369,2005-003617-33, A Randomised Cross-Over Study to Explore  the Pathophysiological Mechanisms Involved in the  Treatment of Actinic Keratoses with Solaraze,22-05-2006,NA,US NCT number,protocol
370,2005-003617-33, A Randomised Cross-Over Study to Explore  the Pathophysiological Mechanisms Involved in the  Treatment of Actinic Keratoses with Solaraze,22-05-2006,NA,other,protocol
371,2005-003617-33, A Randomised Cross-Over Study to Explore  the Pathophysiological Mechanisms Involved in the  Treatment of Actinic Keratoses with Solaraze,22-05-2006,NA,US NCT number,results
372,2005-003617-33, A Randomised Cross-Over Study to Explore  the Pathophysiological Mechanisms Involved in the  Treatment of Actinic Keratoses with Solaraze,22-05-2006,NA,ISRCTN number,results
373,2005-003644-59, A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema. ,22-08-2006,NA,US NCT number,protocol
374,2005-003644-59, A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema. ,22-08-2006,NA,other,protocol
375,2005-003644-59, A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema. ,22-08-2006,NA,US NCT number,results
376,2005-003644-59, A two months study of the utility of Elidel cream 1% (pimecrolimus) in the long term management of atopic hand eczema. ,22-08-2006,NA,ISRCTN number,results
377,2005-003648-70," Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",20-02-2007,NA,US NCT number,protocol
378,2005-003648-70," Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",20-02-2007,NA,other,protocol
379,2005-003648-70," Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",20-02-2007,NA,US NCT number,results
380,2005-003648-70," Randomised, double-blinded phase IIIb study to optimise antiviral therapy response of a standard therapy consisting of peginterferon-alfa-2a and ribavirin plus the additional use of bezafibrat 400 mg/d in untreated patients with chronic hepatits C typ 1.",20-02-2007,NA,ISRCTN number,results
381,2005-003714-15, Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,28-09-2005,NA,US NCT number,protocol
382,2005-003714-15, Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,28-09-2005,NA,other,protocol
383,2005-003714-15, Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,28-09-2005,NA,US NCT number,results
384,2005-003714-15, Mechanismen der Glukagon-induzierten Stimulation des Wachstumshormons; die Rolle des Glukagons in der Ghrelin-Regulation,28-09-2005,NA,ISRCTN number,results
385,2005-003762-41, Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®),26-09-2006,NA,US NCT number,protocol
386,2005-003762-41, Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®),26-09-2006,NA,other,protocol
387,2005-003762-41, Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®),26-09-2006,NA,US NCT number,results
388,2005-003762-41, Diffusionstensorgewichtete MRT bei der Alzheimer Krankheit: Prädiktion und Darstellung von symptomatischen und krankheitsmodifizierenden Behandlungseffekten von Galantamin (Reminyl®),26-09-2006,NA,ISRCTN number,results
389,2005-003812-31, Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome,24-10-2006,NA,US NCT number,protocol
390,2005-003812-31, Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome,24-10-2006,NA,other,protocol
391,2005-003812-31, Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome,24-10-2006,NA,US NCT number,results
392,2005-003812-31, Niaspan in combination with fluvastatin compared to fluvastatin-monotherapy fpr patients with metabolic syndrome,24-10-2006,NA,ISRCTN number,results
393,2005-003832-24," An open, prospective, randomized, comparative study to evaluate the effect of Iodixanol 320 compared to Iomeprol 350 on contrast medium induced nephropathy in patients with impaired renal function undergoing percutaneous coronary intervention",18-04-2006,NA,US NCT number,protocol
394,2005-003832-24," An open, prospective, randomized, comparative study to evaluate the effect of Iodixanol 320 compared to Iomeprol 350 on contrast medium induced nephropathy in patients with impaired renal function undergoing percutaneous coronary intervention",18-04-2006,NA,other,protocol
395,2005-003832-24," An open, prospective, randomized, comparative study to evaluate the effect of Iodixanol 320 compared to Iomeprol 350 on contrast medium induced nephropathy in patients with impaired renal function undergoing percutaneous coronary intervention",18-04-2006,NA,US NCT number,results
396,2005-003832-24," An open, prospective, randomized, comparative study to evaluate the effect of Iodixanol 320 compared to Iomeprol 350 on contrast medium induced nephropathy in patients with impaired renal function undergoing percutaneous coronary intervention",18-04-2006,NA,ISRCTN number,results
397,2005-003854-80, Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,04-01-2006,NA,US NCT number,protocol
398,2005-003854-80, Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,04-01-2006,NA,other,protocol
399,2005-003854-80, Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,04-01-2006,NA,US NCT number,results
400,2005-003854-80, Modulation of the Surgical Inflammatory Response by Etoricoxib: Peripheral versus Central,04-01-2006,NA,ISRCTN number,results
401,2005-003855-11, Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combination,21-06-2006,NA,US NCT number,protocol
402,2005-003855-11, Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combination,21-06-2006,NA,other,protocol
403,2005-003855-11, Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combination,21-06-2006,NA,US NCT number,results
404,2005-003855-11, Gemcitabine and cisplatin in combination with hyperthermia in patients with locally advanced or metastatic pancreatic cancer as second-line therapy after adjuvant or first-line chemotherapy with Gemcitabine or Gemcitabine combination,21-06-2006,NA,ISRCTN number,results
405,2005-003910-13, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Cetuximab und Bevacizumab in der Erstlinientherapie von,25-10-2005,NA,US NCT number,protocol
406,2005-003910-13, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Cetuximab und Bevacizumab in der Erstlinientherapie von,25-10-2005,NA,other,protocol
407,2005-003910-13, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Cetuximab und Bevacizumab in der Erstlinientherapie von,25-10-2005,NA,US NCT number,results
408,2005-003910-13, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Cetuximab und Bevacizumab in der Erstlinientherapie von,25-10-2005,NA,ISRCTN number,results
409,2005-003911-63, Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial,26-10-2005,NA,US NCT number,protocol
410,2005-003911-63, Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial,26-10-2005,NA,other,protocol
411,2005-003911-63, Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial,26-10-2005,NA,US NCT number,results
412,2005-003911-63, Combined Radiochemotherapy with Erbitux (Cetuximab) plus Temozolomide in the primary therapy of Glioblastoma Multiforme (GBM) - Phase I/II Trial,26-10-2005,NA,ISRCTN number,results
413,2005-003943-30, Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting,05-05-2006,NA,US NCT number,protocol
414,2005-003943-30, Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting,05-05-2006,NA,other,protocol
415,2005-003943-30, Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting,05-05-2006,NA,US NCT number,results
416,2005-003943-30, Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting,05-05-2006,NA,ISRCTN number,results
417,2005-004051-35, Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients,20-01-2006,NA,US NCT number,protocol
418,2005-004051-35, Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients,20-01-2006,NA,other,protocol
419,2005-004051-35, Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients,20-01-2006,NA,US NCT number,results
420,2005-004051-35, Intramyocardial Application of Stem Cells in combination with transmyocardial Laser Revascularisation (TMLR) in CABG Patients,20-01-2006,NA,ISRCTN number,results
421,2005-004123-19, Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma,02-11-2005,NA,US NCT number,protocol
422,2005-004123-19, Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma,02-11-2005,NA,other,protocol
423,2005-004123-19, Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma,02-11-2005,NA,US NCT number,results
424,2005-004123-19, Metabolic Response Evaluation for an Individualization of Neoadjuvant Chemo- and Radiotherapy in Esophageal Adenocarcinoma,02-11-2005,NA,ISRCTN number,results
425,2005-004137-18, First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT),21-07-2006,NA,US NCT number,protocol
426,2005-004137-18, First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT),21-07-2006,NA,other,protocol
427,2005-004137-18, First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT),21-07-2006,NA,US NCT number,results
428,2005-004137-18, First International Randomized trial in locally advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT),21-07-2006,NA,ISRCTN number,results
429,2005-004139-23," An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with",30-03-2006,NA,US NCT number,protocol
430,2005-004139-23," An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with",30-03-2006,RACE 2005-004139-23,other,protocol
431,2005-004139-23," An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with",30-03-2006,NA,US NCT number,results
432,2005-004139-23," An open-label, non-randomized phase I/II trial of neoadjuvant radio-immunochemotherapy with",30-03-2006,NA,ISRCTN number,results
433,2005-004151-35, Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy,14-06-2006,NA,US NCT number,protocol
434,2005-004151-35, Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy,14-06-2006,NA,other,protocol
435,2005-004151-35, Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy,14-06-2006,NA,US NCT number,results
436,2005-004151-35, Pharmacokinetics of oral cefuroxime-axetil compared to intravenous cefuroxime in term neonates and possible adjustment of the oral therapy,14-06-2006,NA,ISRCTN number,results
437,2005-004186-41, Cholinerg/dopaminerge Kontrolle von Aufmerksamkeitsprozessen bei schizophrenen Störungen,10-01-2006,NA,US NCT number,protocol
438,2005-004186-41, Cholinerg/dopaminerge Kontrolle von Aufmerksamkeitsprozessen bei schizophrenen Störungen,10-01-2006,NA,other,protocol
439,2005-004186-41, Cholinerg/dopaminerge Kontrolle von Aufmerksamkeitsprozessen bei schizophrenen Störungen,10-01-2006,NA,US NCT number,results
440,2005-004186-41, Cholinerg/dopaminerge Kontrolle von Aufmerksamkeitsprozessen bei schizophrenen Störungen,10-01-2006,NA,ISRCTN number,results
441,2005-004218-34, Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins,06-02-2006,NA,US NCT number,protocol
442,2005-004218-34, Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins,06-02-2006,NA,other,protocol
443,2005-004218-34, Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins,06-02-2006,NA,US NCT number,results
444,2005-004218-34, Effect of extended-release niacin on myocardial blood flow and flow reserve in patients with coronary artery disease treated with statins,06-02-2006,NA,ISRCTN number,results
445,2005-004234-41, Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®),14-03-2008,NA,US NCT number,protocol
446,2005-004234-41, Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®),14-03-2008,NA,other,protocol
447,2005-004234-41, Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®),14-03-2008,NA,US NCT number,results
448,2005-004234-41, Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®),14-03-2008,NA,ISRCTN number,results
449,2005-004236-40, Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,08-10-2007,NA,US NCT number,protocol
450,2005-004236-40, Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,08-10-2007,NA,other,protocol
451,2005-004236-40, Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,08-10-2007,NA,US NCT number,results
452,2005-004236-40, Phase II study: Docetaxel plus Oxaliplatin as second-line therapy in patients with advanced metastatic pancreatic cancer,08-10-2007,NA,ISRCTN number,results
453,2005-004325-25, Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®,20-09-2006,NA,US NCT number,protocol
454,2005-004325-25, Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®,20-09-2006,NA,other,protocol
455,2005-004325-25, Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®,20-09-2006,NA,US NCT number,results
456,2005-004325-25, Comprehensive whole-body 3T MRA of Patients with Low or Moderate Clinical Probability for Pulmonary Embolism using an Intravascular MR Contrast Agent Vasovist®,20-09-2006,NA,ISRCTN number,results
457,2005-004378-25," A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxel + Prednison vs. Placebo + Docetaxel + Prednison",29-12-2005,NA,US NCT number,protocol
458,2005-004378-25," A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxel + Prednison vs. Placebo + Docetaxel + Prednison",29-12-2005,NA,other,protocol
459,2005-004378-25," A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxel + Prednison vs. Placebo + Docetaxel + Prednison",29-12-2005,NA,US NCT number,results
460,2005-004378-25," A randomized, double-blinded, multicentric phase II trial to optimize the treatment of the hormon refractory prostatic carcinoma in patients without preceding chemotherapy with Sorafenib + Docetaxel + Prednison vs. Placebo + Docetaxel + Prednison",29-12-2005,NA,ISRCTN number,results
461,2005-004406-93, Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom,22-02-2007,NA,US NCT number,protocol
462,2005-004406-93, Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom,22-02-2007,NA,other,protocol
463,2005-004406-93, Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom,22-02-2007,NA,US NCT number,results
464,2005-004406-93, Photodynamische Diagnostik mit 5-Aminolävulinsäure zur Beurteilung der intraoperativen Absetzungsränder im Rahmen der radikalen Prostatovesikulektomie bei Patienten mit einem Prostatakarzinom,22-02-2007,NA,ISRCTN number,results
465,2005-004427-19, Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.,01-09-2006,NA,US NCT number,protocol
466,2005-004427-19, Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.,01-09-2006,NA,other,protocol
467,2005-004427-19, Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.,01-09-2006,NA,US NCT number,results
468,2005-004427-19, Health-related quality of life (QoL) and psychological well-being after withdrawal from hormone therapy (HT). A randomised double-blind placebo-controlled trial.,01-09-2006,NA,ISRCTN number,results
469,2005-004437-18," Placebo-controlled double-blind study about the effectiveness of longtime 	acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid intolerance",19-05-2006,NA,US NCT number,protocol
470,2005-004437-18," Placebo-controlled double-blind study about the effectiveness of longtime 	acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid intolerance",19-05-2006,NA,other,protocol
471,2005-004437-18," Placebo-controlled double-blind study about the effectiveness of longtime 	acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid intolerance",19-05-2006,NA,US NCT number,results
472,2005-004437-18," Placebo-controlled double-blind study about the effectiveness of longtime 	acetylsalicylic acid desactivation therapy as prevention of recurrens of poyposis nasi in case of acetylsalicylic acid intolerance",19-05-2006,NA,ISRCTN number,results
473,2005-004454-27," Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine intensive Chemotherapie nicht möglich ist",04-05-2006,NA,US NCT number,protocol
474,2005-004454-27," Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine intensive Chemotherapie nicht möglich ist",04-05-2006,NA,other,protocol
475,2005-004454-27," Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine intensive Chemotherapie nicht möglich ist",04-05-2006,NA,US NCT number,results
476,2005-004454-27," Klinische Phase II-Prüfung zur Bestimmung von Wirksamkeit und Verträglichkeit der Kombination von 5-Azacytidin und Valproinsäure bei Personen mit MDS und anderen myeloischen Neoplasien, bei denen eine intensive Chemotherapie nicht möglich ist",04-05-2006,NA,ISRCTN number,results
477,2005-004468-22," HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-temporal spikes",23-08-2006,NA,US NCT number,protocol
478,2005-004468-22," HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-temporal spikes",23-08-2006,NA,other,protocol
479,2005-004468-22," HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-temporal spikes",23-08-2006,NA,US NCT number,results
480,2005-004468-22," HEAD-TO-HEAD evaluation of the antiepileptic drugs Levetiracetam (LEV) vs. Sulthiame (STM) in a German multi-centre, doubleblind controlled trial in children with benign epilepsy with centro-temporal spikes",23-08-2006,ISRCTN97864911,ISRCTN number,results
481,2005-004492-37, Untersuchung über den Einfluss einer Omega-3 reichen parenteralen Ernährung auf die zelluläre Abwehr an postoperativen Patienten,30-11-2005,NA,US NCT number,protocol
482,2005-004492-37, Untersuchung über den Einfluss einer Omega-3 reichen parenteralen Ernährung auf die zelluläre Abwehr an postoperativen Patienten,30-11-2005,NA,other,protocol
483,2005-004492-37, Untersuchung über den Einfluss einer Omega-3 reichen parenteralen Ernährung auf die zelluläre Abwehr an postoperativen Patienten,30-11-2005,NA,US NCT number,results
484,2005-004492-37, Untersuchung über den Einfluss einer Omega-3 reichen parenteralen Ernährung auf die zelluläre Abwehr an postoperativen Patienten,30-11-2005,NA,ISRCTN number,results
485,2005-004501-28, Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients,21-06-2007,NA,US NCT number,protocol
486,2005-004501-28, Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients,21-06-2007,NA,other,protocol
487,2005-004501-28, Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients,21-06-2007,NA,US NCT number,results
488,2005-004501-28, Study to compare the efficacy of ziprasidone (Zeldox) and aripiprazole (Abilify) on cognitive functioning and quality of sleep in the treatment of schizophrenic patients,21-06-2007,NA,ISRCTN number,results
489,2005-004525-26, Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial,08-02-2006,NA,US NCT number,protocol
490,2005-004525-26, Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial,08-02-2006,NA,other,protocol
491,2005-004525-26, Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial,08-02-2006,NA,US NCT number,results
492,2005-004525-26, Cognitive behavioural therapy vs. sertraline in patients with depression and poorly controlled diabetes mellitus: A randomized controlled trial,08-02-2006,NA,ISRCTN number,results
493,2005-004532-43," Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study",04-11-2005,NA,US NCT number,protocol
494,2005-004532-43," Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study",04-11-2005,NA,other,protocol
495,2005-004532-43," Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study",04-11-2005,NA,US NCT number,results
496,2005-004532-43," Treatment of extraesophageal manifestations of laryngopharyngeal reflux with Nexium (esomeprazole) 20mg bid, a doubleblind placebo controlled study",04-11-2005,NA,ISRCTN number,results
497,2005-004540-31," Monozentrische, randomisierte, placebo-kontrollierte Studie zur Evaluation der Nephroprotektion durch Theophyllin unter Cisplatin-haltiger Chemotherapie",18-09-2006,NA,US NCT number,protocol
498,2005-004540-31," Monozentrische, randomisierte, placebo-kontrollierte Studie zur Evaluation der Nephroprotektion durch Theophyllin unter Cisplatin-haltiger Chemotherapie",18-09-2006,NA,other,protocol
499,2005-004540-31," Monozentrische, randomisierte, placebo-kontrollierte Studie zur Evaluation der Nephroprotektion durch Theophyllin unter Cisplatin-haltiger Chemotherapie",18-09-2006,NA,US NCT number,results
500,2005-004540-31," Monozentrische, randomisierte, placebo-kontrollierte Studie zur Evaluation der Nephroprotektion durch Theophyllin unter Cisplatin-haltiger Chemotherapie",18-09-2006,NA,ISRCTN number,results
501,2005-004640-31, Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel),23-12-2005,NA,US NCT number,protocol
502,2005-004640-31, Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel),23-12-2005,NA,other,protocol
503,2005-004640-31, Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel),23-12-2005,NA,US NCT number,results
504,2005-004640-31, Control of therapy of acne papulopustulosa by visible light with waterfiltered infrared and / or Adapalen (Differin Gel),23-12-2005,NA,ISRCTN number,results
505,2005-004677-20," Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stage IIIB/IV)",27-02-2006,NA,US NCT number,protocol
506,2005-004677-20," Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stage IIIB/IV)",27-02-2006,NA,other,protocol
507,2005-004677-20," Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stage IIIB/IV)",27-02-2006,NA,US NCT number,results
508,2005-004677-20," Randomised Phase II/III Study on Sectional Single Agent Gemcitabine and Docetaxel Versus Carboplatine / Gemcitabine Doublet Therapy, both combined Cetuximab in the Treatment of Advanced NSCLC (Stage IIIB/IV)",27-02-2006,NA,ISRCTN number,results
509,2005-004851-37," Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin oral vs. Placebo oral nach Entfieberung zur Fortführung der initial intravenösen Therapie mit Moxifloxacin.",10-12-2007,NA,US NCT number,protocol
510,2005-004851-37," Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin oral vs. Placebo oral nach Entfieberung zur Fortführung der initial intravenösen Therapie mit Moxifloxacin.",10-12-2007,NA,other,protocol
511,2005-004851-37," Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin oral vs. Placebo oral nach Entfieberung zur Fortführung der initial intravenösen Therapie mit Moxifloxacin.",10-12-2007,NA,US NCT number,results
512,2005-004851-37," Doppelblinde, randomisierte, prospektive multizentrische klinische Studie zur Definition der optimalen antibiotischen Therapiedauer bei Patienten mit unkomplizierter akuter Cholangitis: Moxifloxacin oral vs. Placebo oral nach Entfieberung zur Fortführung der initial intravenösen Therapie mit Moxifloxacin.",10-12-2007,NA,ISRCTN number,results
513,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,protocol
514,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,other,protocol
515,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,results
516,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,ISRCTN number,results
517,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,protocol
518,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,other,protocol
519,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,results
520,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,ISRCTN number,results
521,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,protocol
522,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,other,protocol
523,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,results
524,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,ISRCTN number,results
525,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,protocol
526,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,other,protocol
527,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,US NCT number,results
528,2005-004863-41," Clinical investigation into efficacy, hemodynamics and tolerability of simvastatin vs placebo in patients with pulmonary arterial hypertension",25-07-2006,NA,ISRCTN number,results
529,2005-004917-13, Neoadjuvante Radio-Chemotherapie mit 5-FU/Irinotecan und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Rektumkarzinom,06-04-2006,NA,US NCT number,protocol
530,2005-004917-13, Neoadjuvante Radio-Chemotherapie mit 5-FU/Irinotecan und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Rektumkarzinom,06-04-2006,NA,other,protocol
531,2005-004917-13, Neoadjuvante Radio-Chemotherapie mit 5-FU/Irinotecan und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Rektumkarzinom,06-04-2006,NA,US NCT number,results
532,2005-004917-13, Neoadjuvante Radio-Chemotherapie mit 5-FU/Irinotecan und Cetuximab bei Patienten mit lokal fortgeschrittenem oder metastasiertem Rektumkarzinom,06-04-2006,NA,ISRCTN number,results
533,2005-005017-38, Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,21-06-2006,NA,US NCT number,protocol
534,2005-005017-38, Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,21-06-2006,NA,other,protocol
535,2005-005017-38, Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,21-06-2006,NA,US NCT number,results
536,2005-005017-38, Efficacy of cetuximab in combination with docetaxel for the treatment of relapsed head and neck carcinoma: A clinical phase II trial,21-06-2006,NA,ISRCTN number,results
537,2005-005021-60," Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",05-12-2006,NA,US NCT number,protocol
538,2005-005021-60," Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",05-12-2006,NA,other,protocol
539,2005-005021-60," Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",05-12-2006,NA,US NCT number,results
540,2005-005021-60," Monozentrische, randomisierte, einfach verblindete, Placebo kontrollierte Studie im Cross over Design zur Untersuchung der Wirkung von Telmisartan (Kinzalmono 80 mg) auf Blutdruck und Endothelfunktion bei Patienten unter Hämodialysebehandlung.",05-12-2006,NA,ISRCTN number,results
541,2005-005144-62," Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma ",26-10-2010,NA,US NCT number,protocol
542,2005-005144-62," Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma ",26-10-2010,NA,other,protocol
543,2005-005144-62," Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma ",26-10-2010,NCT01449344,US NCT number,results
544,2005-005144-62," Efficacy and safety of Rituximab, high-dose ARA-C and Dexamethasone (R-HAD) alone or in combination with Bortezomib in patients with relapsed or refractory mantle cell lymphoma ",26-10-2010,NA,ISRCTN number,results
545,2005-005154-44, OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC,11-11-2005,NA,US NCT number,protocol
546,2005-005154-44, OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC,11-11-2005,NA,other,protocol
547,2005-005154-44, OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC,11-11-2005,NA,US NCT number,results
548,2005-005154-44, OPERA: OXALIPLATIN AND CETUXIMAB IN FIRST-LINE TREATMENT OF mCRC,11-11-2005,NA,ISRCTN number,results
549,2005-005168-94, Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer,31-01-2006,NA,US NCT number,protocol
550,2005-005168-94, Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer,31-01-2006,NA,other,protocol
551,2005-005168-94, Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer,31-01-2006,NA,US NCT number,results
552,2005-005168-94, Multicenter Phase II- trial to investigate safety and efficacy of an Adjuvant Therapy with Gemcitabine and Erbitux® in patients with R0 or R1 resected Pancreatic cancer,31-01-2006,NA,ISRCTN number,results
553,2005-005216-24," 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to tolerate high-dose chemotherapy",10-10-2006,NA,US NCT number,protocol
554,2005-005216-24," 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to tolerate high-dose chemotherapy",10-10-2006,NA,other,protocol
555,2005-005216-24," 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to tolerate high-dose chemotherapy",10-10-2006,NA,US NCT number,results
556,2005-005216-24," 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to tolerate high-dose chemotherapy",10-10-2006,NA,ISRCTN number,results
557,2005-005313-38, Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias,03-03-2006,NA,US NCT number,protocol
558,2005-005313-38, Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias,03-03-2006,NA,other,protocol
559,2005-005313-38, Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias,03-03-2006,NA,US NCT number,results
560,2005-005313-38, Somatostatin_octretide for prevention of rebleeding from gastrointestinal angiodysplasias,03-03-2006,NA,ISRCTN number,results
561,2005-005347-25," Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV",23-01-2006,NA,US NCT number,protocol
562,2005-005347-25," Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV",23-01-2006,NA,other,protocol
563,2005-005347-25," Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV",23-01-2006,NA,US NCT number,results
564,2005-005347-25," Impact of 12 weeks of oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: A prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV",23-01-2006,NA,ISRCTN number,results
565,2005-005362-36," A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",07-04-2006,NA,US NCT number,protocol
566,2005-005362-36," A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",07-04-2006,NA,other,protocol
567,2005-005362-36," A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",07-04-2006,NA,US NCT number,results
568,2005-005362-36," A PROSPECTIVE RANDOMISED, OPEN-LABELED, TRIAL COMPARING SIROLIMUS-CONTAINING VERSUS mTOR-INHIBITOR-FREE IMMUNOSUPRESSION IN PATIENTS UNDERGOING LIVER TRANSPLANTATION FOR HEPATOCELLULAR CARCINOMA",07-04-2006,NA,ISRCTN number,results
569,2005-005393-73, A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers,14-12-2007,NA,US NCT number,protocol
570,2005-005393-73, A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers,14-12-2007,NA,other,protocol
571,2005-005393-73, A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers,14-12-2007,NA,US NCT number,results
572,2005-005393-73, A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT- PET for Early Prediction of Non-Progression in Patients with Advanced Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and to Associate PET Findings with Molecular Markers,14-12-2007,NA,ISRCTN number,results
573,2005-005434-12," Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis",28-05-2008,NA,US NCT number,protocol
574,2005-005434-12," Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis",28-05-2008,NA,other,protocol
575,2005-005434-12," Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis",28-05-2008,NA,US NCT number,results
576,2005-005434-12," Randomized, multicenter cross-over study investigating the effect of bicarbonate-based solutions (Physioneal 35 vs. 40) on protein metabolism in children and adolescents on chronic peritoneal dialysis",28-05-2008,NA,ISRCTN number,results
577,2005-005471-15, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts chronic allograft nephropathy ,01-09-2006,NA,US NCT number,protocol
578,2005-005471-15, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts chronic allograft nephropathy ,01-09-2006,NA,other,protocol
579,2005-005471-15, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts chronic allograft nephropathy ,01-09-2006,NA,US NCT number,results
580,2005-005471-15, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts chronic allograft nephropathy ,01-09-2006,NA,ISRCTN number,results
581,2005-005473-29," Randomisierte Phase III-Studie zur Primärtherapie von fortgeschrittenen follikulären Lymphomen bei älteren Patienten (>65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autologer peripherer Blutstammzelltransplantation qualifizieren, durch eine Induktion mit Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung (Arbeitstitel: Primärtherapie fortgeschrittener FL mit einer Induktion durch Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung)",26-09-2006,NA,US NCT number,protocol
582,2005-005473-29," Randomisierte Phase III-Studie zur Primärtherapie von fortgeschrittenen follikulären Lymphomen bei älteren Patienten (>65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autologer peripherer Blutstammzelltransplantation qualifizieren, durch eine Induktion mit Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung (Arbeitstitel: Primärtherapie fortgeschrittener FL mit einer Induktion durch Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung)",26-09-2006,NA,other,protocol
583,2005-005473-29," Randomisierte Phase III-Studie zur Primärtherapie von fortgeschrittenen follikulären Lymphomen bei älteren Patienten (>65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autologer peripherer Blutstammzelltransplantation qualifizieren, durch eine Induktion mit Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung (Arbeitstitel: Primärtherapie fortgeschrittener FL mit einer Induktion durch Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung)",26-09-2006,NA,US NCT number,results
584,2005-005473-29," Randomisierte Phase III-Studie zur Primärtherapie von fortgeschrittenen follikulären Lymphomen bei älteren Patienten (>65 J.) und jüngeren Patienten, die nicht für eine Hochdosistherapie mit autologer peripherer Blutstammzelltransplantation qualifizieren, durch eine Induktion mit Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung (Arbeitstitel: Primärtherapie fortgeschrittener FL mit einer Induktion durch Immunchemotherapien gefolgt von einer Erhaltungstherapie mit Rituximab versus Beobachtung)",26-09-2006,NA,ISRCTN number,results
585,2005-005563-28, PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan,29-08-2006,NA,US NCT number,protocol
586,2005-005563-28, PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan,29-08-2006,NA,other,protocol
587,2005-005563-28, PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan,29-08-2006,NA,US NCT number,results
588,2005-005563-28, PRevention of Atherosclerosis In High-Risk Patients: Aggressive Risk Modification including NiAspan,29-08-2006,NA,ISRCTN number,results
589,2005-005612-24, PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA ,24-04-2006,NA,US NCT number,protocol
590,2005-005612-24, PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA ,24-04-2006,NA,other,protocol
591,2005-005612-24, PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA ,24-04-2006,NA,US NCT number,results
592,2005-005612-24, PHASE II STUDY OF CETUXIMAB FOR THE TREATMENT OF REFRACTORY OR RELAPSED MULTIPLE MYELOMA ,24-04-2006,NA,ISRCTN number,results
593,2005-005638-10, Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,25-09-2006,NA,US NCT number,protocol
594,2005-005638-10, Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,25-09-2006,NA,other,protocol
595,2005-005638-10, Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,25-09-2006,NA,US NCT number,results
596,2005-005638-10, Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease,25-09-2006,NA,ISRCTN number,results
597,2005-005678-61, Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden,29-12-2005,NA,US NCT number,protocol
598,2005-005678-61, Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden,29-12-2005,NA,other,protocol
599,2005-005678-61, Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden,29-12-2005,NA,US NCT number,results
600,2005-005678-61, Entwicklung einer Untersuchungsmethode zur Bestimmung des NO-Transferfaktors der Lunge Evaluierung der Methode und Normwerterhebung an gesunden Probanden,29-12-2005,NA,ISRCTN number,results
601,2005-005709-50, Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells  in patients with chronic ischemic heart disease,09-01-2006,NA,US NCT number,protocol
602,2005-005709-50, Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells  in patients with chronic ischemic heart disease,09-01-2006,NA,other,protocol
603,2005-005709-50, Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells  in patients with chronic ischemic heart disease,09-01-2006,NA,US NCT number,results
604,2005-005709-50, Extracorporal shock wave therapy for induction of therapeutic neovascularization and homing of bone marrow progenitor cells  in patients with chronic ischemic heart disease,09-01-2006,NA,ISRCTN number,results
605,2005-005719-83, Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study,15-08-2006,NA,US NCT number,protocol
606,2005-005719-83, Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study,15-08-2006,NA,other,protocol
607,2005-005719-83, Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study,15-08-2006,NA,US NCT number,results
608,2005-005719-83, Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study,15-08-2006,NA,ISRCTN number,results
609,2005-005839-10, Efficacy and safety of quetiapine in treating affective symptoms of patients with first-episode psychosis - a pilot study,23-08-2006,NA,US NCT number,protocol
610,2005-005839-10, Efficacy and safety of quetiapine in treating affective symptoms of patients with first-episode psychosis - a pilot study,23-08-2006,NA,other,protocol
611,2005-005839-10, Efficacy and safety of quetiapine in treating affective symptoms of patients with first-episode psychosis - a pilot study,23-08-2006,NA,US NCT number,results
612,2005-005839-10, Efficacy and safety of quetiapine in treating affective symptoms of patients with first-episode psychosis - a pilot study,23-08-2006,NA,ISRCTN number,results
613,2005-005862-36, Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer,17-08-2007,NA,US NCT number,protocol
614,2005-005862-36, Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer,17-08-2007,NA,other,protocol
615,2005-005862-36, Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer,17-08-2007,NA,US NCT number,results
616,2005-005862-36, Prospectively Randomized Phase I/II Trial of Liposomal-encapsulated Doxorubicin and Cisplatin +/- Locoregional Hyperthermia in patients with Metastatic Breast Cancer,17-08-2007,NA,ISRCTN number,results
617,2005-005930-11," Einfach maskierte, randomisierte , cross over Studie zur Bestimmung der Wirkung von COSOPT® (Dorzolamid/ Timolol, MSD) auf die Perfusion und Sauerstoffsättigung der retinalen Gefäße bei Glaukompatienten im Vergleich zu dem Sympatholytikum Timolol (Timolol®-CV 0,5 %, Novartis Pharma)",22-06-2006,NA,US NCT number,protocol
618,2005-005930-11," Einfach maskierte, randomisierte , cross over Studie zur Bestimmung der Wirkung von COSOPT® (Dorzolamid/ Timolol, MSD) auf die Perfusion und Sauerstoffsättigung der retinalen Gefäße bei Glaukompatienten im Vergleich zu dem Sympatholytikum Timolol (Timolol®-CV 0,5 %, Novartis Pharma)",22-06-2006,NA,other,protocol
619,2005-005930-11," Einfach maskierte, randomisierte , cross over Studie zur Bestimmung der Wirkung von COSOPT® (Dorzolamid/ Timolol, MSD) auf die Perfusion und Sauerstoffsättigung der retinalen Gefäße bei Glaukompatienten im Vergleich zu dem Sympatholytikum Timolol (Timolol®-CV 0,5 %, Novartis Pharma)",22-06-2006,NA,US NCT number,results
620,2005-005930-11," Einfach maskierte, randomisierte , cross over Studie zur Bestimmung der Wirkung von COSOPT® (Dorzolamid/ Timolol, MSD) auf die Perfusion und Sauerstoffsättigung der retinalen Gefäße bei Glaukompatienten im Vergleich zu dem Sympatholytikum Timolol (Timolol®-CV 0,5 %, Novartis Pharma)",22-06-2006,NA,ISRCTN number,results
621,2005-005966-35," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",08-02-2006,NA,US NCT number,protocol
622,2005-005966-35," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",08-02-2006,NA,other,protocol
623,2005-005966-35," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",08-02-2006,NA,US NCT number,results
624,2005-005966-35," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML",08-02-2006,NA,ISRCTN number,results
625,2005-005987-94, Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,25-04-2006,NA,US NCT number,protocol
626,2005-005987-94, Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,25-04-2006,NA,other,protocol
627,2005-005987-94, Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,25-04-2006,NA,US NCT number,results
628,2005-005987-94, Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B,25-04-2006,NA,ISRCTN number,results
629,2005-006024-11," Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma",14-07-2006,NA,US NCT number,protocol
630,2005-006024-11," Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma",14-07-2006,NA,other,protocol
631,2005-006024-11," Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma",14-07-2006,NA,US NCT number,results
632,2005-006024-11," Prospective, open label, multi center phase II clinical trial of oral BAY 43-9006 (Sorafenib) in patients with relapsed or refractory multiple myeloma",14-07-2006,NA,ISRCTN number,results
633,2005-006037-33, Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.,01-09-2006,NA,US NCT number,protocol
634,2005-006037-33, Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.,01-09-2006,NA,other,protocol
635,2005-006037-33, Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.,01-09-2006,NA,US NCT number,results
636,2005-006037-33, Überwachung einer Therapie mit Bromocriptin bei Patienten mit klinisch relevanter Risperidon-induzierter Hyperprolaktinämie. Eine psychiatrisch-endokrinologische Ver-laufsbeobachtung.,01-09-2006,NA,ISRCTN number,results
637,2005-006097-10, Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus ,02-03-2006,NA,US NCT number,protocol
638,2005-006097-10, Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus ,02-03-2006,NA,other,protocol
639,2005-006097-10, Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus ,02-03-2006,NA,US NCT number,results
640,2005-006097-10, Pilot study of dose-escalated radiotherapy with PET/CT based treatment planning in combination with induction and concurrent chemotherapy in locally advanced (uT3/T4) squamous cell cancer of the esophagus ,02-03-2006,NA,ISRCTN number,results
641,2005-006098-29," Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin plus Cisplatin und  Plazebo in der Therapie des lokal fortgeschrittenen bzw. metastasierten Urothelkarzinoms",01-09-2006,NA,US NCT number,protocol
642,2005-006098-29," Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin plus Cisplatin und  Plazebo in der Therapie des lokal fortgeschrittenen bzw. metastasierten Urothelkarzinoms",01-09-2006,NA,other,protocol
643,2005-006098-29," Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin plus Cisplatin und  Plazebo in der Therapie des lokal fortgeschrittenen bzw. metastasierten Urothelkarzinoms",01-09-2006,NA,US NCT number,results
644,2005-006098-29," Prospektiv, randomisierte, doppelblinde, multizentrische Phase-II- Studie zum Vergleich der Wirksamkeit einer Chemotherapie mit Gemcitabin plus Cisplatin und Sorafenib (BAY 43-9006) versus Gemcitabin plus Cisplatin und  Plazebo in der Therapie des lokal fortgeschrittenen bzw. metastasierten Urothelkarzinoms",01-09-2006,NA,ISRCTN number,results
645,2005-006113-40, Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regulation der endothelialen Bioverfügbarkeit von NO bei Patienten mit Koronarkrankheit.,30-10-2006,NA,US NCT number,protocol
646,2005-006113-40, Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regulation der endothelialen Bioverfügbarkeit von NO bei Patienten mit Koronarkrankheit.,30-10-2006,NA,other,protocol
647,2005-006113-40, Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regulation der endothelialen Bioverfügbarkeit von NO bei Patienten mit Koronarkrankheit.,30-10-2006,NA,US NCT number,results
648,2005-006113-40, Untersuchung der Modulation der Endothelfunktion durch Enoxaparin bei Patienten mit Koronarkrankheit. Bedeutung der Enoxaparin-vermittelten Dissoziation endothelial gebundener Oxidasen für die Regulation der endothelialen Bioverfügbarkeit von NO bei Patienten mit Koronarkrankheit.,30-10-2006,NA,ISRCTN number,results
649,2005-006133-32," An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",28-06-2006,NA,US NCT number,protocol
650,2005-006133-32," An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",28-06-2006,NA,other,protocol
651,2005-006133-32," An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",28-06-2006,NA,US NCT number,results
652,2005-006133-32," An exploratory phase IV, randomised, double-blind, placebo controlled crossover study to assess and compare the effects of 5 mg vs. 20 mg Desloratadine on the development of experimentally induced urticaria lesions",28-06-2006,NA,ISRCTN number,results
653,2005-006151-20, Quetiapine and the dopaminergic epigenetic control – a pilot study,24-07-2006,NA,US NCT number,protocol
654,2005-006151-20, Quetiapine and the dopaminergic epigenetic control – a pilot study,24-07-2006,NA,other,protocol
655,2005-006151-20, Quetiapine and the dopaminergic epigenetic control – a pilot study,24-07-2006,NA,US NCT number,results
656,2005-006151-20, Quetiapine and the dopaminergic epigenetic control – a pilot study,24-07-2006,NA,ISRCTN number,results
657,2005-006208-21," Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control.",15-08-2006,NA,US NCT number,protocol
658,2005-006208-21," Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control.",15-08-2006,NA,other,protocol
659,2005-006208-21," Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control.",15-08-2006,NA,US NCT number,results
660,2005-006208-21," Clinical Efficacy of Pimecrolimus Cream in Seborrheic Dermatitis. Efficacy of pimecrolimus in normalizing clinical symptoms, explorative study of barrier function, hydration, lipid content and differentiation in seborrheic dermatitis: a randomized, double-blind study in adults with seborrheic dermatitis treated with 1 % pimecrolimus cream versus 2 % ketoconazole cream as control.",15-08-2006,NA,ISRCTN number,results
661,2006-000001-27, Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie,10-05-2007,NA,US NCT number,protocol
662,2006-000001-27, Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie,10-05-2007,NA,other,protocol
663,2006-000001-27, Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie,10-05-2007,NA,US NCT number,results
664,2006-000001-27, Untersuchung der antiinflammatorischen Eigenschaften von Clopidogrel im Vergleich zu Acetylsalicylsäure bei Patienten mit chronischer ischämischer Kardiomyopathie,10-05-2007,NA,ISRCTN number,results
665,2006-000171-15," Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confirmed arteriosclerosis",05-09-2006,NA,US NCT number,protocol
666,2006-000171-15," Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confirmed arteriosclerosis",05-09-2006,NA,other,protocol
667,2006-000171-15," Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confirmed arteriosclerosis",05-09-2006,NA,US NCT number,results
668,2006-000171-15," Randomized, placebo-controlled, double-blinded study evaluating the effects of Pioglitazone on intima-media-thickness (IMT) of the carotid arteries measured by MRI in non-diabetic patients with confirmed arteriosclerosis",05-09-2006,NA,ISRCTN number,results
669,2006-000186-11, Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary heart disease ,05-09-2006,NA,US NCT number,protocol
670,2006-000186-11, Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary heart disease ,05-09-2006,NA,other,protocol
671,2006-000186-11, Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary heart disease ,05-09-2006,NA,US NCT number,results
672,2006-000186-11, Double blind randomized placebo controlled study by virtual histology on the influence of oral pioglitazone for 9 month on the development of coronary plaques in non-diabetic patients with coronary heart disease ,05-09-2006,NA,ISRCTN number,results
673,2006-000208-17," An open-label, non-randomized phase II trial of cetuximab in combination with irinotecan and 5-FU/FA for patients with metastatic gastric cancer",07-03-2006,NA,US NCT number,protocol
674,2006-000208-17," An open-label, non-randomized phase II trial of cetuximab in combination with irinotecan and 5-FU/FA for patients with metastatic gastric cancer",07-03-2006,NA,other,protocol
675,2006-000208-17," An open-label, non-randomized phase II trial of cetuximab in combination with irinotecan and 5-FU/FA for patients with metastatic gastric cancer",07-03-2006,NA,US NCT number,results
676,2006-000208-17," An open-label, non-randomized phase II trial of cetuximab in combination with irinotecan and 5-FU/FA for patients with metastatic gastric cancer",07-03-2006,NA,ISRCTN number,results
677,2006-000222-31, Vergleich einer strukturierten störungsspezifischen Gruppenpsychotherapie plus Placebo oder Methylphenidat versus einer psychiatrischen Beratung plus Placebo oder Methylphenidat ,22-09-2006,NA,US NCT number,protocol
678,2006-000222-31, Vergleich einer strukturierten störungsspezifischen Gruppenpsychotherapie plus Placebo oder Methylphenidat versus einer psychiatrischen Beratung plus Placebo oder Methylphenidat ,22-09-2006,NA,other,protocol
679,2006-000222-31, Vergleich einer strukturierten störungsspezifischen Gruppenpsychotherapie plus Placebo oder Methylphenidat versus einer psychiatrischen Beratung plus Placebo oder Methylphenidat ,22-09-2006,NA,US NCT number,results
680,2006-000222-31, Vergleich einer strukturierten störungsspezifischen Gruppenpsychotherapie plus Placebo oder Methylphenidat versus einer psychiatrischen Beratung plus Placebo oder Methylphenidat ,22-09-2006,NA,ISRCTN number,results
681,2006-000282-11, Clinical trial for the research into changes in renal function of adolescent and adult patients with Glycogen storage disease type Ia.,28-02-2006,NA,US NCT number,protocol
682,2006-000282-11, Clinical trial for the research into changes in renal function of adolescent and adult patients with Glycogen storage disease type Ia.,28-02-2006,NA,other,protocol
683,2006-000282-11, Clinical trial for the research into changes in renal function of adolescent and adult patients with Glycogen storage disease type Ia.,28-02-2006,NA,US NCT number,results
684,2006-000282-11, Clinical trial for the research into changes in renal function of adolescent and adult patients with Glycogen storage disease type Ia.,28-02-2006,NA,ISRCTN number,results
685,2006-000284-28, Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion,08-03-2006,NA,US NCT number,protocol
686,2006-000284-28, Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion,08-03-2006,NA,other,protocol
687,2006-000284-28, Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion,08-03-2006,NA,US NCT number,results
688,2006-000284-28, Einfluss einer Behandlung mit dem HMG-CoA Reduktasehemmer Fluvastatin auf die Erektionsfähigkeit bei Patienten mit kardiovaskulären Risikofaktoren und erektiler Dysfunktion,08-03-2006,NA,ISRCTN number,results
689,2006-000358-38, Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the initial concentration and the initial decline of the HCV RNA,23-03-2006,NA,US NCT number,protocol
690,2006-000358-38, Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the initial concentration and the initial decline of the HCV RNA,23-03-2006,NA,other,protocol
691,2006-000358-38, Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the initial concentration and the initial decline of the HCV RNA,23-03-2006,NA,US NCT number,results
692,2006-000358-38, Individually adapted therapy duration from 24 to 72 weeks for the treatment of patients with a chronic hepatitis C genotype 1 infection with Peginterferon alfa-2b plus Ribavirin in dependence of the initial concentration and the initial decline of the HCV RNA,23-03-2006,NA,ISRCTN number,results
693,2006-000368-10, High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.,07-03-2006,NA,US NCT number,protocol
694,2006-000368-10, High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.,07-03-2006,NA,other,protocol
695,2006-000368-10, High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.,07-03-2006,NA,US NCT number,results
696,2006-000368-10, High-dose therapy with Esomeprazol in combination with Baclofen therapy for symptomatic therapy-resistant gastrooesophageal reflux disease.,07-03-2006,NA,ISRCTN number,results
697,2006-000369-12," An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response to cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",06-03-2006,NA,US NCT number,protocol
698,2006-000369-12," An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response to cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",06-03-2006,NA,other,protocol
699,2006-000369-12," An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response to cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",06-03-2006,NA,US NCT number,results
700,2006-000369-12," An open, randomized, single-center study assessing the serum time-concentration curves and the effect of prophylactic moxifloxacin (in comparison with cefuroxime) on the early inflammatory response to cardiopulmonary bypass in patients undergoing coronary artery bypass grafting",06-03-2006,NA,ISRCTN number,results
701,2006-000393-76, Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical  related and non-related donators in pediatric patients with and without malignant systemic diseases. ,21-04-2006,NA,US NCT number,protocol
702,2006-000393-76, Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical  related and non-related donators in pediatric patients with and without malignant systemic diseases. ,21-04-2006,NA,other,protocol
703,2006-000393-76, Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical  related and non-related donators in pediatric patients with and without malignant systemic diseases. ,21-04-2006,NA,US NCT number,results
704,2006-000393-76, Allogenic stem cell transplantation with CD3/CD19 depleted stem cells from haploidentical  related and non-related donators in pediatric patients with and without malignant systemic diseases. ,21-04-2006,NA,ISRCTN number,results
705,2006-000475-16," Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients",10-05-2007,NA,US NCT number,protocol
706,2006-000475-16," Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients",10-05-2007,NA,other,protocol
707,2006-000475-16," Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients",10-05-2007,NA,US NCT number,results
708,2006-000475-16," Prospective, randomized, open, crossover, patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients",10-05-2007,NA,ISRCTN number,results
709,2006-000476-33," An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer",23-08-2006,NA,US NCT number,protocol
710,2006-000476-33," An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer",23-08-2006,NA,other,protocol
711,2006-000476-33," An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer",23-08-2006,NA,US NCT number,results
712,2006-000476-33," An open-label, multicenter phase II trial of Sunitinib for patients with chemo-refractory metastatic gastric cancer",23-08-2006,NA,ISRCTN number,results
713,2006-000501-37," Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseitenvergleich ",04-08-2006,NA,US NCT number,protocol
714,2006-000501-37," Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseitenvergleich ",04-08-2006,NA,other,protocol
715,2006-000501-37," Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseitenvergleich ",04-08-2006,NA,US NCT number,results
716,2006-000501-37," Monozentrische, offene Therapiestudie zur Behandlung von Psoriasis-Patienten ab vollendetem 18. Lebensjahr mit Fumaderm® in Kombination mit einer UVB-Therapie (311 nm) im intraindividuellen Halbseitenvergleich ",04-08-2006,NA,ISRCTN number,results
717,2006-000504-17, Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 μg/l ,11-04-2006,NA,US NCT number,protocol
718,2006-000504-17, Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 μg/l ,11-04-2006,NA,other,protocol
719,2006-000504-17, Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 μg/l ,11-04-2006,NA,US NCT number,results
720,2006-000504-17, Konsekutive Aderlass- und Peginterferon alfa-2a -Ribavirin-Standardtherapie im Vergleich zu einer Peginterferon alfa-2a-Ribavirin-Standardtherapie bei naiven Patienten mit HCV Genotyp 1 und Ferritin > 200 μg/l ,11-04-2006,NA,ISRCTN number,results
721,2006-000511-26, Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease,28-08-2006,NA,US NCT number,protocol
722,2006-000511-26, Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease,28-08-2006,NA,other,protocol
723,2006-000511-26, Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease,28-08-2006,NA,US NCT number,results
724,2006-000511-26, Change of the inspiratory peak flow after bronchial dilatation on patients with median to severe chronic obstruktiv lung disease,28-08-2006,NA,ISRCTN number,results
725,2006-000673-30, Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini,26-02-2007,NA,US NCT number,protocol
726,2006-000673-30, Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini,26-02-2007,NA,other,protocol
727,2006-000673-30, Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini,26-02-2007,NA,US NCT number,results
728,2006-000673-30, Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini,26-02-2007,NA,ISRCTN number,results
729,2006-000754-40, Interaktion von Statinen mit Clopidogrel als Sekundärprophylaxe bei der akuten zerebralen Ischämie - CLOPISTAT,12-07-2006,NA,US NCT number,protocol
730,2006-000754-40, Interaktion von Statinen mit Clopidogrel als Sekundärprophylaxe bei der akuten zerebralen Ischämie - CLOPISTAT,12-07-2006,NA,other,protocol
731,2006-000754-40, Interaktion von Statinen mit Clopidogrel als Sekundärprophylaxe bei der akuten zerebralen Ischämie - CLOPISTAT,12-07-2006,NA,US NCT number,results
732,2006-000754-40, Interaktion von Statinen mit Clopidogrel als Sekundärprophylaxe bei der akuten zerebralen Ischämie - CLOPISTAT,12-07-2006,NA,ISRCTN number,results
733,2006-000799-33, A Study of the efficacy and safety of Rizatriptan 10 mg  PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment,03-07-2006,NA,US NCT number,protocol
734,2006-000799-33, A Study of the efficacy and safety of Rizatriptan 10 mg  PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment,03-07-2006,NA,other,protocol
735,2006-000799-33, A Study of the efficacy and safety of Rizatriptan 10 mg  PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment,03-07-2006,NA,US NCT number,results
736,2006-000799-33, A Study of the efficacy and safety of Rizatriptan 10 mg  PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment,03-07-2006,NA,ISRCTN number,results
737,2006-000811-12, A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies,07-01-2007,NCT00450203,US NCT number,protocol
738,2006-000811-12, A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies,07-01-2007,NA,other,protocol
739,2006-000811-12, A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies,07-01-2007,NCT00450203,US NCT number,results
740,2006-000811-12, A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinoma and (in selected centres) MRI and FDG-PET/CT Sub-studies,07-01-2007,ISRCTN46020948,ISRCTN number,results
741,2006-000815-24, A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses,16-05-2006,NA,US NCT number,protocol
742,2006-000815-24, A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses,16-05-2006,NA,other,protocol
743,2006-000815-24, A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses,16-05-2006,NA,US NCT number,results
744,2006-000815-24, A randomized study of topical 3% Diclofenac in a 2.5% Hyaluronate base (Solaraze® 3% Gel) versus topical 5% 5-Fluorouracil (Efudix® Cream) versus liquid nitrogen spray cryotherapy in immunosufficient patients with actinic keratoses,16-05-2006,NA,ISRCTN number,results
745,2006-000821-74," A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem cell transplantation ",04-10-2006,NA,US NCT number,protocol
746,2006-000821-74," A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem cell transplantation ",04-10-2006,NA,other,protocol
747,2006-000821-74," A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem cell transplantation ",04-10-2006,NA,US NCT number,results
748,2006-000821-74," A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem cell transplantation ",04-10-2006,NA,ISRCTN number,results
749,2006-000995-33, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,05-09-2006,NCT00433459,US NCT number,protocol
750,2006-000995-33, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,05-09-2006,NA,other,protocol
751,2006-000995-33, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,05-09-2006,NA,US NCT number,results
752,2006-000995-33, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,05-09-2006,NA,ISRCTN number,results
753,2006-001040-31," Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA""",14-07-2006,NA,US NCT number,protocol
754,2006-001040-31," Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA""",14-07-2006,NA,other,protocol
755,2006-001040-31," Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA""",14-07-2006,NA,US NCT number,results
756,2006-001040-31," Treatment of the haematological relapse in patients suffering from acute myeloid leukaemia or myelodysplastic syndrome with 5-Azacytidin (Vidaza®) after hematopoietic stem cell transplantation ""RELAZA""",14-07-2006,NA,ISRCTN number,results
757,2006-001075-37, A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.,23-04-2007,NA,US NCT number,protocol
758,2006-001075-37, A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.,23-04-2007,NA,other,protocol
759,2006-001075-37, A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.,23-04-2007,NA,US NCT number,results
760,2006-001075-37, A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplantation in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia.,23-04-2007,NA,ISRCTN number,results
761,2006-001079-39," Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. ",16-03-2006,NA,US NCT number,protocol
762,2006-001079-39," Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. ",16-03-2006,NA,other,protocol
763,2006-001079-39," Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. ",16-03-2006,NA,US NCT number,results
764,2006-001079-39," Interozeptive Aufmerksamkeit, Hitze-Schwelle und körperliche Symptome bei Patienten mit einer depressiven Episode, vor und nach Behandlung mit Duloxetin. ",16-03-2006,NA,ISRCTN number,results
765,2006-001097-24, Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,22-05-2006,NA,US NCT number,protocol
766,2006-001097-24, Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,22-05-2006,NA,other,protocol
767,2006-001097-24, Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,22-05-2006,NCT00425425,US NCT number,results
768,2006-001097-24, Phase I/II study of continous infusion with 5-FU and weekly Oxaliplatin / Cetuximab combined with concurrent radiation as neoadjuvant treatment in locally advanced oesophageal squamous cell carcinoma.,22-05-2006,NA,ISRCTN number,results
769,2006-001108-35," CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY",10-04-2006,NA,US NCT number,protocol
770,2006-001108-35," CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY",10-04-2006,NA,other,protocol
771,2006-001108-35," CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY",10-04-2006,NA,US NCT number,results
772,2006-001108-35," CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY",10-04-2006,NA,ISRCTN number,results
773,2006-001146-13," ""Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit""",31-03-2006,NA,US NCT number,protocol
774,2006-001146-13," ""Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit""",31-03-2006,NA,other,protocol
775,2006-001146-13," ""Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit""",31-03-2006,NA,US NCT number,results
776,2006-001146-13," ""Investigation of Caspofungin Plasma Concentration and Pharmacokinetic for the Improvement of the Antifungal Therapy in Patients of Surgical Intensive Care Unit""",31-03-2006,NA,ISRCTN number,results
777,2006-001212-72, Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherapy-Trial/ MIR),09-05-2007,NA,US NCT number,protocol
778,2006-001212-72, Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherapy-Trial/ MIR),09-05-2007,NA,other,protocol
779,2006-001212-72, Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherapy-Trial/ MIR),09-05-2007,NA,US NCT number,results
780,2006-001212-72, Therapie des nodalen Follikulären Non-Hodgkin-Lymphoms (WHO Grad I/II) im klinischen Stadium I / II mittels involved-field Bestrahlung in Kombination mit Rituximab (Mabthera Involved-field Radiotherapy-Trial/ MIR),09-05-2007,NA,ISRCTN number,results
781,2006-001269-40, Induction of Tolerance with Immunoablation and ,11-03-2008,NA,US NCT number,protocol
782,2006-001269-40, Induction of Tolerance with Immunoablation and ,11-03-2008,NA,other,protocol
783,2006-001269-40, Induction of Tolerance with Immunoablation and ,11-03-2008,NA,US NCT number,results
784,2006-001269-40, Induction of Tolerance with Immunoablation and ,11-03-2008,NA,ISRCTN number,results
785,2006-001353-96, Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit entweder kombiniert verhaltenstherapeutisch-medikamentöser Behandlung (Methylphenidat) oder unspezifisch-beratender Kontrollbehandlung,28-08-2006,NA,US NCT number,protocol
786,2006-001353-96, Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit entweder kombiniert verhaltenstherapeutisch-medikamentöser Behandlung (Methylphenidat) oder unspezifisch-beratender Kontrollbehandlung,28-08-2006,NA,other,protocol
787,2006-001353-96, Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit entweder kombiniert verhaltenstherapeutisch-medikamentöser Behandlung (Methylphenidat) oder unspezifisch-beratender Kontrollbehandlung,28-08-2006,NA,US NCT number,results
788,2006-001353-96, Wirksamkeit eines Elterntrainings zur Behandlung der Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) bei Kindern in Abhängigkeit von der Behandlung ihrer ebenfalls betroffenen Mütter mit entweder kombiniert verhaltenstherapeutisch-medikamentöser Behandlung (Methylphenidat) oder unspezifisch-beratender Kontrollbehandlung,28-08-2006,NA,ISRCTN number,results
789,2006-001375-38, Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV,10-07-2006,NA,US NCT number,protocol
790,2006-001375-38, Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV,10-07-2006,NA,other,protocol
791,2006-001375-38, Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV,10-07-2006,NA,US NCT number,results
792,2006-001375-38, Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV,10-07-2006,NA,ISRCTN number,results
793,2006-001407-11, A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention of transplant nephropathy in pediatric renal allografts recipients.,16-05-2006,NA,US NCT number,protocol
794,2006-001407-11, A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention of transplant nephropathy in pediatric renal allografts recipients.,16-05-2006,NA,other,protocol
795,2006-001407-11, A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention of transplant nephropathy in pediatric renal allografts recipients.,16-05-2006,NA,US NCT number,results
796,2006-001407-11, A single center study investigating ciclosporine A microemulsion in combination with basiliximab and prednisolon and switch to low-dose ciclosporine A and everolimus without steroids in the prevention of transplant nephropathy in pediatric renal allografts recipients.,16-05-2006,NA,ISRCTN number,results
797,2006-001528-38, Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive ,17-10-2006,NA,US NCT number,protocol
798,2006-001528-38, Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive ,17-10-2006,NA,other,protocol
799,2006-001528-38, Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive ,17-10-2006,NA,US NCT number,results
800,2006-001528-38, Prevention of skin cancer in high risk patients after conversion a to Sirolimus-based immunosuppressive ,17-10-2006,NA,ISRCTN number,results
801,2006-001641-33, Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome,25-04-2007,NA,US NCT number,protocol
802,2006-001641-33, Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome,25-04-2007,NA,other,protocol
803,2006-001641-33, Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome,25-04-2007,NCT00554164,US NCT number,results
804,2006-001641-33, Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome,25-04-2007,NA,ISRCTN number,results
805,2006-001732-53," Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie",13-06-2006,NA,US NCT number,protocol
806,2006-001732-53," Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie",13-06-2006,NA,other,protocol
807,2006-001732-53," Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie",13-06-2006,NA,US NCT number,results
808,2006-001732-53," Eine multizentrische, randomisierte, kontrollierte Studie zur Untersuchung von Adalimumab bei der Behandlung verschiedener Formen von refraktärer Uveitis im Vergleich zur Standardtherapie",13-06-2006,NA,ISRCTN number,results
809,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,protocol
810,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,other,protocol
811,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,results
812,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,ISRCTN number,results
813,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,protocol
814,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,other,protocol
815,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,results
816,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,ISRCTN number,results
817,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,protocol
818,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,other,protocol
819,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,results
820,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,ISRCTN number,results
821,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,protocol
822,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,other,protocol
823,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,US NCT number,results
824,2006-001791-20," A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome",02-01-2008,NA,ISRCTN number,results
825,2006-001935-23, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy ,24-10-2006,NA,US NCT number,protocol
826,2006-001935-23, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy ,24-10-2006,NA,other,protocol
827,2006-001935-23, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy ,24-10-2006,NA,US NCT number,results
828,2006-001935-23, Real-time contrast-enhanced sonography of renal transplant recipients accurately predicts vascular allograft nephropathy ,24-10-2006,NA,ISRCTN number,results
829,2006-001936-30, A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,24-10-2006,NA,US NCT number,protocol
830,2006-001936-30, A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,24-10-2006,NA,other,protocol
831,2006-001936-30, A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,24-10-2006,NA,US NCT number,results
832,2006-001936-30, A phase II dose escalation study of caspofungin in patients with invasive aspergillosis,24-10-2006,NA,ISRCTN number,results
833,2006-001984-53, Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,19-01-2007,NA,US NCT number,protocol
834,2006-001984-53, Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,19-01-2007,NA,other,protocol
835,2006-001984-53, Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,19-01-2007,NA,US NCT number,results
836,2006-001984-53, Effectiveness of Dalteparin Therapy as Intervention in recurrent pregnancy loss,19-01-2007,NA,ISRCTN number,results
837,2006-002006-60, Functional neuroanatomy and regional metabolism in depressed patients with quetiapin: An fMRI-guided MRS study on a 7 Tesla scanner,07-06-2006,NA,US NCT number,protocol
838,2006-002006-60, Functional neuroanatomy and regional metabolism in depressed patients with quetiapin: An fMRI-guided MRS study on a 7 Tesla scanner,07-06-2006,NA,other,protocol
839,2006-002006-60, Functional neuroanatomy and regional metabolism in depressed patients with quetiapin: An fMRI-guided MRS study on a 7 Tesla scanner,07-06-2006,NA,US NCT number,results
840,2006-002006-60, Functional neuroanatomy and regional metabolism in depressed patients with quetiapin: An fMRI-guided MRS study on a 7 Tesla scanner,07-06-2006,NA,ISRCTN number,results
841,2006-002056-14, Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie),13-06-2006,NA,US NCT number,protocol
842,2006-002056-14, Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie),13-06-2006,NA,other,protocol
843,2006-002056-14, Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie),13-06-2006,NA,US NCT number,results
844,2006-002056-14, Akute Cholezystitis – Frühe laparoskopische Operation versus antibiotischer Therapie mit elektiver Cholezystektomie im Intervall (ACDC-Studie),13-06-2006,NA,ISRCTN number,results
845,2006-002085-19," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER TRIAL OF ABCIXIMAB AND BIVALIRUDIN IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS",15-05-2006,NA,US NCT number,protocol
846,2006-002085-19," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER TRIAL OF ABCIXIMAB AND BIVALIRUDIN IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS",15-05-2006,NA,other,protocol
847,2006-002085-19," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER TRIAL OF ABCIXIMAB AND BIVALIRUDIN IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS",15-05-2006,NA,US NCT number,results
848,2006-002085-19," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED, MULTICENTER TRIAL OF ABCIXIMAB AND BIVALIRUDIN IN PATIENTS WITH NON-ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS",15-05-2006,NA,ISRCTN number,results
849,2006-002207-13," Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial ",17-05-2006,NA,US NCT number,protocol
850,2006-002207-13," Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial ",17-05-2006,NA,other,protocol
851,2006-002207-13," Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial ",17-05-2006,NA,US NCT number,results
852,2006-002207-13," Ziprasidone for severe conduct and other disruptive behavior disorders in children and adolescents – a placebo controlled, randomized, double blind clinical trial ",17-05-2006,NA,ISRCTN number,results
853,2006-002290-52, Telmisartan und systemische Inflammationsparameter bei Patienten mit arterieller Hypertonie und asymtomatischer Koronarer Herzkrankheit,17-09-2007,NA,US NCT number,protocol
854,2006-002290-52, Telmisartan und systemische Inflammationsparameter bei Patienten mit arterieller Hypertonie und asymtomatischer Koronarer Herzkrankheit,17-09-2007,NA,other,protocol
855,2006-002290-52, Telmisartan und systemische Inflammationsparameter bei Patienten mit arterieller Hypertonie und asymtomatischer Koronarer Herzkrankheit,17-09-2007,NA,US NCT number,results
856,2006-002290-52, Telmisartan und systemische Inflammationsparameter bei Patienten mit arterieller Hypertonie und asymtomatischer Koronarer Herzkrankheit,17-09-2007,NA,ISRCTN number,results
857,2006-002306-64, Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,04-10-2006,NA,US NCT number,protocol
858,2006-002306-64, Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,04-10-2006,NA,other,protocol
859,2006-002306-64, Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,04-10-2006,NA,US NCT number,results
860,2006-002306-64, Open label clinical trial with Rituximab (MabThera ®) in Ankylosing Spondylitis - Extension of open label trial: Re-Treatment of patients who have shown response to first course of Rituximab,04-10-2006,NA,ISRCTN number,results
861,2006-002338-39, Pharmakokinetik von Linezolid bei Dialyse,17-08-2006,NA,US NCT number,protocol
862,2006-002338-39, Pharmakokinetik von Linezolid bei Dialyse,17-08-2006,NA,other,protocol
863,2006-002338-39, Pharmakokinetik von Linezolid bei Dialyse,17-08-2006,NA,US NCT number,results
864,2006-002338-39, Pharmakokinetik von Linezolid bei Dialyse,17-08-2006,NA,ISRCTN number,results
865,2006-002346-11, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study),26-09-2006,NA,US NCT number,protocol
866,2006-002346-11, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study),26-09-2006,NA,other,protocol
867,2006-002346-11, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study),26-09-2006,NA,US NCT number,results
868,2006-002346-11, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an omeprazole therapy in patients with GERD -- a pilot study (phase IV-study),26-09-2006,NA,ISRCTN number,results
869,2006-002385-20, Prospective randomised multicenter phase-III-study:,29-05-2006,NA,US NCT number,protocol
870,2006-002385-20, Prospective randomised multicenter phase-III-study:,29-05-2006,NA,other,protocol
871,2006-002385-20, Prospective randomised multicenter phase-III-study:,29-05-2006,NA,US NCT number,results
872,2006-002385-20, Prospective randomised multicenter phase-III-study:,29-05-2006,NA,ISRCTN number,results
873,2006-002546-11, Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid,31-01-2007,NA,US NCT number,protocol
874,2006-002546-11, Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid,31-01-2007,NA,other,protocol
875,2006-002546-11, Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid,31-01-2007,NA,US NCT number,results
876,2006-002546-11, Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid,31-01-2007,NA,ISRCTN number,results
877,2006-002605-31, ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE,30-11-2006,NA,US NCT number,protocol
878,2006-002605-31, ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE,30-11-2006,NA,other,protocol
879,2006-002605-31, ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE,30-11-2006,NA,US NCT number,results
880,2006-002605-31, ALDOSTERONE RECEPTOR BLOCKADE IN DIASTOLIC HEART FAILURE,30-11-2006,NA,ISRCTN number,results
881,2006-002639-26," Treatment of Helicobacter pylori infection with high dose esomeprazole, amoxicillin and metronidazole in pediatric patients infected with double resistant Helicobacter pylori strains",25-01-2007,NA,US NCT number,protocol
882,2006-002639-26," Treatment of Helicobacter pylori infection with high dose esomeprazole, amoxicillin and metronidazole in pediatric patients infected with double resistant Helicobacter pylori strains",25-01-2007,NA,other,protocol
883,2006-002639-26," Treatment of Helicobacter pylori infection with high dose esomeprazole, amoxicillin and metronidazole in pediatric patients infected with double resistant Helicobacter pylori strains",25-01-2007,NA,US NCT number,results
884,2006-002639-26," Treatment of Helicobacter pylori infection with high dose esomeprazole, amoxicillin and metronidazole in pediatric patients infected with double resistant Helicobacter pylori strains",25-01-2007,NA,ISRCTN number,results
885,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,protocol
886,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,other,protocol
887,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,results
888,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,ISRCTN number,results
889,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,protocol
890,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,other,protocol
891,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,results
892,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,ISRCTN number,results
893,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,protocol
894,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,other,protocol
895,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,results
896,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,ISRCTN number,results
897,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,protocol
898,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,other,protocol
899,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,US NCT number,results
900,2006-002675-41," A non-randomised, multi-center Phase I/II trial of safety, tolerability and efficacy of Everolimus (RAD001) in relapsed or refractory Multiple Myeloma",15-12-2006,NA,ISRCTN number,results
901,2006-002767-41, Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus,29-05-2007,NA,US NCT number,protocol
902,2006-002767-41, Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus,29-05-2007,NA,other,protocol
903,2006-002767-41, Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus,29-05-2007,NA,US NCT number,results
904,2006-002767-41, Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus,29-05-2007,NA,ISRCTN number,results
905,2006-002886-38, A Multicenter Study on Regenerative Effects of Erythropoitin (LDE) in Burn and Scaled Injuries,19-12-2007,NA,US NCT number,protocol
906,2006-002886-38, A Multicenter Study on Regenerative Effects of Erythropoitin (LDE) in Burn and Scaled Injuries,19-12-2007,NA,other,protocol
907,2006-002886-38, A Multicenter Study on Regenerative Effects of Erythropoitin (LDE) in Burn and Scaled Injuries,19-12-2007,NA,US NCT number,results
908,2006-002886-38, A Multicenter Study on Regenerative Effects of Erythropoitin (LDE) in Burn and Scaled Injuries,19-12-2007,ISRCTN95777824,ISRCTN number,results
909,2006-002938-38, EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,07-09-2006,NA,US NCT number,protocol
910,2006-002938-38, EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,07-09-2006,NA,other,protocol
911,2006-002938-38, EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,07-09-2006,NA,US NCT number,results
912,2006-002938-38, EFFECT OF ERYTHROPOIETIN ON RENAL FUNCTION AFTER KIDNEY TRANSPLANTATION,07-09-2006,NA,ISRCTN number,results
913,2006-002962-20, Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention,22-11-2006,NA,US NCT number,protocol
914,2006-002962-20, Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention,22-11-2006,NA,other,protocol
915,2006-002962-20, Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention,22-11-2006,NA,US NCT number,results
916,2006-002962-20, Elimination of the preleukemic clone in children with Down syndrome and transient myeloproloferative disorder (TMD) to prevent AML - Model of leukemia prevention,22-11-2006,NA,ISRCTN number,results
917,2006-003115-49, Einsatz von Mycophenolsäure (Myfortic) bei antikörpervermittelten immunologischen Erkrankungen:  ,27-10-2006,NA,US NCT number,protocol
918,2006-003115-49, Einsatz von Mycophenolsäure (Myfortic) bei antikörpervermittelten immunologischen Erkrankungen:  ,27-10-2006,NA,other,protocol
919,2006-003115-49, Einsatz von Mycophenolsäure (Myfortic) bei antikörpervermittelten immunologischen Erkrankungen:  ,27-10-2006,NA,US NCT number,results
920,2006-003115-49, Einsatz von Mycophenolsäure (Myfortic) bei antikörpervermittelten immunologischen Erkrankungen:  ,27-10-2006,NA,ISRCTN number,results
921,2006-003122-28, Argatroban versus Lepirudin in Critically Ill Patients ,22-08-2008,NA,US NCT number,protocol
922,2006-003122-28, Argatroban versus Lepirudin in Critically Ill Patients ,22-08-2008,NA,other,protocol
923,2006-003122-28, Argatroban versus Lepirudin in Critically Ill Patients ,22-08-2008,NA,US NCT number,results
924,2006-003122-28, Argatroban versus Lepirudin in Critically Ill Patients ,22-08-2008,NA,ISRCTN number,results
925,2006-003146-41, A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,23-11-2006,NA,US NCT number,protocol
926,2006-003146-41, A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,23-11-2006,NA,other,protocol
927,2006-003146-41, A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,23-11-2006,NA,US NCT number,results
928,2006-003146-41, A CONTROLLED RANDOMIZED DOUBLE-BLIND MULTICENTER STUDY COMPARING TWO THERAPY STRATEGIES IN DMARD-NAIVE EARLY RHEUMATOID ARTHRITIS PATIENTS OVER 48 WEEKS: INDUCTION THERAPY WITH ADALIMUMAB AND METHOTREXATE OVER 24 WEEKS FOLLOWED BY METHOTREXATE MONOTHERAPY UP TO WEEK 48 VS. METHOTREXATE MONOTHERAPY,23-11-2006,NA,ISRCTN number,results
929,2006-003451-20, Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct,07-12-2006,NA,US NCT number,protocol
930,2006-003451-20, Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct,07-12-2006,NA,other,protocol
931,2006-003451-20, Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct,07-12-2006,NA,US NCT number,results
932,2006-003451-20, Phase II study to evaluate the efficacy of a chemotherapy combination with Imatinib (Glivec®) and 5-FU/leucovorin in patients with advanced carcinoma of the gallbladder and bile duct,07-12-2006,NA,ISRCTN number,results
933,2006-003470-10, Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,06-03-2007,NA,US NCT number,protocol
934,2006-003470-10, Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,06-03-2007,NA,other,protocol
935,2006-003470-10, Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,06-03-2007,NA,US NCT number,results
936,2006-003470-10, Randomised Phase II study with non-pegylated liposomal Doxorubicin (Myocet) plus Ifosfamid versus Doxorubicin plus Ifosfamid in the first-line treatment of locally advanced or metastatic soft tissue carcinoma.,06-03-2007,NA,ISRCTN number,results
937,2006-003567-31, Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,29-03-2007,NA,US NCT number,protocol
938,2006-003567-31, Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,29-03-2007,NA,other,protocol
939,2006-003567-31, Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,29-03-2007,NA,US NCT number,results
940,2006-003567-31, Regulation of Inflammatory Parameters by Telmisartan in Hypertensive Patients,29-03-2007,NA,ISRCTN number,results
941,2006-003590-27," Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwendung des Cytochrom-P (CYP) Inhibitors Ketokonazol",19-06-2008,NA,US NCT number,protocol
942,2006-003590-27," Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwendung des Cytochrom-P (CYP) Inhibitors Ketokonazol",19-06-2008,NA,other,protocol
943,2006-003590-27," Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwendung des Cytochrom-P (CYP) Inhibitors Ketokonazol",19-06-2008,NA,US NCT number,results
944,2006-003590-27," Untersuchungen zur antipsoriatischen Wirkung der UVB-induzierten Synthese von 1alpha, 25-Dihydroxyvitamin D3 (1alpha, 25(OH)2D3, Calcitriol) in Keratinozyten läsionaler psoriatischer Haut unter Verwendung des Cytochrom-P (CYP) Inhibitors Ketokonazol",19-06-2008,NA,ISRCTN number,results
945,2006-003667-31, Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,23-04-2007,NA,US NCT number,protocol
946,2006-003667-31, Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,23-04-2007,NA,other,protocol
947,2006-003667-31, Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,23-04-2007,NA,US NCT number,results
948,2006-003667-31, Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study,23-04-2007,NA,ISRCTN number,results
949,2006-003686-13," An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",29-03-2007,NA,US NCT number,protocol
950,2006-003686-13," An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",29-03-2007,NA,other,protocol
951,2006-003686-13," An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",29-03-2007,NA,US NCT number,results
952,2006-003686-13," An exploratory phase III, randomised, double blind, therapeutic single dose-related effect, parallel group study to assess and compare the effects of 5mg vs. 20mg Desloratadine on skin lesions in patients with chronic urticaria (CU).",29-03-2007,NA,ISRCTN number,results
953,2006-003816-23, Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,13-10-2006,NA,US NCT number,protocol
954,2006-003816-23, Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,13-10-2006,NA,other,protocol
955,2006-003816-23, Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,13-10-2006,NA,US NCT number,results
956,2006-003816-23, Multicenter phase II study with pemetrexed in patients with pre-treated metastatic soft tissue sarcomas,13-10-2006,NA,ISRCTN number,results
957,2006-003819-45," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.",26-10-2006,NA,US NCT number,protocol
958,2006-003819-45," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.",26-10-2006,NA,other,protocol
959,2006-003819-45," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.",26-10-2006,NA,US NCT number,results
960,2006-003819-45," PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF ERYTHROPOIETIN IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION UNDERGOING PERCUTANEOUS CORONARY INTERVENTION.",26-10-2006,NA,ISRCTN number,results
961,2006-003934-14," „Eine randomisierte, placebokontrollierte Doppelblindstudie zur Evaluation der Effektivität oral verabreichten Doxycyclins bei  Patienten mit Creutzfeldt-Jakob-Krankheit“",11-03-2009,NA,US NCT number,protocol
962,2006-003934-14," „Eine randomisierte, placebokontrollierte Doppelblindstudie zur Evaluation der Effektivität oral verabreichten Doxycyclins bei  Patienten mit Creutzfeldt-Jakob-Krankheit“",11-03-2009,NA,other,protocol
963,2006-003934-14," „Eine randomisierte, placebokontrollierte Doppelblindstudie zur Evaluation der Effektivität oral verabreichten Doxycyclins bei  Patienten mit Creutzfeldt-Jakob-Krankheit“",11-03-2009,NA,US NCT number,results
964,2006-003934-14," „Eine randomisierte, placebokontrollierte Doppelblindstudie zur Evaluation der Effektivität oral verabreichten Doxycyclins bei  Patienten mit Creutzfeldt-Jakob-Krankheit“",11-03-2009,NA,ISRCTN number,results
965,2006-003999-35, Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients ,10-10-2006,NA,US NCT number,protocol
966,2006-003999-35, Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients ,10-10-2006,NA,other,protocol
967,2006-003999-35, Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients ,10-10-2006,NA,US NCT number,results
968,2006-003999-35, Efficacy and safety of levetiracetam in prevention of alcohol relapse in recently detoxified alcohol dependent patients ,10-10-2006,NA,ISRCTN number,results
969,2006-004030-32, Randomisierte Studie ,09-11-2006,NA,US NCT number,protocol
970,2006-004030-32, Randomisierte Studie ,09-11-2006,NA,other,protocol
971,2006-004030-32, Randomisierte Studie ,09-11-2006,NA,US NCT number,results
972,2006-004030-32, Randomisierte Studie ,09-11-2006,NA,ISRCTN number,results
973,2006-004065-34," Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer",02-11-2006,NA,US NCT number,protocol
974,2006-004065-34," Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer",02-11-2006,NA,other,protocol
975,2006-004065-34," Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer",02-11-2006,NA,US NCT number,results
976,2006-004065-34," Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer",02-11-2006,NA,ISRCTN number,results
977,2006-004073-10, Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD,16-08-2006,NA,US NCT number,protocol
978,2006-004073-10, Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD,16-08-2006,NA,other,protocol
979,2006-004073-10, Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD,16-08-2006,NA,US NCT number,results
980,2006-004073-10, Effect of Atomoxetine and a standardized behavior therapy on attention deficits in adult ADHD,16-08-2006,NA,ISRCTN number,results
981,2006-004122-90," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.",14-12-2006,NA,US NCT number,protocol
982,2006-004122-90," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.",14-12-2006,NA,other,protocol
983,2006-004122-90," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.",14-12-2006,NA,US NCT number,results
984,2006-004122-90," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with bacterial cholangitis. A double blind, randomiized study.",14-12-2006,NA,ISRCTN number,results
985,2006-004162-13," Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",06-10-2006,NA,US NCT number,protocol
986,2006-004162-13," Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",06-10-2006,NA,other,protocol
987,2006-004162-13," Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",06-10-2006,NA,US NCT number,results
988,2006-004162-13," Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease",06-10-2006,NA,ISRCTN number,results
989,2006-004224-37, Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie,15-11-2006,NA,US NCT number,protocol
990,2006-004224-37, Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie,15-11-2006,NA,other,protocol
991,2006-004224-37, Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie,15-11-2006,NA,US NCT number,results
992,2006-004224-37, Everolimus in der Therapie von Patienten mit pulmonaler Hypertonie,15-11-2006,NA,ISRCTN number,results
993,2006-004290-97," A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",17-10-2006,NA,US NCT number,protocol
994,2006-004290-97," A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",17-10-2006,NA,other,protocol
995,2006-004290-97," A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",17-10-2006,NA,US NCT number,results
996,2006-004290-97," A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS).",17-10-2006,NA,ISRCTN number,results
997,2006-004323-10," Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.",19-01-2007,NA,US NCT number,protocol
998,2006-004323-10," Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.",19-01-2007,NA,other,protocol
999,2006-004323-10," Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.",19-01-2007,NA,US NCT number,results
1000,2006-004323-10," Effektivität und Verträglichkeit von Esomeprazol, Moxifloxacin und Amoxicillin in der Reservetherapie der Helicobacter pylori Infektion.",19-01-2007,NA,ISRCTN number,results
1001,2006-004349-41, Supportive Schmerztherapie-Studie - Einfluss von Physostigmin auf die patientenkontrollierte Analgesie (PCA) in der postoperativen Phase bei Intensivpatienten,06-09-2006,NA,US NCT number,protocol
1002,2006-004349-41, Supportive Schmerztherapie-Studie - Einfluss von Physostigmin auf die patientenkontrollierte Analgesie (PCA) in der postoperativen Phase bei Intensivpatienten,06-09-2006,NA,other,protocol
1003,2006-004349-41, Supportive Schmerztherapie-Studie - Einfluss von Physostigmin auf die patientenkontrollierte Analgesie (PCA) in der postoperativen Phase bei Intensivpatienten,06-09-2006,NA,US NCT number,results
1004,2006-004349-41, Supportive Schmerztherapie-Studie - Einfluss von Physostigmin auf die patientenkontrollierte Analgesie (PCA) in der postoperativen Phase bei Intensivpatienten,06-09-2006,NA,ISRCTN number,results
1005,2006-004374-27," Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)",07-09-2006,NA,US NCT number,protocol
1006,2006-004374-27," Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)",07-09-2006,NA,other,protocol
1007,2006-004374-27," Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)",07-09-2006,NA,US NCT number,results
1008,2006-004374-27," Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent)",07-09-2006,NA,ISRCTN number,results
1009,2006-004434-32, Prevention of postoperative delirium with donepezil,20-02-2007,NA,US NCT number,protocol
1010,2006-004434-32, Prevention of postoperative delirium with donepezil,20-02-2007,NA,other,protocol
1011,2006-004434-32, Prevention of postoperative delirium with donepezil,20-02-2007,NA,US NCT number,results
1012,2006-004434-32, Prevention of postoperative delirium with donepezil,20-02-2007,NA,ISRCTN number,results
1013,2006-004467-65, Influence of pioglitazone for renal transplant function in diabetics,26-10-2006,NA,US NCT number,protocol
1014,2006-004467-65, Influence of pioglitazone for renal transplant function in diabetics,26-10-2006,NA,other,protocol
1015,2006-004467-65, Influence of pioglitazone for renal transplant function in diabetics,26-10-2006,NA,US NCT number,results
1016,2006-004467-65, Influence of pioglitazone for renal transplant function in diabetics,26-10-2006,NA,ISRCTN number,results
1017,2006-004504-39, ,24-04-2007,NCT00511446,US NCT number,protocol
1018,2006-004504-39, ,24-04-2007,NA,other,protocol
1019,2006-004504-39, ,24-04-2007,NA,US NCT number,results
1020,2006-004504-39, ,24-04-2007,NA,ISRCTN number,results
1021,2006-004533-15, Effect of 8 weeks oral Pentaerithrityltetranitrate on ,13-08-2007,NA,US NCT number,protocol
1022,2006-004533-15, Effect of 8 weeks oral Pentaerithrityltetranitrate on ,13-08-2007,NA,other,protocol
1023,2006-004533-15, Effect of 8 weeks oral Pentaerithrityltetranitrate on ,13-08-2007,NA,US NCT number,results
1024,2006-004533-15, Effect of 8 weeks oral Pentaerithrityltetranitrate on ,13-08-2007,NA,ISRCTN number,results
1025,2006-004628-34," Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",15-12-2006,NA,US NCT number,protocol
1026,2006-004628-34," Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",15-12-2006,NA,other,protocol
1027,2006-004628-34," Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",15-12-2006,NA,US NCT number,results
1028,2006-004628-34," Topotecan plus Carboplatin im Vergleich zur Standardtherapie (Paclitaxel plus Carboplatin oder Gemcitabin plus Carboplatin oder pegyliertes liposomales Doxorubicin plus Carboplatin) in der Therapie von Patientinnen mit Platin-sensitivem rezidivierten epithelialen Ovarialkarzinom, Peritonealkarzinom oder Tubenkarzinom",15-12-2006,NA,ISRCTN number,results
1029,2006-004644-24," Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib  in patients with primarily advanced  ovarian cancer (FIGO IIIC + IV) and ascites (>500ml)",13-04-2007,NA,US NCT number,protocol
1030,2006-004644-24," Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib  in patients with primarily advanced  ovarian cancer (FIGO IIIC + IV) and ascites (>500ml)",13-04-2007,NA,other,protocol
1031,2006-004644-24," Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib  in patients with primarily advanced  ovarian cancer (FIGO IIIC + IV) and ascites (>500ml)",13-04-2007,NA,US NCT number,results
1032,2006-004644-24," Prospective, open label, multi center phase II clinical trial with neoadjuvant chemotherapy in addition with Sorafenib  in patients with primarily advanced  ovarian cancer (FIGO IIIC + IV) and ascites (>500ml)",13-04-2007,NA,ISRCTN number,results
1033,2006-004667-61, Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study,19-01-2007,NA,US NCT number,protocol
1034,2006-004667-61, Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study,19-01-2007,NA,other,protocol
1035,2006-004667-61, Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study,19-01-2007,NA,US NCT number,results
1036,2006-004667-61, Prospective open-labeled non randomized Phase-II study of SU011248 (Sunitinib) in male patients with relapsed or cisplatin-refractory germ cell cancer - A CUOG/GTCSG cooperative phase II study,19-01-2007,NA,ISRCTN number,results
1037,2006-004698-86, Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie-,25-09-2007,NA,US NCT number,protocol
1038,2006-004698-86, Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie-,25-09-2007,NA,other,protocol
1039,2006-004698-86, Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie-,25-09-2007,NA,US NCT number,results
1040,2006-004698-86, Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie-,25-09-2007,NA,ISRCTN number,results
1041,2006-004860-29, D-Cycloserine supported exposure in panic disorder,07-12-2006,NA,US NCT number,protocol
1042,2006-004860-29, D-Cycloserine supported exposure in panic disorder,07-12-2006,NA,other,protocol
1043,2006-004860-29, D-Cycloserine supported exposure in panic disorder,07-12-2006,NA,US NCT number,results
1044,2006-004860-29, D-Cycloserine supported exposure in panic disorder,07-12-2006,NA,ISRCTN number,results
1045,2006-004891-10, Future strategies for vocational rehabilitation schizophrenia,22-11-2006,NA,US NCT number,protocol
1046,2006-004891-10, Future strategies for vocational rehabilitation schizophrenia,22-11-2006,NA,other,protocol
1047,2006-004891-10, Future strategies for vocational rehabilitation schizophrenia,22-11-2006,NA,US NCT number,results
1048,2006-004891-10, Future strategies for vocational rehabilitation schizophrenia,22-11-2006,NA,ISRCTN number,results
1049,2006-004977-91," Inhalative Sedierung mit Sevofluran im Vergleich zu Propofol bei beatmeten, postoperativen Intensivpatienten – Einfluss auf Extubationszeiten und Aufwachverhalten, Nieren- und Leberfunktion, Hämodynamik und Kardioprotektion sowie Kostenanalyse des Sedierungsregimes",06-10-2006,NA,US NCT number,protocol
1050,2006-004977-91," Inhalative Sedierung mit Sevofluran im Vergleich zu Propofol bei beatmeten, postoperativen Intensivpatienten – Einfluss auf Extubationszeiten und Aufwachverhalten, Nieren- und Leberfunktion, Hämodynamik und Kardioprotektion sowie Kostenanalyse des Sedierungsregimes",06-10-2006,NA,other,protocol
1051,2006-004977-91," Inhalative Sedierung mit Sevofluran im Vergleich zu Propofol bei beatmeten, postoperativen Intensivpatienten – Einfluss auf Extubationszeiten und Aufwachverhalten, Nieren- und Leberfunktion, Hämodynamik und Kardioprotektion sowie Kostenanalyse des Sedierungsregimes",06-10-2006,NA,US NCT number,results
1052,2006-004977-91," Inhalative Sedierung mit Sevofluran im Vergleich zu Propofol bei beatmeten, postoperativen Intensivpatienten – Einfluss auf Extubationszeiten und Aufwachverhalten, Nieren- und Leberfunktion, Hämodynamik und Kardioprotektion sowie Kostenanalyse des Sedierungsregimes",06-10-2006,NA,ISRCTN number,results
1053,2006-005025-31, Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) versus Placebo in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD),11-06-2008,NA,US NCT number,protocol
1054,2006-005025-31, Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) versus Placebo in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD),11-06-2008,NA,other,protocol
1055,2006-005025-31, Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) versus Placebo in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD),11-06-2008,NA,US NCT number,results
1056,2006-005025-31, Efficacy and Safety of St. John´s Wort/Valerian Extract (Sedariston Concentrate) versus Placebo in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD),11-06-2008,NA,ISRCTN number,results
1057,2006-005034-20," Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiierte “Proof-of-Concept“-Studie",22-11-2006,NA,US NCT number,protocol
1058,2006-005034-20," Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiierte “Proof-of-Concept“-Studie",22-11-2006,NA,other,protocol
1059,2006-005034-20," Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiierte “Proof-of-Concept“-Studie",22-11-2006,NA,US NCT number,results
1060,2006-005034-20," Doppelblinde, prospektiv-randomisierte, intraindividuell-halbseitenvergleichende Studie zur klinischen Wirksamkeit von Verrumal® Lsg. bei aktinischen Keratosen gegen Vehikel: Investigator-initiierte “Proof-of-Concept“-Studie",22-11-2006,NA,ISRCTN number,results
1061,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,protocol
1062,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,other,protocol
1063,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,results
1064,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,ISRCTN number,results
1065,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,protocol
1066,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,other,protocol
1067,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,results
1068,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,ISRCTN number,results
1069,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,protocol
1070,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,other,protocol
1071,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,results
1072,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,ISRCTN number,results
1073,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,protocol
1074,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,other,protocol
1075,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,US NCT number,results
1076,2006-005104-14, A pilot study to investigate the safety and efficacy of a combined treatment with Gemcitabine and Sulfasalazine in pancreatic ductal adenocarcinoma,20-06-2007,NA,ISRCTN number,results
1077,2006-005249-13, Influence of the OATP1B1 genotype on  the hepatic uptake of Primovist®  in healthy volunteers and in patients with liver disease   ,25-01-2007,NA,US NCT number,protocol
1078,2006-005249-13, Influence of the OATP1B1 genotype on  the hepatic uptake of Primovist®  in healthy volunteers and in patients with liver disease   ,25-01-2007,NA,other,protocol
1079,2006-005249-13, Influence of the OATP1B1 genotype on  the hepatic uptake of Primovist®  in healthy volunteers and in patients with liver disease   ,25-01-2007,NA,US NCT number,results
1080,2006-005249-13, Influence of the OATP1B1 genotype on  the hepatic uptake of Primovist®  in healthy volunteers and in patients with liver disease   ,25-01-2007,NA,ISRCTN number,results
1081,2006-005262-39, Flupirtin as Oral Treatment in MS,09-03-2007,NA,US NCT number,protocol
1082,2006-005262-39, Flupirtin as Oral Treatment in MS,09-03-2007,NA,other,protocol
1083,2006-005262-39, Flupirtin as Oral Treatment in MS,09-03-2007,NA,US NCT number,results
1084,2006-005262-39, Flupirtin as Oral Treatment in MS,09-03-2007,NA,ISRCTN number,results
1085,2006-005289-37, Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion,16-08-2007,NA,US NCT number,protocol
1086,2006-005289-37, Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion,16-08-2007,NA,other,protocol
1087,2006-005289-37, Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion,16-08-2007,NA,US NCT number,results
1088,2006-005289-37, Anwendung von HELIOX an einem Modell der oberen Atemwegsobstruktion,16-08-2007,NA,ISRCTN number,results
1089,2006-005296-18, Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose,10-04-2007,NA,US NCT number,protocol
1090,2006-005296-18, Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose,10-04-2007,NA,other,protocol
1091,2006-005296-18, Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose,10-04-2007,NA,US NCT number,results
1092,2006-005296-18, Einsatz von Haemateâ HS bei Patienten mit schweren Blutungskomplikationen bei Herzklappenersatz wegen Aortenstenose,10-04-2007,NA,ISRCTN number,results
1093,2006-005308-15, Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection.,20-02-2007,NA,US NCT number,protocol
1094,2006-005308-15, Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection.,20-02-2007,NA,other,protocol
1095,2006-005308-15, Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection.,20-02-2007,NA,US NCT number,results
1096,2006-005308-15, Pilot study of the safety and tolerance of preoperative melatonin application in patients undergoing major liver resection.,20-02-2007,NA,ISRCTN number,results
1097,2006-005410-13," EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",21-01-2008,NA,US NCT number,protocol
1098,2006-005410-13," EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",21-01-2008,NA,other,protocol
1099,2006-005410-13," EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",21-01-2008,NA,US NCT number,results
1100,2006-005410-13," EFFICACY, SAFETY AND TOLERABILITY STUDY OF 45 mg PIOGLITAZONE IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) RECEIVING STANDARD THERAPY (RILUZOLE).",21-01-2008,NA,ISRCTN number,results
1101,2006-005450-71, INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO),09-01-2007,NA,US NCT number,protocol
1102,2006-005450-71, INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO),09-01-2007,NA,other,protocol
1103,2006-005450-71, INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO),09-01-2007,NA,US NCT number,results
1104,2006-005450-71, INTRAVITREAL RANIBIZUMAB THERAPY FOR MACULA EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (RAVO),09-01-2007,NA,ISRCTN number,results
1105,2006-005500-14," A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid  (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION)",12-04-2007,NA,US NCT number,protocol
1106,2006-005500-14," A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid  (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION)",12-04-2007,NA,other,protocol
1107,2006-005500-14," A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid  (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION)",12-04-2007,NA,US NCT number,results
1108,2006-005500-14," A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid  (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGASYS®) and Ribavirin (COPEGUS®) Therapy in Patients with Genotype 1-Chronic Hepatitis C and Non-Response to a Previous Course of Peg-Interferon alfa-/Ribavirin Combination (ATRACTION)",12-04-2007,NA,ISRCTN number,results
1109,2006-005531-17, Xenon als Antidepressivum,14-08-2007,NA,US NCT number,protocol
1110,2006-005531-17, Xenon als Antidepressivum,14-08-2007,NA,other,protocol
1111,2006-005531-17, Xenon als Antidepressivum,14-08-2007,NA,US NCT number,results
1112,2006-005531-17, Xenon als Antidepressivum,14-08-2007,NA,ISRCTN number,results
1113,2006-005567-26, Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome,19-07-2007,NA,US NCT number,protocol
1114,2006-005567-26, Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome,19-07-2007,NA,other,protocol
1115,2006-005567-26, Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome,19-07-2007,NA,US NCT number,results
1116,2006-005567-26, Effects of deep brain stimulation of the nucleus accumbens on the dopaminergic activity in patients with Gilles-de-la-Tourette-syndrome,19-07-2007,NA,ISRCTN number,results
1117,2006-005710-12, Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),18-06-2007,NA,US NCT number,protocol
1118,2006-005710-12, Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),18-06-2007,NA,other,protocol
1119,2006-005710-12, Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),18-06-2007,NA,US NCT number,results
1120,2006-005710-12, Evaluation of the effect of NICOtinic acid (niacin) on elevated Lipoprotein(a) levels (NICOLa Study),18-06-2007,NA,ISRCTN number,results
1121,2006-005778-34, Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma  (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,05-01-2007,NA,US NCT number,protocol
1122,2006-005778-34, Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma  (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,05-01-2007,NA,other,protocol
1123,2006-005778-34, Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma  (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,05-01-2007,NCT00772655,US NCT number,results
1124,2006-005778-34, Multicenter European pilot study of 90Yttrium-ibritumomab tiuxetan as first line therapy for stage III – IV follicular lymphoma  (and selected patients with extended stage II) followed by consolidation Rituximab for patients in complete remission but with persistent molecular disease,05-01-2007,NA,ISRCTN number,results
1125,2006-005819-10, Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation,26-10-2007,NA,US NCT number,protocol
1126,2006-005819-10, Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation,26-10-2007,NA,other,protocol
1127,2006-005819-10, Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation,26-10-2007,NA,US NCT number,results
1128,2006-005819-10, Influence of tiotropium bromide (Spiriva ®) plus salbutamol versus salbutamol on the mucin secretion and sputum properties in subjects with a COPD exacerbation,26-10-2007,NA,ISRCTN number,results
1129,2006-005854-61, Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization,19-12-2007,NA,US NCT number,protocol
1130,2006-005854-61, Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization,19-12-2007,NA,other,protocol
1131,2006-005854-61, Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization,19-12-2007,NCT00707369,US NCT number,results
1132,2006-005854-61, Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization,19-12-2007,ISRCTN64254080,ISRCTN number,results
1133,2006-005906-30," The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit  Ezetimib 10 mg vs. Monotherapie mit Simvastatin 20 mg vs.  Kombinationsbehandlung mit Ezetimib 10 mg und Simvastatin 20 mg auf die LDL-Subfraktionen bei Patienten mit Typ II Diabetes)",23-04-2007,NA,US NCT number,protocol
1134,2006-005906-30," The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit  Ezetimib 10 mg vs. Monotherapie mit Simvastatin 20 mg vs.  Kombinationsbehandlung mit Ezetimib 10 mg und Simvastatin 20 mg auf die LDL-Subfraktionen bei Patienten mit Typ II Diabetes)",23-04-2007,NA,other,protocol
1135,2006-005906-30," The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit  Ezetimib 10 mg vs. Monotherapie mit Simvastatin 20 mg vs.  Kombinationsbehandlung mit Ezetimib 10 mg und Simvastatin 20 mg auf die LDL-Subfraktionen bei Patienten mit Typ II Diabetes)",23-04-2007,NA,US NCT number,results
1136,2006-005906-30," The effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg plus 10 mg Ezetimibe on LDL-Subfractions in patients with Type 2 Diabetes (Die Wirkung einer Monotherapie mit  Ezetimib 10 mg vs. Monotherapie mit Simvastatin 20 mg vs.  Kombinationsbehandlung mit Ezetimib 10 mg und Simvastatin 20 mg auf die LDL-Subfraktionen bei Patienten mit Typ II Diabetes)",23-04-2007,NA,ISRCTN number,results
1137,2006-005970-26," A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",11-01-2007,NA,US NCT number,protocol
1138,2006-005970-26," A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",11-01-2007,NA,other,protocol
1139,2006-005970-26," A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",11-01-2007,NA,US NCT number,results
1140,2006-005970-26," A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer",11-01-2007,NA,ISRCTN number,results
1141,2006-006004-11, Phase II – Studie P-ICE,19-11-2007,NA,US NCT number,protocol
1142,2006-006004-11, Phase II – Studie P-ICE,19-11-2007,NA,other,protocol
1143,2006-006004-11, Phase II – Studie P-ICE,19-11-2007,NA,US NCT number,results
1144,2006-006004-11, Phase II – Studie P-ICE,19-11-2007,NA,ISRCTN number,results
1145,2006-006088-22, Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) ,14-02-2011,NA,US NCT number,protocol
1146,2006-006088-22, Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) ,14-02-2011,NA,other,protocol
1147,2006-006088-22, Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) ,14-02-2011,NCT02158988,US NCT number,results
1148,2006-006088-22, Prospective multicenter phase III clinical trial using cytoreductive surgery with hyperthermic intraoperative chemotherapy (HIPEC) ,14-02-2011,NA,ISRCTN number,results
1149,2006-006091-38," Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektomie operablen Larynx-/Hypopharynxkarzinoms",10-04-2007,NA,US NCT number,protocol
1150,2006-006091-38," Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektomie operablen Larynx-/Hypopharynxkarzinoms",10-04-2007,NA,other,protocol
1151,2006-006091-38," Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektomie operablen Larynx-/Hypopharynxkarzinoms",10-04-2007,NA,US NCT number,results
1152,2006-006091-38," Randomisierte Phase II Screeningstudie zum Einsatz einer TP/TPF-Chemotherapie (Kurzinduktion) vor TP/TPF-Induktion, Radiotherapie mit und ohne Cetuximab in der Primärtherapie des nur durch Laryngektomie operablen Larynx-/Hypopharynxkarzinoms",10-04-2007,NA,ISRCTN number,results
1153,2006-006137-41," Prospective, randomized, open, 2-arm national multi-center study to ",26-03-2007,NA,US NCT number,protocol
1154,2006-006137-41," Prospective, randomized, open, 2-arm national multi-center study to ",26-03-2007,NA,other,protocol
1155,2006-006137-41," Prospective, randomized, open, 2-arm national multi-center study to ",26-03-2007,NA,US NCT number,results
1156,2006-006137-41," Prospective, randomized, open, 2-arm national multi-center study to ",26-03-2007,NA,ISRCTN number,results
1157,2006-006166-42," Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -	offene, prospektive Phase II-Studie -",02-01-2007,NA,US NCT number,protocol
1158,2006-006166-42," Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -	offene, prospektive Phase II-Studie -",02-01-2007,NA,other,protocol
1159,2006-006166-42," Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -	offene, prospektive Phase II-Studie -",02-01-2007,NA,US NCT number,results
1160,2006-006166-42," Exelon bei dementiellem Syndrom bei Patienten mit Progressiver Supranukleärer Parese -	offene, prospektive Phase II-Studie -",02-01-2007,NA,ISRCTN number,results
1161,2006-006180-23," Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus",03-04-2007,NA,US NCT number,protocol
1162,2006-006180-23," Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus",03-04-2007,NA,other,protocol
1163,2006-006180-23," Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus",03-04-2007,NA,US NCT number,results
1164,2006-006180-23," Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus",03-04-2007,NA,ISRCTN number,results
1165,2006-006231-49," Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) ",06-03-2007,NA,US NCT number,protocol
1166,2006-006231-49," Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) ",06-03-2007,NA,other,protocol
1167,2006-006231-49," Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) ",06-03-2007,NA,US NCT number,results
1168,2006-006231-49," Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome) ",06-03-2007,NA,ISRCTN number,results
1169,2006-006233-40," Ranibizumab in idiopathic macular telangiectasia, type2 ",06-03-2007,NA,US NCT number,protocol
1170,2006-006233-40," Ranibizumab in idiopathic macular telangiectasia, type2 ",06-03-2007,NA,other,protocol
1171,2006-006233-40," Ranibizumab in idiopathic macular telangiectasia, type2 ",06-03-2007,NA,US NCT number,results
1172,2006-006233-40," Ranibizumab in idiopathic macular telangiectasia, type2 ",06-03-2007,NA,ISRCTN number,results
1173,2006-006323-39, Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,05-03-2007,NA,US NCT number,protocol
1174,2006-006323-39, Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,05-03-2007,NA,other,protocol
1175,2006-006323-39, Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,05-03-2007,NA,US NCT number,results
1176,2006-006323-39, Sunphenon (Epigallocatechin-Gallate) in relapsing-remitting multiple sclerosis,05-03-2007,NA,ISRCTN number,results
1177,2006-006384-24, Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“,16-03-2007,NA,US NCT number,protocol
1178,2006-006384-24, Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“,16-03-2007,NA,other,protocol
1179,2006-006384-24, Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“,16-03-2007,NA,US NCT number,results
1180,2006-006384-24, Bestimmung der stimulierten ß-Zell-Kapazität im oralen Nateglinide 50 g Glukose-Toleranz-Test - „Nateglinide-Test“,16-03-2007,NA,ISRCTN number,results
1181,2006-006398-26, Antibiotika versus Ibuprofen zur Therapie unkomplizierter Harnwegsinfekte: Eine Therapie-Pilotstudie in hausärztlichen Praxen,17-08-2007,NA,US NCT number,protocol
1182,2006-006398-26, Antibiotika versus Ibuprofen zur Therapie unkomplizierter Harnwegsinfekte: Eine Therapie-Pilotstudie in hausärztlichen Praxen,17-08-2007,NA,other,protocol
1183,2006-006398-26, Antibiotika versus Ibuprofen zur Therapie unkomplizierter Harnwegsinfekte: Eine Therapie-Pilotstudie in hausärztlichen Praxen,17-08-2007,NA,US NCT number,results
1184,2006-006398-26, Antibiotika versus Ibuprofen zur Therapie unkomplizierter Harnwegsinfekte: Eine Therapie-Pilotstudie in hausärztlichen Praxen,17-08-2007,NA,ISRCTN number,results
1185,2006-006465-16, Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis,03-05-2007,NA,US NCT number,protocol
1186,2006-006465-16, Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis,03-05-2007,NA,other,protocol
1187,2006-006465-16, Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis,03-05-2007,NCT01541605,US NCT number,results
1188,2006-006465-16, Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis,03-05-2007,NA,ISRCTN number,results
1189,2006-006516-30, Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,18-04-2007,NA,US NCT number,protocol
1190,2006-006516-30, Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,18-04-2007,NA,other,protocol
1191,2006-006516-30, Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,18-04-2007,NA,US NCT number,results
1192,2006-006516-30, Combined systemic an intrathecal chemotherapy with succeeding high dosis chemotherapy and autologous stem cell transplantation of patients with CNS relapses of agressive lymphomas.,18-04-2007,NA,ISRCTN number,results
1193,2006-006566-42, Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients not eligible for Cisplatin-based Adjuvant Chemotherapy,14-08-2007,NA,US NCT number,protocol
1194,2006-006566-42, Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients not eligible for Cisplatin-based Adjuvant Chemotherapy,14-08-2007,NA,other,protocol
1195,2006-006566-42, Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients not eligible for Cisplatin-based Adjuvant Chemotherapy,14-08-2007,NA,US NCT number,results
1196,2006-006566-42, Sorafenib in Resected NSCLC (SIRN) - A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment following Resection of Non-small Cell Lung Carcinoma (NSCLC) in Patients not eligible for Cisplatin-based Adjuvant Chemotherapy,14-08-2007,NA,ISRCTN number,results
1197,2006-006573-24," Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicenter study",01-02-2007,NA,US NCT number,protocol
1198,2006-006573-24," Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicenter study",01-02-2007,NA,other,protocol
1199,2006-006573-24," Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicenter study",01-02-2007,NA,US NCT number,results
1200,2006-006573-24," Prospective influence of bedtime insulin glargine on mobilization and function of endothelial progenitor cells in patients with type 2 diabetes: a partially double-blind, randomized, three-arm unicenter study",01-02-2007,NA,ISRCTN number,results
1201,2006-006823-38, D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis,11-05-2007,NA,US NCT number,protocol
1202,2006-006823-38, D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis,11-05-2007,NA,other,protocol
1203,2006-006823-38, D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis,11-05-2007,NA,US NCT number,results
1204,2006-006823-38, D-Dimer guided oral anticoagulation therapy for secondary prevention after venous thrombosis,11-05-2007,NA,ISRCTN number,results
1205,2006-006824-20," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study",23-07-2007,NA,US NCT number,protocol
1206,2006-006824-20," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study",23-07-2007,NA,other,protocol
1207,2006-006824-20," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study",23-07-2007,NA,US NCT number,results
1208,2006-006824-20," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Pheochromocytoma – proof of concept study",23-07-2007,NA,ISRCTN number,results
1209,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,protocol
1210,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,other,protocol
1211,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,results
1212,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,ISRCTN number,results
1213,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,protocol
1214,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,other,protocol
1215,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,results
1216,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,ISRCTN number,results
1217,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,protocol
1218,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,other,protocol
1219,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,results
1220,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,ISRCTN number,results
1221,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,protocol
1222,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,other,protocol
1223,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,US NCT number,results
1224,2006-006912-31, Vereidung maschineller Beatmung bei sehr kleinen Frühgeborenen - Avoid mechanical ventilation (The AMV-Trial),25-04-2007,NA,ISRCTN number,results
1225,2006-006957-29, Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression,19-04-2007,NA,US NCT number,protocol
1226,2006-006957-29, Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression,19-04-2007,NA,other,protocol
1227,2006-006957-29, Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression,19-04-2007,NA,US NCT number,results
1228,2006-006957-29, Influence of Duloxetin on C-fiber function and perception of deep somatic pain in major depression,19-04-2007,NA,ISRCTN number,results
1229,2006-006962-41, Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,13-08-2007,NA,US NCT number,protocol
1230,2006-006962-41, Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,13-08-2007,NA,other,protocol
1231,2006-006962-41, Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,13-08-2007,NA,US NCT number,results
1232,2006-006962-41, Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia,13-08-2007,NA,ISRCTN number,results
1233,2006-006984-21," prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function of patients with severe sepsis and septic shock",02-02-2007,NA,US NCT number,protocol
1234,2006-006984-21," prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function of patients with severe sepsis and septic shock",02-02-2007,NA,other,protocol
1235,2006-006984-21," prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function of patients with severe sepsis and septic shock",02-02-2007,NA,US NCT number,results
1236,2006-006984-21," prospective, randomized, open, multicentre trial to assess the influence of empiric antibiotic monotherapy with meropenem (Meronem) versus combination with moxifloxacin (Avalox) on the organ function of patients with severe sepsis and septic shock",02-02-2007,NA,ISRCTN number,results
1237,2006-007036-95," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study",23-01-2009,NA,US NCT number,protocol
1238,2006-007036-95," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study",23-01-2009,NA,other,protocol
1239,2006-007036-95," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study",23-01-2009,NA,US NCT number,results
1240,2006-007036-95," Monocenter, double blinded, exploratory, randomized, study investigating the influence of Pasireotide on the hormonal activity of Prolactinomas - proof of concept study",23-01-2009,NA,ISRCTN number,results
1241,2007-000088-12," A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)",06-08-2009,NA,US NCT number,protocol
1242,2007-000088-12," A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)",06-08-2009,NA,other,protocol
1243,2007-000088-12," A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)",06-08-2009,NA,US NCT number,results
1244,2007-000088-12," A prospective, single-blinded (rater-blinded), randomized, parallel group study of the efficacy of Quetiapine XR in the treatment of patients with Acute Stress Disorder (DSM-VI 308.3)",06-08-2009,NA,ISRCTN number,results
1245,2007-000128-42," International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adolescents < 18 years.",02-06-2008,NA,US NCT number,protocol
1246,2007-000128-42," International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adolescents < 18 years.",02-06-2008,NA,other,protocol
1247,2007-000128-42," International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adolescents < 18 years.",02-06-2008,NA,US NCT number,results
1248,2007-000128-42," International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adolescents < 18 years.",02-06-2008,NA,ISRCTN number,results
1249,2007-000224-41, A,12-07-2007,NA,US NCT number,protocol
1250,2007-000224-41, A,12-07-2007,NA,other,protocol
1251,2007-000224-41, A,12-07-2007,NA,US NCT number,results
1252,2007-000224-41, A,12-07-2007,NA,ISRCTN number,results
1253,2007-000233-18, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,20-05-2008,NA,US NCT number,protocol
1254,2007-000233-18, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,20-05-2008,NA,other,protocol
1255,2007-000233-18, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,20-05-2008,NA,US NCT number,results
1256,2007-000233-18, Phase I/II Studie zum Einsatz von Capecitabin und Oxaliplatin (XELOX) in Kombination mit Bevacizumab und Imatinib in der Erstlinientherapie von Patienten mit fortgeschrittenem kolorektalem Karzinom,20-05-2008,NA,ISRCTN number,results
1257,2007-000242-12," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der Pharmakokinetik von Voriconazol nach einmaliger und wiederholter Gabe von 2x4mg/kg pro Tag bei niereninsuffizienten Patienten mit Geniusdialyse- oder CVVH-Therapie unter besonderer Berücksichtigung einer möglichen Kumulation des Lösungsvermittlers SBECD",14-08-2007,NA,US NCT number,protocol
1258,2007-000242-12," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der Pharmakokinetik von Voriconazol nach einmaliger und wiederholter Gabe von 2x4mg/kg pro Tag bei niereninsuffizienten Patienten mit Geniusdialyse- oder CVVH-Therapie unter besonderer Berücksichtigung einer möglichen Kumulation des Lösungsvermittlers SBECD",14-08-2007,NA,other,protocol
1259,2007-000242-12," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der Pharmakokinetik von Voriconazol nach einmaliger und wiederholter Gabe von 2x4mg/kg pro Tag bei niereninsuffizienten Patienten mit Geniusdialyse- oder CVVH-Therapie unter besonderer Berücksichtigung einer möglichen Kumulation des Lösungsvermittlers SBECD",14-08-2007,NA,US NCT number,results
1260,2007-000242-12," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der Pharmakokinetik von Voriconazol nach einmaliger und wiederholter Gabe von 2x4mg/kg pro Tag bei niereninsuffizienten Patienten mit Geniusdialyse- oder CVVH-Therapie unter besonderer Berücksichtigung einer möglichen Kumulation des Lösungsvermittlers SBECD",14-08-2007,NA,ISRCTN number,results
1261,2007-000259-33, Perioperative protective effects of lidocaine - clinical study on the route and timing of administration,01-02-2007,NCT00413127,US NCT number,protocol
1262,2007-000259-33, Perioperative protective effects of lidocaine - clinical study on the route and timing of administration,01-02-2007,NA,other,protocol
1263,2007-000259-33, Perioperative protective effects of lidocaine - clinical study on the route and timing of administration,01-02-2007,NA,US NCT number,results
1264,2007-000259-33, Perioperative protective effects of lidocaine - clinical study on the route and timing of administration,01-02-2007,NA,ISRCTN number,results
1265,2007-000353-65," Weight gain, eating patterns, and development of body composition during initiation of basal insulin therapy: a comparison of insulin detemir and insulin glargine",13-08-2007,NA,US NCT number,protocol
1266,2007-000353-65," Weight gain, eating patterns, and development of body composition during initiation of basal insulin therapy: a comparison of insulin detemir and insulin glargine",13-08-2007,NA,other,protocol
1267,2007-000353-65," Weight gain, eating patterns, and development of body composition during initiation of basal insulin therapy: a comparison of insulin detemir and insulin glargine",13-08-2007,NA,US NCT number,results
1268,2007-000353-65," Weight gain, eating patterns, and development of body composition during initiation of basal insulin therapy: a comparison of insulin detemir and insulin glargine",13-08-2007,NA,ISRCTN number,results
1269,2007-000390-31," Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phase IV)",28-07-2009,NA,US NCT number,protocol
1270,2007-000390-31," Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phase IV)",28-07-2009,NA,other,protocol
1271,2007-000390-31," Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phase IV)",28-07-2009,NA,US NCT number,results
1272,2007-000390-31," Application of hypertonic hyperoncotic solutions for improvement of cardiac output after open heart surgery in children - monocentric, randomised, placebo controlled, double-blind clinical trial (phase IV)",28-07-2009,NA,ISRCTN number,results
1273,2007-000410-37, Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.,15-05-2007,NA,US NCT number,protocol
1274,2007-000410-37, Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.,15-05-2007,NA,other,protocol
1275,2007-000410-37, Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.,15-05-2007,NA,US NCT number,results
1276,2007-000410-37, Determination of glomerular filtration rate (GFR) using MR nephrography in patients with chronic kidney disease.,15-05-2007,NA,ISRCTN number,results
1277,2007-000443-99," Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis ",13-11-2008,NA,US NCT number,protocol
1278,2007-000443-99," Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis ",13-11-2008,NA,other,protocol
1279,2007-000443-99," Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis ",13-11-2008,NA,US NCT number,results
1280,2007-000443-99," Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-Nephritis ",13-11-2008,NA,ISRCTN number,results
1281,2007-000460-24, Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,21-11-2008,NA,US NCT number,protocol
1282,2007-000460-24, Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,21-11-2008,NA,other,protocol
1283,2007-000460-24, Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,21-11-2008,NCT01051167,US NCT number,results
1284,2007-000460-24, Bi-weekly Cetuximab combined with FOLFOX-6 as first-line treatment in metastatic colorectal cancer patients with wild-type k-ras status,21-11-2008,NA,ISRCTN number,results
1285,2007-000479-40, Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,26-02-2009,NA,US NCT number,protocol
1286,2007-000479-40, Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,26-02-2009,NA,other,protocol
1287,2007-000479-40, Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,26-02-2009,NA,US NCT number,results
1288,2007-000479-40, Effects of quetiapine on ultrastructural hippocampal and neurochemical changes in patients with bipolar disorder: searching for the antidepressant and mood stabilising neurophysiology,26-02-2009,NA,ISRCTN number,results
1289,2007-000501-29, Low grade albuminuria: reaching a new target for irbesartan,30-05-2008,NA,US NCT number,protocol
1290,2007-000501-29, Low grade albuminuria: reaching a new target for irbesartan,30-05-2008,NA,other,protocol
1291,2007-000501-29, Low grade albuminuria: reaching a new target for irbesartan,30-05-2008,NA,US NCT number,results
1292,2007-000501-29, Low grade albuminuria: reaching a new target for irbesartan,30-05-2008,NA,ISRCTN number,results
1293,2007-000502-70, An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia,14-12-2007,NA,US NCT number,protocol
1294,2007-000502-70, An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia,14-12-2007,NA,other,protocol
1295,2007-000502-70, An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia,14-12-2007,NA,US NCT number,results
1296,2007-000502-70, An open-label phase I/II (proof of concept) trial of an combination of Nilotinib (AMN 107) and RAD001 in patients with acute myeloid leukemia,14-12-2007,NA,ISRCTN number,results
1297,2007-000506-78," Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsinfektion.",15-03-2007,NA,US NCT number,protocol
1298,2007-000506-78," Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsinfektion.",15-03-2007,NA,other,protocol
1299,2007-000506-78," Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsinfektion.",15-03-2007,NA,US NCT number,results
1300,2007-000506-78," Monozentrische, prospektive, offene Studie zur Untersuchung der „steady state“-Pharmakokinetik von Tigecyclin im Plasma, im ELF und in Alveolarmakrophagen bei Intensivpatienten mit tiefer Atemwegsinfektion.",15-03-2007,NA,ISRCTN number,results
1301,2007-000512-82," Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",15-08-2007,NA,US NCT number,protocol
1302,2007-000512-82," Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",15-08-2007,NA,other,protocol
1303,2007-000512-82," Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",15-08-2007,NA,US NCT number,results
1304,2007-000512-82," Optimal Duration of Olazapine Add-on therapy in Major Depression: A double-blind, placebo-controlled, randomized, Phase III, Pilot Study in parallel group Design",15-08-2007,NA,ISRCTN number,results
1305,2007-000517-10," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mit neu aufgetretenem Fieber und radiologisch nachgewiesener Lungeninfiltration unter Immunsuppression",09-05-2007,NA,US NCT number,protocol
1306,2007-000517-10," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mit neu aufgetretenem Fieber und radiologisch nachgewiesener Lungeninfiltration unter Immunsuppression",09-05-2007,NA,other,protocol
1307,2007-000517-10," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mit neu aufgetretenem Fieber und radiologisch nachgewiesener Lungeninfiltration unter Immunsuppression",09-05-2007,NA,US NCT number,results
1308,2007-000517-10," Monozentrische, prospektiv durchgeführte Studie zur Untersuchung der „steady state“ - Pharmakokinetik von Caspofungin im Plasma, im ELF und in Alveolarmakrophagen bei beatmeten Intensivpatienten mit neu aufgetretenem Fieber und radiologisch nachgewiesener Lungeninfiltration unter Immunsuppression",09-05-2007,NA,ISRCTN number,results
1309,2007-000550-31, Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study,25-04-2007,NA,US NCT number,protocol
1310,2007-000550-31, Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study,25-04-2007,NA,other,protocol
1311,2007-000550-31, Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study,25-04-2007,NA,US NCT number,results
1312,2007-000550-31, Quetiapine vs. Placebo in alcohol relapse prevention- a pilot study,25-04-2007,NA,ISRCTN number,results
1313,2007-000579-40," Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",02-10-2007,NA,US NCT number,protocol
1314,2007-000579-40," Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",02-10-2007,NA,other,protocol
1315,2007-000579-40," Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",02-10-2007,NA,US NCT number,results
1316,2007-000579-40," Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study",02-10-2007,NA,ISRCTN number,results
1317,2007-000624-40, PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS,02-03-2010,NA,US NCT number,protocol
1318,2007-000624-40, PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS,02-03-2010,NA,other,protocol
1319,2007-000624-40, PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS,02-03-2010,NA,US NCT number,results
1320,2007-000624-40, PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UNACCEPTABLE FUNCTION LOSS,02-03-2010,NA,ISRCTN number,results
1321,2007-000718-35," CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie ",18-10-2007,NA,US NCT number,protocol
1322,2007-000718-35," CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie ",18-10-2007,NA,other,protocol
1323,2007-000718-35," CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie ",18-10-2007,NA,US NCT number,results
1324,2007-000718-35," CONKO-006 Additive Therapie beim R1-resezierten Pankreaskarzinom mit Gemcitabin plus Sorafenib versus Gemcitabin plus Placebo über 12 Monate - eine doppelblinde, placebokontrollierte Phase IIb Studie ",18-10-2007,NA,ISRCTN number,results
1325,2007-000730-40, Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC),10-05-2007,NA,US NCT number,protocol
1326,2007-000730-40, Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC),10-05-2007,NA,other,protocol
1327,2007-000730-40, Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC),10-05-2007,NA,US NCT number,results
1328,2007-000730-40, Phase II study evaluating transarterial chemoembolization (TACE) in combination with sorafenib for the treatment of advanced hepatocellular carcinoma (HCC),10-05-2007,NA,ISRCTN number,results
1329,2007-000775-42," Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial",19-09-2007,NA,US NCT number,protocol
1330,2007-000775-42," Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial",19-09-2007,NA,other,protocol
1331,2007-000775-42," Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial",19-09-2007,NA,US NCT number,results
1332,2007-000775-42," Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trial",19-09-2007,NA,ISRCTN number,results
1333,2007-000821-23," A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)",29-03-2007,NA,US NCT number,protocol
1334,2007-000821-23," A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)",29-03-2007,NA,other,protocol
1335,2007-000821-23," A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)",29-03-2007,NA,US NCT number,results
1336,2007-000821-23," A randomised Phase III trial to evaluate the efficacy of chemoimmunotherapy with the monoclonal antibody Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) versus 2-weekly CHOP alone in elderly patients with previously untreated systemic T- cell Lymphoma Short Title: A-CHOP-14 (elderly)",29-03-2007,NA,ISRCTN number,results
1337,2007-000871-41, Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy,27-11-2007,NA,US NCT number,protocol
1338,2007-000871-41, Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy,27-11-2007,NA,other,protocol
1339,2007-000871-41, Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy,27-11-2007,NA,US NCT number,results
1340,2007-000871-41, Supportive versus Immunosuppressive Therapy for the treatment Of Progressive IgA Nephropathy,27-11-2007,NA,ISRCTN number,results
1341,2007-001052-39, Auto-versus Allotransplantation in T-NHL - ,07-09-2009,NA,US NCT number,protocol
1342,2007-001052-39, Auto-versus Allotransplantation in T-NHL - ,07-09-2009,NA,other,protocol
1343,2007-001052-39, Auto-versus Allotransplantation in T-NHL - ,07-09-2009,NA,US NCT number,results
1344,2007-001052-39, Auto-versus Allotransplantation in T-NHL - ,07-09-2009,NA,ISRCTN number,results
1345,2007-001094-29," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment",06-12-2007,NA,US NCT number,protocol
1346,2007-001094-29," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment",06-12-2007,NA,other,protocol
1347,2007-001094-29," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment",06-12-2007,NCT00670878,US NCT number,results
1348,2007-001094-29," Simultaneous Study of Gemcitabine-Docetaxel Combination adjuvant treatment, as well as Biological Targeted Treatment",06-12-2007,NA,ISRCTN number,results
1349,2007-001165-15, Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC),09-05-2007,NA,US NCT number,protocol
1350,2007-001165-15, Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC),09-05-2007,NA,other,protocol
1351,2007-001165-15, Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC),09-05-2007,NA,US NCT number,results
1352,2007-001165-15, Sunitinib in Refractory Adrenocortical-Carcinoma patients progressing after cytotoxic chemotherapy (SIRAC),09-05-2007,NA,ISRCTN number,results
1353,2007-001166-33," A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation  ",17-08-2007,NA,US NCT number,protocol
1354,2007-001166-33," A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation  ",17-08-2007,NA,other,protocol
1355,2007-001166-33," A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation  ",17-08-2007,NA,US NCT number,results
1356,2007-001166-33," A prospective, randomised, multicenter clinical trial investigating the reduction of Calcineurin inhibitor toxicity by means of steroid free long-term immune suppression with Ciclosporin A and Mycophenolat mofetil in children and adolescents after kidney transplantation  ",17-08-2007,NA,ISRCTN number,results
1357,2007-001194-29," An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy",20-06-2007,NA,US NCT number,protocol
1358,2007-001194-29," An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy",20-06-2007,NA,other,protocol
1359,2007-001194-29," An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy",20-06-2007,NA,US NCT number,results
1360,2007-001194-29," An open-label, multi-center Phase I/II trial evaluating the safety and efficacy of azacitidine (Vidaza®) in patients with acute myeloid leukaemia not eligible for or resistant to chemotherapy",20-06-2007,NA,ISRCTN number,results
1361,2007-001200-20," A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",03-04-2007,NA,US NCT number,protocol
1362,2007-001200-20," A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",03-04-2007,NA,other,protocol
1363,2007-001200-20," A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",03-04-2007,NA,US NCT number,results
1364,2007-001200-20," A Multicenter, Randomized Phase II Trial Assessing the Activity of Gemcitabine – Oxaliplatin Chemotherapy Alone or in Combination with Cetuximab in Patients with Advanced Biliary Cancer",03-04-2007,NA,ISRCTN number,results
1365,2007-001339-69," Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multicenter, non-randomized, open, prospective clinical trial",06-02-2008,NA,US NCT number,protocol
1366,2007-001339-69," Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multicenter, non-randomized, open, prospective clinical trial",06-02-2008,NA,other,protocol
1367,2007-001339-69," Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multicenter, non-randomized, open, prospective clinical trial",06-02-2008,NA,US NCT number,results
1368,2007-001339-69," Protocol for standardized diagnostic procedures, registration, and treatment recommendations in children and adolescents with Philadelphia chromosome-positive chronic myeloid leukemia (CML). A multicenter, non-randomized, open, prospective clinical trial",06-02-2008,NA,ISRCTN number,results
1369,2007-001478-10," CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults",09-07-2008,NA,US NCT number,protocol
1370,2007-001478-10," CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults",09-07-2008,NA,other,protocol
1371,2007-001478-10," CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults",09-07-2008,NA,US NCT number,results
1372,2007-001478-10," CWS-2007-HR: A randomised phase-III trial of the Cooperative Weichteilsarkom Studiengruppe for localised high-risk Rhabdomyosarcoma and localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in children, adolescents, and young adults",09-07-2008,NA,ISRCTN number,results
1373,2007-001548-36, Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und ,27-07-2009,NA,US NCT number,protocol
1374,2007-001548-36, Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und ,27-07-2009,NA,other,protocol
1375,2007-001548-36, Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und ,27-07-2009,NA,US NCT number,results
1376,2007-001548-36, Nasale Inhalation von Pulmozyme bei Patienten mit Mukoviszidose und ,27-07-2009,NA,ISRCTN number,results
1377,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,protocol
1378,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,other,protocol
1379,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,results
1380,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,ISRCTN number,results
1381,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,protocol
1382,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,other,protocol
1383,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,results
1384,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,ISRCTN number,results
1385,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,protocol
1386,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,other,protocol
1387,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,results
1388,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,ISRCTN number,results
1389,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,protocol
1390,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,other,protocol
1391,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,US NCT number,results
1392,2007-001558-21, Phase II Studie:  Neoadjuvante Radiochemotherapie mit Capecitabin und Oxaliplatin plus Bevacizumab beim lokal fortgeschrittenen Rektumkarzinom,05-12-2007,NA,ISRCTN number,results
1393,2007-001565-15, Konzentrationen von Ertapenem in kolorektalem Gewebe.,28-07-2009,NA,US NCT number,protocol
1394,2007-001565-15, Konzentrationen von Ertapenem in kolorektalem Gewebe.,28-07-2009,NA,other,protocol
1395,2007-001565-15, Konzentrationen von Ertapenem in kolorektalem Gewebe.,28-07-2009,NA,US NCT number,results
1396,2007-001565-15, Konzentrationen von Ertapenem in kolorektalem Gewebe.,28-07-2009,NA,ISRCTN number,results
1397,2007-001573-28, Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.,06-03-2008,NA,US NCT number,protocol
1398,2007-001573-28, Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.,06-03-2008,NA,other,protocol
1399,2007-001573-28, Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.,06-03-2008,NA,US NCT number,results
1400,2007-001573-28, Prevent: Secondary Prevention of Schizophrenia. A randomized controlled trial.,06-03-2008,ISRCTN02658871,ISRCTN number,results
1401,2007-001602-24, Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS),02-06-2009,NA,US NCT number,protocol
1402,2007-001602-24, Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS),02-06-2009,NA,other,protocol
1403,2007-001602-24, Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS),02-06-2009,NA,US NCT number,results
1404,2007-001602-24, Intraprostatic injection of Botulinumtoxin type A in patients with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS),02-06-2009,NA,ISRCTN number,results
1405,2007-001677-28," Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",02-07-2007,NA,US NCT number,protocol
1406,2007-001677-28," Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",02-07-2007,NA,other,protocol
1407,2007-001677-28," Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",02-07-2007,NA,US NCT number,results
1408,2007-001677-28," Quantification of the anesthetic effect of nitrous oxide using intravenous ""closed-loop"" anesthesia",02-07-2007,NA,ISRCTN number,results
1409,2007-001685-33, Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification.,13-11-2007,NA,US NCT number,protocol
1410,2007-001685-33, Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification.,13-11-2007,NA,other,protocol
1411,2007-001685-33, Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification.,13-11-2007,NA,US NCT number,results
1412,2007-001685-33, Prospective Comparison of Phenpocoumon (Marcumar) and Acetylsalicylic Acid (ASS) as to Progression of the Valvular and Coronary Calcification.,13-11-2007,NA,ISRCTN number,results
1413,2007-001744-53," Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not show any or an adequate reaction to a previous sole active Hepatitis B immunisation",04-02-2008,NA,US NCT number,protocol
1414,2007-001744-53," Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not show any or an adequate reaction to a previous sole active Hepatitis B immunisation",04-02-2008,NA,other,protocol
1415,2007-001744-53," Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not show any or an adequate reaction to a previous sole active Hepatitis B immunisation",04-02-2008,NA,US NCT number,results
1416,2007-001744-53," Open, randomized study for evaluation of an active Hepatitis B vaccination(HBVAXPRO) in combination with a passive immunisation with Hepatitis B immunoglobulins (Hepatect) for subjects, who did not show any or an adequate reaction to a previous sole active Hepatitis B immunisation",04-02-2008,NA,ISRCTN number,results
1417,2007-001787-71, The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,17-12-2007,NA,US NCT number,protocol
1418,2007-001787-71, The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,17-12-2007,NA,other,protocol
1419,2007-001787-71, The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,17-12-2007,NA,US NCT number,results
1420,2007-001787-71, The influence of Rimonabant induced cannabinoid receptor blocking on the mass and function of the left ventricle in patients with abdominal adiposity,17-12-2007,NA,ISRCTN number,results
1421,2007-001796-11, ,03-09-2007,NA,US NCT number,protocol
1422,2007-001796-11, ,03-09-2007,NA,other,protocol
1423,2007-001796-11, ,03-09-2007,NA,US NCT number,results
1424,2007-001796-11, ,03-09-2007,NA,ISRCTN number,results
1425,2007-001802-25," An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist vs. the conventional contrast agent Magnevist",09-05-2008,NA,US NCT number,protocol
1426,2007-001802-25," An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist vs. the conventional contrast agent Magnevist",09-05-2008,NA,other,protocol
1427,2007-001802-25," An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist vs. the conventional contrast agent Magnevist",09-05-2008,NA,US NCT number,results
1428,2007-001802-25," An exploratory, open label phase II study to evaluate the feasibility of contrast-enhanced MRI for measurement of perfusion in squamous cell cancer of the head & neck: comparison of the intravascular contrast agent Vasovist vs. the conventional contrast agent Magnevist",09-05-2008,NA,ISRCTN number,results
1429,2007-001888-29, Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.,23-10-2007,NA,US NCT number,protocol
1430,2007-001888-29, Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.,23-10-2007,NA,other,protocol
1431,2007-001888-29, Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.,23-10-2007,NA,US NCT number,results
1432,2007-001888-29, Chronic inflammatory activation in fat tissue: an atherogenic factor in severe coronary artery disease.,23-10-2007,NA,ISRCTN number,results
1433,2007-001892-12, Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation,12-06-2007,NA,US NCT number,protocol
1434,2007-001892-12, Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation,12-06-2007,NA,other,protocol
1435,2007-001892-12, Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation,12-06-2007,NA,US NCT number,results
1436,2007-001892-12, Everolimus and mycophenolate as GvHD-prophylaxis in the allogenous blood stem cell transplantation,12-06-2007,NA,ISRCTN number,results
1437,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,protocol
1438,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,other,protocol
1439,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,results
1440,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,ISRCTN number,results
1441,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,protocol
1442,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,other,protocol
1443,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,results
1444,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,ISRCTN number,results
1445,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,protocol
1446,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,other,protocol
1447,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,results
1448,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,ISRCTN number,results
1449,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,protocol
1450,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,other,protocol
1451,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,US NCT number,results
1452,2007-001918-16," Combined Treatment of Sorafenib and pegylated interferon α2b in stage IV metastatic melanoma: a prospective non-randomized, multicenter Phase II Study",14-04-2009,NA,ISRCTN number,results
1453,2007-001962-34, Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie,05-11-2007,NA,US NCT number,protocol
1454,2007-001962-34, Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie,05-11-2007,NA,other,protocol
1455,2007-001962-34, Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie,05-11-2007,NA,US NCT number,results
1456,2007-001962-34, Klassische Konditionierung immunologischer Reaktionen bei Patienten mit Multipler Sklerose während Mitoxantrontherapie,05-11-2007,NA,ISRCTN number,results
1457,2007-002023-32, Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,04-06-2007,NA,US NCT number,protocol
1458,2007-002023-32, Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,04-06-2007,NA,other,protocol
1459,2007-002023-32, Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,04-06-2007,NA,US NCT number,results
1460,2007-002023-32, Niaspan for the treatment of endothelial dysfunction in patients without hyperlipoproteinemia,04-06-2007,NA,ISRCTN number,results
1461,2007-002031-92," Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.",28-07-2009,NA,US NCT number,protocol
1462,2007-002031-92," Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.",28-07-2009,NA,other,protocol
1463,2007-002031-92," Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.",28-07-2009,NA,US NCT number,results
1464,2007-002031-92," Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.",28-07-2009,NA,ISRCTN number,results
1465,2007-002036-28," Prospektive, randomisierte, kontrollierte, unizentrische, offene,  Studie zur Thromboembolieprophylaxe mit  Enoxaparin bei nicht-chirurgischen onkologischen Patienten  unter systemischer antineoplastischer Therapie",26-02-2009,NA,US NCT number,protocol
1466,2007-002036-28," Prospektive, randomisierte, kontrollierte, unizentrische, offene,  Studie zur Thromboembolieprophylaxe mit  Enoxaparin bei nicht-chirurgischen onkologischen Patienten  unter systemischer antineoplastischer Therapie",26-02-2009,NA,other,protocol
1467,2007-002036-28," Prospektive, randomisierte, kontrollierte, unizentrische, offene,  Studie zur Thromboembolieprophylaxe mit  Enoxaparin bei nicht-chirurgischen onkologischen Patienten  unter systemischer antineoplastischer Therapie",26-02-2009,NA,US NCT number,results
1468,2007-002036-28," Prospektive, randomisierte, kontrollierte, unizentrische, offene,  Studie zur Thromboembolieprophylaxe mit  Enoxaparin bei nicht-chirurgischen onkologischen Patienten  unter systemischer antineoplastischer Therapie",26-02-2009,NA,ISRCTN number,results
1469,2007-002119-17, EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion ,22-08-2007,NA,US NCT number,protocol
1470,2007-002119-17, EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion ,22-08-2007,NA,other,protocol
1471,2007-002119-17, EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion ,22-08-2007,NA,US NCT number,results
1472,2007-002119-17, EPLERAF-Studie: Eplerenon in der Prävention von Vorhofflimmer-Rezidiven nach Kardioversion ,22-08-2007,NA,ISRCTN number,results
1473,2007-002223-32," A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",07-02-2008,NA,US NCT number,protocol
1474,2007-002223-32," A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",07-02-2008,NA,other,protocol
1475,2007-002223-32," A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",07-02-2008,NA,US NCT number,results
1476,2007-002223-32," A multicentre, double-blind, randomised placebo-controlled trial of sodium bicarbonate to prevent acute kidney injury in patients undergoing cardiopulmonary bypass surgery.",07-02-2008,NA,ISRCTN number,results
1477,2007-002331-89, Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktären Prostatakarzinoms mit Docetaxel + Prednison versus ,22-06-2007,NA,US NCT number,protocol
1478,2007-002331-89, Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktären Prostatakarzinoms mit Docetaxel + Prednison versus ,22-06-2007,NA,other,protocol
1479,2007-002331-89, Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktären Prostatakarzinoms mit Docetaxel + Prednison versus ,22-06-2007,NA,US NCT number,results
1480,2007-002331-89, Randomisierte Phase II Studie zur Therapieoptimierung der Behandlung des hormonrefraktären Prostatakarzinoms mit Docetaxel + Prednison versus ,22-06-2007,NA,ISRCTN number,results
1481,2007-002384-27," Hyperbarer Sauerstoff (HBO) in der Behandlung der radiogenen Xerostomie - Eine randomisierte, prospektive Multizenter-Studie",10-12-2007,NA,US NCT number,protocol
1482,2007-002384-27," Hyperbarer Sauerstoff (HBO) in der Behandlung der radiogenen Xerostomie - Eine randomisierte, prospektive Multizenter-Studie",10-12-2007,NA,other,protocol
1483,2007-002384-27," Hyperbarer Sauerstoff (HBO) in der Behandlung der radiogenen Xerostomie - Eine randomisierte, prospektive Multizenter-Studie",10-12-2007,NA,US NCT number,results
1484,2007-002384-27," Hyperbarer Sauerstoff (HBO) in der Behandlung der radiogenen Xerostomie - Eine randomisierte, prospektive Multizenter-Studie",10-12-2007,NA,ISRCTN number,results
1485,2007-002420-15, Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF ,09-08-2007,NA,US NCT number,protocol
1486,2007-002420-15, Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF ,09-08-2007,NA,other,protocol
1487,2007-002420-15, Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF ,09-08-2007,NA,US NCT number,results
1488,2007-002420-15, Phase II-Studie zur Effizienz der vorzeitigen Reduktion von CSA/MMF ,09-08-2007,NA,ISRCTN number,results
1489,2007-002433-37, Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT),15-10-2007,NA,US NCT number,protocol
1490,2007-002433-37, Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT),15-10-2007,NA,other,protocol
1491,2007-002433-37, Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT),15-10-2007,NA,US NCT number,results
1492,2007-002433-37, Lenalidomide maintenance therapy in patients with MDS or AML with cytogenetic abnormalities involving monosomy 5 or del5q after allogeneic hematopoietic stem cell transplantation (HSCT),15-10-2007,NA,ISRCTN number,results
1493,2007-002560-10, Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07),06-08-2009,NA,US NCT number,protocol
1494,2007-002560-10, Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07),06-08-2009,NA,other,protocol
1495,2007-002560-10, Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07),06-08-2009,NCT01614132,US NCT number,results
1496,2007-002560-10, Multicentre pilot-study for the therapy of medulloblastoma of adults (NOA-07),06-08-2009,NA,ISRCTN number,results
1497,2007-002659-17," Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.",08-10-2007,NA,US NCT number,protocol
1498,2007-002659-17," Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.",08-10-2007,NA,other,protocol
1499,2007-002659-17," Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.",08-10-2007,NA,US NCT number,results
1500,2007-002659-17," Multicenter, open-label phase II trial on post-surgery chemoradiation in combination with cetuximab in squamous cell carcinoma of the head and neck with high risk of locoregional recurrence.",08-10-2007,NA,ISRCTN number,results
1501,2007-002755-16, Pharmakokinetik von Posaconazol verabreicht über Magensonde  -  POLICE-Studie (POsaconazoLe via gastrIC tubE),27-08-2007,NA,US NCT number,protocol
1502,2007-002755-16, Pharmakokinetik von Posaconazol verabreicht über Magensonde  -  POLICE-Studie (POsaconazoLe via gastrIC tubE),27-08-2007,NA,other,protocol
1503,2007-002755-16, Pharmakokinetik von Posaconazol verabreicht über Magensonde  -  POLICE-Studie (POsaconazoLe via gastrIC tubE),27-08-2007,NA,US NCT number,results
1504,2007-002755-16, Pharmakokinetik von Posaconazol verabreicht über Magensonde  -  POLICE-Studie (POsaconazoLe via gastrIC tubE),27-08-2007,NA,ISRCTN number,results
1505,2007-002765-12, Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),06-07-2007,NA,US NCT number,protocol
1506,2007-002765-12, Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),06-07-2007,NA,other,protocol
1507,2007-002765-12, Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),06-07-2007,NA,US NCT number,results
1508,2007-002765-12, Influence of the angiotensin receptor blocker Telmisartan on the red blood cell function and the microcirculatory perfusion (ITEM),06-07-2007,NA,ISRCTN number,results
1509,2007-002824-13," Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20%  for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CPAP-Therapy.",11-09-2008,NA,US NCT number,protocol
1510,2007-002824-13," Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20%  for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CPAP-Therapy.",11-09-2008,NA,other,protocol
1511,2007-002824-13," Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20%  for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CPAP-Therapy.",11-09-2008,NA,US NCT number,results
1512,2007-002824-13," Prospective, placebo-controlled blinded clinical trial to study the efficacy of orally administered Glucose 20%  for relieving pain during nasopharyngeal suctioning in preterm infants > 1500g under CPAP-Therapy.",11-09-2008,NA,ISRCTN number,results
1513,2007-002888-27," Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read",08-07-2008,NA,US NCT number,protocol
1514,2007-002888-27," Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read",08-07-2008,NA,other,protocol
1515,2007-002888-27," Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read",08-07-2008,NA,US NCT number,results
1516,2007-002888-27," Intra-individual, randomized comparison of the MRI contrast agents Gadovist® 1.0 versus Prohance® in patients with primary and secondary brain tumors, evaluated in a blinded read",08-07-2008,NA,ISRCTN number,results
1517,2007-002967-28, Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,24-08-2007,NA,US NCT number,protocol
1518,2007-002967-28, Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,24-08-2007,NA,other,protocol
1519,2007-002967-28, Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,24-08-2007,NA,US NCT number,results
1520,2007-002967-28, Pilot open label clinical trial with Abatacept in Ankylosing Spondylitis,24-08-2007,NA,ISRCTN number,results
1521,2007-003003-12, Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“),28-08-2008,NA,US NCT number,protocol
1522,2007-003003-12, Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“),28-08-2008,NA,other,protocol
1523,2007-003003-12, Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“),28-08-2008,NA,US NCT number,results
1524,2007-003003-12, Die Bedeutung der Inflammationslast („inflammatory/pathogen burden“),28-08-2008,NA,ISRCTN number,results
1525,2007-003099-20," A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic  leukemia which is associated with 17p deletion or is refractory to fludarabine.",23-08-2007,NA,US NCT number,protocol
1526,2007-003099-20," A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic  leukemia which is associated with 17p deletion or is refractory to fludarabine.",23-08-2007,NA,other,protocol
1527,2007-003099-20," A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic  leukemia which is associated with 17p deletion or is refractory to fludarabine.",23-08-2007,NA,US NCT number,results
1528,2007-003099-20," A prospective, multi-center phase II study of subcutaneous alemtuzumab combined with oral dexamethasone, followed by alemtuzumab maintenance or allogeneic stem-cell transplantation, in chronic lymphocytic  leukemia which is associated with 17p deletion or is refractory to fludarabine.",23-08-2007,NA,ISRCTN number,results
1529,2007-003103-12," A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia",20-08-2008,NA,US NCT number,protocol
1530,2007-003103-12," A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia",20-08-2008,NA,other,protocol
1531,2007-003103-12," A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia",20-08-2008,NA,US NCT number,results
1532,2007-003103-12," A Randomized, Risk and Age Adapted Comparison of the Dose-Dense Regimen S-HAM (sequential high dose cytosine arabinoside and mitoxantrone) versus Standard Double Induction for Initial Chemotherapy of Adult Patients with Acute Myeloid Leukemia",20-08-2008,NA,ISRCTN number,results
1533,2007-003106-99," Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks",17-08-2007,NA,US NCT number,protocol
1534,2007-003106-99," Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks",17-08-2007,NA,other,protocol
1535,2007-003106-99," Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks",17-08-2007,NA,US NCT number,results
1536,2007-003106-99," Pimecrolimus and Epidermal Barrier Function: Role for pimecrolimus in restoring skin barrier function and normalizing epidermal lipid content and differentiation in atopic epidermis: a randomized, intra-patient, double-blind (right/left arm) study in adults with atopic dermatitis treated with 1% pimecrolimus cream and 0.1% triamcinolone acetonide cream as treatment control twice daily for 3 weeks",17-08-2007,NA,ISRCTN number,results
1537,2007-003111-31, Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,16-05-2008,NA,US NCT number,protocol
1538,2007-003111-31, Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,16-05-2008,ARTVI ARTVI,other,protocol
1539,2007-003111-31, Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,16-05-2008,NA,US NCT number,results
1540,2007-003111-31, Influence of postoperative influenza vaccination versus GM-CSF in immune-compromised patients undergoing pancreatic or esophageal resection on the course of immunosuppression and the postoperative infection rate.,16-05-2008,NA,ISRCTN number,results
1541,2007-003187-22, HD18 for advanced stages in Hodgkins Lymphoma,07-12-2007,NA,US NCT number,protocol
1542,2007-003187-22, HD18 for advanced stages in Hodgkins Lymphoma,07-12-2007,ClinicalTrials.gov ID NCT00515554,other,protocol
1543,2007-003187-22, HD18 for advanced stages in Hodgkins Lymphoma,07-12-2007,NCT00515554,US NCT number,results
1544,2007-003187-22, HD18 for advanced stages in Hodgkins Lymphoma,07-12-2007,NA,ISRCTN number,results
1545,2007-003262-17, Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,08-07-2008,NA,US NCT number,protocol
1546,2007-003262-17, Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,08-07-2008,NA,other,protocol
1547,2007-003262-17, Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,08-07-2008,NA,US NCT number,results
1548,2007-003262-17, Impact of irbesartan on oxidative stress and C-reactive protein levels in patients with persistent atrial fibrillation,08-07-2008,NA,ISRCTN number,results
1549,2007-003263-52, Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in der intravasalen Phase („steady state“) bei 3.OT,15-08-2007,NA,US NCT number,protocol
1550,2007-003263-52, Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in der intravasalen Phase („steady state“) bei 3.OT,15-08-2007,NA,other,protocol
1551,2007-003263-52, Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in der intravasalen Phase („steady state“) bei 3.OT,15-08-2007,NA,US NCT number,results
1552,2007-003263-52, Gadofosveset Trisodium (Vasovist®) zur kontrastverstärkten MR-Angiographie der supraaortalen Arterien und zur Darstellung der Gefäßwand in der primären Kontrastmittelpassage („first pass“) und in der intravasalen Phase („steady state“) bei 3.OT,15-08-2007,NA,ISRCTN number,results
1553,2007-003370-26," A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",18-06-2009,NA,US NCT number,protocol
1554,2007-003370-26," A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",18-06-2009,NA,other,protocol
1555,2007-003370-26," A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",18-06-2009,NA,US NCT number,results
1556,2007-003370-26," A prospective, single center, double blind, placebo controlled study of adipocytokines, adipose tissue gene expression and hepatic insulin clearance in the therapeutic response to vildagliptin in man",18-06-2009,NA,ISRCTN number,results
1557,2007-003467-48," A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma",02-10-2007,NA,US NCT number,protocol
1558,2007-003467-48," A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma",02-10-2007,NA,other,protocol
1559,2007-003467-48," A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma",02-10-2007,NCT00512980,US NCT number,results
1560,2007-003467-48," A randomized phase II study of prednisone, vinblastine, doxorubicin, and gemcitabine in patients with intermediate stage Hodgkin's lymphoma",02-10-2007,NA,ISRCTN number,results
1561,2007-003561-40," A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function - PATRON-Study",26-02-2008,NA,US NCT number,protocol
1562,2007-003561-40," A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function - PATRON-Study",26-02-2008,NA,other,protocol
1563,2007-003561-40," A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function - PATRON-Study",26-02-2008,NA,US NCT number,results
1564,2007-003561-40," A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients with Impaired Renal Function - PATRON-Study",26-02-2008,NA,ISRCTN number,results
1565,2007-003634-42," Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer",21-08-2007,NA,US NCT number,protocol
1566,2007-003634-42," Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer",21-08-2007,NA,other,protocol
1567,2007-003634-42," Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer",21-08-2007,NA,US NCT number,results
1568,2007-003634-42," Prospective phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2-overexpressing breast cancer",21-08-2007,NA,ISRCTN number,results
1569,2007-003642-15," A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",24-01-2008,NA,US NCT number,protocol
1570,2007-003642-15," A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",24-01-2008,NA,other,protocol
1571,2007-003642-15," A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",24-01-2008,NA,US NCT number,results
1572,2007-003642-15," A Randomized, Double-blind Superiority Trial to Evaluate the Safety, Tolerability, and Efficacy of Belimumab in Refractory ITP Subjects",24-01-2008,NA,ISRCTN number,results
1573,2007-003710-34, EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY ,07-01-2009,NA,US NCT number,protocol
1574,2007-003710-34, EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY ,07-01-2009,NA,other,protocol
1575,2007-003710-34, EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY ,07-01-2009,NA,US NCT number,results
1576,2007-003710-34, EFFECT OF BROMOCRIPTINE ON LEFT VENTRICULAR FUNCTION IN WOMEN WITH PERIPARTUM CARDIOMYOPATHY ,07-01-2009,NA,ISRCTN number,results
1577,2007-003775-39," Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",09-09-2008,NA,US NCT number,protocol
1578,2007-003775-39," Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",09-09-2008,NA,other,protocol
1579,2007-003775-39," Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",09-09-2008,NA,US NCT number,results
1580,2007-003775-39," Randomised, placebo-controlled parallel-group trial to evaluate an oral dose of 10 mg Olanzapin combined with Riluzol for the treatment of appetite loss on patients with amyotrophic lateral sklerosis",09-09-2008,NA,ISRCTN number,results
1581,2007-003784-42, Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation,04-09-2008,NA,US NCT number,protocol
1582,2007-003784-42, Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation,04-09-2008,NA,other,protocol
1583,2007-003784-42, Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation,04-09-2008,NA,US NCT number,results
1584,2007-003784-42, Dose-finding study of lenalidomide as maintenance therapy in multiple myeloma after allogeneic stem cell transplantation,04-09-2008,NA,ISRCTN number,results
1585,2007-003813-15, CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib,26-10-2007,NA,US NCT number,protocol
1586,2007-003813-15, CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib,26-10-2007,NA,other,protocol
1587,2007-003813-15, CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib,26-10-2007,NA,US NCT number,results
1588,2007-003813-15, CONKO-005: Adjuvante Therapie des R0-resezierten Pankreaskarzinoms mit Gemcitabin plus Erlotinib,26-10-2007,NA,ISRCTN number,results
1589,2007-003858-29, Prospektive multizentrische Phase-III-Studie zur,25-02-2008,NA,US NCT number,protocol
1590,2007-003858-29, Prospektive multizentrische Phase-III-Studie zur,25-02-2008,NA,other,protocol
1591,2007-003858-29, Prospektive multizentrische Phase-III-Studie zur,25-02-2008,NA,US NCT number,results
1592,2007-003858-29, Prospektive multizentrische Phase-III-Studie zur,25-02-2008,NA,ISRCTN number,results
1593,2007-003922-70," Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)",08-08-2007,NA,US NCT number,protocol
1594,2007-003922-70," Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)",08-08-2007,NA,other,protocol
1595,2007-003922-70," Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)",08-08-2007,NA,US NCT number,results
1596,2007-003922-70," Uncontrolled, open Phase IIa study to investigate efficacy and safety of efalizumab in patients with moderate to severe palmoplantar pustular psoriasis (PPP)",08-08-2007,NA,ISRCTN number,results
1597,2007-003941-34, SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial,04-07-2008,NA,US NCT number,protocol
1598,2007-003941-34, SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial,04-07-2008,NA,other,protocol
1599,2007-003941-34, SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial,04-07-2008,NA,US NCT number,results
1600,2007-003941-34, SAFETY AND EFFICACY OF SITAGLIPTIN PLUS GRANULOCYTE-COLONY STIMULATING FACTOR IN PATIENTS SUFFERING FROM ACUTE MYOCARDIAL INFARCTION - SITAGRAMI-Trial,04-07-2008,NA,ISRCTN number,results
1601,2007-003986-42," Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",19-10-2007,NA,US NCT number,protocol
1602,2007-003986-42," Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",19-10-2007,NA,other,protocol
1603,2007-003986-42," Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",19-10-2007,NCT00979056,US NCT number,results
1604,2007-003986-42," Prospective, randomised, placebo controlled, double blind monocenter trial for the prophylactic treatment of diarrhoea with rifaximin for travellers to South- and Southeast-Asia",19-10-2007,NA,ISRCTN number,results
1605,2007-004092-19, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,10-03-2009,NCT01088750,US NCT number,protocol
1606,2007-004092-19, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,10-03-2009,NA,other,protocol
1607,2007-004092-19, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,10-03-2009,NA,US NCT number,results
1608,2007-004092-19, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,10-03-2009,NA,ISRCTN number,results
1609,2007-004134-16, Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom ,16-02-2009,NA,US NCT number,protocol
1610,2007-004134-16, Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom ,16-02-2009,NA,other,protocol
1611,2007-004134-16, Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom ,16-02-2009,NA,US NCT number,results
1612,2007-004134-16, Effectiveness and Safety of Pregabalin (Lyrica) in treatment of in-patients with ethanol withdrawal syndrom ,16-02-2009,NA,ISRCTN number,results
1613,2007-004150-85, Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors ,04-12-2007,NA,US NCT number,protocol
1614,2007-004150-85, Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors ,04-12-2007,NA,other,protocol
1615,2007-004150-85, Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors ,04-12-2007,NA,US NCT number,results
1616,2007-004150-85, Cardiac failure with normal ejection fraction: possible role of phosphodiesterase type 5 inhibitors ,04-12-2007,NA,ISRCTN number,results
1617,2007-004222-24," Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read",21-11-2007,NA,US NCT number,protocol
1618,2007-004222-24," Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read",21-11-2007,NA,other,protocol
1619,2007-004222-24," Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read",21-11-2007,NA,US NCT number,results
1620,2007-004222-24," Intra-individual, randomized comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem when imaging the pelvis in patients with spondylarthritides, evaluated in a blinded read",21-11-2007,NA,ISRCTN number,results
1621,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,protocol
1622,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,other,protocol
1623,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,results
1624,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,ISRCTN number,results
1625,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,protocol
1626,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,other,protocol
1627,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,results
1628,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,ISRCTN number,results
1629,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,protocol
1630,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,other,protocol
1631,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,results
1632,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,ISRCTN number,results
1633,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,protocol
1634,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,other,protocol
1635,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,US NCT number,results
1636,2007-004270-43, International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,23-10-2009,NA,ISRCTN number,results
1637,2007-004279-20, Comparison of the atrophogenic effect of hydrocortisone 1% cream and Elidel (Pimecrolimus 1% cream) assessed by Optical Coherence Tomography (OCT) and 20-MHZ ultrasound of uninvolved skin in patients with atopic dermatitis,30-07-2009,NA,US NCT number,protocol
1638,2007-004279-20, Comparison of the atrophogenic effect of hydrocortisone 1% cream and Elidel (Pimecrolimus 1% cream) assessed by Optical Coherence Tomography (OCT) and 20-MHZ ultrasound of uninvolved skin in patients with atopic dermatitis,30-07-2009,NA,other,protocol
1639,2007-004279-20, Comparison of the atrophogenic effect of hydrocortisone 1% cream and Elidel (Pimecrolimus 1% cream) assessed by Optical Coherence Tomography (OCT) and 20-MHZ ultrasound of uninvolved skin in patients with atopic dermatitis,30-07-2009,NA,US NCT number,results
1640,2007-004279-20, Comparison of the atrophogenic effect of hydrocortisone 1% cream and Elidel (Pimecrolimus 1% cream) assessed by Optical Coherence Tomography (OCT) and 20-MHZ ultrasound of uninvolved skin in patients with atopic dermatitis,30-07-2009,NA,ISRCTN number,results
1641,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,protocol
1642,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,other,protocol
1643,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,results
1644,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,ISRCTN number,results
1645,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,protocol
1646,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,other,protocol
1647,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,results
1648,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,ISRCTN number,results
1649,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,protocol
1650,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,other,protocol
1651,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,results
1652,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,ISRCTN number,results
1653,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,protocol
1654,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,other,protocol
1655,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,US NCT number,results
1656,2007-004280-22, Re-irradiation combined with cetuximab for the treatment of patients with locally recurrent or with secondary squamous cell carcinoma of the head and neck,18-05-2010,NA,ISRCTN number,results
1657,2007-004333-42," Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (open) on the survival of patients with severe sepsis and septic shock.",07-03-2008,NCT00832039,US NCT number,protocol
1658,2007-004333-42," Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (open) on the survival of patients with severe sepsis and septic shock.",07-03-2008,NA,other,protocol
1659,2007-004333-42," Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (open) on the survival of patients with severe sepsis and septic shock.",07-03-2008,NA,US NCT number,results
1660,2007-004333-42," Prospective randomized clinical multicenter trial about the effect of an adjunctive intravenous treatment with sodium selenite (selenase®T, double-blind) and a procalcitonin guided causal therapy (open) on the survival of patients with severe sepsis and septic shock.",07-03-2008,NA,ISRCTN number,results
1661,2007-004401-10, Hydrocortisone for Prevention of Septic Shock ,28-02-2008,NA,US NCT number,protocol
1662,2007-004401-10, Hydrocortisone for Prevention of Septic Shock ,28-02-2008,clinical trials NCT 00670254,other,protocol
1663,2007-004401-10, Hydrocortisone for Prevention of Septic Shock ,28-02-2008,NCT00670254,US NCT number,results
1664,2007-004401-10, Hydrocortisone for Prevention of Septic Shock ,28-02-2008,NA,ISRCTN number,results
1665,2007-004474-24, HD16 for early stages in Hodgkins Lymphoma,27-03-2009,NA,US NCT number,protocol
1666,2007-004474-24, HD16 for early stages in Hodgkins Lymphoma,27-03-2009,ClinicalTrials.gov ID NCT00736320,other,protocol
1667,2007-004474-24, HD16 for early stages in Hodgkins Lymphoma,27-03-2009,NCT00736320,US NCT number,results
1668,2007-004474-24, HD16 for early stages in Hodgkins Lymphoma,27-03-2009,NA,ISRCTN number,results
1669,2007-004517-34," Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",10-04-2008,NCT00606723,US NCT number,protocol
1670,2007-004517-34," Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",10-04-2008,NA,other,protocol
1671,2007-004517-34," Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",10-04-2008,NA,US NCT number,results
1672,2007-004517-34," Allogeneic stem cell transplantation for children, adolescents and young adults with relapsed or refractory AML",10-04-2008,NA,ISRCTN number,results
1673,2007-004528-19, Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,19-11-2007,NA,US NCT number,protocol
1674,2007-004528-19, Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,19-11-2007,NA,other,protocol
1675,2007-004528-19, Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,19-11-2007,NA,US NCT number,results
1676,2007-004528-19, Electrophysiological measurement of anterior cingulate cortex (ACC) function in schizophrenic patients treated with Seroquel® or Fluanxol®,19-11-2007,NA,ISRCTN number,results
1677,2007-004535-33, Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab).,09-03-2009,NA,US NCT number,protocol
1678,2007-004535-33, Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab).,09-03-2009,NA,other,protocol
1679,2007-004535-33, Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab).,09-03-2009,NA,US NCT number,results
1680,2007-004535-33, Phase II study on curative resectability of not optimally resectable liver and/or lung metastases from colorectal carcinoma (CRC) under intensified chemotherapy (FLOFOXIRI/Bevacizumab).,09-03-2009,NA,ISRCTN number,results
1681,2007-004541-15, A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma ,29-08-2007,NA,US NCT number,protocol
1682,2007-004541-15, A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma ,29-08-2007,NA,other,protocol
1683,2007-004541-15, A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma ,29-08-2007,NA,US NCT number,results
1684,2007-004541-15, A Randomized Controlled Open-Label Phase IV Mono Center Study to Compare the Reponse Profiles of Montelukast versus Fluticason in Children with Preschool Asthma ,29-08-2007,NA,ISRCTN number,results
1685,2007-004603-35," Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck.",14-01-2009,NA,US NCT number,protocol
1686,2007-004603-35," Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck.",14-01-2009,NA,other,protocol
1687,2007-004603-35," Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck.",14-01-2009,NA,US NCT number,results
1688,2007-004603-35," Radiotherapy (IMRT), Erbitux And Chemotherapy For Unresectable Carcinomas Of Head and Neck.",14-01-2009,NA,ISRCTN number,results
1689,2007-004611-61," Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",31-10-2007,NA,US NCT number,protocol
1690,2007-004611-61," Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",31-10-2007,NA,other,protocol
1691,2007-004611-61," Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",31-10-2007,NA,US NCT number,results
1692,2007-004611-61," Prospektive, randomisierte, monozentrische 2-armige Studie zum Einsatz von Daptomycin in der antibiotischen Prophylaxe von sternalen Wundinfektionen nach medianer Sternotomie",31-10-2007,NA,ISRCTN number,results
1693,2007-004674-49, Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,30-10-2007,NA,US NCT number,protocol
1694,2007-004674-49, Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,30-10-2007,NA,other,protocol
1695,2007-004674-49, Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,30-10-2007,NA,US NCT number,results
1696,2007-004674-49, Levosimendan vor Herz-Lungen-Maschine bei Coronary artery bypass graft-Operationen,30-10-2007,NA,ISRCTN number,results
1697,2007-004699-38," A prospective phase I/II, one-arm, multi-center, open label study of ",05-11-2007,NA,US NCT number,protocol
1698,2007-004699-38," A prospective phase I/II, one-arm, multi-center, open label study of ",05-11-2007,NA,other,protocol
1699,2007-004699-38," A prospective phase I/II, one-arm, multi-center, open label study of ",05-11-2007,NA,US NCT number,results
1700,2007-004699-38," A prospective phase I/II, one-arm, multi-center, open label study of ",05-11-2007,NA,ISRCTN number,results
1701,2007-004790-25, Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.,30-07-2009,NA,US NCT number,protocol
1702,2007-004790-25, Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.,30-07-2009,NA,other,protocol
1703,2007-004790-25, Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.,30-07-2009,NA,US NCT number,results
1704,2007-004790-25, Evaluation of the benefit of fluorescence diagnostics using Metvix® and the Dyaderm system for the preoperational estimation of the lateral tumour spread in basal cell carcinomas.,30-07-2009,NA,ISRCTN number,results
1705,2007-004857-27, Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone,07-10-2008,NA,US NCT number,protocol
1706,2007-004857-27, Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone,07-10-2008,NA,other,protocol
1707,2007-004857-27, Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone,07-10-2008,NA,US NCT number,results
1708,2007-004857-27, Ventral striatal function in patients with schizophrenia before and under medication with atypical antipsychotics: a comparison of sertindole and risperidone,07-10-2008,NA,ISRCTN number,results
1709,2007-004874-14," Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Koronarsyndrom (Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome; REPAIR - ACS)",04-12-2007,NA,US NCT number,protocol
1710,2007-004874-14," Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Koronarsyndrom (Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome; REPAIR - ACS)",04-12-2007,NA,other,protocol
1711,2007-004874-14," Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Koronarsyndrom (Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome; REPAIR - ACS)",04-12-2007,NA,US NCT number,results
1712,2007-004874-14," Doppel-blinde, randomisierte, kontrollierte Studie zur Erfassung des Effektes einer intrakoronaren Applikation von Knochenmark-Progenitorzellen auf die koronare Flußreserve bei Patienten mit akutem Koronarsyndrom (Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Coronary Syndrome; REPAIR - ACS)",04-12-2007,NA,ISRCTN number,results
1713,2007-004928-21, Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study,28-03-2008,NA,US NCT number,protocol
1714,2007-004928-21, Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study,28-03-2008,NA,other,protocol
1715,2007-004928-21, Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study,28-03-2008,NCT00777998,US NCT number,results
1716,2007-004928-21, Autologous-Allogeneic Tandem Stem Cell Transplantation and Maintenance Therapy with Thalidomide / DLI for patients with Multiple Myeloma (MM) and age <= 60 years: A phase II-study,28-03-2008,NA,ISRCTN number,results
1717,2007-004941-13, Serumspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten,15-10-2007,NA,US NCT number,protocol
1718,2007-004941-13, Serumspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten,15-10-2007,NA,other,protocol
1719,2007-004941-13, Serumspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten,15-10-2007,NA,US NCT number,results
1720,2007-004941-13, Serumspiegel von intravenös und enteral appliziertem Moxifloxacin bei kritisch kranken Intensivpatienten,15-10-2007,NA,ISRCTN number,results
1721,2007-004979-19, In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET),03-08-2009,NA,US NCT number,protocol
1722,2007-004979-19, In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET),03-08-2009,NA,other,protocol
1723,2007-004979-19, In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET),03-08-2009,NA,US NCT number,results
1724,2007-004979-19, In-vivo assessment of nicotinic acetylcholine receptor binding in neurodegenerative diseases using the radioligand 2-[18F]FA-85380 and positron emission tomography (PET),03-08-2009,NA,ISRCTN number,results
1725,2007-004990-24," Comparison of the concentrations of the antibiotic compound Daptomycin in serum,  cartilage-, muscle and subcutaneous tissue after a preoperative intravenous administration ",20-12-2007,NA,US NCT number,protocol
1726,2007-004990-24," Comparison of the concentrations of the antibiotic compound Daptomycin in serum,  cartilage-, muscle and subcutaneous tissue after a preoperative intravenous administration ",20-12-2007,NA,other,protocol
1727,2007-004990-24," Comparison of the concentrations of the antibiotic compound Daptomycin in serum,  cartilage-, muscle and subcutaneous tissue after a preoperative intravenous administration ",20-12-2007,NA,US NCT number,results
1728,2007-004990-24," Comparison of the concentrations of the antibiotic compound Daptomycin in serum,  cartilage-, muscle and subcutaneous tissue after a preoperative intravenous administration ",20-12-2007,NA,ISRCTN number,results
1729,2007-005063-96, Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,01-10-2007,NA,US NCT number,protocol
1730,2007-005063-96, Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,01-10-2007,NA,other,protocol
1731,2007-005063-96, Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,01-10-2007,NA,US NCT number,results
1732,2007-005063-96, Prospective trial of intravenous levetiracetam in patients with primary brain tumors and at least one symptomatic seizure who undergo biopsy or cytoreductive surgery.,01-10-2007,NA,ISRCTN number,results
1733,2007-005116-12, Phase II study of the mTOR-Inhibitor EVEROLIMUS as,05-11-2007,NA,US NCT number,protocol
1734,2007-005116-12, Phase II study of the mTOR-Inhibitor EVEROLIMUS as,05-11-2007,NA,other,protocol
1735,2007-005116-12, Phase II study of the mTOR-Inhibitor EVEROLIMUS as,05-11-2007,NA,US NCT number,results
1736,2007-005116-12, Phase II study of the mTOR-Inhibitor EVEROLIMUS as,05-11-2007,NA,ISRCTN number,results
1737,2007-005352-17," A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia ",05-08-2009,NA,US NCT number,protocol
1738,2007-005352-17," A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia ",05-08-2009,NA,other,protocol
1739,2007-005352-17," A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia ",05-08-2009,NA,US NCT number,results
1740,2007-005352-17," A twelve-week, multicenter, randomized, double-blind, placebo-controlled trail of Bupropion for the treatment of apathy in Alzheimer’s Dementia ",05-08-2009,NA,ISRCTN number,results
1741,2007-005475-34, Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,03-03-2008,NA,US NCT number,protocol
1742,2007-005475-34, Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,03-03-2008,NA,other,protocol
1743,2007-005475-34, Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,03-03-2008,NA,US NCT number,results
1744,2007-005475-34, Prospektive Studie zur potentiellen Protektion der Ovarfunktion von Frauen mit gynäkologischen Malignomen unter Chemotherapie mittels GnRH-Analoga-Applikation,03-03-2008,NA,ISRCTN number,results
1745,2007-005503-17, Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histologic proof of an infiltrate with CD20-positive Lymphocytes in proof of the superiority of a therapy with Steroidboli plus Rituximab/MabThera® in comparison to a solitary therapy with Steroidboli with regard to kidney function after one year.  ,30-10-2007,NA,US NCT number,protocol
1746,2007-005503-17, Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histologic proof of an infiltrate with CD20-positive Lymphocytes in proof of the superiority of a therapy with Steroidboli plus Rituximab/MabThera® in comparison to a solitary therapy with Steroidboli with regard to kidney function after one year.  ,30-10-2007,NA,other,protocol
1747,2007-005503-17, Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histologic proof of an infiltrate with CD20-positive Lymphocytes in proof of the superiority of a therapy with Steroidboli plus Rituximab/MabThera® in comparison to a solitary therapy with Steroidboli with regard to kidney function after one year.  ,30-10-2007,NA,US NCT number,results
1748,2007-005503-17, Randomized multicenter double-blind study of phase III in patients after kidney transplantation with an acute cellular rejection with a tubulointerstinal component in kidney transplant with histologic proof of an infiltrate with CD20-positive Lymphocytes in proof of the superiority of a therapy with Steroidboli plus Rituximab/MabThera® in comparison to a solitary therapy with Steroidboli with regard to kidney function after one year.  ,30-10-2007,NA,ISRCTN number,results
1749,2007-005537-11," Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia",18-09-2009,NA,US NCT number,protocol
1750,2007-005537-11," Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia",18-09-2009,NA,other,protocol
1751,2007-005537-11," Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia",18-09-2009,NCT01422499,US NCT number,results
1752,2007-005537-11," Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia",18-09-2009,NA,ISRCTN number,results
1753,2007-005548-25," Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas",19-11-2007,NA,US NCT number,protocol
1754,2007-005548-25," Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas",19-11-2007,NA,other,protocol
1755,2007-005548-25," Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas",19-11-2007,NA,US NCT number,results
1756,2007-005548-25," Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas",19-11-2007,NA,ISRCTN number,results
1757,2007-005585-12," Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);",06-11-2007,NA,US NCT number,protocol
1758,2007-005585-12," Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);",06-11-2007,NA,other,protocol
1759,2007-005585-12," Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);",06-11-2007,NA,US NCT number,results
1760,2007-005585-12," Prospektive, offene Studie zur Prüfung der Wirksamkeit der zusätzlichen Gabe des Somatostatinanalogon Octreotid (Sandostatin) bzw. des Dopaminagonisten Cabergolin (Dostinex) bei Patientin mit Akromegalie unter laufender Therapie mit Pegvisomant (Somavert);",06-11-2007,NA,ISRCTN number,results
1761,2007-005679-33, Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis,04-10-2010,NA,US NCT number,protocol
1762,2007-005679-33, Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis,04-10-2010,NA,other,protocol
1763,2007-005679-33, Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis,04-10-2010,NA,US NCT number,results
1764,2007-005679-33, Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis,04-10-2010,NA,ISRCTN number,results
1765,2007-005796-34," A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the biliary tract  ",07-01-2008,NA,US NCT number,protocol
1766,2007-005796-34," A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the biliary tract  ",07-01-2008,NA,other,protocol
1767,2007-005796-34," A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the biliary tract  ",07-01-2008,NA,US NCT number,results
1768,2007-005796-34," A randomized, double-blind, multicenter phase II trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemo-naive advanced or metastatic adenocarcinoma of the biliary tract  ",07-01-2008,NA,ISRCTN number,results
1769,2007-005865-37," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.",06-12-2007,NA,US NCT number,protocol
1770,2007-005865-37," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.",06-12-2007,NA,other,protocol
1771,2007-005865-37," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.",06-12-2007,NA,US NCT number,results
1772,2007-005865-37," Levofloxacin vs Piperacillin/Sulbactam and Sultamicillin in patients with acute cholecystitis. A double blind, randomized study.",06-12-2007,NA,ISRCTN number,results
1773,2007-005920-34, HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,16-06-2011,NCT01356680,US NCT number,protocol
1774,2007-005920-34, HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,16-06-2011,ClinicalTrials.gov ID NCT01356680,other,protocol
1775,2007-005920-34, HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,16-06-2011,NCT01356680,US NCT number,results
1776,2007-005920-34, HD17 for Intermediate Stage Hodgkin Lymphoma - Treatment Optimization Trial in the First-Line Treatment of intermediate Stage Hodgkin lymhoma; Therapy stratification by means of FDG-PET,16-06-2011,NA,ISRCTN number,results
1777,2007-006014-41, Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,07-02-2008,NA,US NCT number,protocol
1778,2007-006014-41, Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,07-02-2008,NA,other,protocol
1779,2007-006014-41, Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,07-02-2008,NA,US NCT number,results
1780,2007-006014-41, Determination of Diagnostic Accuracy and Added Value of Vasovist®-Enhanced Peripheral MRA in Comparison to Intra-arterial Digital Subtraction Angiography (i.a. DSA) in Patients with Peripheral Artery Disease,07-02-2008,NA,ISRCTN number,results
1781,2007-006016-33, Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,12-03-2008,NA,US NCT number,protocol
1782,2007-006016-33, Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,12-03-2008,NA,other,protocol
1783,2007-006016-33, Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,12-03-2008,NA,US NCT number,results
1784,2007-006016-33, Multicenter Phase II study of haploidentical hematopoietic cell transplantation with CD3/CD19 depleted grafts after a reduced intensity conditioning regimen for adult patients with acute leukemia,12-03-2008,NA,ISRCTN number,results
1785,2007-006051-39, Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space ,16-02-2009,NA,US NCT number,protocol
1786,2007-006051-39, Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space ,16-02-2009,NA,other,protocol
1787,2007-006051-39, Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space ,16-02-2009,NA,US NCT number,results
1788,2007-006051-39, Pharmakokinetic investigation on the tissue penetration of moxifloxacin within the pericardial space ,16-02-2009,NA,ISRCTN number,results
1789,2007-006087-30, Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei langzeitsedierten Intensivpatienten,11-09-2008,NA,US NCT number,protocol
1790,2007-006087-30, Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei langzeitsedierten Intensivpatienten,11-09-2008,NA,other,protocol
1791,2007-006087-30, Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei langzeitsedierten Intensivpatienten,11-09-2008,NA,US NCT number,results
1792,2007-006087-30, Prospektive randomisierte klinische Studie zur Beurteilung der Effizienz und Sicherheit einer inhalativen Sedierung mit Sevofluran im Vergleich zu einem intravenösen Sedierungskonzept mit Propofol bei langzeitsedierten Intensivpatienten,11-09-2008,NA,ISRCTN number,results
1793,2007-006126-10, pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,22-07-2008,NA,US NCT number,protocol
1794,2007-006126-10, pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,22-07-2008,NA,other,protocol
1795,2007-006126-10, pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,22-07-2008,NA,US NCT number,results
1796,2007-006126-10, pilot study to evaluate the efficacy of Efalizumab in patients with cutaneous t-cell lymphoma,22-07-2008,NA,ISRCTN number,results
1797,2007-006263-68," RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT ",12-03-2008,NA,US NCT number,protocol
1798,2007-006263-68," RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT ",12-03-2008,NA,other,protocol
1799,2007-006263-68," RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT ",12-03-2008,NCT00661206,US NCT number,results
1800,2007-006263-68," RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF 6 MONTHS VERSUS 12 MONTHS CLOPIDOGREL THERAPY AFTER IMPLANTATION OF A DRUG-ELUTING STENT ",12-03-2008,NA,ISRCTN number,results
1801,2007-006272-11, Validation of Dermatophot for the assessment of steroid induced skin atrophy,01-04-2008,NA,US NCT number,protocol
1802,2007-006272-11, Validation of Dermatophot for the assessment of steroid induced skin atrophy,01-04-2008,NA,other,protocol
1803,2007-006272-11, Validation of Dermatophot for the assessment of steroid induced skin atrophy,01-04-2008,NA,US NCT number,results
1804,2007-006272-11, Validation of Dermatophot for the assessment of steroid induced skin atrophy,01-04-2008,NA,ISRCTN number,results
1805,2007-006438-33, Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,22-04-2008,NA,US NCT number,protocol
1806,2007-006438-33, Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,22-04-2008,NA,other,protocol
1807,2007-006438-33, Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,22-04-2008,NA,US NCT number,results
1808,2007-006438-33, Influence of I(f) blockade on orthostatic tolerance and sympathic activity in healthy subjects.,22-04-2008,NA,ISRCTN number,results
1809,2007-006516-31," Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study)",17-03-2008,NA,US NCT number,protocol
1810,2007-006516-31," Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study)",17-03-2008,NA,other,protocol
1811,2007-006516-31," Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study)",17-03-2008,NCT00724022,US NCT number,results
1812,2007-006516-31," Triple arm, prospective-randomised multi centre study phase IV to evaluate calcineurin inhibitor reduced, steroid free immunosuppression after renal transplantation in low-risk patients (HARMONY-Study)",17-03-2008,NA,ISRCTN number,results
1813,2007-006561-32, Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders,08-09-2009,NA,US NCT number,protocol
1814,2007-006561-32, Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders,08-09-2009,NA,other,protocol
1815,2007-006561-32, Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders,08-09-2009,NA,US NCT number,results
1816,2007-006561-32, Effects of intranasal application of oxytocin on empathy and mentalising in patients with psychotic disorders and severe personality disorders,08-09-2009,NA,ISRCTN number,results
1817,2007-006606-16," The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification 			regulation (fetuin-A levels) in CKD stage 5D patients ",30-07-2009,NA,US NCT number,protocol
1818,2007-006606-16," The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification 			regulation (fetuin-A levels) in CKD stage 5D patients ",30-07-2009,NA,other,protocol
1819,2007-006606-16," The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification 			regulation (fetuin-A levels) in CKD stage 5D patients ",30-07-2009,NA,US NCT number,results
1820,2007-006606-16," The Effects of Paricalcitol capsules on Inflammation (CRP levels) and Calcification 			regulation (fetuin-A levels) in CKD stage 5D patients ",30-07-2009,NA,ISRCTN number,results
1821,2007-006609-25," Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients",27-03-2008,NA,US NCT number,protocol
1822,2007-006609-25," Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients",27-03-2008,NA,other,protocol
1823,2007-006609-25," Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients",27-03-2008,NA,US NCT number,results
1824,2007-006609-25," Effects of selective serotonin re-uptake inhibition on morbidity, mortality and mood in Depressed Heart Failure patients",27-03-2008,ISRCTN33128015,ISRCTN number,results
1825,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,protocol
1826,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,other,protocol
1827,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,results
1828,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,ISRCTN13704604,ISRCTN number,results
1829,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,protocol
1830,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,other,protocol
1831,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,results
1832,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,ISRCTN13704604,ISRCTN number,results
1833,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,protocol
1834,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,other,protocol
1835,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,results
1836,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,ISRCTN13704604,ISRCTN number,results
1837,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,protocol
1838,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,other,protocol
1839,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,NA,US NCT number,results
1840,2007-006658-24, A randomised controlled trial to compare the safety and effectiveness of doxycycline (200 mg/day) with prednisolone (0.5 mg/kg/day) ,22-10-2008,ISRCTN13704604,ISRCTN number,results
1841,2007-006914-41, Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,03-08-2009,NA,US NCT number,protocol
1842,2007-006914-41, Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,03-08-2009,NA,other,protocol
1843,2007-006914-41, Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,03-08-2009,NA,US NCT number,results
1844,2007-006914-41, Differential responses to Cognitive Behavioural Analysis System of Psychotherapy (CBASP) versus escitalopram in chronic major depression with and without early trauma,03-08-2009,NA,ISRCTN number,results
1845,2007-007011-85, Topical application of morphine for wound healing and analgesia in patients with painful oral lesions ,29-01-2010,NA,US NCT number,protocol
1846,2007-007011-85, Topical application of morphine for wound healing and analgesia in patients with painful oral lesions ,29-01-2010,NA,other,protocol
1847,2007-007011-85, Topical application of morphine for wound healing and analgesia in patients with painful oral lesions ,29-01-2010,NA,US NCT number,results
1848,2007-007011-85, Topical application of morphine for wound healing and analgesia in patients with painful oral lesions ,29-01-2010,NA,ISRCTN number,results
1849,2007-007034-18, Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,15-08-2008,NA,US NCT number,protocol
1850,2007-007034-18, Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,15-08-2008,NA,other,protocol
1851,2007-007034-18, Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,15-08-2008,NA,US NCT number,results
1852,2007-007034-18, Phase II-Studie zur Erfassung der Effektivität einer wöchentlich verabreichten Docetaxel-Carboplatin/Cisplatin-Cetuximab-Kombination (DCC) bei fortgeschrittenen Plattenepithelkarzinomen des Oropharynx und der Mundhöhle,15-08-2008,NA,ISRCTN number,results
1853,2007-007170-30, Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten ,11-01-2008,NA,US NCT number,protocol
1854,2007-007170-30, Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten ,11-01-2008,NA,other,protocol
1855,2007-007170-30, Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten ,11-01-2008,NA,US NCT number,results
1856,2007-007170-30, Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten ,11-01-2008,NA,ISRCTN number,results
1857,2007-007489-39," Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception ",30-01-2008,NA,US NCT number,protocol
1858,2007-007489-39," Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception ",30-01-2008,NA,other,protocol
1859,2007-007489-39," Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception ",30-01-2008,NA,US NCT number,results
1860,2007-007489-39," Effects of the oral monophasic contraceptive pill CG 5025 (Belara/0,03 mg etinyl estradiol and 2 mg chlormadinonacetate) on the cosmetic hairquality in women wishing to use hormonal contraception ",30-01-2008,NA,ISRCTN number,results
1861,2007-007553-31, Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age,14-05-2008,NA,US NCT number,protocol
1862,2007-007553-31, Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age,14-05-2008,NA,other,protocol
1863,2007-007553-31, Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age,14-05-2008,NA,US NCT number,results
1864,2007-007553-31, Phase I/II Clinical Study of SU11248 (Sutent) combined with Standard Chemotherapy with Cytosine Arabinoside and Daunorubicin in Patients with FLT3 mutated AML over 60 years of age,14-05-2008,NA,ISRCTN number,results
1865,2007-007587-21," Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia",28-04-2008,NA,US NCT number,protocol
1866,2007-007587-21," Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia",28-04-2008,NA,other,protocol
1867,2007-007587-21," Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia",28-04-2008,NCT00769522,US NCT number,results
1868,2007-007587-21," Phase III trial of combined immunochemotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) versus Bendamustine and Rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia",28-04-2008,NA,ISRCTN number,results
1869,2007-007637-39, Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) ,15-04-2008,NA,US NCT number,protocol
1870,2007-007637-39, Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) ,15-04-2008,NA,other,protocol
1871,2007-007637-39, Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) ,15-04-2008,NA,US NCT number,results
1872,2007-007637-39, Effects of NSAIDs on RAdiographic Damage in AS (ENRADAS) ,15-04-2008,NA,ISRCTN number,results
1873,2007-007657-31, Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,26-02-2008,NA,US NCT number,protocol
1874,2007-007657-31, Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,26-02-2008,NA,other,protocol
1875,2007-007657-31, Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,26-02-2008,NA,US NCT number,results
1876,2007-007657-31, Efficacy and safety of Miltefosine in antihistamine resistant chronic urticaria,26-02-2008,NA,ISRCTN number,results
1877,2007-007792-17, Vasovist®-enhanced MRI in Preoperative Lymph Node Staging of Lung Cancer: Comparison with 18F FDG PET/CT,05-05-2008,NA,US NCT number,protocol
1878,2007-007792-17, Vasovist®-enhanced MRI in Preoperative Lymph Node Staging of Lung Cancer: Comparison with 18F FDG PET/CT,05-05-2008,NA,other,protocol
1879,2007-007792-17, Vasovist®-enhanced MRI in Preoperative Lymph Node Staging of Lung Cancer: Comparison with 18F FDG PET/CT,05-05-2008,NA,US NCT number,results
1880,2007-007792-17, Vasovist®-enhanced MRI in Preoperative Lymph Node Staging of Lung Cancer: Comparison with 18F FDG PET/CT,05-05-2008,NA,ISRCTN number,results
1881,2007-007794-23," Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",23-01-2009,NA,US NCT number,protocol
1882,2007-007794-23," Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",23-01-2009,NA,other,protocol
1883,2007-007794-23," Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",23-01-2009,NA,US NCT number,results
1884,2007-007794-23," Prospektive, doppelblinde, randomisierte, Plazebo-kontrollierte Cross-over Studie zur Wirkung von intravenösen Immunglobulinen bei komplex-regionalem Schmerzsyndrom Typ I (M. Sudeck)",23-01-2009,NA,ISRCTN number,results
1885,2007-007805-58, The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2,23-09-2009,NA,US NCT number,protocol
1886,2007-007805-58, The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2,23-09-2009,NA,other,protocol
1887,2007-007805-58, The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2,23-09-2009,NA,US NCT number,results
1888,2007-007805-58, The effect of sitagliptin on postprandial lipoprotein metabolism in patients with diabetes mellitus type 2,23-09-2009,NA,ISRCTN number,results
1889,2007-007847-28," A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma",12-11-2010,NCT01983748,US NCT number,protocol
1890,2007-007847-28," A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma",12-11-2010,NA,other,protocol
1891,2007-007847-28," A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma",12-11-2010,NA,US NCT number,results
1892,2007-007847-28," A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected monosomy 3 uveal melanoma",12-11-2010,NA,ISRCTN number,results
1893,2007-007864-63," Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial infarction",08-02-2008,NA,US NCT number,protocol
1894,2007-007864-63," Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial infarction",08-02-2008,NA,other,protocol
1895,2007-007864-63," Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial infarction",08-02-2008,NCT00712101,US NCT number,results
1896,2007-007864-63," Prospective, randomized and controlled clinical trial comparing i.v. bolus application of Abciximab to i.c.application of Abciximab during primary PCU in patients with acute ST-elevation myocardial infarction",08-02-2008,NA,ISRCTN number,results
1897,2007-007970-47, Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study,05-08-2009,NA,US NCT number,protocol
1898,2007-007970-47, Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study,05-08-2009,NA,other,protocol
1899,2007-007970-47, Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study,05-08-2009,NA,US NCT number,results
1900,2007-007970-47, Central nervous effects of exendin-4 on hunger and satiety in obesity and diabetes mellitus type 2: an fMRI study,05-08-2009,NA,ISRCTN number,results
1901,2008-000007-28," Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myelom",17-02-2009,NA,US NCT number,protocol
1902,2008-000007-28," Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myelom",17-02-2009,NA,other,protocol
1903,2008-000007-28," Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myelom",17-02-2009,NCT00925821,US NCT number,results
1904,2008-000007-28," Lenalidomide (Revlimid®), Adriamycin and Dexamethasone (RAD) as an Induction Therapy in Newly Diagnosed Multiple Myeloma Followed by a Risk-Defined Transplant Strategy and Lenalidomide Maintenance – A Multicenter Phase II Trial by Deutsche Studiengruppe Multiples Myelom",17-02-2009,NA,ISRCTN number,results
1905,2008-000041-60, Quetiapine in the treatment of psychotic depression. A pilot study,19-03-2008,NA,US NCT number,protocol
1906,2008-000041-60, Quetiapine in the treatment of psychotic depression. A pilot study,19-03-2008,NA,other,protocol
1907,2008-000041-60, Quetiapine in the treatment of psychotic depression. A pilot study,19-03-2008,NA,US NCT number,results
1908,2008-000041-60, Quetiapine in the treatment of psychotic depression. A pilot study,19-03-2008,NA,ISRCTN number,results
1909,2008-000106-37, Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris,13-05-2008,NA,US NCT number,protocol
1910,2008-000106-37, Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris,13-05-2008,NA,other,protocol
1911,2008-000106-37, Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris,13-05-2008,NA,US NCT number,results
1912,2008-000106-37, Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris,13-05-2008,NA,ISRCTN number,results
1913,2008-000121-19, A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival,17-06-2008,NA,US NCT number,protocol
1914,2008-000121-19, A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival,17-06-2008,NA,other,protocol
1915,2008-000121-19, A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival,17-06-2008,NA,US NCT number,results
1916,2008-000121-19, A Randomized Multicentre Phase II Trial Comparing Adjuvant Therapy in Patients with Resected Pancreatic Adenocarcinoma Treated with Interferon Alpha-2b and 5-FU Alone or in Combination with Either External Radiation Treatment and Cisplatin (CapRI) or Radiation alone regarding Event-Free Survival,17-06-2008,NA,ISRCTN number,results
1917,2008-000164-17, Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei ,26-05-2008,NA,US NCT number,protocol
1918,2008-000164-17, Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei ,26-05-2008,NA,other,protocol
1919,2008-000164-17, Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei ,26-05-2008,NA,US NCT number,results
1920,2008-000164-17, Nasale Inhalation von Tobramycin mit dem Pari Sinus-Vernebler bei ,26-05-2008,NA,ISRCTN number,results
1921,2008-000247-34, Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom,05-08-2008,NA,US NCT number,protocol
1922,2008-000247-34, Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom,05-08-2008,NA,other,protocol
1923,2008-000247-34, Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom,05-08-2008,NA,US NCT number,results
1924,2008-000247-34, Prospektive randomisierte Phase II/III-Studie zur selektiven COX-2-Inhibition beim chronischen Subduralhämatom,05-08-2008,NA,ISRCTN number,results
1925,2008-000459-88," Prospective, randomized study of the efficacy of photodynamic therapy in actinic keratosis",14-10-2008,NA,US NCT number,protocol
1926,2008-000459-88," Prospective, randomized study of the efficacy of photodynamic therapy in actinic keratosis",14-10-2008,NA,other,protocol
1927,2008-000459-88," Prospective, randomized study of the efficacy of photodynamic therapy in actinic keratosis",14-10-2008,NA,US NCT number,results
1928,2008-000459-88," Prospective, randomized study of the efficacy of photodynamic therapy in actinic keratosis",14-10-2008,NA,ISRCTN number,results
1929,2008-000584-42, Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz),14-04-2008,NA,US NCT number,protocol
1930,2008-000584-42, Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz),14-04-2008,NA,other,protocol
1931,2008-000584-42, Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz),14-04-2008,NA,US NCT number,results
1932,2008-000584-42, Effekte von Zuclopenthixol auf aggressives Verhalten bei Kindern und Jugendlichen mit einer geistigen oder Lernbehinderung (unterdurchschnittlichen Intelligenz),14-04-2008,NA,ISRCTN number,results
1933,2008-000653-36, Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,27-05-2008,NA,US NCT number,protocol
1934,2008-000653-36, Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,27-05-2008,NA,other,protocol
1935,2008-000653-36, Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,27-05-2008,NA,US NCT number,results
1936,2008-000653-36, Efficacy and tolerability of Docetaxel-Gemcitabin in patients with advanced non-small cell lung cancer and an ECOG-Performance-Index of 2. A multicenter phase II-trial.,27-05-2008,NA,ISRCTN number,results
1937,2008-000654-12, PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY,04-06-2008,NA,US NCT number,protocol
1938,2008-000654-12, PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY,04-06-2008,NA,other,protocol
1939,2008-000654-12, PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY,04-06-2008,NA,US NCT number,results
1940,2008-000654-12, PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY,04-06-2008,NA,ISRCTN number,results
1941,2008-000678-19, Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network,17-09-2009,NA,US NCT number,protocol
1942,2008-000678-19, Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network,17-09-2009,NA,other,protocol
1943,2008-000678-19, Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network,17-09-2009,NA,US NCT number,results
1944,2008-000678-19, Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network,17-09-2009,NA,ISRCTN number,results
1945,2008-000706-36, Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response,29-05-2008,NA,US NCT number,protocol
1946,2008-000706-36, Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response,29-05-2008,NA,other,protocol
1947,2008-000706-36, Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response,29-05-2008,NA,US NCT number,results
1948,2008-000706-36, Optimization of treatment for patients with chronic hepatitis C infected with HCV-genotype 2 or 3: 12 vs. 24 weeks of treatment extension for patients without rapid virological response,29-05-2008,NA,ISRCTN number,results
1949,2008-000766-23, Effects of QuetiapineXR in schizophrenic patients with cannabis abuse,14-05-2008,NA,US NCT number,protocol
1950,2008-000766-23, Effects of QuetiapineXR in schizophrenic patients with cannabis abuse,14-05-2008,NA,other,protocol
1951,2008-000766-23, Effects of QuetiapineXR in schizophrenic patients with cannabis abuse,14-05-2008,NA,US NCT number,results
1952,2008-000766-23, Effects of QuetiapineXR in schizophrenic patients with cannabis abuse,14-05-2008,NA,ISRCTN number,results
1953,2008-000815-13," Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.",03-04-2008,NA,US NCT number,protocol
1954,2008-000815-13," Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.",03-04-2008,NA,other,protocol
1955,2008-000815-13," Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.",03-04-2008,NA,US NCT number,results
1956,2008-000815-13," Analysis of cerebral, renal, peripheral, and retinal hemodynamics in adults with type 2 diabetes before, during, and after administration of pioglitazone or placebo.",03-04-2008,NA,ISRCTN number,results
1957,2008-000896-30, Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks,15-01-2009,NCT00751959,US NCT number,protocol
1958,2008-000896-30, Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks,15-01-2009,NA,other,protocol
1959,2008-000896-30, Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks,15-01-2009,NA,US NCT number,results
1960,2008-000896-30, Surfactant application during spontaneous breathing with CPAP or during mechanical ventilation in the therapy of IRDS in premature infants <27 weeks,15-01-2009,NA,ISRCTN number,results
1961,2008-001015-38," A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia",13-05-2008,NA,US NCT number,protocol
1962,2008-001015-38," A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia",13-05-2008,NA,other,protocol
1963,2008-001015-38," A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia",13-05-2008,NA,US NCT number,results
1964,2008-001015-38," A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia",13-05-2008,NA,ISRCTN number,results
1965,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,protocol
1966,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,other,protocol
1967,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,results
1968,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,ISRCTN number,results
1969,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,protocol
1970,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,other,protocol
1971,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,results
1972,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,ISRCTN number,results
1973,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,protocol
1974,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,other,protocol
1975,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,results
1976,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,ISRCTN number,results
1977,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,protocol
1978,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,other,protocol
1979,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,US NCT number,results
1980,2008-001032-12," Phase 2 trial of pemetrexed (Alimta™) combined with paclitaxel in patients with recurrent/advanced follicular, papillary or anaplastic thyroid cancer",29-07-2008,NA,ISRCTN number,results
1981,2008-001090-15," Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",04-07-2008,NA,US NCT number,protocol
1982,2008-001090-15," Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",04-07-2008,NA,other,protocol
1983,2008-001090-15," Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",04-07-2008,NA,US NCT number,results
1984,2008-001090-15," Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar®) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",04-07-2008,NA,ISRCTN number,results
1985,2008-001107-27, PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT,07-12-2009,NA,US NCT number,protocol
1986,2008-001107-27, PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT,07-12-2009,NA,other,protocol
1987,2008-001107-27, PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT,07-12-2009,NA,US NCT number,results
1988,2008-001107-27, PHASE I-II MULTICENTER STUDY OF P210-B2A2 DERIVED PEPTIDE VACCINE IN CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE CYTOGENETIC RESPONSE WITH PERSISTENT MOLECULAR RESIDUAL DISEASE DURING IMATINIB TREATMENT,07-12-2009,NA,ISRCTN number,results
1989,2008-001291-71, Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD),09-06-2008,NA,US NCT number,protocol
1990,2008-001291-71, Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD),09-06-2008,NA,other,protocol
1991,2008-001291-71, Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD),09-06-2008,NA,US NCT number,results
1992,2008-001291-71, Electrophysiological correlates of putative endophenotypes of attention-deficit / hyperactivity disorder (ADHD),09-06-2008,NA,ISRCTN number,results
1993,2008-001302-16, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study),21-04-2008,NA,US NCT number,protocol
1994,2008-001302-16, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study),21-04-2008,NA,other,protocol
1995,2008-001302-16, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study),21-04-2008,NA,US NCT number,results
1996,2008-001302-16, Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of an esomeprazole therapy in patients with GERD -- a pilot study (phase IV-study),21-04-2008,NA,ISRCTN number,results
1997,2008-001371-30, Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,15-12-2008,NA,US NCT number,protocol
1998,2008-001371-30, Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,15-12-2008,NA,other,protocol
1999,2008-001371-30, Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,15-12-2008,NA,US NCT number,results
2000,2008-001371-30, Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia,15-12-2008,NA,ISRCTN number,results
2001,2008-001421-34, Phase II Trial of Combined Immunochemotherapy with,02-10-2009,NA,US NCT number,protocol
2002,2008-001421-34, Phase II Trial of Combined Immunochemotherapy with,02-10-2009,NA,other,protocol
2003,2008-001421-34, Phase II Trial of Combined Immunochemotherapy with,02-10-2009,NCT01186640,US NCT number,results
2004,2008-001421-34, Phase II Trial of Combined Immunochemotherapy with,02-10-2009,NA,ISRCTN number,results
2005,2008-001560-37, Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom,14-05-2008,NA,US NCT number,protocol
2006,2008-001560-37, Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom,14-05-2008,NA,other,protocol
2007,2008-001560-37, Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom,14-05-2008,NA,US NCT number,results
2008,2008-001560-37, Sequentielle Kombination einer Chemotherapie mit Gemcitabine/Oxaliplatin und photodynamischen Therapie beim fortgeschrittenen Gallengangskarzinom,14-05-2008,NA,ISRCTN number,results
2009,2008-001669-27, A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Group (GCTSG) (GCLLSG/GCTSG CLL-X2 protocol),03-09-2010,NA,US NCT number,protocol
2010,2008-001669-27, A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Group (GCTSG) (GCLLSG/GCTSG CLL-X2 protocol),03-09-2010,NA,other,protocol
2011,2008-001669-27, A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Group (GCTSG) (GCLLSG/GCTSG CLL-X2 protocol),03-09-2010,NA,US NCT number,results
2012,2008-001669-27, A phase-III study on the value of allogeneic stem cell transplantation in poor-risk chronic lymphocytic leukemia by the German CLL Study Group (GCLLSG) and the German Cooperative Transplant Study Group (GCTSG) (GCLLSG/GCTSG CLL-X2 protocol),03-09-2010,NA,ISRCTN number,results
2013,2008-001686-28, Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,02-04-2008,NA,US NCT number,protocol
2014,2008-001686-28, Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,02-04-2008,NA,other,protocol
2015,2008-001686-28, Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,02-04-2008,NA,US NCT number,results
2016,2008-001686-28, Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma,02-04-2008,NA,ISRCTN number,results
2017,2008-001755-22, STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY,11-02-2009,NCT00657878,US NCT number,protocol
2018,2008-001755-22, STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY,11-02-2009,NA,other,protocol
2019,2008-001755-22, STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY,11-02-2009,NA,US NCT number,results
2020,2008-001755-22, STEALTH LIPOSOMAL DOXORUBICIN vs CARBOPLATIN/PACLITAXEL IN PATIENTS WITH OVARIAN CANCER RECURRENCE BETWEEN SIX AND TWELVE MONTHS AFTER PREVIOUS PLATINUM BASED CHEMOTHERAPY: PHASE III MULTICENTER RANDOMIZED STUDY,11-02-2009,NA,ISRCTN number,results
2021,2008-001770-33," INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME ",22-04-2008,NA,US NCT number,protocol
2022,2008-001770-33," INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME ",22-04-2008,NA,other,protocol
2023,2008-001770-33," INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME ",22-04-2008,NA,US NCT number,results
2024,2008-001770-33," INVESTIGATOR-INITIATED SINGLE BLIND, TWO-ARMED, RANDOMIZED PHASE 3 CLINICAL TRIAL TO COMPARE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM (5% MTF) ONCE DAILY VERSUS 2% MINOXIDIL TOPICAL SOLUTION (2% MTS) TWICE DAILY IN APPLICATION ON FEMALES WITH SLIGHTLY TO MODERATE ANDROGENETIC ALOPECIA CONCERNING HAIR VOLUME ",22-04-2008,NA,ISRCTN number,results
2025,2008-001787-36, Verbessert die perioperative Applikation von Esketamin in subanästhetischer Dosierung die postoperative Analgesie?,28-08-2008,NA,US NCT number,protocol
2026,2008-001787-36, Verbessert die perioperative Applikation von Esketamin in subanästhetischer Dosierung die postoperative Analgesie?,28-08-2008,NA,other,protocol
2027,2008-001787-36, Verbessert die perioperative Applikation von Esketamin in subanästhetischer Dosierung die postoperative Analgesie?,28-08-2008,NA,US NCT number,results
2028,2008-001787-36, Verbessert die perioperative Applikation von Esketamin in subanästhetischer Dosierung die postoperative Analgesie?,28-08-2008,NA,ISRCTN number,results
2029,2008-001833-87," Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign lymphoma, phase IV study",26-05-2008,NA,US NCT number,protocol
2030,2008-001833-87," Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign lymphoma, phase IV study",26-05-2008,NA,other,protocol
2031,2008-001833-87," Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign lymphoma, phase IV study",26-05-2008,NA,US NCT number,results
2032,2008-001833-87," Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malign lymphoma, phase IV study",26-05-2008,NA,ISRCTN number,results
2033,2008-001849-26," Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus. ",29-07-2008,NA,US NCT number,protocol
2034,2008-001849-26," Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus. ",29-07-2008,NA,other,protocol
2035,2008-001849-26," Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus. ",29-07-2008,NA,US NCT number,results
2036,2008-001849-26," Multicentre, open phase II trial to evaluate safety and efficacy of a perioperative chemotherapy with docetaxel, cisplatin and capecitabin in patients suffering from adenocarcinoma of the stomach, gastroesophageal junction or distal esophagus. ",29-07-2008,NA,ISRCTN number,results
2037,2008-001885-96," Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 ",19-03-2009,NA,US NCT number,protocol
2038,2008-001885-96," Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 ",19-03-2009,NA,other,protocol
2039,2008-001885-96," Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 ",19-03-2009,NA,US NCT number,results
2040,2008-001885-96," Treatment with Lenalidomide, Bendamustine and Prednisone (RBP) in Patients with Relapsed or Refractory Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077 ",19-03-2009,NA,ISRCTN number,results
2041,2008-002090-12, Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on ,12-11-2008,NA,US NCT number,protocol
2042,2008-002090-12, Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on ,12-11-2008,NA,other,protocol
2043,2008-002090-12, Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on ,12-11-2008,NA,US NCT number,results
2044,2008-002090-12, Effect of Iloprost inhalation before and during extracorporeal circulation (ECC) on ,12-11-2008,NA,ISRCTN number,results
2045,2008-002117-46, Veränderungen der endogenen Insulin- und Glukagonsekretion während einer basalen Insulin-Substitution,30-05-2008,NA,US NCT number,protocol
2046,2008-002117-46, Veränderungen der endogenen Insulin- und Glukagonsekretion während einer basalen Insulin-Substitution,30-05-2008,NA,other,protocol
2047,2008-002117-46, Veränderungen der endogenen Insulin- und Glukagonsekretion während einer basalen Insulin-Substitution,30-05-2008,NA,US NCT number,results
2048,2008-002117-46, Veränderungen der endogenen Insulin- und Glukagonsekretion während einer basalen Insulin-Substitution,30-05-2008,NA,ISRCTN number,results
2049,2008-002123-93, Mycophenolate sodium in Graves’ orbitopathy,16-04-2009,NA,US NCT number,protocol
2050,2008-002123-93, Mycophenolate sodium in Graves’ orbitopathy,16-04-2009,NA,other,protocol
2051,2008-002123-93, Mycophenolate sodium in Graves’ orbitopathy,16-04-2009,NA,US NCT number,results
2052,2008-002123-93, Mycophenolate sodium in Graves’ orbitopathy,16-04-2009,NA,ISRCTN number,results
2053,2008-002130-30, Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT),09-06-2008,NA,US NCT number,protocol
2054,2008-002130-30, Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT),09-06-2008,NA,other,protocol
2055,2008-002130-30, Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT),09-06-2008,NA,US NCT number,results
2056,2008-002130-30, Targeted Natural Killer (NK) cell based adoptive immunotherapy for the treatment of patients with Non-Small Cell Lung Cancer (NSCLC) after radiochemotherapy (RCT),09-06-2008,NA,ISRCTN number,results
2057,2008-002226-11, Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,03-09-2008,NA,US NCT number,protocol
2058,2008-002226-11, Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,03-09-2008,NA,other,protocol
2059,2008-002226-11, Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,03-09-2008,NA,US NCT number,results
2060,2008-002226-11, Randomized Controlled Trial of Simvastatin in Amnestic MCI Patients,03-09-2008,NA,ISRCTN number,results
2061,2008-002269-29," A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study [HEILIVCA STUDY]",27-01-2009,NA,US NCT number,protocol
2062,2008-002269-29," A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study [HEILIVCA STUDY]",27-01-2009,NA,other,protocol
2063,2008-002269-29," A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study [HEILIVCA STUDY]",27-01-2009,NA,US NCT number,results
2064,2008-002269-29," A prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolisation (TACE) combined with Sorafenib vs. TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) – Heidelberg Liver Cancer Study [HEILIVCA STUDY]",27-01-2009,NA,ISRCTN number,results
2065,2008-002278-37, Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart failure,23-06-2008,NA,US NCT number,protocol
2066,2008-002278-37, Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart failure,23-06-2008,NA,other,protocol
2067,2008-002278-37, Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart failure,23-06-2008,NA,US NCT number,results
2068,2008-002278-37, Auswirkungen von Pantoprazol auf die myokardiale Kontraktilität bei Patienten mit Herzinsuffizienz - influence of pantoprazole on human myocardial contractility at patients with congestive heart failure,23-06-2008,NA,ISRCTN number,results
2069,2008-002325-37," Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial",04-08-2009,NA,US NCT number,protocol
2070,2008-002325-37," Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial",04-08-2009,NA,other,protocol
2071,2008-002325-37," Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial",04-08-2009,NA,US NCT number,results
2072,2008-002325-37," Effects of Exenatide (Byetta®) on biochemical and histological parameters of liver function in patients with Nonalcoholic Steatohepatitis (NASH) – a randomized, placebo-controlled, parallel-group trial",04-08-2009,NA,ISRCTN number,results
2073,2008-002338-31, Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus,31-07-2008,NA,US NCT number,protocol
2074,2008-002338-31, Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus,31-07-2008,NA,other,protocol
2075,2008-002338-31, Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus,31-07-2008,NA,US NCT number,results
2076,2008-002338-31, Prospektive randomisierte Phase II Studie zur Behandlung von Patienten mit fortgeschrittenem hormonrefraktären Prostatakarzinom mittels LHRH-Analoga und Somatostatin-Analoga unter Berücksichtigung der neuroendokrinen Expression sowie des Androgenrezeptorstatus,31-07-2008,NA,ISRCTN number,results
2077,2008-002667-13, A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC),09-07-2008,NA,US NCT number,protocol
2078,2008-002667-13, A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC),09-07-2008,NA,other,protocol
2079,2008-002667-13, A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC),09-07-2008,NA,US NCT number,results
2080,2008-002667-13, A single-center controlled pilot study to investigate pre- and perioperative therapy with Sorafenib (Nexavar®) in patients who are candidates for a curative surgery of renal cell cancer (PREST = preoperative Sorafenib Therapy in RCC),09-07-2008,NA,ISRCTN number,results
2081,2008-002721-37," An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T",12-02-2009,NA,US NCT number,protocol
2082,2008-002721-37," An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T",12-02-2009,NA,other,protocol
2083,2008-002721-37," An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T",12-02-2009,NA,US NCT number,results
2084,2008-002721-37," An open-label, uncontrolled phase II trial of HDAC inhibitor LBH589 in patients with chemo-refractory metastatic gastric cancer overexpressing histone deacetylases - CLBH589BDE03T",12-02-2009,NA,ISRCTN number,results
2085,2008-002985-70," Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.",17-12-2008,NA,US NCT number,protocol
2086,2008-002985-70," Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.",17-12-2008,NA,other,protocol
2087,2008-002985-70," Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.",17-12-2008,NA,US NCT number,results
2088,2008-002985-70," Evaluation of the preventive effect of pentoxifylline and ursodeoxycholic acid to radiation induced liver toxicity after brachytherapy of liver metastases, assessed in a prospective randomised trial.",17-12-2008,NA,ISRCTN number,results
2089,2008-003064-19," Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma",23-10-2008,NA,US NCT number,protocol
2090,2008-003064-19," Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma",23-10-2008,NA,other,protocol
2091,2008-003064-19," Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma",23-10-2008,NA,US NCT number,results
2092,2008-003064-19," Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma",23-10-2008,NA,ISRCTN number,results
2093,2008-003120-37, EV(E)A Studie,06-10-2008,NA,US NCT number,protocol
2094,2008-003120-37, EV(E)A Studie,06-10-2008,NA,other,protocol
2095,2008-003120-37, EV(E)A Studie,06-10-2008,NA,US NCT number,results
2096,2008-003120-37, EV(E)A Studie,06-10-2008,NA,ISRCTN number,results
2097,2008-003174-18," Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)",09-12-2008,NCT00894569,US NCT number,protocol
2098,2008-003174-18," Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)",09-12-2008,NA,other,protocol
2099,2008-003174-18," Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)",09-12-2008,NA,US NCT number,results
2100,2008-003174-18," Open-labeled, randomized multi-center phase II study evaluating the efficacy and safety of Paclitaxel/ Carboplatin with and without Cetuximab as first-line treatment of adeno- and undifferentiated carcinoma of unknown primary (CUP)",09-12-2008,NA,ISRCTN number,results
2101,2008-003249-10," Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)",11-02-2009,NA,US NCT number,protocol
2102,2008-003249-10," Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)",11-02-2009,NA,other,protocol
2103,2008-003249-10," Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)",11-02-2009,NA,US NCT number,results
2104,2008-003249-10," Olmesartan, Oxidant Stress and in Vivo Re-Endothelialization Capacity of Endothelial Progenitor Cells from Patients with Chronic Kidney Disease (OECD Study)",11-02-2009,NA,ISRCTN number,results
2105,2008-003256-29, Effect of Methylnaltrexone on Postoperative Analgesic Demands,20-01-2009,NA,US NCT number,protocol
2106,2008-003256-29, Effect of Methylnaltrexone on Postoperative Analgesic Demands,20-01-2009,NA,other,protocol
2107,2008-003256-29, Effect of Methylnaltrexone on Postoperative Analgesic Demands,20-01-2009,NA,US NCT number,results
2108,2008-003256-29, Effect of Methylnaltrexone on Postoperative Analgesic Demands,20-01-2009,NA,ISRCTN number,results
2109,2008-003285-26, Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents diagnosed with ADHD,24-06-2008,NA,US NCT number,protocol
2110,2008-003285-26, Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents diagnosed with ADHD,24-06-2008,NA,other,protocol
2111,2008-003285-26, Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents diagnosed with ADHD,24-06-2008,NA,US NCT number,results
2112,2008-003285-26, Effect of methylphenidate formulation on ADHD-patients' adherence to medical treatment. A comparison of Medikinet retard® (ER) once daily and Medikinet® (IR) twice daily in children and adolescents diagnosed with ADHD,24-06-2008,NA,ISRCTN number,results
2113,2008-003331-20," Effect of quetiapine XR on sleep in patients with major depression, as compared with mirtazapine",14-07-2008,NA,US NCT number,protocol
2114,2008-003331-20," Effect of quetiapine XR on sleep in patients with major depression, as compared with mirtazapine",14-07-2008,NA,other,protocol
2115,2008-003331-20," Effect of quetiapine XR on sleep in patients with major depression, as compared with mirtazapine",14-07-2008,NA,US NCT number,results
2116,2008-003331-20," Effect of quetiapine XR on sleep in patients with major depression, as compared with mirtazapine",14-07-2008,NA,ISRCTN number,results
2117,2008-003392-40, Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN1A,20-01-2009,NA,US NCT number,protocol
2118,2008-003392-40, Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN1A,20-01-2009,NA,other,protocol
2119,2008-003392-40, Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN1A,20-01-2009,NA,US NCT number,results
2120,2008-003392-40, Untersuchung des Einflusses von Carbamazepin auf die mittels transkranieller Magnetstimulation gemessene kortikale Exzitabilität des menschlichen Motorkortex in Abhängigkeit vom Polymorphismus für SCN1A,20-01-2009,NA,ISRCTN number,results
2121,2008-003658-13, EWING 2008,19-08-2008,NA,US NCT number,protocol
2122,2008-003658-13, EWING 2008,19-08-2008,ClinicalTrials.gov NCT00824083,other,protocol
2123,2008-003658-13, EWING 2008,19-08-2008,NA,US NCT number,results
2124,2008-003658-13, EWING 2008,19-08-2008,NA,ISRCTN number,results
2125,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,protocol
2126,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,other,protocol
2127,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,results
2128,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,ISRCTN number,results
2129,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,protocol
2130,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,other,protocol
2131,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,results
2132,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,ISRCTN number,results
2133,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,protocol
2134,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,other,protocol
2135,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,results
2136,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,ISRCTN number,results
2137,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,protocol
2138,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,other,protocol
2139,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,US NCT number,results
2140,2008-003833-25," Efficacy ans safety of subcutaneous Efalizumab in the treatment of patients with cutaneous lupus erythematosus: A mono-centre, open-label, prospective pilot study",16-10-2008,NA,ISRCTN number,results
2141,2008-003966-25," Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo.",04-11-2008,NA,US NCT number,protocol
2142,2008-003966-25," Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo.",04-11-2008,NA,other,protocol
2143,2008-003966-25," Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo.",04-11-2008,NA,US NCT number,results
2144,2008-003966-25," Double-blind, placebo controlled, randomised, monocenter cross-over studie to evaluate the effect of Desmopressin on the nocturnal polyuria in patients with idiopathic Parkinson Syndrome compared to placebo.",04-11-2008,NA,ISRCTN number,results
2145,2008-004182-26," Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",02-02-2009,NA,US NCT number,protocol
2146,2008-004182-26," Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",02-02-2009,NA,other,protocol
2147,2008-004182-26," Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",02-02-2009,NA,US NCT number,results
2148,2008-004182-26," Antidepressive efficacy, safety, tolerability and genetic response predictors of lithium augmentation in Escitalopram-treated patients with major depression",02-02-2009,NA,ISRCTN number,results
2149,2008-004231-38, Effects of vildagliptin (Galvus®) on beta-cell function ,08-08-2008,NA,US NCT number,protocol
2150,2008-004231-38, Effects of vildagliptin (Galvus®) on beta-cell function ,08-08-2008,NA,other,protocol
2151,2008-004231-38, Effects of vildagliptin (Galvus®) on beta-cell function ,08-08-2008,NA,US NCT number,results
2152,2008-004231-38, Effects of vildagliptin (Galvus®) on beta-cell function ,08-08-2008,NA,ISRCTN number,results
2153,2008-004583-40," A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML.",07-01-2009,NA,US NCT number,protocol
2154,2008-004583-40," A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML.",07-01-2009,NA,other,protocol
2155,2008-004583-40," A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML.",07-01-2009,NA,US NCT number,results
2156,2008-004583-40," A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML.",07-01-2009,NA,ISRCTN number,results
2157,2008-004675-22, Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD,03-09-2008,NA,US NCT number,protocol
2158,2008-004675-22, Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD,03-09-2008,NA,other,protocol
2159,2008-004675-22, Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD,03-09-2008,NCT00976222,US NCT number,results
2160,2008-004675-22, Intravitreal ranibizumab in patients with retinal pigment epithelial detachments secondary to AMD,03-09-2008,NA,ISRCTN number,results
2161,2008-004696-22, An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution,26-02-2009,NA,US NCT number,protocol
2162,2008-004696-22, An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution,26-02-2009,NA,other,protocol
2163,2008-004696-22, An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution,26-02-2009,NA,US NCT number,results
2164,2008-004696-22, An Open Label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution,26-02-2009,NA,ISRCTN number,results
2165,2008-004802-14, A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine plus Capecitabine (Arm GC) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH) ,09-04-2009,NCT01077427,US NCT number,protocol
2166,2008-004802-14, A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine plus Capecitabine (Arm GC) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH) ,09-04-2009,AIO Number. AIO-PAK-0111,other,protocol
2167,2008-004802-14, A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine plus Capecitabine (Arm GC) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH) ,09-04-2009,NA,US NCT number,results
2168,2008-004802-14, A randomized two-armed open study on the adjuvant therapy in patients with R0/R1 resected pancreatic carcinoma with Gemcitabine plus Capecitabine (Arm GC) vs. Gemcitabine plus Cisplatin with regional hyperthermia (Arm GPH) ,09-04-2009,NA,ISRCTN number,results
2169,2008-004926-18, Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease ,30-10-2008,NA,US NCT number,protocol
2170,2008-004926-18, Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease ,30-10-2008,NA,other,protocol
2171,2008-004926-18, Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease ,30-10-2008,NA,US NCT number,results
2172,2008-004926-18, Comparison of the human TNF-alpha antibody adalimumab with infliximab in induction and maintenance of steroid-free remission in patients with moderate to severe Crohn’s disease ,30-10-2008,NA,ISRCTN number,results
2173,2008-004968-40," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age",13-11-2008,NA,US NCT number,protocol
2174,2008-004968-40," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age",13-11-2008,NA,other,protocol
2175,2008-004968-40," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age",13-11-2008,NCT00893373,US NCT number,results
2176,2008-004968-40," A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in patients with newly diagnosed AML ≤ 60 years of age",13-11-2008,NA,ISRCTN number,results
2177,2008-004991-28, Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes,27-02-2009,NA,US NCT number,protocol
2178,2008-004991-28, Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes,27-02-2009,NA,other,protocol
2179,2008-004991-28, Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes,27-02-2009,NA,US NCT number,results
2180,2008-004991-28, Assessment of focal liver lesions in fluoroscopic MR using Primovist and fast dynamic imaging sequences for interventional purposes,27-02-2009,NA,ISRCTN number,results
2181,2008-005085-30, Einfluss von Rasagilin auf das Riechvermögen von Patienten mit ,04-03-2009,NA,US NCT number,protocol
2182,2008-005085-30, Einfluss von Rasagilin auf das Riechvermögen von Patienten mit ,04-03-2009,NA,other,protocol
2183,2008-005085-30, Einfluss von Rasagilin auf das Riechvermögen von Patienten mit ,04-03-2009,NA,US NCT number,results
2184,2008-005085-30, Einfluss von Rasagilin auf das Riechvermögen von Patienten mit ,04-03-2009,NA,ISRCTN number,results
2185,2008-005167-33, Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,16-03-2010,NA,US NCT number,protocol
2186,2008-005167-33, Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,16-03-2010,NA,other,protocol
2187,2008-005167-33, Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,16-03-2010,NA,US NCT number,results
2188,2008-005167-33, Effect of gabapentine as symptomatic therapy for cerebellar ataxia in degenerative and inflammatory CNS-disease,16-03-2010,NA,ISRCTN number,results
2189,2008-005213-22, SUPREMES - Sunphenon in progressive forms of multiple sclerosis ,22-08-2008,NA,US NCT number,protocol
2190,2008-005213-22, SUPREMES - Sunphenon in progressive forms of multiple sclerosis ,22-08-2008,NA,other,protocol
2191,2008-005213-22, SUPREMES - Sunphenon in progressive forms of multiple sclerosis ,22-08-2008,NCT00799890,US NCT number,results
2192,2008-005213-22, SUPREMES - Sunphenon in progressive forms of multiple sclerosis ,22-08-2008,NA,ISRCTN number,results
2193,2008-005306-39, Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification,19-11-2008,NCT00785109,US NCT number,protocol
2194,2008-005306-39, Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification,19-11-2008,NA,other,protocol
2195,2008-005306-39, Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification,19-11-2008,NA,US NCT number,results
2196,2008-005306-39, Food supplementation with Vitamin K for MGP-activation and inhibition of progression of aortic valve calcification,19-11-2008,NA,ISRCTN number,results
2197,2008-005312-41, Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma,05-01-2011,NA,US NCT number,protocol
2198,2008-005312-41, Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma,05-01-2011,NA,other,protocol
2199,2008-005312-41, Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma,05-01-2011,NCT01266187,US NCT number,results
2200,2008-005312-41, Perioperative chemotherapy with FOLFOX plus Cetuximab versus adjuvant FOLFOX plus Cetuximab for patients with resectable liver metastases of colorectal carcinoma,05-01-2011,NA,ISRCTN number,results
2201,2008-005365-61," A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",03-12-2009,NA,US NCT number,protocol
2202,2008-005365-61," A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",03-12-2009,NA,other,protocol
2203,2008-005365-61," A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",03-12-2009,NA,US NCT number,results
2204,2008-005365-61," A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY STUDY OF APREMILAST (CC-10004) IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",03-12-2009,NA,ISRCTN number,results
2205,2008-005433-30, Taxotere-Enoxaparin-(ENOXA)-Studie:,06-01-2009,NA,US NCT number,protocol
2206,2008-005433-30, Taxotere-Enoxaparin-(ENOXA)-Studie:,06-01-2009,NA,other,protocol
2207,2008-005433-30, Taxotere-Enoxaparin-(ENOXA)-Studie:,06-01-2009,NA,US NCT number,results
2208,2008-005433-30, Taxotere-Enoxaparin-(ENOXA)-Studie:,06-01-2009,NA,ISRCTN number,results
2209,2008-005451-23," Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",26-01-2009,NA,US NCT number,protocol
2210,2008-005451-23," Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",26-01-2009,NA,other,protocol
2211,2008-005451-23," Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",26-01-2009,NA,US NCT number,results
2212,2008-005451-23," Vergleichende, randomisierte, kontrollierte und doppelblinde In-situ-Studie zur Wirkung von Speichelersatzmitteln auf Schmelz und Dentin",26-01-2009,NA,ISRCTN number,results
2213,2008-005453-38, Simultaneous Study of Docetaxel Based Anthracycline Free,20-10-2008,NA,US NCT number,protocol
2214,2008-005453-38, Simultaneous Study of Docetaxel Based Anthracycline Free,20-10-2008,NA,other,protocol
2215,2008-005453-38, Simultaneous Study of Docetaxel Based Anthracycline Free,20-10-2008,NA,US NCT number,results
2216,2008-005453-38, Simultaneous Study of Docetaxel Based Anthracycline Free,20-10-2008,NA,ISRCTN number,results
2217,2008-005560-13, A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),05-06-2009,NA,US NCT number,protocol
2218,2008-005560-13, A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),05-06-2009,NA,other,protocol
2219,2008-005560-13, A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),05-06-2009,NCT00932971,US NCT number,results
2220,2008-005560-13, A multicenter randomised study comparing the efficacy of pegylated interferon-alfa-2a plus placebo vs. pegylated interfeorn-alfa-2a plus tenofovir for the treatment of chronic delta hepatitis- The Hep-Net International Delta hepatits Interventional Trial II (HIDIT-II),05-06-2009,NA,ISRCTN number,results
2221,2008-005609-21, Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,03-06-2009,NA,US NCT number,protocol
2222,2008-005609-21, Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,03-06-2009,NA,other,protocol
2223,2008-005609-21, Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,03-06-2009,NA,US NCT number,results
2224,2008-005609-21, Exploratory study to assess the predictive value of 99mTc-labeled albumin spheres for the intrahepatic distribution of 90Y SIR Spheres in patients with liver metastases of colorectal tumors.,03-06-2009,NA,ISRCTN number,results
2225,2008-005653-37," Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",14-01-2009,NA,US NCT number,protocol
2226,2008-005653-37," Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",14-01-2009,NA,other,protocol
2227,2008-005653-37," Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",14-01-2009,NA,US NCT number,results
2228,2008-005653-37," Multicenter, prospective randomized trial on the use of prothrombin complex and fresh frozen plasma in patients with intracerebral hemorrhage related to vitamin K antagonists (VKA)",14-01-2009,NA,ISRCTN number,results
2229,2008-005746-22," Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",26-01-2009,NA,US NCT number,protocol
2230,2008-005746-22," Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",26-01-2009,NA,other,protocol
2231,2008-005746-22," Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",26-01-2009,NA,US NCT number,results
2232,2008-005746-22," Multi-center, double blind, dose escalating study to compare the effects of 5 mg, 10mg and 20mg of Desloratadine in patients with acquired cold urticaria (ACU)",26-01-2009,NA,ISRCTN number,results
2233,2008-005786-60," A prospective, multicentre trial on the value of ",14-01-2014,NA,US NCT number,protocol
2234,2008-005786-60," A prospective, multicentre trial on the value of ",14-01-2014,NA,other,protocol
2235,2008-005786-60," A prospective, multicentre trial on the value of ",14-01-2014,NA,US NCT number,results
2236,2008-005786-60," A prospective, multicentre trial on the value of ",14-01-2014,NA,ISRCTN number,results
2237,2008-005828-84, Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,28-01-2009,NA,US NCT number,protocol
2238,2008-005828-84, Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,28-01-2009,NA,other,protocol
2239,2008-005828-84, Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,28-01-2009,NA,US NCT number,results
2240,2008-005828-84, Inflammatory mediators in nasal discharge of chronic rhinosinusitis patients treated with erythromycin.,28-01-2009,NA,ISRCTN number,results
2241,2008-005862-30, Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. ,15-12-2008,NA,US NCT number,protocol
2242,2008-005862-30, Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. ,15-12-2008,NA,other,protocol
2243,2008-005862-30, Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. ,15-12-2008,NA,US NCT number,results
2244,2008-005862-30, Pre-emptive therapy of acute graft versus host disease according to specific proteomic patterns after allogeneic hematopoietic stem cell transplantation. ,15-12-2008,NA,ISRCTN number,results
2245,2008-005925-12, Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy,29-12-2010,NA,US NCT number,protocol
2246,2008-005925-12, Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy,29-12-2010,NA,other,protocol
2247,2008-005925-12, Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy,29-12-2010,NA,US NCT number,results
2248,2008-005925-12, Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy,29-12-2010,NA,ISRCTN number,results
2249,2008-005976-28, Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study,07-04-2009,NA,US NCT number,protocol
2250,2008-005976-28, Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study,07-04-2009,NA,other,protocol
2251,2008-005976-28, Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study,07-04-2009,NA,US NCT number,results
2252,2008-005976-28, Prevention of HBV reinfection after liver transplantation using entecavir monotherapy after short-term HBIg administration: A pilot study,07-04-2009,NA,ISRCTN number,results
2253,2008-006055-52, Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,17-11-2008,NA,US NCT number,protocol
2254,2008-006055-52, Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,17-11-2008,NA,other,protocol
2255,2008-006055-52, Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,17-11-2008,NA,US NCT number,results
2256,2008-006055-52, Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer,17-11-2008,NA,ISRCTN number,results
2257,2008-006135-12, Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,11-11-2008,NA,US NCT number,protocol
2258,2008-006135-12, Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,11-11-2008,NA,other,protocol
2259,2008-006135-12, Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,11-11-2008,NA,US NCT number,results
2260,2008-006135-12, Balanced crystalloids versus balanced colloids within a goal-directed hemodynamic protocol in patients undergoing gynaecological tumor resection.,11-11-2008,NA,ISRCTN number,results
2261,2008-006227-31, Inflammatory Topoproteome of Psoriasis under Etanercept Treatment,13-01-2009,NA,US NCT number,protocol
2262,2008-006227-31, Inflammatory Topoproteome of Psoriasis under Etanercept Treatment,13-01-2009,NA,other,protocol
2263,2008-006227-31, Inflammatory Topoproteome of Psoriasis under Etanercept Treatment,13-01-2009,NA,US NCT number,results
2264,2008-006227-31, Inflammatory Topoproteome of Psoriasis under Etanercept Treatment,13-01-2009,NA,ISRCTN number,results
2265,2008-006242-26, Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes,07-08-2009,NA,US NCT number,protocol
2266,2008-006242-26, Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes,07-08-2009,NA,other,protocol
2267,2008-006242-26, Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes,07-08-2009,NCT01351272,US NCT number,results
2268,2008-006242-26, Genetic modulation of functional brain activity of attention-deficit/hyperactivity disorder-related working memory processes,07-08-2009,NA,ISRCTN number,results
2269,2008-006268-12, Early treatment with deferasirox (Exjade®) in low risk MDS,20-07-2009,NA,US NCT number,protocol
2270,2008-006268-12, Early treatment with deferasirox (Exjade®) in low risk MDS,20-07-2009,NA,other,protocol
2271,2008-006268-12, Early treatment with deferasirox (Exjade®) in low risk MDS,20-07-2009,NA,US NCT number,results
2272,2008-006268-12, Early treatment with deferasirox (Exjade®) in low risk MDS,20-07-2009,NA,ISRCTN number,results
2273,2008-006381-29," Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer",12-06-2009,NA,US NCT number,protocol
2274,2008-006381-29," Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer",12-06-2009,NA,other,protocol
2275,2008-006381-29," Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer",12-06-2009,NA,US NCT number,results
2276,2008-006381-29," Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer",12-06-2009,NA,ISRCTN number,results
2277,2008-006871-60," Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",02-03-2009,NA,US NCT number,protocol
2278,2008-006871-60," Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",02-03-2009,NA,other,protocol
2279,2008-006871-60," Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",02-03-2009,NA,US NCT number,results
2280,2008-006871-60," Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma",02-03-2009,NA,ISRCTN number,results
2281,2008-006905-18, Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon,27-07-2010,NA,US NCT number,protocol
2282,2008-006905-18, Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon,27-07-2010,NA,other,protocol
2283,2008-006905-18, Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon,27-07-2010,NA,US NCT number,results
2284,2008-006905-18, Pharmakotherapie kognitiver Defizite bei schizophrenen Störungen – Randomisierte placebokontrollierte Doppelblindstudie mit Pergolid versus Tolcapon,27-07-2010,NA,ISRCTN number,results
2285,2008-007031-41," Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",14-09-2009,NA,US NCT number,protocol
2286,2008-007031-41," Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",14-09-2009,NA,other,protocol
2287,2008-007031-41," Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",14-09-2009,NA,US NCT number,results
2288,2008-007031-41," Beta-Blocker in Acute Ischemic Stroke – a prospective, randomized, double-blinded, placebo-controlled safety and efficacy trial of early treatment",14-09-2009,NA,ISRCTN number,results
2289,2008-007237-47, Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,19-11-2008,NA,US NCT number,protocol
2290,2008-007237-47, Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,19-11-2008,NA,other,protocol
2291,2008-007237-47, Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,19-11-2008,NA,US NCT number,results
2292,2008-007237-47, Perioperative physostigmine prophylaxis for liver resection patients at risk for delirium and postoperative cognitive dysfunction,19-11-2008,NA,ISRCTN number,results
2293,2008-007520-26," A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",13-11-2009,NA,US NCT number,protocol
2294,2008-007520-26," A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",13-11-2009,NA,other,protocol
2295,2008-007520-26," A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",13-11-2009,NA,US NCT number,results
2296,2008-007520-26," A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to assess the Efficacy, Tolerability and Safety of Rasagiline in Subjects with Progressive Supranuclear Palsy (Phase III)",13-11-2009,NA,ISRCTN number,results
2297,2008-007546-56, A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,21-08-2009,NA,US NCT number,protocol
2298,2008-007546-56, A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,21-08-2009,NA,other,protocol
2299,2008-007546-56, A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,21-08-2009,NA,US NCT number,results
2300,2008-007546-56, A Phase II Multicentre Study of perioperative Chemotherapy for resectable Adenocarcinoma of the Gastroesophageal Junction and of the Stomach,21-08-2009,NA,ISRCTN number,results
2301,2008-007609-36, Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SMAT,10-05-2010,NA,US NCT number,protocol
2302,2008-007609-36, Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SMAT,10-05-2010,NA,other,protocol
2303,2008-007609-36, Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SMAT,10-05-2010,NA,US NCT number,results
2304,2008-007609-36, Prospektiv randomisierte multizentrische Phase II-Studie zur Metastasenresektion von Lungenfiliae (poor-prognosis) beim klarzelligen Nierenzellkarzinom +/- adjuvante Sunitinibtherapie über 1 Jahr - SMAT,10-05-2010,NA,ISRCTN number,results
2305,2008-007645-31, Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie,16-03-2009,NA,US NCT number,protocol
2306,2008-007645-31, Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie,16-03-2009,NA,other,protocol
2307,2008-007645-31, Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie,16-03-2009,NCT00989352,US NCT number,results
2308,2008-007645-31, Freiburger Studie zur Behandlung von Primären ZNS-Lymphomen bei Patienten über 65 Jahre: Methotrexat-basierte Chemo-Immuntherapie mit anschließender Erhaltungstherapie,16-03-2009,NA,ISRCTN number,results
2309,2008-007667-17," Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitus",14-04-2009,NA,US NCT number,protocol
2310,2008-007667-17," Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitus",14-04-2009,NA,other,protocol
2311,2008-007667-17," Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitus",14-04-2009,NA,US NCT number,results
2312,2008-007667-17," Doppelblinde, randomisierte Placebo-kontrollierte crossover-Studie zur Erfassung des Effektes einer DPP-IV-Hemmung auf die Zahl und Funktion von Progenitorzellen sowie die Endothelfunktion von Patienten mit Diabetes mellitus",14-04-2009,NA,ISRCTN number,results
2313,2008-007877-19, Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.,28-05-2009,NA,US NCT number,protocol
2314,2008-007877-19, Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.,28-05-2009,NA,other,protocol
2315,2008-007877-19, Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.,28-05-2009,NA,US NCT number,results
2316,2008-007877-19, Nasale Inhalation von Colistin mit dem Pari-Sinus-Vernebler bei Patienten mit Mukoviszidose und Pseudomonasnachweis im Nasen-Nasennebenhöhlenbereich.,28-05-2009,NA,ISRCTN number,results
2317,2008-008232-87, Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,09-03-2009,NA,US NCT number,protocol
2318,2008-008232-87, Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,09-03-2009,NA,other,protocol
2319,2008-008232-87, Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,09-03-2009,NA,US NCT number,results
2320,2008-008232-87, Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,09-03-2009,NA,ISRCTN number,results
2321,2008-008238-35," Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) ",23-03-2009,NCT00850382,US NCT number,protocol
2322,2008-008238-35," Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) ",23-03-2009,NA,other,protocol
2323,2008-008238-35," Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) ",23-03-2009,NCT00850382,US NCT number,results
2324,2008-008238-35," Open-Label, Multicenter Phase II Study For the Evaluation of Dasatinib (Sprycel™) Following Induction and Consolidation Therapy as well as in Maintenance Therapy in Patients With Newly Diagnosed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML) ",23-03-2009,NA,ISRCTN number,results
2325,2008-008239-27, Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),30-12-2008,NA,US NCT number,protocol
2326,2008-008239-27, Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),30-12-2008,NA,other,protocol
2327,2008-008239-27, Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),30-12-2008,NA,US NCT number,results
2328,2008-008239-27, Dosisfindungsstudie Sugammadex und Neostigmin bei geringer neuromuskulärer Restblockade (Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade),30-12-2008,NA,ISRCTN number,results
2329,2008-008280-96, Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,14-07-2009,NA,US NCT number,protocol
2330,2008-008280-96, Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,14-07-2009,NA,other,protocol
2331,2008-008280-96, Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,14-07-2009,NA,US NCT number,results
2332,2008-008280-96, Randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder – the EMC trial.,14-07-2009,NA,ISRCTN number,results
2333,2008-008287-28, Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes,13-04-2010,NA,US NCT number,protocol
2334,2008-008287-28, Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes,13-04-2010,NA,other,protocol
2335,2008-008287-28, Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes,13-04-2010,NA,US NCT number,results
2336,2008-008287-28, Effect of direct renin-inhibition aliskiren on renal haemodynamic and metabolic parameters in patients with prediabetes,13-04-2010,NA,ISRCTN number,results
2337,2008-008474-31, Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,26-06-2009,NA,US NCT number,protocol
2338,2008-008474-31, Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,26-06-2009,NA,other,protocol
2339,2008-008474-31, Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,26-06-2009,NCT02094287,US NCT number,results
2340,2008-008474-31, Nutzen des Placeboeffektes bei atopischer Dermatitis - Steigerung der pharmakologischen Wirkung bei Juckreiz durch Klassische Konditionierung und Erwartungsprozesse: Eine randomisierte kontrollierte Studie,26-06-2009,ISRCTN12345678,ISRCTN number,results
2341,2008-008513-19," Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen.",23-06-2009,NA,US NCT number,protocol
2342,2008-008513-19," Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen.",23-06-2009,NA,other,protocol
2343,2008-008513-19," Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen.",23-06-2009,NCT00918489,US NCT number,results
2344,2008-008513-19," Phase II Studie zur Wirksamkeit und Verträglichkeit von Vorinostat bei Patienten mit fortgeschrittenen, metastasierten Weichteilsarkomen.",23-06-2009,NA,ISRCTN number,results
2345,2008-008527-14," A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone",17-02-2009,NA,US NCT number,protocol
2346,2008-008527-14," A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone",17-02-2009,NA,other,protocol
2347,2008-008527-14," A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone",17-02-2009,NA,US NCT number,results
2348,2008-008527-14," A Randomized, Double-Blind, Active Controlled Study Comparing the Intravenous Dose of Morphine and Oxycodone Combined in a Ratio of 1:1 Versus Morphine Alone Required to Achieve Effective Pain Control After Total Hip Replacement and the Untoward Effects of Combined Morphine and Oxycodone vs. Morphine Alone",17-02-2009,NA,ISRCTN number,results
2349,2008-008555-41, Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),10-08-2010,NA,US NCT number,protocol
2350,2008-008555-41, Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),10-08-2010,NA,other,protocol
2351,2008-008555-41, Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),10-08-2010,NA,US NCT number,results
2352,2008-008555-41, Comparative study of the effect of intranasal insulin on memory deficits in type 2 diabetes and early Alzheimer´s dementia (INSULA),10-08-2010,NA,ISRCTN number,results
2353,2008-008754-23, A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation.,16-02-2009,NA,US NCT number,protocol
2354,2008-008754-23, A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation.,16-02-2009,NA,other,protocol
2355,2008-008754-23, A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation.,16-02-2009,NA,US NCT number,results
2356,2008-008754-23, A Therapeutic Exploratory Study to Determine the Efficacy and Safety of Calcineurin-Inhibitor-Free de-novo Immunosuppression after Liver Transplantation.,16-02-2009,NA,ISRCTN number,results
2357,2008-008896-32," Memory, Ageing, and the Cholinergic System",21-07-2009,NA,US NCT number,protocol
2358,2008-008896-32," Memory, Ageing, and the Cholinergic System",21-07-2009,NA,other,protocol
2359,2008-008896-32," Memory, Ageing, and the Cholinergic System",21-07-2009,NA,US NCT number,results
2360,2008-008896-32," Memory, Ageing, and the Cholinergic System",21-07-2009,NA,ISRCTN number,results
2361,2009-009277-10, Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer,18-11-2010,NA,US NCT number,protocol
2362,2009-009277-10, Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer,18-11-2010,NA,other,protocol
2363,2009-009277-10, Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer,18-11-2010,NA,US NCT number,results
2364,2009-009277-10, Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer,18-11-2010,NA,ISRCTN number,results
2365,2009-009426-81, Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions,02-07-2009,NA,US NCT number,protocol
2366,2009-009426-81, Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions,02-07-2009,NA,other,protocol
2367,2009-009426-81, Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions,02-07-2009,NA,US NCT number,results
2368,2009-009426-81, Contrast-enhanced Imaging of the Abdomen: Gadovist® vs. Dotarem® – Intraindividual comparison of 0.1mmol/kg bw gadoterate meglumine with 0.1mmol/kg bw gadobutrol for dynamic abdominal imaging in patients with suspected focal liver or renal lesions,02-07-2009,NA,ISRCTN number,results
2369,2009-009476-12, Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,28-05-2009,NA,US NCT number,protocol
2370,2009-009476-12, Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,28-05-2009,NA,other,protocol
2371,2009-009476-12, Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,28-05-2009,NA,US NCT number,results
2372,2009-009476-12, Non-invasive detection of prostate cancer using functional MRI in patients with histopathologically confirmed prostate cancer before prostatectomy,28-05-2009,NA,ISRCTN number,results
2373,2009-009656-20, Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease  ,13-03-2009,NA,US NCT number,protocol
2374,2009-009656-20, Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease  ,13-03-2009,NA,other,protocol
2375,2009-009656-20, Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease  ,13-03-2009,NA,US NCT number,results
2376,2009-009656-20, Sunphenon EGCg (Epigallocatechin-Gallat) in the early stage of Alzheimer´s Disease  ,13-03-2009,NA,ISRCTN number,results
2377,2009-009871-36, Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy ,06-08-2009,NA,US NCT number,protocol
2378,2009-009871-36, Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy ,06-08-2009,NA,other,protocol
2379,2009-009871-36, Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy ,06-08-2009,NA,US NCT number,results
2380,2009-009871-36, Effect and Safety of preventive Treatment with ACE-Inhibitor and Beta-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy ,06-08-2009,NA,ISRCTN number,results
2381,2009-009894-88, Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial,25-06-2009,NA,US NCT number,protocol
2382,2009-009894-88, Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial,25-06-2009,NA,other,protocol
2383,2009-009894-88, Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial,25-06-2009,NA,US NCT number,results
2384,2009-009894-88, Lapatinib versus Lapatinib with Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A randomized phase II trial,25-06-2009,NA,ISRCTN number,results
2385,2009-009909-25," Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial",17-03-2009,NA,US NCT number,protocol
2386,2009-009909-25," Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial",17-03-2009,NA,other,protocol
2387,2009-009909-25," Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial",17-03-2009,NA,US NCT number,results
2388,2009-009909-25," Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial",17-03-2009,NA,ISRCTN number,results
2389,2009-009916-33, Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy,11-10-2010,NA,US NCT number,protocol
2390,2009-009916-33, Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy,11-10-2010,NA,other,protocol
2391,2009-009916-33, Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy,11-10-2010,NCT00867672,US NCT number,results
2392,2009-009916-33, Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients > 60 years with acute myeloid leukemia who are ineligible for induction chemotherapy,11-10-2010,NA,ISRCTN number,results
2393,2009-009928-37, Phase 1/2 Studie:,12-08-2009,NA,US NCT number,protocol
2394,2009-009928-37, Phase 1/2 Studie:,12-08-2009,NA,other,protocol
2395,2009-009928-37, Phase 1/2 Studie:,12-08-2009,NA,US NCT number,results
2396,2009-009928-37, Phase 1/2 Studie:,12-08-2009,NA,ISRCTN number,results
2397,2009-009956-20," Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy",17-03-2009,NA,US NCT number,protocol
2398,2009-009956-20," Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy",17-03-2009,NA,other,protocol
2399,2009-009956-20," Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy",17-03-2009,NA,US NCT number,results
2400,2009-009956-20," Prospective, randomized, controlled, mono-centric, two-armed, single-blinded pilot study for the treatment of venous and capillary vascular malformations by Indocyanine Green-augmented laser therapy",17-03-2009,NA,ISRCTN number,results
2401,2009-009998-10," Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",02-12-2009,NA,US NCT number,protocol
2402,2009-009998-10," Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",02-12-2009,NA,other,protocol
2403,2009-009998-10," Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",02-12-2009,NA,US NCT number,results
2404,2009-009998-10," Myfortic (enteric-coated mycophenolate sodium) for the treatment of non-infectous intermediate uveitis – a prospective, controlled randomized multicenter trial",02-12-2009,NA,ISRCTN number,results
2405,2009-010093-38, Multi-institutional Phase I/II Study:,07-05-2012,NA,US NCT number,protocol
2406,2009-010093-38, Multi-institutional Phase I/II Study:,07-05-2012,NA,other,protocol
2407,2009-010093-38, Multi-institutional Phase I/II Study:,07-05-2012,NA,US NCT number,results
2408,2009-010093-38, Multi-institutional Phase I/II Study:,07-05-2012,NA,ISRCTN number,results
2409,2009-010207-83," Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance",19-03-2009,NA,US NCT number,protocol
2410,2009-010207-83," Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance",19-03-2009,NA,other,protocol
2411,2009-010207-83," Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance",19-03-2009,NA,US NCT number,results
2412,2009-010207-83," Effect of Omega-3 Fatty Acids (n3-PUFA, Zodin®) on Post-Prandial Triglyceride Tolerance",19-03-2009,NA,ISRCTN number,results
2413,2009-010700-28, GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia,22-04-2010,NA,US NCT number,protocol
2414,2009-010700-28, GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia,22-04-2010,DRKS-Nr. DRKS00000218,other,protocol
2415,2009-010700-28, GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia,22-04-2010,NA,US NCT number,results
2416,2009-010700-28, GRANITE-1 - Granulocyte-transfusions for patients with febrile neutropenia,22-04-2010,NA,ISRCTN number,results
2417,2009-010727-91, Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),05-06-2012,NA,US NCT number,protocol
2418,2009-010727-91, Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),05-06-2012,NA,other,protocol
2419,2009-010727-91, Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),05-06-2012,NA,US NCT number,results
2420,2009-010727-91, Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten),05-06-2012,NA,ISRCTN number,results
2421,2009-010738-23, Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,09-09-2009,NCT01237808,US NCT number,protocol
2422,2009-010738-23, Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,09-09-2009,NA,other,protocol
2423,2009-010738-23, Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,09-09-2009,NCT00949364,US NCT number,results
2424,2009-010738-23, Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage,09-09-2009,NA,ISRCTN number,results
2425,2009-011088-35, Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial,05-02-2010,NA,US NCT number,protocol
2426,2009-011088-35, Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial,05-02-2010,NA,other,protocol
2427,2009-011088-35, Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial,05-02-2010,NA,US NCT number,results
2428,2009-011088-35, Pituitary adenylate cyclase activating polypeptide in stressed patients with Multiple sclerosis (MS) or clinically isolated syndrome suggestive for MS under treatment with glatiramer acetate (PACAMUS) - a randomized controlled trial,05-02-2010,NA,ISRCTN number,results
2429,2009-011093-15, The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.,23-09-2009,NA,US NCT number,protocol
2430,2009-011093-15, The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.,23-09-2009,NA,other,protocol
2431,2009-011093-15, The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.,23-09-2009,NA,US NCT number,results
2432,2009-011093-15, The role of the neurotransmitters dopamine and acetylcholine in the interaction of selective attention and working memory.,23-09-2009,NA,ISRCTN number,results
2433,2009-011095-30, Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) ,03-07-2009,NA,US NCT number,protocol
2434,2009-011095-30, Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) ,03-07-2009,NA,other,protocol
2435,2009-011095-30, Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) ,03-07-2009,NA,US NCT number,results
2436,2009-011095-30, Intra-individual comparison of Gd-EOB-DTPA disodium (Primovist) ,03-07-2009,NA,ISRCTN number,results
2437,2009-011252-22, Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),03-05-2010,NA,US NCT number,protocol
2438,2009-011252-22, Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),03-05-2010,NA,other,protocol
2439,2009-011252-22, Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),03-05-2010,NA,US NCT number,results
2440,2009-011252-22, Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients (CeTeG),03-05-2010,NA,ISRCTN number,results
2441,2009-011277-33, A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,26-05-2009,NA,US NCT number,protocol
2442,2009-011277-33, A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,26-05-2009,NA,other,protocol
2443,2009-011277-33, A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,26-05-2009,NCT00942747,US NCT number,results
2444,2009-011277-33, A therapy and pharmacokinetics study of temsirolimus in patients with refractory and recidivated primary CNS lymphoma,26-05-2009,NA,ISRCTN number,results
2445,2009-011324-60, Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients,13-03-2009,NA,US NCT number,protocol
2446,2009-011324-60, Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients,13-03-2009,NA,other,protocol
2447,2009-011324-60, Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients,13-03-2009,NA,US NCT number,results
2448,2009-011324-60, Prospective randomized trial to compare a twice daily to a once daily administration of the Tacrolimus in lung transplanted patients,13-03-2009,NA,ISRCTN number,results
2449,2009-011354-18," Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants",28-12-2009,NA,US NCT number,protocol
2450,2009-011354-18," Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants",28-12-2009,NA,other,protocol
2451,2009-011354-18," Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants",28-12-2009,NA,US NCT number,results
2452,2009-011354-18," Randomised, open-label, comparative phase IV study on the bioavailability of Ciclosporin Pro (Teva) versus Sandimmun® Optoral (Novartis) under fasting versus fed conditions in patients with stable renal transplants",28-12-2009,NA,ISRCTN number,results
2453,2009-011397-14, Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis,11-08-2009,NA,US NCT number,protocol
2454,2009-011397-14, Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis,11-08-2009,NA,other,protocol
2455,2009-011397-14, Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis,11-08-2009,NA,US NCT number,results
2456,2009-011397-14, Effect of anti-TNF-alpha therapy on endothelial progenitor cells and endothelial dysfunction in patients with psoriasis without risk factors for atherosclerosis,11-08-2009,NA,ISRCTN number,results
2457,2009-011454-17, Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia,17-11-2009,NA,US NCT number,protocol
2458,2009-011454-17, Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia,17-11-2009,NA,other,protocol
2459,2009-011454-17, Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia,17-11-2009,NA,US NCT number,results
2460,2009-011454-17, Phase II pharmacokinetic study to assess the age-dependency in the clearance of doxorubicin in paediatric patients with solid tumours and leukaemia,17-11-2009,NA,ISRCTN number,results
2461,2009-011594-33," A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia",06-10-2009,NA,US NCT number,protocol
2462,2009-011594-33," A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia",06-10-2009,NA,other,protocol
2463,2009-011594-33," A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia",06-10-2009,NA,US NCT number,results
2464,2009-011594-33," A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia",06-10-2009,NA,ISRCTN number,results
2465,2009-011737-27, A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy,16-10-2009,NA,US NCT number,protocol
2466,2009-011737-27, A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy,16-10-2009,NA,other,protocol
2467,2009-011737-27, A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy,16-10-2009,NA,US NCT number,results
2468,2009-011737-27, A multi centre randomised placebo-controlled double-blind clinical trial for the evaluation of efficacy of specific immunotherapy with an aluminium hydroxide-adsorbed recombinant hypoallergenic derivative of the major birch pollen allergen r Bet v1-FV on Bet v 1 associated soy allergy,16-10-2009,ISRCTN67316358,ISRCTN number,results
2469,2009-011881-27, Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study.,20-01-2010,NA,US NCT number,protocol
2470,2009-011881-27, Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study.,20-01-2010,NA,other,protocol
2471,2009-011881-27, Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study.,20-01-2010,NA,US NCT number,results
2472,2009-011881-27, Changes of cerebral spinal fluid APPSα levels under oral therapy with acitretin 30 mg daily in patients with mild to moderate Alzheimer’s disease: a multicenter prospective randomised placebo-controlled parallel-group study.,20-01-2010,NA,ISRCTN number,results
2473,2009-011889-28, Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation ,27-05-2009,NCT00893399,US NCT number,protocol
2474,2009-011889-28, Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation ,27-05-2009,NA,other,protocol
2475,2009-011889-28, Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation ,27-05-2009,NCT00893399,US NCT number,results
2476,2009-011889-28, Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation ,27-05-2009,NA,ISRCTN number,results
2477,2009-011898-33, Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study,10-06-2011,NA,US NCT number,protocol
2478,2009-011898-33, Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study,10-06-2011,DKSR StudienID: 588,other,protocol
2479,2009-011898-33, Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study,10-06-2011,NA,US NCT number,results
2480,2009-011898-33, Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study,10-06-2011,NA,ISRCTN number,results
2481,2009-011902-41, Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer,22-06-2009,NA,US NCT number,protocol
2482,2009-011902-41, Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer,22-06-2009,NA,other,protocol
2483,2009-011902-41, Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer,22-06-2009,NA,US NCT number,results
2484,2009-011902-41, Split-dose TPF-Induction chemotherapy before Surgery of Oropharyngeal and cavity of the mouth Cancer,22-06-2009,NA,ISRCTN number,results
2485,2009-011904-47, Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial,13-07-2010,NA,US NCT number,protocol
2486,2009-011904-47, Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial,13-07-2010,NA,other,protocol
2487,2009-011904-47, Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial,13-07-2010,NA,US NCT number,results
2488,2009-011904-47, Sorafenib plus doxorubicin versus sorafenib alone for the treatment of advanced hepatocellular carcinoma: a randomized phase II trial,13-07-2010,NA,ISRCTN number,results
2489,2009-011911-19, Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients,21-04-2009,NA,US NCT number,protocol
2490,2009-011911-19, Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients,21-04-2009,NA,other,protocol
2491,2009-011911-19, Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients,21-04-2009,NA,US NCT number,results
2492,2009-011911-19, Impact of quetiapine prolong and escitalopram on the hypothalamic-pituitary-adrenocortical (HPA)-axis activity in depressed patients,21-04-2009,NA,ISRCTN number,results
2493,2009-011922-33," A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",14-10-2009,NA,US NCT number,protocol
2494,2009-011922-33," A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",14-10-2009,NA,other,protocol
2495,2009-011922-33," A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",14-10-2009,NCT01047891,US NCT number,results
2496,2009-011922-33," A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resistant recurrent ovarian cancer",14-10-2009,NA,ISRCTN number,results
2497,2009-011968-11, Radio-/Chemotherapie des Pankreaskarzinoms,31-05-2010,NA,US NCT number,protocol
2498,2009-011968-11, Radio-/Chemotherapie des Pankreaskarzinoms,31-05-2010,NA,other,protocol
2499,2009-011968-11, Radio-/Chemotherapie des Pankreaskarzinoms,31-05-2010,NA,US NCT number,results
2500,2009-011968-11, Radio-/Chemotherapie des Pankreaskarzinoms,31-05-2010,NA,ISRCTN number,results
2501,2009-011990-34, Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib,11-11-2010,NA,US NCT number,protocol
2502,2009-011990-34, Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib,11-11-2010,NA,other,protocol
2503,2009-011990-34, Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib,11-11-2010,NA,US NCT number,results
2504,2009-011990-34, Cytokines and Inflammatory Marker during Therapy in Major Depression with Celecoxib,11-11-2010,NA,ISRCTN number,results
2505,2009-012031-15, The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment,23-07-2009,NA,US NCT number,protocol
2506,2009-012031-15, The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment,23-07-2009,NA,other,protocol
2507,2009-012031-15, The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment,23-07-2009,NCT01029769,US NCT number,results
2508,2009-012031-15, The switch study - efficacy of early antipsychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment,23-07-2009,NA,ISRCTN number,results
2509,2009-012088-32, Prospektive und randomisierte Multicenter-Studie (Phase III-Studie) zur Verbesserung der Funktion des Nervus facialis und des Nervus vestibulocochlearis nach der Resektion von Akustikusneurinomen durch die prophylaktische Gabe von vasoaktiven Medikamenten,21-10-2009,NA,US NCT number,protocol
2510,2009-012088-32, Prospektive und randomisierte Multicenter-Studie (Phase III-Studie) zur Verbesserung der Funktion des Nervus facialis und des Nervus vestibulocochlearis nach der Resektion von Akustikusneurinomen durch die prophylaktische Gabe von vasoaktiven Medikamenten,21-10-2009,NA,other,protocol
2511,2009-012088-32, Prospektive und randomisierte Multicenter-Studie (Phase III-Studie) zur Verbesserung der Funktion des Nervus facialis und des Nervus vestibulocochlearis nach der Resektion von Akustikusneurinomen durch die prophylaktische Gabe von vasoaktiven Medikamenten,21-10-2009,NA,US NCT number,results
2512,2009-012088-32, Prospektive und randomisierte Multicenter-Studie (Phase III-Studie) zur Verbesserung der Funktion des Nervus facialis und des Nervus vestibulocochlearis nach der Resektion von Akustikusneurinomen durch die prophylaktische Gabe von vasoaktiven Medikamenten,21-10-2009,NA,ISRCTN number,results
2513,2009-012108-15," Korrelation von freiem IgE mit klinischen Parametern bei Asthma-Patienten unter Therapie mit Omalizumab, einem monoklonalen Antikörper gegen körpereigenes IgE",24-04-2009,NA,US NCT number,protocol
2514,2009-012108-15," Korrelation von freiem IgE mit klinischen Parametern bei Asthma-Patienten unter Therapie mit Omalizumab, einem monoklonalen Antikörper gegen körpereigenes IgE",24-04-2009,NA,other,protocol
2515,2009-012108-15," Korrelation von freiem IgE mit klinischen Parametern bei Asthma-Patienten unter Therapie mit Omalizumab, einem monoklonalen Antikörper gegen körpereigenes IgE",24-04-2009,NA,US NCT number,results
2516,2009-012108-15," Korrelation von freiem IgE mit klinischen Parametern bei Asthma-Patienten unter Therapie mit Omalizumab, einem monoklonalen Antikörper gegen körpereigenes IgE",24-04-2009,NA,ISRCTN number,results
2517,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,protocol
2518,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,other,protocol
2519,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,results
2520,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,ISRCTN number,results
2521,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,protocol
2522,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,other,protocol
2523,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,results
2524,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,ISRCTN number,results
2525,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,protocol
2526,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,other,protocol
2527,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,results
2528,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,ISRCTN number,results
2529,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,protocol
2530,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,other,protocol
2531,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,US NCT number,results
2532,2009-012198-36, Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie,23-10-2009,NA,ISRCTN number,results
2533,2009-012200-98," Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun® Optoral and Certican® in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.",24-09-2010,NA,US NCT number,protocol
2534,2009-012200-98," Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun® Optoral and Certican® in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.",24-09-2010,NA,other,protocol
2535,2009-012200-98," Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun® Optoral and Certican® in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.",24-09-2010,NA,US NCT number,results
2536,2009-012200-98," Open-label, prospective, randomized, parallel group study investigating a CNI-low dose regimen with Sandimmun® Optoral and Certican® in comparison to standard immunosuppressive therapy in renal transplant patients with creeping creatinine.",24-09-2010,NA,ISRCTN number,results
2537,2009-012203-26, Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,22-06-2009,NA,US NCT number,protocol
2538,2009-012203-26, Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,22-06-2009,NA,other,protocol
2539,2009-012203-26, Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,22-06-2009,NCT01035190,US NCT number,results
2540,2009-012203-26, Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia,22-06-2009,NA,ISRCTN number,results
2541,2009-012275-98, HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.,11-08-2010,NA,US NCT number,protocol
2542,2009-012275-98, HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.,11-08-2010,NA,other,protocol
2543,2009-012275-98, HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.,11-08-2010,NA,US NCT number,results
2544,2009-012275-98, HEXVIX® VERUS WHITE LIGHT GUIDED TURB FOR EORTC SCORE INTERMEDIATE RISK NON-MUSCLE INVASIVE BLADDER CANCER FOLLOWED BY ATTENUATED INTRAVESICAL ADJUVANT CHEMOTHERAPY.,11-08-2010,NA,ISRCTN number,results
2545,2009-012432-32," Randomized phase II trial on primary chemotherapy with high-dose  methotrexate and high-dose cytarabine with or without thiotepa, and  with or without rituximab, followed by brain irradiation vs. high-dose  chemotherapy supported by autologous stem cells transplantation for  immunocompetent patients with newly diagnosed primary cns lymphoma.",15-09-2009,NA,US NCT number,protocol
2546,2009-012432-32," Randomized phase II trial on primary chemotherapy with high-dose  methotrexate and high-dose cytarabine with or without thiotepa, and  with or without rituximab, followed by brain irradiation vs. high-dose  chemotherapy supported by autologous stem cells transplantation for  immunocompetent patients with newly diagnosed primary cns lymphoma.",15-09-2009,NA,other,protocol
2547,2009-012432-32," Randomized phase II trial on primary chemotherapy with high-dose  methotrexate and high-dose cytarabine with or without thiotepa, and  with or without rituximab, followed by brain irradiation vs. high-dose  chemotherapy supported by autologous stem cells transplantation for  immunocompetent patients with newly diagnosed primary cns lymphoma.",15-09-2009,NA,US NCT number,results
2548,2009-012432-32," Randomized phase II trial on primary chemotherapy with high-dose  methotrexate and high-dose cytarabine with or without thiotepa, and  with or without rituximab, followed by brain irradiation vs. high-dose  chemotherapy supported by autologous stem cells transplantation for  immunocompetent patients with newly diagnosed primary cns lymphoma.",15-09-2009,NA,ISRCTN number,results
2549,2009-012436-32," A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients.",07-07-2009,NA,US NCT number,protocol
2550,2009-012436-32," A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients.",07-07-2009,NA,other,protocol
2551,2009-012436-32," A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients.",07-07-2009,NA,US NCT number,results
2552,2009-012436-32," A multicenter, randomized, open-labeled study to steer immunsuppressive and antiviral therapy by measurement of virus- (CMV, ADV, HSV) specific T cells in addition to determination of trough levels of immunosuppressants in pediatric kidney allograft recipients.",07-07-2009,NA,ISRCTN number,results
2553,2009-012576-27, Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma,17-12-2009,NCT01126645,US NCT number,protocol
2554,2009-012576-27, Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma,17-12-2009,NA,other,protocol
2555,2009-012576-27, Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma,17-12-2009,NA,US NCT number,results
2556,2009-012576-27, Evaluation of Sorafenib in combination with local micro-therapy guided by Gd-EOB-DTPA enhanced MRI in patients with inoperable hepatocellular carcinoma,17-12-2009,NA,ISRCTN number,results
2557,2009-012607-26, MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,08-09-2009,NA,US NCT number,protocol
2558,2009-012607-26, MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,08-09-2009,NA,other,protocol
2559,2009-012607-26, MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,08-09-2009,NCT01047059,US NCT number,results
2560,2009-012607-26, MIMEB - Molecular Imaging with erlotinib and bevacizumab. A Phase II Clinical Trial to Evaluate the Accuracy of FDG-/FLT-PET and DCE-MRI for Early Prediction of Non-Progression in Patients with Advanced Non Squamous Cell Non Small Cell Lung Cancer (NSCLC) treated with Erlotinib and Bevacizumab and to Associate Imaging Findings with Molecular Markers,08-09-2009,NA,ISRCTN number,results
2561,2009-012706-39," Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine (DepoCyte®) for the treatment of meningeal metastasis or meningeal metastasis plus brain metastases in HER2-positive breast-cancer patients",09-09-2009,NA,US NCT number,protocol
2562,2009-012706-39," Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine (DepoCyte®) for the treatment of meningeal metastasis or meningeal metastasis plus brain metastases in HER2-positive breast-cancer patients",09-09-2009,NA,other,protocol
2563,2009-012706-39," Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine (DepoCyte®) for the treatment of meningeal metastasis or meningeal metastasis plus brain metastases in HER2-positive breast-cancer patients",09-09-2009,NA,US NCT number,results
2564,2009-012706-39," Multicentric, open-label, single-arm phase II study with oral lapatinib in combination with oral capecitabine plus intrathecally administered liposomal cytarabine (DepoCyte®) for the treatment of meningeal metastasis or meningeal metastasis plus brain metastases in HER2-positive breast-cancer patients",09-09-2009,NA,ISRCTN number,results
2565,2009-012758-18, A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology ,04-01-2010,NA,US NCT number,protocol
2566,2009-012758-18, A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology ,04-01-2010,NA,other,protocol
2567,2009-012758-18, A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology ,04-01-2010,NA,US NCT number,results
2568,2009-012758-18, A randomized multi-center treatment study (COALL 08-09) to improve the survival of children with acute lymphoblastic leukemia on behalf of the German Society of Pediatric Hematology and Oncology ,04-01-2010,NA,ISRCTN number,results
2569,2009-012815-16, Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),24-09-2009,NA,US NCT number,protocol
2570,2009-012815-16, Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),24-09-2009,NA,other,protocol
2571,2009-012815-16, Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),24-09-2009,NA,US NCT number,results
2572,2009-012815-16, Dosis-Wirkungsstudie von Rocuronium unter Propofol-Anästhesie (Rocuronium Dose Finding Study after single shot or steady state propofol anesthesia),24-09-2009,NA,ISRCTN number,results
2573,2009-012957-39," A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",10-08-2010,NA,US NCT number,protocol
2574,2009-012957-39," A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",10-08-2010,NA,other,protocol
2575,2009-012957-39," A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",10-08-2010,NA,US NCT number,results
2576,2009-012957-39," A phase I/II safety and efficacy trial of a combination of bendamustine, rituximab and lenalidomide (BRL) in patients with relapsed or refractory chronic lymphocytic leukemia",10-08-2010,NA,ISRCTN number,results
2577,2009-013099-38," Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab ",04-06-2010,NA,US NCT number,protocol
2578,2009-013099-38," Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab ",04-06-2010,NA,other,protocol
2579,2009-013099-38," Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab ",04-06-2010,NA,US NCT number,results
2580,2009-013099-38," Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumab ",04-06-2010,NA,ISRCTN number,results
2581,2009-013279-23, In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study,02-02-2010,NA,US NCT number,protocol
2582,2009-013279-23, In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study,02-02-2010,NA,other,protocol
2583,2009-013279-23, In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study,02-02-2010,NA,US NCT number,results
2584,2009-013279-23, In vivo response monitoring of treatment with the EGFR-monoclonal-antibody Cetuximab in metastatic colorectal cancer – a single center phase II study,02-02-2010,NA,ISRCTN number,results
2585,2009-013294-18," Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",02-10-2009,NA,US NCT number,protocol
2586,2009-013294-18," Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",02-10-2009,NA,other,protocol
2587,2009-013294-18," Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",02-10-2009,NA,US NCT number,results
2588,2009-013294-18," Magnesiumsulfate in the prevention of post-ERCP pancreatitis – a prospective randomized, placebo-controlled multicenter study",02-10-2009,NA,ISRCTN number,results
2589,2009-013351-30," A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphoma or mantle cell lymphoma in fist to third relapse",26-10-2009,NA,US NCT number,protocol
2590,2009-013351-30," A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphoma or mantle cell lymphoma in fist to third relapse",26-10-2009,NA,other,protocol
2591,2009-013351-30," A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphoma or mantle cell lymphoma in fist to third relapse",26-10-2009,NA,US NCT number,results
2592,2009-013351-30," A phase I/II trail to evaluate the safety, feasibility and efficacy of the addition of temsirolimus (Torisel™) to a regimen of bendamustine and rituximab for the treatment of patients with follicular lymphoma or mantle cell lymphoma in fist to third relapse",26-10-2009,NA,ISRCTN number,results
2593,2009-013432-20," Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",22-06-2009,NA,US NCT number,protocol
2594,2009-013432-20," Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",22-06-2009,NA,other,protocol
2595,2009-013432-20," Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",22-06-2009,NA,US NCT number,results
2596,2009-013432-20," Intra-individual, randomized comparison of the MRI contrast agents gadobutrol versus gadoterate meglumine in breast MR imaging",22-06-2009,NA,ISRCTN number,results
2597,2009-013458-33, Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),21-09-2009,NA,US NCT number,protocol
2598,2009-013458-33, Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),21-09-2009,NA,other,protocol
2599,2009-013458-33, Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),21-09-2009,NA,US NCT number,results
2600,2009-013458-33, Modulation of Cytochrome-P450 dependent eicosanoid formation by treatment with omega-3 PUFA (Omacor®),21-09-2009,NA,ISRCTN number,results
2601,2009-013499-29," Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade at a train of four ratio of 0.2]",21-08-2009,NA,US NCT number,protocol
2602,2009-013499-29," Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade at a train of four ratio of 0.2]",21-08-2009,NA,other,protocol
2603,2009-013499-29," Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade at a train of four ratio of 0.2]",21-08-2009,NA,US NCT number,results
2604,2009-013499-29," Dosisfindungsstudie für Sugammadex und Neostigmin zur Reversierung einer geringen neuromuskulären Restblockade (train of four ratio 0,2) [Sugammadex and Neostigmine dose finding study for reversal of residual neuromuscular blockade at a train of four ratio of 0.2]",21-08-2009,NA,ISRCTN number,results
2605,2009-013701-34," Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-",08-04-2011,NA,US NCT number,protocol
2606,2009-013701-34," Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-",08-04-2011,NA,other,protocol
2607,2009-013701-34," Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-",08-04-2011,NA,US NCT number,results
2608,2009-013701-34," Prophylactic treatment of vestibular migraine with metoprolol: a double-blind, placebo-",08-04-2011,NA,ISRCTN number,results
2609,2009-013702-14," Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",05-05-2010,NA,US NCT number,protocol
2610,2009-013702-14," Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",05-05-2010,NA,other,protocol
2611,2009-013702-14," Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",05-05-2010,NA,US NCT number,results
2612,2009-013702-14," Effects of betahistine on central vestibular compensation in acute unilateral vestibular failure: a double-blind, placebo-controlled trial",05-05-2010,NA,ISRCTN number,results
2613,2009-013856-61," A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide",30-12-2009,NA,US NCT number,protocol
2614,2009-013856-61," A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide",30-12-2009,NA,other,protocol
2615,2009-013856-61," A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide",30-12-2009,NA,US NCT number,results
2616,2009-013856-61," A phase III national, multicentre, randomized open-label study with Lenalidomide/Dexamethasone versus Lenalidomide/Dexamethasone and autologous stem cell transplantation followed by Lenalidomide",30-12-2009,ISRCTN16345835,ISRCTN number,results
2617,2009-013956-62," Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.",25-03-2010,NA,US NCT number,protocol
2618,2009-013956-62," Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.",25-03-2010,NA,other,protocol
2619,2009-013956-62," Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.",25-03-2010,NA,US NCT number,results
2620,2009-013956-62," Preparation of Neuroplant® 300mg N in film-coated tablets (St. John´s wort, SJW) in the treatment of mild to moderate Major Depressive Disorder (MDD) in adolescents from 12 to 17 years (inclusive): a parallel group, randomized, double-blind, placebo (PBO)-controlled, multicentre clinical trial to evaluate the efficacy, safety, somatic and behavioral Adverse Events (AEs) and pharmacokinetics of SJW in mild to moderate MDD in adolescents.",25-03-2010,NA,ISRCTN number,results
2621,2009-013976-38, Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),07-12-2009,NA,US NCT number,protocol
2622,2009-013976-38, Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),07-12-2009,NA,other,protocol
2623,2009-013976-38, Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),07-12-2009,NCT01693393,US NCT number,results
2624,2009-013976-38, Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS),07-12-2009,NA,ISRCTN number,results
2625,2009-014040-11," Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study.",01-07-2010,NCT01540344,US NCT number,protocol
2626,2009-014040-11," Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study.",01-07-2010,NA,other,protocol
2627,2009-014040-11," Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study.",01-07-2010,NA,US NCT number,results
2628,2009-014040-11," Multimodality treatment including pre- and postoperative systemic chemotherapy plus cetuximab, cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from wild type K-ras colon cancer: A prospective multicenter phase II study.",01-07-2010,NA,ISRCTN number,results
2629,2009-014300-55," Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",10-12-2009,NA,US NCT number,protocol
2630,2009-014300-55," Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",10-12-2009,NA,other,protocol
2631,2009-014300-55," Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",10-12-2009,NA,US NCT number,results
2632,2009-014300-55," Phase II study on the combined systemic and intrathecal chemotherapy with methotrexate, ifosfamide and liposomal cytarabine (DepoCyte®) in patients with HER-2/neu-negative breast cancer and leptomeningeal spread",10-12-2009,NA,ISRCTN number,results
2633,2009-014336-38," A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI",20-08-2009,NA,US NCT number,protocol
2634,2009-014336-38," A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI",20-08-2009,NA,other,protocol
2635,2009-014336-38," A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI",20-08-2009,NA,US NCT number,results
2636,2009-014336-38," A randomized, placebo-controlled phase II trial investigating SUNITINIB versus placebo in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus treated with chemotherapy FOLFIRI",20-08-2009,NA,ISRCTN number,results
2637,2009-014373-41, A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR),17-03-2010,NCT01227135,US NCT number,protocol
2638,2009-014373-41, A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR),17-03-2010,CTC-A Number  11-130,other,protocol
2639,2009-014373-41, A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR),17-03-2010,NA,US NCT number,results
2640,2009-014373-41, A randomised Phase II trial of Imatinib (IM) versus Hydroxychloroquine (HCQ) and Imatinib (IM) for patients with Chronic Myeloid Leukaemia (CML) in Cytogenetic Response (CyR) with residual disease detectable by quantitative polymerase chain reaction (Q-PCR),17-03-2010,ISRCTN61568166,ISRCTN number,results
2641,2009-014383-18," A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",13-07-2010,NA,US NCT number,protocol
2642,2009-014383-18," A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",13-07-2010,NA,other,protocol
2643,2009-014383-18," A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",13-07-2010,NA,US NCT number,results
2644,2009-014383-18," A single arm, open-label multicenter phase II trial of everolimus in patients with relapsed/refractory germ cell cancer",13-07-2010,NA,ISRCTN number,results
2645,2009-014396-43," A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)",20-01-2010,NA,US NCT number,protocol
2646,2009-014396-43," A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)",20-01-2010,NA,other,protocol
2647,2009-014396-43," A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)",20-01-2010,NA,US NCT number,results
2648,2009-014396-43," A single arm, open-label multicenter phase II trial of temsirolimus in patients with relapsed/ recurrent squamous cell cancer of the Head and Neck (HNSCC)",20-01-2010,NA,ISRCTN number,results
2649,2009-014476-21," Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial:",20-12-2012,NA,US NCT number,protocol
2650,2009-014476-21," Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial:",20-12-2012,NA,other,protocol
2651,2009-014476-21," Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial:",20-12-2012,NA,US NCT number,results
2652,2009-014476-21," Chemoradiation following induction chemotherapy in locally advanced, unresectable pancreatic cancer -a randomised phase 3 trial:",20-12-2012,NA,ISRCTN number,results
2653,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,protocol
2654,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,other,protocol
2655,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,results
2656,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,ISRCTN number,results
2657,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,protocol
2658,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,other,protocol
2659,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,results
2660,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,ISRCTN number,results
2661,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,protocol
2662,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,other,protocol
2663,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,results
2664,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,ISRCTN number,results
2665,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,protocol
2666,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,other,protocol
2667,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,US NCT number,results
2668,2009-014532-37," Effekte von oraler Cortisol oder Propranolol-Gabe auf die Verarbeitung alkoholbezogener Schlüsselreize, den Schlaf und das Rückfallrisiko von alkoholabhängigen Patienten (Copro-Studie).",05-10-2010,NA,ISRCTN number,results
2669,2009-014582-51, Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels,12-10-2009,NA,US NCT number,protocol
2670,2009-014582-51, Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels,12-10-2009,NA,other,protocol
2671,2009-014582-51, Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels,12-10-2009,NA,US NCT number,results
2672,2009-014582-51, Pilot study - sequential combination therapy using selective immunoglobulin apheresis and omalizumab in patients with severe atopic dermatitis and elevated total IgE levels,12-10-2009,NA,ISRCTN number,results
2673,2009-014641-88," Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion.",22-07-2009,NA,US NCT number,protocol
2674,2009-014641-88," Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion.",22-07-2009,NA,other,protocol
2675,2009-014641-88," Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion.",22-07-2009,NA,US NCT number,results
2676,2009-014641-88," Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 positive chronic lymphocytic leukemia (CLL), low and high grade non-Hodgkin´s lymphoma (NHL) after allogeneic stem cell transplantion.",22-07-2009,NA,ISRCTN number,results
2677,2009-014724-32," SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):",26-10-2010,NA,US NCT number,protocol
2678,2009-014724-32," SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):",26-10-2010,NA,other,protocol
2679,2009-014724-32," SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):",26-10-2010,NCT01450124,US NCT number,results
2680,2009-014724-32," SAFETY, TOLERABILITY AND MECHANISM OF ACTION OF BOSWELLIC ACIDS (BA) IN MULTIPLE SCLEROSIS (MS) AND CLINICALLY ISOLATED SYNDROME (CIS):",26-10-2010,NA,ISRCTN number,results
2681,2009-014728-44, A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory metastatic colorectal cancer and k-ras wild-type tumours,04-11-2009,NCT01060423,US NCT number,protocol
2682,2009-014728-44, A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory metastatic colorectal cancer and k-ras wild-type tumours,04-11-2009,NA,other,protocol
2683,2009-014728-44, A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory metastatic colorectal cancer and k-ras wild-type tumours,04-11-2009,NA,US NCT number,results
2684,2009-014728-44, A randomized phase II trial of irinotecan drug-eluting beads administered by hepatic chemoembolization with intravenous cetuximab (DEBIRITUX) versus systemic treatment with intravenous cetuximab and irinotecan in patients with refractory metastatic colorectal cancer and k-ras wild-type tumours,04-11-2009,NA,ISRCTN number,results
2685,2009-014768-21, Treatment of MDS patients with single agent temsirolimus – a pilot study ,05-01-2010,NA,US NCT number,protocol
2686,2009-014768-21, Treatment of MDS patients with single agent temsirolimus – a pilot study ,05-01-2010,NA,other,protocol
2687,2009-014768-21, Treatment of MDS patients with single agent temsirolimus – a pilot study ,05-01-2010,NA,US NCT number,results
2688,2009-014768-21, Treatment of MDS patients with single agent temsirolimus – a pilot study ,05-01-2010,NA,ISRCTN number,results
2689,2009-014844-13, Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,29-12-2009,NA,US NCT number,protocol
2690,2009-014844-13, Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,29-12-2009,NA,other,protocol
2691,2009-014844-13, Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,29-12-2009,NA,US NCT number,results
2692,2009-014844-13, Phase I/II clinical trial with Bendamustine and Temsirolimus in patients with relapsed or refractory mantle cell lymphoma that are not eligible for high dose chemotherapy and stem cell transplantation.,29-12-2009,NA,ISRCTN number,results
2693,2009-014857-34," Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T",21-12-2009,NA,US NCT number,protocol
2694,2009-014857-34," Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T",21-12-2009,NA,other,protocol
2695,2009-014857-34," Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T",21-12-2009,NA,US NCT number,results
2696,2009-014857-34," Intra-individual, randomized multicentric comparison of the MRI contrast agents Gadovist 1.0 versus Dotarem in patients with Multiple Sclerosis at 3T",21-12-2009,NA,ISRCTN number,results
2697,2009-014895-23, Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive parenteral nutrition and physical activity in patients with advanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junction - impact on quality of life and fatigue: FLOTIRI - gastric cancer trial,17-01-2013,NA,US NCT number,protocol
2698,2009-014895-23, Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive parenteral nutrition and physical activity in patients with advanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junction - impact on quality of life and fatigue: FLOTIRI - gastric cancer trial,17-01-2013,NA,other,protocol
2699,2009-014895-23, Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive parenteral nutrition and physical activity in patients with advanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junction - impact on quality of life and fatigue: FLOTIRI - gastric cancer trial,17-01-2013,NA,US NCT number,results
2700,2009-014895-23, Phase II clinical trial of a sequential therapy involving the FLOT regiment in palliative first-line treatment followed by AIO plus irinotecan in second-line treatment combined with supportive parenteral nutrition and physical activity in patients with advanced non-resectable adenocarcinoma of the stomach and the gastro-oesophageal junction - impact on quality of life and fatigue: FLOTIRI - gastric cancer trial,17-01-2013,NA,ISRCTN number,results
2701,2009-015125-36," Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie",20-08-2009,NA,US NCT number,protocol
2702,2009-015125-36," Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie",20-08-2009,NA,other,protocol
2703,2009-015125-36," Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie",20-08-2009,NA,US NCT number,results
2704,2009-015125-36," Clostridium botulinum Typ A Neurotoxinkomplex zur adjuvanten Behandlung von depressiven Störungen – Eine randomisierte, kontrollierte Pilotstudie",20-08-2009,NA,ISRCTN number,results
2705,2009-015159-26," UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",18-11-2010,NA,US NCT number,protocol
2706,2009-015159-26," UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",18-11-2010,NA,other,protocol
2707,2009-015159-26," UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",18-11-2010,NA,US NCT number,results
2708,2009-015159-26," UKW-Inf-001: Prospective trial to evaluate pharmacokinetic, safety and efficacy of intermittent application of increased doses of caspofungin for antifungal prophylaxis in high risk patients.",18-11-2010,NA,ISRCTN number,results
2709,2009-015217-52, Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - ,12-02-2010,NA,US NCT number,protocol
2710,2009-015217-52, Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - ,12-02-2010,NA,other,protocol
2711,2009-015217-52, Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - ,12-02-2010,NA,US NCT number,results
2712,2009-015217-52, Pilotstudie zur Pyridoxalphosphattherapie bei Patienten mit primärer Hyperoxalurie Typ I - ,12-02-2010,NA,ISRCTN number,results
2713,2009-015319-41, Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),04-02-2011,NA,US NCT number,protocol
2714,2009-015319-41, Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),04-02-2011,NA,other,protocol
2715,2009-015319-41, Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),04-02-2011,NA,US NCT number,results
2716,2009-015319-41, Trichuris suis Oozyten (TSO®) in remittent-recurrent Multiple Sclerosis (MS) and Clinically Isolated Syndrom (CIS),04-02-2011,NA,ISRCTN number,results
2717,2009-015383-33," Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",14-06-2010,NA,US NCT number,protocol
2718,2009-015383-33," Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",14-06-2010,NA,other,protocol
2719,2009-015383-33," Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",14-06-2010,NA,US NCT number,results
2720,2009-015383-33," Die perioperative Anwendung von Etoricoxib verglichen mit Diclofenac bei Patienten nach Implantation einer Hüftgelenkstotalendoprothese, prospektive, doppelt blinde Phase IIIb Studie",14-06-2010,NA,ISRCTN number,results
2721,2009-015410-22," A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant",03-02-2010,NA,US NCT number,protocol
2722,2009-015410-22," A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant",03-02-2010,NA,other,protocol
2723,2009-015410-22," A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant",03-02-2010,NA,US NCT number,results
2724,2009-015410-22," A multicenter, randomized, double-blind study with 2 groups as prove of concept for the treatment of ACE induced angioedema with subcutaneous Icatibant",03-02-2010,NA,ISRCTN number,results
2725,2009-015499-88, Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.,03-12-2009,NA,US NCT number,protocol
2726,2009-015499-88, Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.,03-12-2009,NA,other,protocol
2727,2009-015499-88, Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.,03-12-2009,NA,US NCT number,results
2728,2009-015499-88, Senkung einer erhöhten Herzfrequenz durch Ivabradin bei Patienten mit Multiorgandysfunktionssyndrom.,03-12-2009,NA,ISRCTN number,results
2729,2009-015537-67," Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie",26-10-2009,NA,US NCT number,protocol
2730,2009-015537-67," Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie",26-10-2009,NA,other,protocol
2731,2009-015537-67," Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie",26-10-2009,NA,US NCT number,results
2732,2009-015537-67," Untersuchung der Wirksamkeit und Sicherheit von Vareniclin in der Postakutbehandlung der Alkoholabhängigkeit - eine prospektive, bizentrische, doppelblinde, placebokontrollierte, randomisierte Phase II Studie",26-10-2009,NA,ISRCTN number,results
2733,2009-015538-30, Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control,22-02-2010,NA,US NCT number,protocol
2734,2009-015538-30, Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control,22-02-2010,NA,other,protocol
2735,2009-015538-30, Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control,22-02-2010,NA,US NCT number,results
2736,2009-015538-30, Effect of intranasal oxytocin on social approach in patients with social phobia and healthy control,22-02-2010,NA,ISRCTN number,results
2737,2009-015600-26, An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension,09-11-2009,NA,US NCT number,protocol
2738,2009-015600-26, An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension,09-11-2009,NA,other,protocol
2739,2009-015600-26, An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension,09-11-2009,NA,US NCT number,results
2740,2009-015600-26, An open label prospective pilot-study to determine the improvement of impaired endothelial function and endothelial progenitor cell numbers following treatment with Aliskiren 300 mg in patients with coronary artery disease and hypertension,09-11-2009,NA,ISRCTN number,results
2741,2009-015739-34," Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)",14-09-2009,NA,US NCT number,protocol
2742,2009-015739-34," Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)",14-09-2009,NA,other,protocol
2743,2009-015739-34," Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)",14-09-2009,NA,US NCT number,results
2744,2009-015739-34," Status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and neuroprotection in children with Ataxia telangiectasia (AT)",14-09-2009,NA,ISRCTN number,results
2745,2009-015740-42," A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION",12-01-2010,NA,US NCT number,protocol
2746,2009-015740-42," A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION",12-01-2010,NA,other,protocol
2747,2009-015740-42," A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION",12-01-2010,NA,US NCT number,results
2748,2009-015740-42," A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION",12-01-2010,NA,ISRCTN number,results
2749,2009-015749-22," A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",20-09-2010,NA,US NCT number,protocol
2750,2009-015749-22," A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",20-09-2010,NA,other,protocol
2751,2009-015749-22," A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",20-09-2010,NA,US NCT number,results
2752,2009-015749-22," A prospective, monocentric clinical trial with adalimumab for topical treatment in chronic wounds",20-09-2010,NA,ISRCTN number,results
2753,2009-015904-24," An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in ART naive subjects with HCV co-infection",12-07-2010,NA,US NCT number,protocol
2754,2009-015904-24," An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in ART naive subjects with HCV co-infection",12-07-2010,NA,other,protocol
2755,2009-015904-24," An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in ART naive subjects with HCV co-infection",12-07-2010,NA,US NCT number,results
2756,2009-015904-24," An open, prospective study to compare the safety and efficacy of raltegravir vs. atazanavir / ritonavir, both in combination with tenofovir DF and emtricitabine, in the treatment of HIV-infection in ART naive subjects with HCV co-infection",12-07-2010,NA,ISRCTN number,results
2757,2009-015936-14, PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,02-02-2010,NA,US NCT number,protocol
2758,2009-015936-14, PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,02-02-2010,NA,other,protocol
2759,2009-015936-14, PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,02-02-2010,NA,US NCT number,results
2760,2009-015936-14, PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA,02-02-2010,NA,ISRCTN number,results
2761,2009-015950-39, Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,28-12-2009,NA,US NCT number,protocol
2762,2009-015950-39, Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,28-12-2009,NA,other,protocol
2763,2009-015950-39, Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,28-12-2009,NCT01244958,US NCT number,results
2764,2009-015950-39, Addition of Rituximab to Leflunomide in patients with active rheumatoid arthritis,28-12-2009,NA,ISRCTN number,results
2765,2009-016043-19, Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,09-02-2010,NA,US NCT number,protocol
2766,2009-016043-19, Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,09-02-2010,NA,other,protocol
2767,2009-016043-19, Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,09-02-2010,NA,US NCT number,results
2768,2009-016043-19, Impact of a balanced infusion solution compound of 50% cristalloid and 50% colloid versus a unbalanced infusion solution of 100% cristalloid within a goal-directed hemodynamic protocol on acid-base balance in patients undergoing elective hip replacement surgery,09-02-2010,NA,ISRCTN number,results
2769,2009-016142-44, Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,06-07-2010,NCT01180322,US NCT number,protocol
2770,2009-016142-44, Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,06-07-2010,NA,other,protocol
2771,2009-016142-44, Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,06-07-2010,NCT01180322,US NCT number,results
2772,2009-016142-44, Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine,06-07-2010,NA,ISRCTN number,results
2773,2009-016463-10, Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial,11-01-2010,NA,US NCT number,protocol
2774,2009-016463-10, Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial,11-01-2010,NA,other,protocol
2775,2009-016463-10, Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial,11-01-2010,NA,US NCT number,results
2776,2009-016463-10, Antidepressive response to add-on occupational therapy in patients with major depression: A randomized controlled multicentre trial,11-01-2010,NA,ISRCTN number,results
2777,2009-016482-28, SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,15-03-2010,NA,US NCT number,protocol
2778,2009-016482-28, SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,15-03-2010,NA,other,protocol
2779,2009-016482-28, SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,15-03-2010,NA,US NCT number,results
2780,2009-016482-28, SUNIMUD - Sunphenon EGCg (Epigallocatechin-Gallate) in Duchenne Muscular Dystrophy,15-03-2010,NA,ISRCTN number,results
2781,2009-016489-10," Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynx",04-05-2010,NA,US NCT number,protocol
2782,2009-016489-10," Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynx",04-05-2010,NA,other,protocol
2783,2009-016489-10," Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynx",04-05-2010,NA,US NCT number,results
2784,2009-016489-10," Phase II study of induction chemotherapy with TPF followed by radioimmunotherapy with Cetuximab and intensity modulated radiotherapy (IMRT) in combination with a carbon ion boost for locally advanced tumors of the oro- , hypopharynx and larynx",04-05-2010,NA,ISRCTN number,results
2785,2009-016616-21," Lenalidomide, Adriamycin, Dexamethasone (RAD)",13-07-2011,NA,US NCT number,protocol
2786,2009-016616-21," Lenalidomide, Adriamycin, Dexamethasone (RAD)",13-07-2011,NA,other,protocol
2787,2009-016616-21," Lenalidomide, Adriamycin, Dexamethasone (RAD)",13-07-2011,NA,US NCT number,results
2788,2009-016616-21," Lenalidomide, Adriamycin, Dexamethasone (RAD)",13-07-2011,NA,ISRCTN number,results
2789,2009-016631-35, Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous  preexisting immune response to NY-ESO-1,31-05-2010,NA,US NCT number,protocol
2790,2009-016631-35, Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous  preexisting immune response to NY-ESO-1,31-05-2010,NA,other,protocol
2791,2009-016631-35, Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous  preexisting immune response to NY-ESO-1,31-05-2010,NA,US NCT number,results
2792,2009-016631-35, Phase II Trial of Ipilimumab in Patients with advanced melanoma and spontaneous  preexisting immune response to NY-ESO-1,31-05-2010,NA,ISRCTN number,results
2793,2009-016641-26, The influence of propofol and inhalational anesthetics on postoperative pain perception,22-04-2010,NA,US NCT number,protocol
2794,2009-016641-26, The influence of propofol and inhalational anesthetics on postoperative pain perception,22-04-2010,NA,other,protocol
2795,2009-016641-26, The influence of propofol and inhalational anesthetics on postoperative pain perception,22-04-2010,NA,US NCT number,results
2796,2009-016641-26, The influence of propofol and inhalational anesthetics on postoperative pain perception,22-04-2010,NA,ISRCTN number,results
2797,2009-016748-38," Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and photodamage on the back of the hands using Intense Pulsed Light (IPL) devices",03-02-2010,NA,US NCT number,protocol
2798,2009-016748-38," Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and photodamage on the back of the hands using Intense Pulsed Light (IPL) devices",03-02-2010,NA,other,protocol
2799,2009-016748-38," Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and photodamage on the back of the hands using Intense Pulsed Light (IPL) devices",03-02-2010,NA,US NCT number,results
2800,2009-016748-38," Prospective, randomized, placebo-controlled, monocentric, two-armed, observer-blinded and within-patient study for Photodynamic Therapy (PDT) with MAL in the treatment of actinic keratoses (AK) and photodamage on the back of the hands using Intense Pulsed Light (IPL) devices",03-02-2010,NA,ISRCTN number,results
2801,2009-016907-41," Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",13-08-2012,NA,US NCT number,protocol
2802,2009-016907-41," Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",13-08-2012,NA,other,protocol
2803,2009-016907-41," Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",13-08-2012,NA,US NCT number,results
2804,2009-016907-41," Investigation of nociceptive and antinociceptive mechanisms under anesthesia using fMRI, EEG and noxious reflexes",13-08-2012,NA,ISRCTN number,results
2805,2009-016966-97," Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Using Eculizumab",08-02-2010,NA,US NCT number,protocol
2806,2009-016966-97," Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Using Eculizumab",08-02-2010,NA,other,protocol
2807,2009-016966-97," Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Using Eculizumab",08-02-2010,NA,US NCT number,results
2808,2009-016966-97," Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease Using Eculizumab",08-02-2010,NA,ISRCTN number,results
2809,2009-016994-13, EUropean Pharmacogenetics of AntiCoagulation Therapy trial,16-12-2009,NA,US NCT number,protocol
2810,2009-016994-13, EUropean Pharmacogenetics of AntiCoagulation Therapy trial,16-12-2009,NA,other,protocol
2811,2009-016994-13, EUropean Pharmacogenetics of AntiCoagulation Therapy trial,16-12-2009,NA,US NCT number,results
2812,2009-016994-13, EUropean Pharmacogenetics of AntiCoagulation Therapy trial,16-12-2009,NA,ISRCTN number,results
2813,2009-017010-68, A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,01-04-2010,NA,US NCT number,protocol
2814,2009-017010-68, A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,01-04-2010,NA,other,protocol
2815,2009-017010-68, A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,01-04-2010,NA,US NCT number,results
2816,2009-017010-68, A TElmisartan and AMlodipine STudy to Assess the cardiovascular PROTECTive effects as measured by endothelial dysfunction in hypertensive at risk patients beyond blood pressure,01-04-2010,NA,ISRCTN number,results
2817,2009-017048-15, Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis,24-02-2010,NA,US NCT number,protocol
2818,2009-017048-15, Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis,24-02-2010,NA,other,protocol
2819,2009-017048-15, Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis,24-02-2010,NA,US NCT number,results
2820,2009-017048-15, Botulinum Neurotoxin Typ A (Xeomin®) als Therapieoption der allergischen und intrinsischen Rhinitis,24-02-2010,NA,ISRCTN number,results
2821,2009-017052-27," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",01-12-2009,NA,US NCT number,protocol
2822,2009-017052-27," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",01-12-2009,NA,other,protocol
2823,2009-017052-27," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",01-12-2009,NA,US NCT number,results
2824,2009-017052-27," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a H1N1 Influenza Vaccine in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",01-12-2009,NA,ISRCTN number,results
2825,2009-017085-22, Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung],11-03-2010,NA,US NCT number,protocol
2826,2009-017085-22, Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung],11-03-2010,NA,other,protocol
2827,2009-017085-22, Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung],11-03-2010,NA,US NCT number,results
2828,2009-017085-22, Sugammadex improves muscle function after standard neuromuscular recovery (SIMAR) [Verbesserung der Muskelfunktion durch Sugammadex nach normaler neuromuskulärer Erholung],11-03-2010,NA,ISRCTN number,results
2829,2009-017192-26," A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in Liver Transplant Recipients with MELD-Scores≥25",17-02-2011,NA,US NCT number,protocol
2830,2009-017192-26," A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in Liver Transplant Recipients with MELD-Scores≥25",17-02-2011,Clinicaltrials.gov NCT01023542,other,protocol
2831,2009-017192-26," A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in Liver Transplant Recipients with MELD-Scores≥25",17-02-2011,NA,US NCT number,results
2832,2009-017192-26," A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in Liver Transplant Recipients with MELD-Scores≥25",17-02-2011,NA,ISRCTN number,results
2833,2009-017261-32, Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,16-05-2011,NA,US NCT number,protocol
2834,2009-017261-32, Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,16-05-2011,AIO AIO-STS-009,other,protocol
2835,2009-017261-32, Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,16-05-2011,NA,US NCT number,results
2836,2009-017261-32, Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcoma,16-05-2011,NA,ISRCTN number,results
2837,2009-017324-11," Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung bei Bedarf",18-01-2010,NA,US NCT number,protocol
2838,2009-017324-11," Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung bei Bedarf",18-01-2010,NA,other,protocol
2839,2009-017324-11," Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung bei Bedarf",18-01-2010,NCT01831947,US NCT number,results
2840,2009-017324-11," Wirksamkeit von Ranibizumab bei Patienten mit CHORIOIDALER NEOVASKULARISATION (CNV), als Folge einer altersbedingten Makuladegeneration (AMD), bei einer Gabe alle zwei Monate gegenüber der Behandlung bei Bedarf",18-01-2010,NA,ISRCTN number,results
2841,2009-017328-25," A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer",28-07-2010,NA,US NCT number,protocol
2842,2009-017328-25," A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer",28-07-2010,NA,other,protocol
2843,2009-017328-25," A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer",28-07-2010,NA,US NCT number,results
2844,2009-017328-25," A phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer",28-07-2010,NA,ISRCTN number,results
2845,2009-017347-33, A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional,09-06-2010,NA,US NCT number,protocol
2846,2009-017347-33, A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional,09-06-2010,NA,other,protocol
2847,2009-017347-33, A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional,09-06-2010,NA,US NCT number,results
2848,2009-017347-33, A multicenter Phase I/II trial investigating the safety and efficacy (CR rate and OS) of low dose AraC with Clofarabine in patients ≥60 years with AML not eligible for conventional,09-06-2010,NA,ISRCTN number,results
2849,2009-017416-33," Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.",21-12-2009,NA,US NCT number,protocol
2850,2009-017416-33," Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.",21-12-2009,NA,other,protocol
2851,2009-017416-33," Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.",21-12-2009,NA,US NCT number,results
2852,2009-017416-33," Standardized clinical trial on the application of Levodopa (LD) / Carbidopa (CD) to patients with Parkinson disease vs LD / CD and Entacapon (EN) vs LD / CD and Tolcapon (TO) concerning the parameters motor function, pharmacokinetics of LD, plasma level of homocystein and serum level of cortisol.",21-12-2009,NA,ISRCTN number,results
2853,2009-017458-11," Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",24-03-2010,NA,US NCT number,protocol
2854,2009-017458-11," Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",24-03-2010,NA,other,protocol
2855,2009-017458-11," Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",24-03-2010,NA,US NCT number,results
2856,2009-017458-11," Homeopathy for Depression: a randomized, four-armed, partial double-blind study.",24-03-2010,NA,ISRCTN number,results
2857,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,protocol
2858,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,other,protocol
2859,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,results
2860,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,ISRCTN number,results
2861,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,protocol
2862,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,other,protocol
2863,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,results
2864,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,ISRCTN number,results
2865,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,protocol
2866,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,other,protocol
2867,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,results
2868,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,ISRCTN number,results
2869,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,protocol
2870,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,other,protocol
2871,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,US NCT number,results
2872,2009-017472-25,"  „Duplex-kontrollierte, katheter-gestützte Schaumsklerosierung (DKKS) von Krampfadern in Kombination mit Tumeszenzlösungsapplikation (TLA)“",20-01-2010,NA,ISRCTN number,results
2873,2009-017520-88, Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,17-08-2010,NA,US NCT number,protocol
2874,2009-017520-88, Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,17-08-2010,NA,other,protocol
2875,2009-017520-88, Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,17-08-2010,NA,US NCT number,results
2876,2009-017520-88, Ciclosporin vs. Alitretinoin for severe atopic hand dermatitis. A randomized controlled investigator-initiated double-blind trial.,17-08-2010,NA,ISRCTN number,results
2877,2009-017581-22, Cognitive impairment in bipolar disorder treated with aripiprazole,07-12-2010,NA,US NCT number,protocol
2878,2009-017581-22, Cognitive impairment in bipolar disorder treated with aripiprazole,07-12-2010,NA,other,protocol
2879,2009-017581-22, Cognitive impairment in bipolar disorder treated with aripiprazole,07-12-2010,NA,US NCT number,results
2880,2009-017581-22, Cognitive impairment in bipolar disorder treated with aripiprazole,07-12-2010,NA,ISRCTN number,results
2881,2009-017595-25, Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery,17-01-2011,NCT01303250,US NCT number,protocol
2882,2009-017595-25, Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery,17-01-2011,NA,other,protocol
2883,2009-017595-25, Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery,17-01-2011,NCT01303250,US NCT number,results
2884,2009-017595-25, Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery,17-01-2011,NA,ISRCTN number,results
2885,2009-017676-24," Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels",18-02-2010,NA,US NCT number,protocol
2886,2009-017676-24," Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels",18-02-2010,NA,other,protocol
2887,2009-017676-24," Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels",18-02-2010,NA,US NCT number,results
2888,2009-017676-24," Randomized, double blind, active-controlled, parallel study to analyse effects of the combination of aliskiren and valsartan on the vascular structure and function of retinal vessels",18-02-2010,NA,ISRCTN number,results
2889,2009-017739-17, Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,04-01-2010,NA,US NCT number,protocol
2890,2009-017739-17, Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,04-01-2010,NA,other,protocol
2891,2009-017739-17, Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,04-01-2010,NA,US NCT number,results
2892,2009-017739-17, Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem,04-01-2010,NA,ISRCTN number,results
2893,2009-018072-33, Prospective Trial for the diagnosis and treatment of ,06-06-2011,NA,US NCT number,protocol
2894,2009-018072-33, Prospective Trial for the diagnosis and treatment of ,06-06-2011,NA,other,protocol
2895,2009-018072-33, Prospective Trial for the diagnosis and treatment of ,06-06-2011,NA,US NCT number,results
2896,2009-018072-33, Prospective Trial for the diagnosis and treatment of ,06-06-2011,NA,ISRCTN number,results
2897,2009-018077-31, A PHASE I/II DOSE SCHEDULE FINDING STUDY,24-09-2010,NCT01701479,US NCT number,protocol
2898,2009-018077-31, A PHASE I/II DOSE SCHEDULE FINDING STUDY,24-09-2010,NA,other,protocol
2899,2009-018077-31, A PHASE I/II DOSE SCHEDULE FINDING STUDY,24-09-2010,NA,US NCT number,results
2900,2009-018077-31, A PHASE I/II DOSE SCHEDULE FINDING STUDY,24-09-2010,NA,ISRCTN number,results
2901,2010-018279-99, Skin Topoproteome under Adalimumab (Humira®) Treatment,15-01-2010,NA,US NCT number,protocol
2902,2010-018279-99, Skin Topoproteome under Adalimumab (Humira®) Treatment,15-01-2010,NA,other,protocol
2903,2010-018279-99, Skin Topoproteome under Adalimumab (Humira®) Treatment,15-01-2010,NA,US NCT number,results
2904,2010-018279-99, Skin Topoproteome under Adalimumab (Humira®) Treatment,15-01-2010,NA,ISRCTN number,results
2905,2010-018291-25," INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",24-06-2010,NCT01319370,US NCT number,protocol
2906,2010-018291-25," INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",24-06-2010,NA,other,protocol
2907,2010-018291-25," INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",24-06-2010,NA,US NCT number,results
2908,2010-018291-25," INVESTIGATOR-INITIATED, DOUBLE BLIND, TWO-ARMED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL WITH AN OPEN-LABEL EXTENSION PHASE, TO INVESTIGATE EFFICACY OF 5% MINOXIDIL TOPICAL FOAM TWICE DAILY IN MEN WITH ANDROGENETIC ALOPECIA IN THE TEMPLE AND VERTEX REGION CONCERNING HAIR VOLUME OVER 24 / 104 WEEKS",24-06-2010,NA,ISRCTN number,results
2909,2010-018343-34, Comparison of 6% Hydroxyethyl Starch and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy (CHART study),26-07-2011,NA,US NCT number,protocol
2910,2010-018343-34, Comparison of 6% Hydroxyethyl Starch and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy (CHART study),26-07-2011,NA,other,protocol
2911,2010-018343-34, Comparison of 6% Hydroxyethyl Starch and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy (CHART study),26-07-2011,NA,US NCT number,results
2912,2010-018343-34, Comparison of 6% Hydroxyethyl Starch and 5% Albumin for Volume Replacement Therapy in Patients Undergoing Cystectomy (CHART study),26-07-2011,NA,ISRCTN number,results
2913,2010-018467-42, Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability,25-10-2010,NA,US NCT number,protocol
2914,2010-018467-42, Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability,25-10-2010,NA,other,protocol
2915,2010-018467-42, Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability,25-10-2010,NA,US NCT number,results
2916,2010-018467-42, Comparison between 5 – azacytidine treatment and 5 – azacytidine followed by allogeneic stem cell transplantation in elderly patients with advanced MDS according to donor availability,25-10-2010,NA,ISRCTN number,results
2917,2010-018517-29, Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.,26-01-2010,NA,US NCT number,protocol
2918,2010-018517-29, Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.,26-01-2010,NA,other,protocol
2919,2010-018517-29, Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.,26-01-2010,NA,US NCT number,results
2920,2010-018517-29, Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.,26-01-2010,NA,ISRCTN number,results
2921,2010-018539-16," A double-blind, placebo-controlled, randomized, multi-center",21-07-2010,NA,US NCT number,protocol
2922,2010-018539-16," A double-blind, placebo-controlled, randomized, multi-center",21-07-2010,NA,other,protocol
2923,2010-018539-16," A double-blind, placebo-controlled, randomized, multi-center",21-07-2010,NA,US NCT number,results
2924,2010-018539-16," A double-blind, placebo-controlled, randomized, multi-center",21-07-2010,NA,ISRCTN number,results
2925,2010-018559-84, AMBITIOUS,20-05-2010,NA,US NCT number,protocol
2926,2010-018559-84, AMBITIOUS,20-05-2010,NA,other,protocol
2927,2010-018559-84, AMBITIOUS,20-05-2010,NA,US NCT number,results
2928,2010-018559-84, AMBITIOUS,20-05-2010,NA,ISRCTN number,results
2929,2010-018624-20, Tolerance of virucidal alcohol-based hand rubs - healthy volunteer trial ,12-04-2010,NA,US NCT number,protocol
2930,2010-018624-20, Tolerance of virucidal alcohol-based hand rubs - healthy volunteer trial ,12-04-2010,NA,other,protocol
2931,2010-018624-20, Tolerance of virucidal alcohol-based hand rubs - healthy volunteer trial ,12-04-2010,NA,US NCT number,results
2932,2010-018624-20, Tolerance of virucidal alcohol-based hand rubs - healthy volunteer trial ,12-04-2010,NA,ISRCTN number,results
2933,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,protocol
2934,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,other,protocol
2935,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,results
2936,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,ISRCTN number,results
2937,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,protocol
2938,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,other,protocol
2939,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,results
2940,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,ISRCTN number,results
2941,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,protocol
2942,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,other,protocol
2943,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,results
2944,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,ISRCTN number,results
2945,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,protocol
2946,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,other,protocol
2947,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,US NCT number,results
2948,2010-018637-21, Intravitreal Injection of Lucentis (Ranibizumab) after Pars Plana Vitrectomy and Subretinal Application of Recombinant Tissue Plasminogen Activator (rtPA) in Patients with Acute Submacular Hemorrhage as Complication of Exsudative Age-related Macular Degeneration (AMD).,17-04-2013,NA,ISRCTN number,results
2949,2010-018639-17, Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome,25-03-2010,NA,US NCT number,protocol
2950,2010-018639-17, Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome,25-03-2010,NA,other,protocol
2951,2010-018639-17, Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome,25-03-2010,NA,US NCT number,results
2952,2010-018639-17, Prospective and open label study with blind end point evaluation on the effect of mineralcorticoid receptor inhibition on endothelial function of the micro- and macrovasculature in patient with metabolic syndrome,25-03-2010,NA,ISRCTN number,results
2953,2010-018665-30, COMFORT-study ,06-04-2010,NA,US NCT number,protocol
2954,2010-018665-30, COMFORT-study ,06-04-2010,NA,other,protocol
2955,2010-018665-30, COMFORT-study ,06-04-2010,NA,US NCT number,results
2956,2010-018665-30, COMFORT-study ,06-04-2010,NA,ISRCTN number,results
2957,2010-018699-26, Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST),20-08-2010,NCT01451268,US NCT number,protocol
2958,2010-018699-26, Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST),20-08-2010,NA,other,protocol
2959,2010-018699-26, Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST),20-08-2010,NCT01451268,US NCT number,results
2960,2010-018699-26, Phase I/II study with oral panobinostat maintenance therapy following allogeneic stem cell transplantation in patients with high risk MDS or AML (PANOBEST),20-08-2010,NA,ISRCTN number,results
2961,2010-018850-11, Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,22-12-2010,NA,US NCT number,protocol
2962,2010-018850-11, Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,22-12-2010,NA,other,protocol
2963,2010-018850-11, Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,22-12-2010,NA,US NCT number,results
2964,2010-018850-11, Panitumumab in combination with cisplatin/gemcitabine chemotherapy in patients with cholangiocarcinomas - a randomized clinical phase II study - PiCCA Study,22-12-2010,NA,ISRCTN number,results
2965,2010-018979-16, EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES,03-05-2010,NA,US NCT number,protocol
2966,2010-018979-16, EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES,03-05-2010,NA,other,protocol
2967,2010-018979-16, EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES,03-05-2010,NA,US NCT number,results
2968,2010-018979-16, EFFECTS OF SAXAGLITPIN ON ENDOTHELIAL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES,03-05-2010,NA,ISRCTN number,results
2969,2010-018980-41, International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,20-09-2013,NA,US NCT number,protocol
2970,2010-018980-41, International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,20-09-2013,NA,other,protocol
2971,2010-018980-41, International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,20-09-2013,NA,US NCT number,results
2972,2010-018980-41, International randomized phase III study on the treatment of children and adolescents with refractory or relapsed acute myeloid leukemia,20-09-2013,NA,ISRCTN number,results
2973,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,protocol
2974,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,other,protocol
2975,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,results
2976,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,ISRCTN number,results
2977,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,protocol
2978,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,other,protocol
2979,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,results
2980,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,ISRCTN number,results
2981,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,protocol
2982,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,other,protocol
2983,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,results
2984,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,ISRCTN number,results
2985,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,protocol
2986,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,other,protocol
2987,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,US NCT number,results
2988,2010-018993-20," Multicenter phase II study of panitumumab, docetaxel, 5-FU, leucovorin and oxaliplatin (P-FLOT) in patients with metastatic or locally advanced Kras wild type adenocarcinoma of the stomach or the gastroesophageal junction",16-05-2012,NA,ISRCTN number,results
2989,2010-019017-25, Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size,08-11-2010,NA,US NCT number,protocol
2990,2010-019017-25, Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size,08-11-2010,NA,other,protocol
2991,2010-019017-25, Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size,08-11-2010,NCT02021942,US NCT number,results
2992,2010-019017-25, Efficacy of medical treatment with SOM230 LAR in patients with primary inoperable thymoma and/or with local recurrent thymoma to reduce tumor size,08-11-2010,NA,ISRCTN number,results
2993,2010-019033-98, A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma,31-08-2011,NA,US NCT number,protocol
2994,2010-019033-98, A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma,31-08-2011,NA,other,protocol
2995,2010-019033-98, A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma,31-08-2011,NCT01480323,US NCT number,results
2996,2010-019033-98, A phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma,31-08-2011,NA,ISRCTN number,results
2997,2010-019110-24," A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",04-11-2010,NA,US NCT number,protocol
2998,2010-019110-24," A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",04-11-2010,NA,other,protocol
2999,2010-019110-24," A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",04-11-2010,NA,US NCT number,results
3000,2010-019110-24," A PHASE 2, SINGLE-CENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF ZOLEDRONATE IN SUBJECTS WITH EROSIVE HAND OSTEOARTHRITIS",04-11-2010,NA,ISRCTN number,results
3001,2010-019173-16, Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment,23-02-2010,NA,US NCT number,protocol
3002,2010-019173-16, Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment,23-02-2010,NA,other,protocol
3003,2010-019173-16, Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment,23-02-2010,NA,US NCT number,results
3004,2010-019173-16, Randomised phase III trial for previously untreated multiple myeloma to evaluate two regimens of bortezomib based induction therapy and lenalidomide consolidation followed by lenalidomide maintenance treatment,23-02-2010,ISRCTN05622749,ISRCTN number,results
3005,2010-019218-26, Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,22-12-2010,NA,US NCT number,protocol
3006,2010-019218-26, Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,22-12-2010,NA,other,protocol
3007,2010-019218-26, Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,22-12-2010,NA,US NCT number,results
3008,2010-019218-26, Offene Verträglichkeitsstudie zur Evaluierung einer subkutanen Injektionslösung von 100 mg Anakinra in Kombination mit Riluzol bei Patienten mit Amyotropher Lateralsklerose (ALS).,22-12-2010,NA,ISRCTN number,results
3009,2010-019344-39," Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU)",15-04-2010,NA,US NCT number,protocol
3010,2010-019344-39," Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU)",15-04-2010,NA,other,protocol
3011,2010-019344-39," Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU)",15-04-2010,NA,US NCT number,results
3012,2010-019344-39," Double-blind, triple cross-over, placebo-controlled study to assess the efficacy, mechanisms, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in cold contact urticaria (CCU)",15-04-2010,NA,ISRCTN number,results
3013,2010-019345-26, Immunmodulatory effects of local anesthetics on neutrophils during sepsis,25-03-2010,NA,US NCT number,protocol
3014,2010-019345-26, Immunmodulatory effects of local anesthetics on neutrophils during sepsis,25-03-2010,NA,other,protocol
3015,2010-019345-26, Immunmodulatory effects of local anesthetics on neutrophils during sepsis,25-03-2010,NA,US NCT number,results
3016,2010-019345-26, Immunmodulatory effects of local anesthetics on neutrophils during sepsis,25-03-2010,NA,ISRCTN number,results
3017,2010-019347-18," Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",20-04-2010,NA,US NCT number,protocol
3018,2010-019347-18," Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",20-04-2010,NA,other,protocol
3019,2010-019347-18," Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",20-04-2010,NA,US NCT number,results
3020,2010-019347-18," Randomized Phase II Study of two different Regimens of TPF Induction Chemotherapy Regimen followed by Radiation Therapy plus cetuximab (TPF-CET-HART) vs. HART and Cisplatinum, 5-FU (PF-HART) in Patients with Locally Advanced Unresectable Squamous Cell Carcinomas of the Head and Neck.",20-04-2010,NA,ISRCTN number,results
3021,2010-019377-15, Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <=60 Jahren mit AML intermediären Risikos (Standardrisiko) und HLA-kompatiblem Geschwister- oder Fremdspender,14-04-2010,NCT01246752,US NCT number,protocol
3022,2010-019377-15, Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <=60 Jahren mit AML intermediären Risikos (Standardrisiko) und HLA-kompatiblem Geschwister- oder Fremdspender,14-04-2010,NA,other,protocol
3023,2010-019377-15, Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <=60 Jahren mit AML intermediären Risikos (Standardrisiko) und HLA-kompatiblem Geschwister- oder Fremdspender,14-04-2010,NA,US NCT number,results
3024,2010-019377-15, Randomisierte Studie zur allogenen hämatopoetischen Stammzelltransplantation im Vergleich zur Standardchemotherapie bei Patienten in erster kompletter Remission im Alter von <=60 Jahren mit AML intermediären Risikos (Standardrisiko) und HLA-kompatiblem Geschwister- oder Fremdspender,14-04-2010,NA,ISRCTN number,results
3025,2010-019415-38," A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome",04-11-2010,NA,US NCT number,protocol
3026,2010-019415-38," A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome",04-11-2010,NA,other,protocol
3027,2010-019415-38," A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome",04-11-2010,NCT01348269,US NCT number,results
3028,2010-019415-38," A prospective, bicentric, randomised, primarily double blind, placebo-controlled study to evaluate the efficacy of zoledronic acid for the treatment of bone marrow syndrome",04-11-2010,NA,ISRCTN number,results
3029,2010-019587-36," Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution",19-04-2011,NCT01478542,US NCT number,protocol
3030,2010-019587-36," Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution",19-04-2011,NA,other,protocol
3031,2010-019587-36," Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution",19-04-2011,NA,US NCT number,results
3032,2010-019587-36," Improvement of outcome and reduction of toxicity in elderly patients with CD20+ aggressive B-cell lymphoma by an optimised schedule of the monoclonal antibody rituximab, substitution of conventional by liposomal vincristine and FDG-PET based reduction of therapy in combination with vitamin D substitution",19-04-2011,NA,ISRCTN number,results
3033,2010-019688-12, Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.,22-04-2010,NA,US NCT number,protocol
3034,2010-019688-12, Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.,22-04-2010,NA,other,protocol
3035,2010-019688-12, Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.,22-04-2010,NA,US NCT number,results
3036,2010-019688-12, Prospective placebo controlled trial: Detection of coronary microembolization by Doppler ultrasound in patients with stable angina pectoris during percutaneous coronary interventions under an adjunctive antithrombotic therapy with abciximab.,22-04-2010,NA,ISRCTN number,results
3037,2010-019715-38," Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanolhaltige Creme)",01-06-2010,NA,US NCT number,protocol
3038,2010-019715-38," Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanolhaltige Creme)",01-06-2010,NA,other,protocol
3039,2010-019715-38," Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanolhaltige Creme)",01-06-2010,NA,US NCT number,results
3040,2010-019715-38," Placebokontrollierte, prospektive Beobachtung des Schmerzempfindens bei Probanden während der mechanischen Epilation mit dem Braun Expressive Epilationsgerät nach Auftragen von Lokaltherapeutika (Emla Creme, Polidocanolhaltige Creme)",01-06-2010,NA,ISRCTN number,results
3041,2010-019748-38, Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,29-09-2010,NA,US NCT number,protocol
3042,2010-019748-38, Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,29-09-2010,NA,other,protocol
3043,2010-019748-38, Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,29-09-2010,NCT01553032,US NCT number,results
3044,2010-019748-38, Hautveränderungen bei Patienten mit Kopf- und Halstumor unter kombinierter RadioImmuno-(chemo)-therapie mit Erbitux®,29-09-2010,NA,ISRCTN number,results
3045,2010-019884-12, Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection ,14-10-2010,NA,US NCT number,protocol
3046,2010-019884-12, Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection ,14-10-2010,NA,other,protocol
3047,2010-019884-12, Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection ,14-10-2010,NA,US NCT number,results
3048,2010-019884-12, Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection ,14-10-2010,NA,ISRCTN number,results
3049,2010-019885-10, Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis to prevent acneforme follicular exanthema,15-10-2010,NCT01315990,US NCT number,protocol
3050,2010-019885-10, Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis to prevent acneforme follicular exanthema,15-10-2010,NA,other,protocol
3051,2010-019885-10, Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis to prevent acneforme follicular exanthema,15-10-2010,NCT01315990,US NCT number,results
3052,2010-019885-10, Non-randomized phase-IV-study to investigate the efficacy of FOLFIRI in combination with cetuximab in the first-line treatment of metastatic colorectal cancer inculding a regular dermal prophylaxis to prevent acneforme follicular exanthema,15-10-2010,NA,ISRCTN number,results
3053,2010-019954-42, Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,07-07-2010,NA,US NCT number,protocol
3054,2010-019954-42, Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,07-07-2010,NA,other,protocol
3055,2010-019954-42, Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,07-07-2010,NA,US NCT number,results
3056,2010-019954-42, Effect of Niacin/ Laropiprant on postprandial lipoprotein and glucose metabolism in patients with severe dyslipoproteinemia,07-07-2010,NA,ISRCTN number,results
3057,2010-019975-30," Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma patients",25-06-2010,NA,US NCT number,protocol
3058,2010-019975-30," Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma patients",25-06-2010,NA,other,protocol
3059,2010-019975-30," Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma patients",25-06-2010,NA,US NCT number,results
3060,2010-019975-30," Investigation of the efficacy and safety of preoperative IOP reduction with preservative-free COSOPT-S® (dorzolamide/timolol, MSD) eye drops versus oral acetazolamide and dexamethasone eye drops and assessment of the clinical outcome of trabeculectomy in glaucoma patients",25-06-2010,NA,ISRCTN number,results
3061,2010-020063-21," “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",21-05-2010,NA,US NCT number,protocol
3062,2010-020063-21," “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",21-05-2010,NA,other,protocol
3063,2010-020063-21," “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",21-05-2010,NA,US NCT number,results
3064,2010-020063-21," “A 20-week open-label study to assess the efficacy and safety of single doses of Ilaris® (Canakinumab, ACZ885) in patients with active, refractory urticarial vasculitis”",21-05-2010,NA,ISRCTN number,results
3065,2010-020299-42," A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)",26-04-2011,NA,US NCT number,protocol
3066,2010-020299-42," A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)",26-04-2011,NA,other,protocol
3067,2010-020299-42," A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)",26-04-2011,NCT01560754,US NCT number,results
3068,2010-020299-42," A randomized, placebo-controlled, double-blind, multi-center trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson's disease in Germany and the USA (NIC-PD)",26-04-2011,NA,ISRCTN number,results
3069,2010-020403-75, ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial,16-06-2011,NA,US NCT number,protocol
3070,2010-020403-75, ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial,16-06-2011,NA,other,protocol
3071,2010-020403-75, ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial,16-06-2011,NA,US NCT number,results
3072,2010-020403-75, ACE inhibitor for lung protection during mechanical Ventilation for acute lung injury - pilot trial,16-06-2011,NA,ISRCTN number,results
3073,2010-020433-13," Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie  ",26-11-2010,NA,US NCT number,protocol
3074,2010-020433-13," Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie  ",26-11-2010,NA,other,protocol
3075,2010-020433-13," Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie  ",26-11-2010,NA,US NCT number,results
3076,2010-020433-13," Eine 8-wöchige, monozentrische, baseline-kontrollierte offene Studie zur Evaluierung des Einflusses einer “Single pill combination” auf die Blutdrucksenkung bei Patienten mit nicht-kontrolliertem Blutdruck unter freier Therapie  ",26-11-2010,NA,ISRCTN number,results
3077,2010-020441-27, Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion,23-02-2011,NA,US NCT number,protocol
3078,2010-020441-27, Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion,23-02-2011,NA,other,protocol
3079,2010-020441-27, Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion,23-02-2011,NA,US NCT number,results
3080,2010-020441-27, Ranibizumab combined with selective peripheral laser photocoagulation for treatment of central retinal vein occlusion,23-02-2011,NA,ISRCTN number,results
3081,2010-020480-21, Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,28-07-2010,NA,US NCT number,protocol
3082,2010-020480-21, Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,28-07-2010,NA,other,protocol
3083,2010-020480-21, Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,28-07-2010,NA,US NCT number,results
3084,2010-020480-21, Feasibility and efficacy of adjuvant gemcitabine chemotherapy after liver transplantation for proximal bile duct cancer,28-07-2010,NA,ISRCTN number,results
3085,2010-020956-69, Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung,20-10-2010,NA,US NCT number,protocol
3086,2010-020956-69, Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung,20-10-2010,NA,other,protocol
3087,2010-020956-69, Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung,20-10-2010,NA,US NCT number,results
3088,2010-020956-69, Effekte von Oxytocin bei Patientinnen und Patienten mit Borderline-Persönlichkeitsstörung,20-10-2010,NA,ISRCTN number,results
3089,2010-021001-21," An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",16-06-2010,NA,US NCT number,protocol
3090,2010-021001-21," An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",16-06-2010,NA,other,protocol
3091,2010-021001-21," An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",16-06-2010,NA,US NCT number,results
3092,2010-021001-21," An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms",16-06-2010,NA,ISRCTN number,results
3093,2010-021086-73," HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma",14-12-2011,NA,US NCT number,protocol
3094,2010-021086-73," HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma",14-12-2011,NA,other,protocol
3095,2010-021086-73," HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma",14-12-2011,NCT01453504,US NCT number,results
3096,2010-021086-73," HD-R3i - A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma",14-12-2011,NA,ISRCTN number,results
3097,2010-021139-15, Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors?,28-06-2010,NA,US NCT number,protocol
3098,2010-021139-15, Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors?,28-06-2010,NA,other,protocol
3099,2010-021139-15, Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors?,28-06-2010,NA,US NCT number,results
3100,2010-021139-15, Do Selective Radiation Dose Escalation and Tumor Hypoxia Status Impact the Locoregional Tumor Control after Radiochemotherapy of Head & Neck Tumors?,28-06-2010,NA,ISRCTN number,results
3101,2010-021264-14," Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",07-09-2012,NA,US NCT number,protocol
3102,2010-021264-14," Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",07-09-2012,NA,other,protocol
3103,2010-021264-14," Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",07-09-2012,NA,US NCT number,results
3104,2010-021264-14," Vitamin K1 to slow vascular calcification in hemodialysis patients. Multicenter, multinational, randomized controlled clinical trial",07-09-2012,NA,ISRCTN number,results
3105,2010-021275-92," Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",01-10-2010,NA,US NCT number,protocol
3106,2010-021275-92," Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",01-10-2010,NA,other,protocol
3107,2010-021275-92," Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",01-10-2010,NA,US NCT number,results
3108,2010-021275-92," Single center, open-label, cross-over study in maintenace kidney allograft recipients to evaluate the bioavailability of CellCept® (Mycophenolate mofetil) in comparison to Myfortic® (Enteric- coated  mycophenolate sodium) in combination with a proton pump inhibitor without co-medication.",01-10-2010,NA,ISRCTN number,results
3109,2010-021333-31, Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation ,14-06-2011,NA,US NCT number,protocol
3110,2010-021333-31, Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation ,14-06-2011,NA,other,protocol
3111,2010-021333-31, Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation ,14-06-2011,NA,US NCT number,results
3112,2010-021333-31, Reduktion des Ischämie-Reperfusionsschadens durch ex-vivo Tacrolimus-Perfusion marginaler Organe vor Lebertransplantation ,14-06-2011,NA,ISRCTN number,results
3113,2010-021369-66, Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy ,28-09-2010,NA,US NCT number,protocol
3114,2010-021369-66, Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy ,28-09-2010,NA,other,protocol
3115,2010-021369-66, Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy ,28-09-2010,NA,US NCT number,results
3116,2010-021369-66, Investigation of pharmacokinetics of Ciprofloxacin and Piperacillin/Tazobactam in Patients receiving continuous renal replacement therapy ,28-09-2010,NA,ISRCTN number,results
3117,2010-021526-36, Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Dotarem) at equimolar dose (0.1 mmol/kg BW) in volunteers and patients with carotid artery stenosis,03-12-2010,NA,US NCT number,protocol
3118,2010-021526-36, Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Dotarem) at equimolar dose (0.1 mmol/kg BW) in volunteers and patients with carotid artery stenosis,03-12-2010,NA,other,protocol
3119,2010-021526-36, Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Dotarem) at equimolar dose (0.1 mmol/kg BW) in volunteers and patients with carotid artery stenosis,03-12-2010,NA,US NCT number,results
3120,2010-021526-36, Dynamic and high-resolution MR angiography of the supraaortic vessels at 3 Tesla: Performance of Gadobutrol (Gadovist) in comparison to Gedobenate Dimeglumine (Multihance) and Gadoterate Meglumine (Dotarem) at equimolar dose (0.1 mmol/kg BW) in volunteers and patients with carotid artery stenosis,03-12-2010,NA,ISRCTN number,results
3121,2010-021576-28, Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial,07-02-2011,NA,US NCT number,protocol
3122,2010-021576-28, Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial,07-02-2011,NA,other,protocol
3123,2010-021576-28, Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial,07-02-2011,NA,US NCT number,results
3124,2010-021576-28, Effects of transfusion thresholds on neurocognitive outcome of extremely low birth weight infants (ETTNO) a blinded randomized controlled multicenter trial,07-02-2011,NA,ISRCTN number,results
3125,2010-021604-16," A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",13-10-2010,NA,US NCT number,protocol
3126,2010-021604-16," A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",13-10-2010,NA,other,protocol
3127,2010-021604-16," A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",13-10-2010,NA,US NCT number,results
3128,2010-021604-16," A double-blind, randomized, placebo controlled study to evaluate the effectiveness of etoricoxib as an additive analgesic to epidural analgesia in colon or rectum fast-track surgery",13-10-2010,NA,ISRCTN number,results
3129,2010-021622-35," A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T",06-06-2011,NA,US NCT number,protocol
3130,2010-021622-35," A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T",06-06-2011,NA,other,protocol
3131,2010-021622-35," A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T",06-06-2011,NA,US NCT number,results
3132,2010-021622-35," A monocenter, non-controlled, non-randomized IST to compare bioavailability of Kaletra softgelcapsules or -suspension to Kaletra tablets in pediatric patients – C2T",06-06-2011,NA,ISRCTN number,results
3133,2010-021624-99," A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected children.",12-04-2012,NA,US NCT number,protocol
3134,2010-021624-99," A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected children.",12-04-2012,NA,other,protocol
3135,2010-021624-99," A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected children.",12-04-2012,NA,US NCT number,results
3136,2010-021624-99," A multi-centre, non-controlled, non-randomised  IST to evaluate the plasma level of antiretroviral substances, the viral resistance profile and their impact on the clinical response in HIV infected children.",12-04-2012,NA,ISRCTN number,results
3137,2010-021719-18, Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),05-10-2011,NA,US NCT number,protocol
3138,2010-021719-18, Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),05-10-2011,NA,other,protocol
3139,2010-021719-18, Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),05-10-2011,NA,US NCT number,results
3140,2010-021719-18, Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA),05-10-2011,NA,ISRCTN number,results
3141,2010-021775-80, Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,14-09-2010,NA,US NCT number,protocol
3142,2010-021775-80, Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,14-09-2010,NA,other,protocol
3143,2010-021775-80, Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,14-09-2010,NCT01466465,US NCT number,results
3144,2010-021775-80, Explorative Untersuchung zum Einfluss der Vitamin D-vermitteltenr Modulation der initialen subkutanen Gräserpollen-spezifischen Immuntherapie bei Allergikern mit Gräserpollen-induzierter Rhinokonjunktivitis mit/ohne allergischem Asthma,14-09-2010,NA,ISRCTN number,results
3145,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,protocol
3146,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,other,protocol
3147,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,results
3148,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,ISRCTN number,results
3149,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,protocol
3150,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,other,protocol
3151,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,results
3152,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,ISRCTN number,results
3153,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,protocol
3154,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,other,protocol
3155,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,results
3156,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,ISRCTN number,results
3157,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,protocol
3158,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,other,protocol
3159,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,US NCT number,results
3160,2010-021777-37," ""A prospective, non-randomized, mono-center, cohort study to evaluate the short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with wet age-related macular degeneration during twelve month"" ",09-08-2010,NA,ISRCTN number,results
3161,2010-021782-70," Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation,  intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term observation)",25-11-2010,NA,US NCT number,protocol
3162,2010-021782-70," Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation,  intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term observation)",25-11-2010,NA,other,protocol
3163,2010-021782-70," Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation,  intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term observation)",25-11-2010,NA,US NCT number,results
3164,2010-021782-70," Open monocentric clinical pilot study in COPD und Asthma patients to investigate static as well as dynamic ventilation,  intrapulmonary ADC and pO2 using helium-3-MRI after inhalation of hyperpolarised helium-3 gas; a comparison with pulmonary function tests und H-MRI (long-term observation)",25-11-2010,NA,ISRCTN number,results
3165,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,protocol
3166,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,other,protocol
3167,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,results
3168,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,ISRCTN number,results
3169,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,protocol
3170,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,other,protocol
3171,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,results
3172,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,ISRCTN number,results
3173,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,protocol
3174,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,other,protocol
3175,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,results
3176,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,ISRCTN number,results
3177,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,protocol
3178,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,other,protocol
3179,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,US NCT number,results
3180,2010-021790-37," Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS)",10-08-2011,NA,ISRCTN number,results
3181,2010-021861-62, Baclofen for the Treatment of Alcohol Dependence,16-09-2010,NA,US NCT number,protocol
3182,2010-021861-62, Baclofen for the Treatment of Alcohol Dependence,16-09-2010,NA,other,protocol
3183,2010-021861-62, Baclofen for the Treatment of Alcohol Dependence,16-09-2010,NCT01266655,US NCT number,results
3184,2010-021861-62, Baclofen for the Treatment of Alcohol Dependence,16-09-2010,NA,ISRCTN number,results
3185,2010-021944-17," Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation",01-03-2011,NA,US NCT number,protocol
3186,2010-021944-17," Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation",01-03-2011,NA,other,protocol
3187,2010-021944-17," Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation",01-03-2011,NA,US NCT number,results
3188,2010-021944-17," Randomized, Multi-centre, Phase II Trial to compare the Event-Free Survival of Clofarabine / Ara-C (ClAraC) or of FLAMSA Treatment in Patients with High Risk AML or Advanced MDS scheduled for Allogeneic Stem Cell Transplantation",01-03-2011,NA,ISRCTN number,results
3189,2010-021946-22, THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA:,08-10-2010,NA,US NCT number,protocol
3190,2010-021946-22, THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA:,08-10-2010,NA,other,protocol
3191,2010-021946-22, THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA:,08-10-2010,NCT01355120,US NCT number,results
3192,2010-021946-22, THE IPI – MULTIBASKET TRIAL IN ADVANCED OCULAR MELANOMA:,08-10-2010,NA,ISRCTN number,results
3193,2010-022057-42, Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors,25-02-2011,NA,US NCT number,protocol
3194,2010-022057-42, Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors,25-02-2011,NA,other,protocol
3195,2010-022057-42, Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors,25-02-2011,NA,US NCT number,results
3196,2010-022057-42, Pilot study to optimise the use and to evaluate the diagnostic value of intraoperative contrast-enhanced 3D-ultrasound with SonoVue® for imaging of intracranial tumors,25-02-2011,NA,ISRCTN number,results
3197,2010-022058-18, A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),03-01-2011,NA,US NCT number,protocol
3198,2010-022058-18, A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),03-01-2011,NA,other,protocol
3199,2010-022058-18, A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),03-01-2011,NCT01283776,US NCT number,results
3200,2010-022058-18, A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY),03-01-2011,NA,ISRCTN number,results
3201,2010-022103-21, Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial,19-11-2010,NA,US NCT number,protocol
3202,2010-022103-21, Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial,19-11-2010,NA,other,protocol
3203,2010-022103-21, Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial,19-11-2010,NA,US NCT number,results
3204,2010-022103-21, Neoadjuvant treatment of locoregional metastases in malignant melanoma (AJCC stage IIIB/C) with Multiferon: a phase IIa DeCOG trial,19-11-2010,NA,ISRCTN number,results
3205,2010-022162-27, FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.,08-04-2011,NCT01321957,US NCT number,protocol
3206,2010-022162-27, FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.,08-04-2011,NA,other,protocol
3207,2010-022162-27, FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.,08-04-2011,NCT01321957,US NCT number,results
3208,2010-022162-27, FOLFOX/bevacizumab with or without irinotecan in first-line treatment for metastatic colorectal cancer. A randomized phase II study.,08-04-2011,NA,ISRCTN number,results
3209,2010-022180-35, Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma,18-01-2011,NA,US NCT number,protocol
3210,2010-022180-35, Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma,18-01-2011,NA,other,protocol
3211,2010-022180-35, Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma,18-01-2011,NCT01187303,US NCT number,results
3212,2010-022180-35, Ofatumumab in relapsed nodular lymphocyte predominant Hodgkin Lymphoma,18-01-2011,NA,ISRCTN number,results
3213,2010-022363-35," Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.",19-10-2010,NA,US NCT number,protocol
3214,2010-022363-35," Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.",19-10-2010,NA,other,protocol
3215,2010-022363-35," Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.",19-10-2010,NA,US NCT number,results
3216,2010-022363-35," Impact of Levodopa vs. Rotigotine on stress hormones and NGF in patients with Parkinson's Disease: A randomised, placebo-controlled double-blind trial.",19-10-2010,NA,ISRCTN number,results
3217,2010-022388-37, Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza),15-06-2011,NA,US NCT number,protocol
3218,2010-022388-37, Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza),15-06-2011,NA,other,protocol
3219,2010-022388-37, Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza),15-06-2011,NA,US NCT number,results
3220,2010-022388-37, Treatment of patients with MDS or AML with an impending hematological relapse with Azacitidin (Vidaza),15-06-2011,NA,ISRCTN number,results
3221,2010-022413-26, Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),20-04-2011,NA,US NCT number,protocol
3222,2010-022413-26, Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),20-04-2011,NA,other,protocol
3223,2010-022413-26, Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),20-04-2011,NA,US NCT number,results
3224,2010-022413-26, Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (IDEAL-Study),20-04-2011,NA,ISRCTN number,results
3225,2010-022425-15," ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)",22-10-2010,NA,US NCT number,protocol
3226,2010-022425-15," ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)",22-10-2010,NA,other,protocol
3227,2010-022425-15," ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)",22-10-2010,NA,US NCT number,results
3228,2010-022425-15," ACCEPT - (ACC, Erbitux® and particle therapy) - Combined treatment of adenoid cystic carcinoma with cetuximab and IMRT plus C12 heavy ion boost (Phase I/II feasibility study)",22-10-2010,NA,ISRCTN number,results
3229,2010-022446-24, Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens,23-05-2012,NA,US NCT number,protocol
3230,2010-022446-24, Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens,23-05-2012,NA,other,protocol
3231,2010-022446-24, Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens,23-05-2012,NA,US NCT number,results
3232,2010-022446-24, Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens,23-05-2012,NA,ISRCTN number,results
3233,2010-022511-18, Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit],06-12-2010,NA,US NCT number,protocol
3234,2010-022511-18, Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit],06-12-2010,NA,other,protocol
3235,2010-022511-18, Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit],06-12-2010,NA,US NCT number,results
3236,2010-022511-18, Behavioral effects and neural correlates of oxytocin on social attention [Verhaltenseffekte und neuronales Korrelat von Oxytocin im Kontext sozialer Aufmerksamkeit],06-12-2010,NA,ISRCTN number,results
3237,2010-022570-13, Gadovit-Studie,28-09-2010,NA,US NCT number,protocol
3238,2010-022570-13, Gadovit-Studie,28-09-2010,NA,other,protocol
3239,2010-022570-13, Gadovit-Studie,28-09-2010,NA,US NCT number,results
3240,2010-022570-13, Gadovit-Studie,28-09-2010,NA,ISRCTN number,results
3241,2010-022584-35, Clofarabine salvage therapy in patients with relapsed or refractory AML,28-09-2010,NA,US NCT number,protocol
3242,2010-022584-35, Clofarabine salvage therapy in patients with relapsed or refractory AML,28-09-2010,NA,other,protocol
3243,2010-022584-35, Clofarabine salvage therapy in patients with relapsed or refractory AML,28-09-2010,NCT01295307,US NCT number,results
3244,2010-022584-35, Clofarabine salvage therapy in patients with relapsed or refractory AML,28-09-2010,NA,ISRCTN number,results
3245,2010-022660-12," A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",22-11-2010,NA,US NCT number,protocol
3246,2010-022660-12," A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",22-11-2010,NA,other,protocol
3247,2010-022660-12," A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",22-11-2010,NA,US NCT number,results
3248,2010-022660-12," A prospective, multi-center, randomized, double blinded, placebo-controlled study for the evaluation of Iloprost in the early postoperative period after liver transplantation",22-11-2010,NA,ISRCTN number,results
3249,2010-022679-71, Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary,15-12-2010,NCT01262729,US NCT number,protocol
3250,2010-022679-71, Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary,15-12-2010,NA,other,protocol
3251,2010-022679-71, Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary,15-12-2010,NA,US NCT number,results
3252,2010-022679-71, Xenon and Therapeutical Hypothermia After Successful Cardiopulmonary,15-12-2010,NA,ISRCTN number,results
3253,2010-022687-12," A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma",14-12-2010,NA,US NCT number,protocol
3254,2010-022687-12," A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma",14-12-2010,NA,other,protocol
3255,2010-022687-12," A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma",14-12-2010,NA,US NCT number,results
3256,2010-022687-12," A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma",14-12-2010,NA,ISRCTN number,results
3257,2010-022791-31, Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®,12-10-2010,NA,US NCT number,protocol
3258,2010-022791-31, Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®,12-10-2010,NA,other,protocol
3259,2010-022791-31, Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®,12-10-2010,NA,US NCT number,results
3260,2010-022791-31, Contrast sensitivity of patients with normal tension glaucoma by application of Azarga®,12-10-2010,NA,ISRCTN number,results
3261,2010-022810-26," MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA",04-11-2010,NA,US NCT number,protocol
3262,2010-022810-26," MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA",04-11-2010,NA,other,protocol
3263,2010-022810-26," MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA",04-11-2010,NA,US NCT number,results
3264,2010-022810-26," MULTICENTER, OPEN-LABEL PHASE II STUDY TO EVALUATE THE EFFICACY OF A 2-CYCLE IMMUNOTHERAPY WITH THE TRI FUNCTIONAL BISPECIFIC ANTIBODY CATUMAXOMAB (ANTI EPCAM X ANTI-CD3) IN ADDITION TO SYSTEMIC CHEMOTHERAPY IN PATIENTS WITH PERITONEAL CARCINOMATOSIS FROM GASTRIC OR COLORECTAL ADENOCARCINOMA",04-11-2010,NA,ISRCTN number,results
3265,2010-022840-19," A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow",23-08-2011,NA,US NCT number,protocol
3266,2010-022840-19," A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow",23-08-2011,NA,other,protocol
3267,2010-022840-19," A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow",23-08-2011,NA,US NCT number,results
3268,2010-022840-19," A monocentric, randomized, placebo-controlled double-blind clinical trial to assess the efficacy of Selenium in Morbus Basedow",23-08-2011,NA,ISRCTN number,results
3269,2010-022854-18, OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE  ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL),25-01-2011,NA,US NCT number,protocol
3270,2010-022854-18, OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE  ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL),25-01-2011,NA,other,protocol
3271,2010-022854-18, OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE  ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL),25-01-2011,NCT01724879,US NCT number,results
3272,2010-022854-18, OPEN LABEL PHASE II STUDY TO EVALUATE THE SAFETY OF STANDARD INDUCTION AND CONSOLIDATION THERAPY IN COMBINATION WITH DASATINIB IN NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE  ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL),25-01-2011,NA,ISRCTN number,results
3273,2010-022855-46, AN OPEN LABEL PHASE II STUDY ,28-06-2011,NA,US NCT number,protocol
3274,2010-022855-46, AN OPEN LABEL PHASE II STUDY ,28-06-2011,Novartis internal Code CAMN107ADE03T,other,protocol
3275,2010-022855-46, AN OPEN LABEL PHASE II STUDY ,28-06-2011,NCT01528085,US NCT number,results
3276,2010-022855-46, AN OPEN LABEL PHASE II STUDY ,28-06-2011,NA,ISRCTN number,results
3277,2010-022864-12, Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab therapy of patients with chronic urticaria (OTTO-Study),24-02-2011,NA,US NCT number,protocol
3278,2010-022864-12, Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab therapy of patients with chronic urticaria (OTTO-Study),24-02-2011,NA,other,protocol
3279,2010-022864-12, Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab therapy of patients with chronic urticaria (OTTO-Study),24-02-2011,NA,US NCT number,results
3280,2010-022864-12, Effect of Omalizumab (Xolair) on the threshold of degranulation and the composition of intracellular granules in skin mast cells and peripheral basophilic granulocytes before and during omalizumab therapy of patients with chronic urticaria (OTTO-Study),24-02-2011,NA,ISRCTN number,results
3281,2010-022871-78," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",30-09-2010,NA,US NCT number,protocol
3282,2010-022871-78," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",30-09-2010,NA,other,protocol
3283,2010-022871-78," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",30-09-2010,NA,US NCT number,results
3284,2010-022871-78," A Phase II Study to Evaluate the Immunogenicity, Safety and Tolerability of a Seasonal Influenza Vaccine including H1N1 in Immunocompromised Adults Who Have Undergone Solid Organ Transplantation or Bone Marrow Transplantation and in Age-Matched Healthy Volunteers",30-09-2010,NA,ISRCTN number,results
3285,2010-023022-20," A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",26-04-2011,NCT01397149,US NCT number,protocol
3286,2010-023022-20," A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",26-04-2011,NA,other,protocol
3287,2010-023022-20," A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",26-04-2011,NCT01397149,US NCT number,results
3288,2010-023022-20," A Phase I/II, Multi-centre Trial to Assess the Safety, Efficacy, and Pharmacokinetics of Eltrombopag, Administered to Thrombocytopenic Chronic Lymphocytic Leukemia Patients Prior to Alkylating Agents and/or Purine Analogue-based Therapy",26-04-2011,NA,ISRCTN number,results
3289,2010-023044-32, Mechanisms of action in exposure therapy:,21-03-2011,NA,US NCT number,protocol
3290,2010-023044-32, Mechanisms of action in exposure therapy:,21-03-2011,NA,other,protocol
3291,2010-023044-32, Mechanisms of action in exposure therapy:,21-03-2011,NA,US NCT number,results
3292,2010-023044-32, Mechanisms of action in exposure therapy:,21-03-2011,NA,ISRCTN number,results
3293,2010-023050-37," A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",21-03-2011,NA,US NCT number,protocol
3294,2010-023050-37," A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",21-03-2011,NA,other,protocol
3295,2010-023050-37," A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",21-03-2011,NA,US NCT number,results
3296,2010-023050-37," A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)",21-03-2011,NA,ISRCTN number,results
3297,2010-023107-10, The influence of liraglutide on hypoglycaemia counterregulation and pulsatile insulin secretion ,29-06-2012,NA,US NCT number,protocol
3298,2010-023107-10, The influence of liraglutide on hypoglycaemia counterregulation and pulsatile insulin secretion ,29-06-2012,NA,other,protocol
3299,2010-023107-10, The influence of liraglutide on hypoglycaemia counterregulation and pulsatile insulin secretion ,29-06-2012,NA,US NCT number,results
3300,2010-023107-10, The influence of liraglutide on hypoglycaemia counterregulation and pulsatile insulin secretion ,29-06-2012,NA,ISRCTN number,results
3301,2010-023208-29, Effects of Oxytocin on opioide withdrawal symptoms,20-12-2010,NA,US NCT number,protocol
3302,2010-023208-29, Effects of Oxytocin on opioide withdrawal symptoms,20-12-2010,NA,other,protocol
3303,2010-023208-29, Effects of Oxytocin on opioide withdrawal symptoms,20-12-2010,NA,US NCT number,results
3304,2010-023208-29, Effects of Oxytocin on opioide withdrawal symptoms,20-12-2010,NA,ISRCTN number,results
3305,2010-023409-37, Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation,14-12-2010,NCT01237808,US NCT number,protocol
3306,2010-023409-37, Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation,14-12-2010,NA,other,protocol
3307,2010-023409-37, Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation,14-12-2010,NCT01237808,US NCT number,results
3308,2010-023409-37, Randomized Phase III Study of Low-Dose Cytarabine and Etoposide with or without All-Trans Retinoic Acid in Older Patients not Eligible for Intensive Chemotherapy with Acute Myeloid Leukemia and NPM1 Mutation,14-12-2010,NA,ISRCTN number,results
3309,2010-023414-31, Ketamine in treatment resistant major depression (TRD),08-03-2012,NA,US NCT number,protocol
3310,2010-023414-31, Ketamine in treatment resistant major depression (TRD),08-03-2012,NA,other,protocol
3311,2010-023414-31, Ketamine in treatment resistant major depression (TRD),08-03-2012,NA,US NCT number,results
3312,2010-023414-31, Ketamine in treatment resistant major depression (TRD),08-03-2012,NA,ISRCTN number,results
3313,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,protocol
3314,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,other,protocol
3315,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,results
3316,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,ISRCTN number,results
3317,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,protocol
3318,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,other,protocol
3319,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,results
3320,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,ISRCTN number,results
3321,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,protocol
3322,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,other,protocol
3323,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,results
3324,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,ISRCTN number,results
3325,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,protocol
3326,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,other,protocol
3327,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,US NCT number,results
3328,2010-023427-18, Definitive radiochemotherapy with 5-FU / cisplatin plus/minus,24-05-2011,NA,ISRCTN number,results
3329,2010-023575-25, Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX).,22-12-2011,NA,US NCT number,protocol
3330,2010-023575-25, Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX).,22-12-2011,NA,other,protocol
3331,2010-023575-25, Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX).,22-12-2011,NA,US NCT number,results
3332,2010-023575-25, Perioperative FOLFOXIRI and bevacizumab compared with postoperative FOLFOX in patients with resectable liver metastases from colorectal cancer (PERIMAX).,22-12-2011,NA,ISRCTN number,results
3333,2010-023584-17, Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO),24-04-2012,NA,US NCT number,protocol
3334,2010-023584-17, Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO),24-04-2012,NA,other,protocol
3335,2010-023584-17, Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO),24-04-2012,NA,US NCT number,results
3336,2010-023584-17, Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicentre Phase I/II study of the East German Hematology and Oncology Study Group (OSHO),24-04-2012,NA,ISRCTN number,results
3337,2010-023645-29," Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",11-01-2011,NA,US NCT number,protocol
3338,2010-023645-29," Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",11-01-2011,NA,other,protocol
3339,2010-023645-29," Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",11-01-2011,NA,US NCT number,results
3340,2010-023645-29," Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study",11-01-2011,NA,ISRCTN number,results
3341,2010-023671-26, Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients,24-05-2011,NA,US NCT number,protocol
3342,2010-023671-26, Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients,24-05-2011,NA,other,protocol
3343,2010-023671-26, Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients,24-05-2011,NA,US NCT number,results
3344,2010-023671-26, Panitumumab after Resection of Liver Metastases from Colorectal Cancer in RAS Wild-type Patients,24-05-2011,NA,ISRCTN number,results
3345,2010-023756-82, Rasagiline treatment for Sleep disorders in Parkinson´s disease,28-04-2011,NA,US NCT number,protocol
3346,2010-023756-82, Rasagiline treatment for Sleep disorders in Parkinson´s disease,28-04-2011,NA,other,protocol
3347,2010-023756-82, Rasagiline treatment for Sleep disorders in Parkinson´s disease,28-04-2011,NA,US NCT number,results
3348,2010-023756-82, Rasagiline treatment for Sleep disorders in Parkinson´s disease,28-04-2011,NA,ISRCTN number,results
3349,2010-023901-36, Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study),13-01-2011,NA,US NCT number,protocol
3350,2010-023901-36, Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study),13-01-2011,NA,other,protocol
3351,2010-023901-36, Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study),13-01-2011,NA,US NCT number,results
3352,2010-023901-36, Psoriasis-topoproteome under ustekinumab treatment (PIROUETTE-Study),13-01-2011,NA,ISRCTN number,results
3353,2010-023941-31, Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington ,17-03-2011,NA,US NCT number,protocol
3354,2010-023941-31, Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington ,17-03-2011,NA,other,protocol
3355,2010-023941-31, Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington ,17-03-2011,NCT01357681,US NCT number,results
3356,2010-023941-31, Effects of EGCG (Epigallocatechin Gallate) in Chorea Huntington ,17-03-2011,NA,ISRCTN number,results
3357,2010-023942-63, The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study,06-12-2010,NA,US NCT number,protocol
3358,2010-023942-63, The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study,06-12-2010,NA,other,protocol
3359,2010-023942-63, The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study,06-12-2010,NA,US NCT number,results
3360,2010-023942-63, The safety and feasibility of delivering xenon to patients before and after coronary artery bypass graft implantation: a pilot study,06-12-2010,NA,ISRCTN number,results
3361,2010-023992-24, International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,18-05-2011,NCT01541605,US NCT number,protocol
3362,2010-023992-24, International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,18-05-2011,NA,other,protocol
3363,2010-023992-24, International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,18-05-2011,NCT01541605,US NCT number,results
3364,2010-023992-24, International randomised double-blind placebo-controlled study on the initial treatment of acute mania with methylphenidate,18-05-2011,NA,ISRCTN number,results
3365,2010-024004-98," Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients(""slow go"") with Aggressive CD-20-positive B-cell Lymphoma ",19-10-2011,NA,US NCT number,protocol
3366,2010-024004-98," Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients(""slow go"") with Aggressive CD-20-positive B-cell Lymphoma ",19-10-2011,NA,other,protocol
3367,2010-024004-98," Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients(""slow go"") with Aggressive CD-20-positive B-cell Lymphoma ",19-10-2011,NA,US NCT number,results
3368,2010-024004-98," Subcutaneous Rituximab and Intravenous Bendamustine in very Elderly Patients or Elderly Medically Non Fit Patients(""slow go"") with Aggressive CD-20-positive B-cell Lymphoma ",19-10-2011,NA,ISRCTN number,results
3369,2010-024094-39," Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. ",10-06-2011,NA,US NCT number,protocol
3370,2010-024094-39," Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. ",10-06-2011,NA,other,protocol
3371,2010-024094-39," Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. ",10-06-2011,NCT01407965,US NCT number,results
3372,2010-024094-39," Offene, monozentrische, nicht kontrollierte und nicht randomisierte Phase IV-Studie zur Bestimmung der Pharmakokinetik von Carbapenemen in adipösen Patienten. ",10-06-2011,NA,ISRCTN number,results
3373,2010-024115-14, Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss,23-03-2011,NCT01345968,US NCT number,protocol
3374,2010-024115-14, Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss,23-03-2011,NA,other,protocol
3375,2010-024115-14, Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss,23-03-2011,NA,US NCT number,results
3376,2010-024115-14, Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss,23-03-2011,NA,ISRCTN number,results
3377,2010-024131-16, Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus,04-02-2011,NA,US NCT number,protocol
3378,2010-024131-16, Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus,04-02-2011,NA,other,protocol
3379,2010-024131-16, Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus,04-02-2011,NA,US NCT number,results
3380,2010-024131-16, Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus,04-02-2011,NA,ISRCTN number,results
3381,2010-024152-29, Canakinumab for Behçet`s Disease Resistant to Standard Treatment,21-06-2011,NA,US NCT number,protocol
3382,2010-024152-29, Canakinumab for Behçet`s Disease Resistant to Standard Treatment,21-06-2011,Active ingredient Canakinumab,other,protocol
3383,2010-024152-29, Canakinumab for Behçet`s Disease Resistant to Standard Treatment,21-06-2011,NA,US NCT number,results
3384,2010-024152-29, Canakinumab for Behçet`s Disease Resistant to Standard Treatment,21-06-2011,NA,ISRCTN number,results
3385,2010-024156-28," A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",07-04-2011,NA,US NCT number,protocol
3386,2010-024156-28," A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",07-04-2011,NA,other,protocol
3387,2010-024156-28," A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",07-04-2011,NA,US NCT number,results
3388,2010-024156-28," A multi-center, double-blind, placebo-controlled phase II study of the efficacy and safety of canakinumab in subjects with Schnitzler syndrome",07-04-2011,NA,ISRCTN number,results
3389,2010-024164-18," Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel",24-03-2011,NA,US NCT number,protocol
3390,2010-024164-18," Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel",24-03-2011,NA,other,protocol
3391,2010-024164-18," Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel",24-03-2011,NA,US NCT number,results
3392,2010-024164-18," Single-arm, open-label, monocentric Phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) for the treatment of patients with HER2-positive, hormone-refractory prostate cancer after failure of treatment with docetaxel or ineligible for treatment with docetaxel",24-03-2011,NA,ISRCTN number,results
3393,2010-024202-34, Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder,09-12-2013,NA,US NCT number,protocol
3394,2010-024202-34, Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder,09-12-2013,NA,other,protocol
3395,2010-024202-34, Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder,09-12-2013,NA,US NCT number,results
3396,2010-024202-34, Effect of oxytocin on therapy results of a group based social skill training in adolescents with Autism Spectrum Disorder,09-12-2013,NA,ISRCTN number,results
3397,2010-024225-20, The impact of phosphate balanced cristalloid infusion on acid-base homeostastis,04-04-2014,NA,US NCT number,protocol
3398,2010-024225-20, The impact of phosphate balanced cristalloid infusion on acid-base homeostastis,04-04-2014,NA,other,protocol
3399,2010-024225-20, The impact of phosphate balanced cristalloid infusion on acid-base homeostastis,04-04-2014,NA,US NCT number,results
3400,2010-024225-20, The impact of phosphate balanced cristalloid infusion on acid-base homeostastis,04-04-2014,NA,ISRCTN number,results
3401,2010-024238-46," DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells",13-09-2011,NA,US NCT number,protocol
3402,2010-024238-46," DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells",13-09-2011,NA,other,protocol
3403,2010-024238-46," DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells",13-09-2011,NA,US NCT number,results
3404,2010-024238-46," DETECT III – A multicenter, randomized, phase III study to compare standard therapy alone versus standard therapy plus Lapatinib in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells",13-09-2011,NA,ISRCTN number,results
3405,2010-024262-22, Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.,29-05-2012,NCT01657604,US NCT number,protocol
3406,2010-024262-22, Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.,29-05-2012,NA,other,protocol
3407,2010-024262-22, Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.,29-05-2012,NA,US NCT number,results
3408,2010-024262-22, Treatment optimization of newly diagnosed Ph/BCR-ABL positive patients with chronic myeloid leukemia (CML) in chronic phase with nilotinib vs. nilotinib plus interferon alpha induction and nilotinib or interferon alpha maintenance therapy.,29-05-2012,NA,ISRCTN number,results
3409,2010-024300-10, Early prospective therapy trial to delay renal failure in children with Alport syndrome.,12-12-2011,NA,US NCT number,protocol
3410,2010-024300-10, Early prospective therapy trial to delay renal failure in children with Alport syndrome.,12-12-2011,NA,other,protocol
3411,2010-024300-10, Early prospective therapy trial to delay renal failure in children with Alport syndrome.,12-12-2011,NCT01485978,US NCT number,results
3412,2010-024300-10, Early prospective therapy trial to delay renal failure in children with Alport syndrome.,12-12-2011,NA,ISRCTN number,results
3413,2010-024379-15," Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study.",20-07-2011,NA,US NCT number,protocol
3414,2010-024379-15," Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study.",20-07-2011,NA,other,protocol
3415,2010-024379-15," Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study.",20-07-2011,NCT01503372,US NCT number,results
3416,2010-024379-15," Pazopanib with 5-Flourouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line treatment in advanced gastric cancer; a randomized Phase II study.",20-07-2011,NA,ISRCTN number,results
3417,2011-000152-42, An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,20-06-2011,NA,US NCT number,protocol
3418,2011-000152-42, An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,20-06-2011,NA,other,protocol
3419,2011-000152-42, An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,20-06-2011,NA,US NCT number,results
3420,2011-000152-42, An evaluator-blind controlled parallel-group study to assess efficacy and safety of Skinoren 15% gel and Differin 0.1 % gel for the treatment and maintenance treatment of facial acne vulgaris and late-type acne in females,20-06-2011,NA,ISRCTN number,results
3421,2011-000218-20," LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial",30-05-2011,NA,US NCT number,protocol
3422,2011-000218-20," LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial",30-05-2011,NA,other,protocol
3423,2011-000218-20," LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial",30-05-2011,NCT01462513,US NCT number,results
3424,2011-000218-20," LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial",30-05-2011,NA,ISRCTN number,results
3425,2011-000259-17, A phase I/II study of Pazopanib and weekly,07-12-2011,NA,US NCT number,protocol
3426,2011-000259-17, A phase I/II study of Pazopanib and weekly,07-12-2011,NA,other,protocol
3427,2011-000259-17, A phase I/II study of Pazopanib and weekly,07-12-2011,NA,US NCT number,results
3428,2011-000259-17, A phase I/II study of Pazopanib and weekly,07-12-2011,NA,ISRCTN number,results
3429,2011-000388-28," Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma",12-04-2011,NA,US NCT number,protocol
3430,2011-000388-28," Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma",12-04-2011,NA,other,protocol
3431,2011-000388-28," Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma",12-04-2011,NCT01394354,US NCT number,results
3432,2011-000388-28," Safety of Vorinostat in combination with Bortezomib, Doxorubicin and Dexamethasone (VBDD) in patients with refractory or relapsed multiple myeloma",12-04-2011,NA,ISRCTN number,results
3433,2011-000440-22, MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,27-02-2012,NCT01596114,US NCT number,protocol
3434,2011-000440-22, MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,27-02-2012,NA,other,protocol
3435,2011-000440-22, MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,27-02-2012,NA,US NCT number,results
3436,2011-000440-22, MULTICENTER TRIAL ESTIMATING THE PERSISTANCE OF MOLECULAR REMISSION IN CHRONIC MYELOID LEUKAEMIA AFTER STOPPING TKI,27-02-2012,NA,ISRCTN number,results
3437,2011-000503-40, DABI-ADP-1:,18-02-2011,NA,US NCT number,protocol
3438,2011-000503-40, DABI-ADP-1:,18-02-2011,NA,other,protocol
3439,2011-000503-40, DABI-ADP-1:,18-02-2011,NA,US NCT number,results
3440,2011-000503-40, DABI-ADP-1:,18-02-2011,NA,ISRCTN number,results
3441,2011-000504-18, DABI-ADP-2:,21-02-2011,NA,US NCT number,protocol
3442,2011-000504-18, DABI-ADP-2:,21-02-2011,NA,other,protocol
3443,2011-000504-18, DABI-ADP-2:,21-02-2011,NA,US NCT number,results
3444,2011-000504-18, DABI-ADP-2:,21-02-2011,NA,ISRCTN number,results
3445,2011-000595-33, Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure,13-09-2012,NA,US NCT number,protocol
3446,2011-000595-33, Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure,13-09-2012,NA,other,protocol
3447,2011-000595-33, Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure,13-09-2012,NA,US NCT number,results
3448,2011-000595-33, Randomized controlled trial to compare the effects of single versus repeated intracoronary application of autologous bone marrow-derived mononuclear cells on total and SHFM-predicted mortality in patients with chronic post-infarction heart failure,13-09-2012,NA,ISRCTN number,results
3449,2011-000624-16, Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome,05-09-2011,NA,US NCT number,protocol
3450,2011-000624-16, Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome,05-09-2011,NA,other,protocol
3451,2011-000624-16, Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome,05-09-2011,NA,US NCT number,results
3452,2011-000624-16, Infertility and inflammatory urogenital diseases as a result of the metabolic syndrome,05-09-2011,NA,ISRCTN number,results
3453,2011-000659-18," Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients",28-06-2011,NA,US NCT number,protocol
3454,2011-000659-18," Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients",28-06-2011,NA,other,protocol
3455,2011-000659-18," Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients",28-06-2011,NA,US NCT number,results
3456,2011-000659-18," Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients",28-06-2011,NA,ISRCTN number,results
3457,2011-000815-15, BOSTRIP,06-04-2011,NA,US NCT number,protocol
3458,2011-000815-15, BOSTRIP,06-04-2011,NA,other,protocol
3459,2011-000815-15, BOSTRIP,06-04-2011,NCT01403012,US NCT number,results
3460,2011-000815-15, BOSTRIP,06-04-2011,NA,ISRCTN number,results
3461,2011-000843-26, ,28-06-2011,NA,US NCT number,protocol
3462,2011-000843-26, ,28-06-2011,NA,other,protocol
3463,2011-000843-26, ,28-06-2011,NA,US NCT number,results
3464,2011-000843-26, ,28-06-2011,NA,ISRCTN number,results
3465,2011-000844-56," UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",09-06-2011,NCT01330901,US NCT number,protocol
3466,2011-000844-56," UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",09-06-2011,NA,other,protocol
3467,2011-000844-56," UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",09-06-2011,NA,US NCT number,results
3468,2011-000844-56," UsTekinumab for the treatment Of Patients with active Ankylosing Spondylitis (TOPAS) – a 28-week, prospective, open-label, proof-of-concept study",09-06-2011,NA,ISRCTN number,results
3469,2011-000911-26, Heart rate control after acute myocardial infarct,13-04-2011,NA,US NCT number,protocol
3470,2011-000911-26, Heart rate control after acute myocardial infarct,13-04-2011,DRKS number DKRS00000766,other,protocol
3471,2011-000911-26, Heart rate control after acute myocardial infarct,13-04-2011,NA,US NCT number,results
3472,2011-000911-26, Heart rate control after acute myocardial infarct,13-04-2011,NA,ISRCTN number,results
3473,2011-000921-61," A phase I/II, randomized, open-label, multi-centre study of BIBF1120 +",17-11-2011,NA,US NCT number,protocol
3474,2011-000921-61," A phase I/II, randomized, open-label, multi-centre study of BIBF1120 +",17-11-2011,NA,other,protocol
3475,2011-000921-61," A phase I/II, randomized, open-label, multi-centre study of BIBF1120 +",17-11-2011,NA,US NCT number,results
3476,2011-000921-61," A phase I/II, randomized, open-label, multi-centre study of BIBF1120 +",17-11-2011,NA,ISRCTN number,results
3477,2011-001027-20," A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",05-12-2011,NA,US NCT number,protocol
3478,2011-001027-20," A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",05-12-2011,NA,other,protocol
3479,2011-001027-20," A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",05-12-2011,NCT02204293,US NCT number,results
3480,2011-001027-20," A Multi-Centre, Placebo-Controlled Phase II Study of Canakinumab for the Treatment of Adult-onset Still's disease (AOSD) including an open-label long term extension.",05-12-2011,NA,ISRCTN number,results
3481,2011-001086-41," A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy",19-09-2011,NCT01488344,US NCT number,protocol
3482,2011-001086-41," A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy",19-09-2011,NA,other,protocol
3483,2011-001086-41," A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy",19-09-2011,NCT01488344,US NCT number,results
3484,2011-001086-41," A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an intensive induction therapy",19-09-2011,NA,ISRCTN number,results
3485,2011-001232-27, Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,27-12-2011,NA,US NCT number,protocol
3486,2011-001232-27, Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,27-12-2011,NA,other,protocol
3487,2011-001232-27, Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,27-12-2011,NA,US NCT number,results
3488,2011-001232-27, Characterization of human peripheral and intestinal T-cell responses after mucosal antigen exposure: induction of tolerance vs. immunization by oral administration of KLH,27-12-2011,NA,ISRCTN number,results
3489,2011-001398-19, D-cycloserine augmented exposure therapy in patients with agoraphobia,30-05-2011,NA,US NCT number,protocol
3490,2011-001398-19, D-cycloserine augmented exposure therapy in patients with agoraphobia,30-05-2011,NA,other,protocol
3491,2011-001398-19, D-cycloserine augmented exposure therapy in patients with agoraphobia,30-05-2011,NCT01928823,US NCT number,results
3492,2011-001398-19, D-cycloserine augmented exposure therapy in patients with agoraphobia,30-05-2011,NA,ISRCTN number,results
3493,2011-001403-12, Carbon Dioxide for the Treatment of Febrile Seizures,28-10-2011,NA,US NCT number,protocol
3494,2011-001403-12, Carbon Dioxide for the Treatment of Febrile Seizures,28-10-2011,NA,other,protocol
3495,2011-001403-12, Carbon Dioxide for the Treatment of Febrile Seizures,28-10-2011,NCT01370044,US NCT number,results
3496,2011-001403-12, Carbon Dioxide for the Treatment of Febrile Seizures,28-10-2011,NA,ISRCTN number,results
3497,2011-001474-25," A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",20-09-2011,NA,US NCT number,protocol
3498,2011-001474-25," A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",20-09-2011,NA,other,protocol
3499,2011-001474-25," A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",20-09-2011,NA,US NCT number,results
3500,2011-001474-25," A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node dissection (CLND) in subjects with stage III malignant melanoma",20-09-2011,NA,ISRCTN number,results
3501,2011-001491-20," A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial",05-07-2012,NA,US NCT number,protocol
3502,2011-001491-20," A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial",05-07-2012,NA,other,protocol
3503,2011-001491-20," A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial",05-07-2012,NCT01653067,US NCT number,results
3504,2011-001491-20," A phase II trial to evaluate the safety, feasibility and efficacy of a salvage therapy consisting of the mTOR inhibitor Temsirolimus (Torisel™) added to the standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial",05-07-2012,NA,ISRCTN number,results
3505,2011-001686-40, INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF,06-06-2011,NA,US NCT number,protocol
3506,2011-001686-40, INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF,06-06-2011,NA,other,protocol
3507,2011-001686-40, INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF,06-06-2011,NA,US NCT number,results
3508,2011-001686-40, INTRACORONARY STENTING AND ANTITHROMBOTIC REGIMEN: ADJUSTING ANTIPLATELET TREATMENT IN PATIENTS BASED ON PLATELET FUNCTION TESTING - ISAR ADAPT-PF,06-06-2011,NA,ISRCTN number,results
3509,2011-001689-16," Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",04-02-2013,NA,US NCT number,protocol
3510,2011-001689-16," Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",04-02-2013,German Register of Clinical Trials DRKS00000796,other,protocol
3511,2011-001689-16," Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",04-02-2013,NA,US NCT number,results
3512,2011-001689-16," Prospective randomized, double-blind, and placebo-controlled clinical trial with hydroxychloroquine (HCQ) in patients with erosive-inflammatory osteoarthritis (OA) of the finger joints (acronym: OA TREAT)",04-02-2013,ISRCTN46445413,ISRCTN number,results
3513,2011-001765-41," Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines",25-10-2011,NA,US NCT number,protocol
3514,2011-001765-41," Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines",25-10-2011,NA,other,protocol
3515,2011-001765-41," Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines",25-10-2011,NA,US NCT number,results
3516,2011-001765-41," Single-arm, open-label, multicentre phase II study evaluating the efficacy and safety of BIBW 2992 (Afatinib) in combination with vinorelbine for the treatment of patients with metastatic breast cancer with intermediate HER2 expression (HER2 2+ by immunohistochemistry, fluorescence in-situ hybridisation (FISH) negative) after failure of first-line therapy in the metastatic setting and having been pre-treated with anthracyclines",25-10-2011,NA,ISRCTN number,results
3517,2011-001795-19, STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING ,27-07-2012,NA,US NCT number,protocol
3518,2011-001795-19, STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING ,27-07-2012,DRKS 00000753,other,protocol
3519,2011-001795-19, STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING ,27-07-2012,NA,US NCT number,results
3520,2011-001795-19, STATIN RECAPTURE THERAPY BEFORE CORONARY ARTERY BYPASS GRAFTING ,27-07-2012,NA,ISRCTN number,results
3521,2011-001963-37, Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC),01-06-2012,NA,US NCT number,protocol
3522,2011-001963-37, Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC),01-06-2012,NA,other,protocol
3523,2011-001963-37, Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC),01-06-2012,NA,US NCT number,results
3524,2011-001963-37, Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell lung cancer (NSCLC),01-06-2012,NA,ISRCTN number,results
3525,2011-002192-41," Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan",27-12-2011,NA,US NCT number,protocol
3526,2011-002192-41," Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan",27-12-2011,NA,other,protocol
3527,2011-002192-41," Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan",27-12-2011,NA,US NCT number,results
3528,2011-002192-41," Multicenter phase II study of peritransplantation immunosuppression using ATG, rituximab, sirolimus and mycophenolate mofetil in patient receiving mismatched hematopoietic cell transplantation after reduced intensity conditioning with fludarabine and treosulfan",27-12-2011,NA,ISRCTN number,results
3529,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,protocol
3530,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,other,protocol
3531,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,results
3532,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,ISRCTN number,results
3533,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,protocol
3534,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,other,protocol
3535,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,results
3536,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,ISRCTN number,results
3537,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,protocol
3538,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,other,protocol
3539,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,results
3540,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,ISRCTN number,results
3541,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,protocol
3542,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,other,protocol
3543,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,US NCT number,results
3544,2011-002202-70," A prospective, non-randomized, mono-center, cohort study to evaluate the effects of 0.5mg intraocular Ranibizumab (Lucentis) injections on retinal function in patients with diabetic macular edema (DME) during twelve months",21-06-2011,NA,ISRCTN number,results
3545,2011-002271-42, ,18-07-2011,NA,US NCT number,protocol
3546,2011-002271-42, ,18-07-2011,NA,other,protocol
3547,2011-002271-42, ,18-07-2011,NA,US NCT number,results
3548,2011-002271-42, ,18-07-2011,NA,ISRCTN number,results
3549,2011-002365-37," A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML",18-01-2012,NCT01611116,US NCT number,protocol
3550,2011-002365-37," A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML",18-01-2012,NA,other,protocol
3551,2011-002365-37," A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML",18-01-2012,NCT01611116,US NCT number,results
3552,2011-002365-37," A double-blind, placebo-controlled, randomized, multicenter phase II trial to assess the efficacy of temsirolimus added to standard primary therapy in elderly patients with newly diagnosed AML",18-01-2012,NA,ISRCTN number,results
3553,2011-002434-40, Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis,18-08-2011,NA,US NCT number,protocol
3554,2011-002434-40, Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis,18-08-2011,NA,other,protocol
3555,2011-002434-40, Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis,18-08-2011,NA,US NCT number,results
3556,2011-002434-40, Highdose Chemotherapy and transplantation of 34+ selected stem cell for progressive systemic sclerosis,18-08-2011,NA,ISRCTN number,results
3557,2011-002539-24, Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis ,13-02-2012,NA,US NCT number,protocol
3558,2011-002539-24, Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis ,13-02-2012,NA,other,protocol
3559,2011-002539-24, Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis ,13-02-2012,NA,US NCT number,results
3560,2011-002539-24, Effect of Mipomersen on LDL-Cholesterol Levels in Patients with Severe LDL-Hypercholesterolemia and Atherosclerosis Treated by Regular LDL-Apheresis ,13-02-2012,NA,ISRCTN number,results
3561,2011-002544-27," Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment",06-09-2011,NA,US NCT number,protocol
3562,2011-002544-27," Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment",06-09-2011,NA,other,protocol
3563,2011-002544-27," Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment",06-09-2011,NCT01462994,US NCT number,results
3564,2011-002544-27," Prospective, explorative trial for the detection of circulating cell-free tumor DNA in the plasma of patients with gastrointestinal stromal tumors (GIST) harboring activating mutations of CKIT or PDGFRA pre/post surgery or pre/under treatment with a tyrosine kinase inhibitor or progressive disease irrespective of current or planned treatment",06-09-2011,NA,ISRCTN number,results
3565,2011-002567-17, A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML,12-09-2011,NA,US NCT number,protocol
3566,2011-002567-17, A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML,12-09-2011,Novartis Study code CPKC412ADE01T,other,protocol
3567,2011-002567-17, A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML,12-09-2011,NCT01830361,US NCT number,results
3568,2011-002567-17, A single-arm phase II trial to assess the efficacy of Midostaurin (PKC412) added to standard primary therapy in patients with newly diagnosed c-KIT or FLT3-ITD mutated t(8;21) AML,12-09-2011,NA,ISRCTN number,results
3569,2011-002687-25, Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency,06-10-2011,NA,US NCT number,protocol
3570,2011-002687-25, Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency,06-10-2011,NA,other,protocol
3571,2011-002687-25, Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency,06-10-2011,NA,US NCT number,results
3572,2011-002687-25, Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency,06-10-2011,NA,ISRCTN number,results
3573,2011-002785-20, Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis ,11-08-2011,NA,US NCT number,protocol
3574,2011-002785-20, Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis ,11-08-2011,NA,other,protocol
3575,2011-002785-20, Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis ,11-08-2011,NA,US NCT number,results
3576,2011-002785-20, Efficacy of Vitamin D Supplementation in relapsing-remitting Multiple Sclerosis ,11-08-2011,NA,ISRCTN number,results
3577,2011-002812-10," A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)ide based treatment on quantitative HBsAg levels in patients with chronic HBeAg-negative hepatitis B",21-11-2011,NA,US NCT number,protocol
3578,2011-002812-10," A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)ide based treatment on quantitative HBsAg levels in patients with chronic HBeAg-negative hepatitis B",21-11-2011,NA,other,protocol
3579,2011-002812-10," A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)ide based treatment on quantitative HBsAg levels in patients with chronic HBeAg-negative hepatitis B",21-11-2011,NA,US NCT number,results
3580,2011-002812-10," A prospective, randomised, open-label phase IIb clinical trial assessing the effect of pegylated Interferon alfa-2a (Pegasys®) 180 µg once weekly for 48 weeks in addition to an ongoing nucelos(t)ide based treatment on quantitative HBsAg levels in patients with chronic HBeAg-negative hepatitis B",21-11-2011,NA,ISRCTN number,results
3581,2011-002920-41, Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum,24-08-2011,NA,US NCT number,protocol
3582,2011-002920-41, Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum,24-08-2011,NA,other,protocol
3583,2011-002920-41, Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum,24-08-2011,NA,US NCT number,results
3584,2011-002920-41, Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum,24-08-2011,NA,ISRCTN number,results
3585,2011-003168-63," Phase-II study evaluating midostaurin in induction, consolidation and",12-01-2012,NCT01477606,US NCT number,protocol
3586,2011-003168-63," Phase-II study evaluating midostaurin in induction, consolidation and",12-01-2012,NA,other,protocol
3587,2011-003168-63," Phase-II study evaluating midostaurin in induction, consolidation and",12-01-2012,NCT01477606,US NCT number,results
3588,2011-003168-63," Phase-II study evaluating midostaurin in induction, consolidation and",12-01-2012,NA,ISRCTN number,results
3589,2011-003179-12, Mineralocorticoid Receptor antagonists in End stage reNal DiseAse ,02-09-2011,NA,US NCT number,protocol
3590,2011-003179-12, Mineralocorticoid Receptor antagonists in End stage reNal DiseAse ,02-09-2011,NA,other,protocol
3591,2011-003179-12, Mineralocorticoid Receptor antagonists in End stage reNal DiseAse ,02-09-2011,NCT01691053,US NCT number,results
3592,2011-003179-12, Mineralocorticoid Receptor antagonists in End stage reNal DiseAse ,02-09-2011,NA,ISRCTN number,results
3593,2011-003273-28, Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:,07-09-2011,NA,US NCT number,protocol
3594,2011-003273-28, Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:,07-09-2011,NA,other,protocol
3595,2011-003273-28, Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:,07-09-2011,NA,US NCT number,results
3596,2011-003273-28, Treatment of patients with metastatic melanoma (AJCC stage IV or III unresectable) with the PDE-inhibitor Tadalafil:,07-09-2011,NA,ISRCTN number,results
3597,2011-003288-31," Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases",10-10-2011,NA,US NCT number,protocol
3598,2011-003288-31," Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases",10-10-2011,NA,other,protocol
3599,2011-003288-31," Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases",10-10-2011,NA,US NCT number,results
3600,2011-003288-31," Open, randomized, multicenter phase II trial with cetuximab /5-FU/FA/irinotecan or cetuximab/5-FU/FA /irinotecan/oxaliplatin in ras wild type patients or with irinotecan/oxaliplatin/5-FU/FA with or without bevacizumab in ras mutant patients as neoadjuvant treatment in patients with non- resectable colorectal liver metastases",10-10-2011,NA,ISRCTN number,results
3601,2011-003473-29, Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea,11-07-2012,NCT01407848,US NCT number,protocol
3602,2011-003473-29, Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea,11-07-2012,NA,other,protocol
3603,2011-003473-29, Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea,11-07-2012,NCT01407848,US NCT number,results
3604,2011-003473-29, Trial on treatment with inhaled furosemide of preterm and term neonates with transient tachypnoea,11-07-2012,NA,ISRCTN number,results
3605,2011-003547-21, A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor of activated T-cells (NFAT) – regulated genes or CsA trough levels,04-12-2012,NA,US NCT number,protocol
3606,2011-003547-21, A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor of activated T-cells (NFAT) – regulated genes or CsA trough levels,04-12-2012,NA,other,protocol
3607,2011-003547-21, A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor of activated T-cells (NFAT) – regulated genes or CsA trough levels,04-12-2012,NA,US NCT number,results
3608,2011-003547-21, A randomized open-label trial to evaluate the cardiovascular risk in stable renal allograft recipients on a ciclosporin A (CsA) based regimen monitored either by residual expression of nuclear factor of activated T-cells (NFAT) – regulated genes or CsA trough levels,04-12-2012,NA,ISRCTN number,results
3609,2011-003614-17, Pretreatment of patients expecting bariatric surgery with ,10-11-2011,NA,US NCT number,protocol
3610,2011-003614-17, Pretreatment of patients expecting bariatric surgery with ,10-11-2011,NA,other,protocol
3611,2011-003614-17, Pretreatment of patients expecting bariatric surgery with ,10-11-2011,NA,US NCT number,results
3612,2011-003614-17, Pretreatment of patients expecting bariatric surgery with ,10-11-2011,NA,ISRCTN number,results
3613,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,protocol
3614,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,other,protocol
3615,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,results
3616,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,ISRCTN number,results
3617,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,protocol
3618,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,other,protocol
3619,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,results
3620,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,ISRCTN number,results
3621,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,protocol
3622,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,other,protocol
3623,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,results
3624,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,ISRCTN number,results
3625,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,protocol
3626,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,other,protocol
3627,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,US NCT number,results
3628,2011-003628-11, Tapentadol PR vs Oxycodon CR,27-09-2011,NA,ISRCTN number,results
3629,2011-003648-31," Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",18-08-2011,NA,US NCT number,protocol
3630,2011-003648-31," Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",18-08-2011,NA,other,protocol
3631,2011-003648-31," Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",18-08-2011,NA,US NCT number,results
3632,2011-003648-31," Pharmacokinetic-pharmacodynamic modeling of the postoperative pain sensation during patient-controlled analgesia with target-controlled infusion of Hydromorphone, taking into account the interaction with intraoperatively administered Sufentanil for elective cardiac surgery",18-08-2011,NA,ISRCTN number,results
3633,2011-003745-18, A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF ,02-04-2012,NA,US NCT number,protocol
3634,2011-003745-18, A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF ,02-04-2012,NA,other,protocol
3635,2011-003745-18, A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF ,02-04-2012,NA,US NCT number,results
3636,2011-003745-18, A PHASE II WINDOW-OF-OPPORTUNITY STUDY OF ,02-04-2012,NA,ISRCTN number,results
3637,2011-003746-41," A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",28-11-2011,NA,US NCT number,protocol
3638,2011-003746-41," A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",28-11-2011,NA,other,protocol
3639,2011-003746-41," A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",28-11-2011,NA,US NCT number,results
3640,2011-003746-41," A two-center, double blind, placebo-controlled study in parallel design to assess the efficacy and safety of 150 and 300 mg omalizumab in subjects with antihistamine-resistant cold contact urticaria (CCU)",28-11-2011,NA,ISRCTN number,results
3641,2011-003894-27, Tolerance and effect of an add-on therapy with an ivy leaves dry extract syrup on lung function in children with asthma. ,15-02-2012,NA,US NCT number,protocol
3642,2011-003894-27, Tolerance and effect of an add-on therapy with an ivy leaves dry extract syrup on lung function in children with asthma. ,15-02-2012,NA,other,protocol
3643,2011-003894-27, Tolerance and effect of an add-on therapy with an ivy leaves dry extract syrup on lung function in children with asthma. ,15-02-2012,NA,US NCT number,results
3644,2011-003894-27, Tolerance and effect of an add-on therapy with an ivy leaves dry extract syrup on lung function in children with asthma. ,15-02-2012,NA,ISRCTN number,results
3645,2011-004062-15," Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma",16-04-2012,NA,US NCT number,protocol
3646,2011-004062-15," Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma",16-04-2012,NA,other,protocol
3647,2011-004062-15," Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma",16-04-2012,NA,US NCT number,results
3648,2011-004062-15," Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high risk neuroblastoma",16-04-2012,NA,ISRCTN number,results
3649,2011-004063-77, Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial,06-08-2012,NA,US NCT number,protocol
3650,2011-004063-77, Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial,06-08-2012,NA,other,protocol
3651,2011-004063-77, Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial,06-08-2012,NA,US NCT number,results
3652,2011-004063-77, Gemcitabine in Combination with the Oral Irreversible ErbB Inhibitor Afatinib versus Gemcitabine Alone in Patients with Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial,06-08-2012,NA,ISRCTN number,results
3653,2011-004094-93," Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",27-01-2012,NA,US NCT number,protocol
3654,2011-004094-93," Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",27-01-2012,NA,other,protocol
3655,2011-004094-93," Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",27-01-2012,NA,US NCT number,results
3656,2011-004094-93," Double-blind, three-way cross-over, placebo controlled study to assess the efficacy, safety and mechanisms of treatment with rupatadine 20 and 40mg in cold contact urticaria (CCU)",27-01-2012,NA,ISRCTN number,results
3657,2011-004168-30, A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,04-06-2012,NA,US NCT number,protocol
3658,2011-004168-30, A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,04-06-2012,NA,other,protocol
3659,2011-004168-30, A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,04-06-2012,NCT01861951,US NCT number,results
3660,2011-004168-30, A randomized phase II trial comparing pazopanib with doxorubicin as first line treatment in elderly patients with metastatic or advanced soft tissue sarcoma,04-06-2012,NA,ISRCTN number,results
3661,2011-004228-37, Translational Validation Trial-B (add-on phase I/II study to the Clinical,19-04-2012,NA,US NCT number,protocol
3662,2011-004228-37, Translational Validation Trial-B (add-on phase I/II study to the Clinical,19-04-2012,NA,other,protocol
3663,2011-004228-37, Translational Validation Trial-B (add-on phase I/II study to the Clinical,19-04-2012,NA,US NCT number,results
3664,2011-004228-37, Translational Validation Trial-B (add-on phase I/II study to the Clinical,19-04-2012,NA,ISRCTN number,results
3665,2011-004301-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,07-12-2011,NCT01656135,US NCT number,protocol
3666,2011-004301-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,07-12-2011,NA,other,protocol
3667,2011-004301-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,07-12-2011,NCT01656135,US NCT number,results
3668,2011-004301-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Reference Group Trial,07-12-2011,NA,ISRCTN number,results
3669,2011-004361-32, Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid,22-05-2012,NA,US NCT number,protocol
3670,2011-004361-32, Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid,22-05-2012,NA,other,protocol
3671,2011-004361-32, Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid,22-05-2012,NA,US NCT number,results
3672,2011-004361-32, Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid,22-05-2012,NA,ISRCTN number,results
3673,2011-004393-28," ""Effectiveness of leech therapy in treatment of chronic low back pain - ",09-12-2011,NA,US NCT number,protocol
3674,2011-004393-28," ""Effectiveness of leech therapy in treatment of chronic low back pain - ",09-12-2011,NA,other,protocol
3675,2011-004393-28," ""Effectiveness of leech therapy in treatment of chronic low back pain - ",09-12-2011,NA,US NCT number,results
3676,2011-004393-28," ""Effectiveness of leech therapy in treatment of chronic low back pain - ",09-12-2011,NA,ISRCTN number,results
3677,2011-004396-36, Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2),14-12-2011,NA,US NCT number,protocol
3678,2011-004396-36, Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2),14-12-2011,AUO study code number AN 33/11,other,protocol
3679,2011-004396-36, Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2),14-12-2011,NCT00439636,US NCT number,results
3680,2011-004396-36, Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced / metastatic renal cell carcinoma (SWITCH 2),14-12-2011,NA,ISRCTN number,results
3681,2011-004405-25, Study for prevention of peritoneal carcinomatosis in patients with stomach cancer,06-01-2012,NA,US NCT number,protocol
3682,2011-004405-25, Study for prevention of peritoneal carcinomatosis in patients with stomach cancer,06-01-2012,NA,other,protocol
3683,2011-004405-25, Study for prevention of peritoneal carcinomatosis in patients with stomach cancer,06-01-2012,NA,US NCT number,results
3684,2011-004405-25, Study for prevention of peritoneal carcinomatosis in patients with stomach cancer,06-01-2012,NA,ISRCTN number,results
3685,2011-004463-69, Investigation of Radiation Retinopathy (RadiRet Study),03-08-2012,NA,US NCT number,protocol
3686,2011-004463-69, Investigation of Radiation Retinopathy (RadiRet Study),03-08-2012,DRKS 00003246,other,protocol
3687,2011-004463-69, Investigation of Radiation Retinopathy (RadiRet Study),03-08-2012,NA,US NCT number,results
3688,2011-004463-69, Investigation of Radiation Retinopathy (RadiRet Study),03-08-2012,NA,ISRCTN number,results
3689,2011-004482-32," Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",21-12-2012,NA,US NCT number,protocol
3690,2011-004482-32," Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",21-12-2012,NA,other,protocol
3691,2011-004482-32," Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",21-12-2012,NCT01879241,US NCT number,results
3692,2011-004482-32," Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients with Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole)",21-12-2012,NA,ISRCTN number,results
3693,2011-004585-15," Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes ",06-09-2012,NA,US NCT number,protocol
3694,2011-004585-15," Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes ",06-09-2012,NA,other,protocol
3695,2011-004585-15," Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes ",06-09-2012,NA,US NCT number,results
3696,2011-004585-15," Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal catumaxomab followed by chemotherapy regimes ",06-09-2012,NA,ISRCTN number,results
3697,2011-004593-29, Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma,09-10-2015,NA,US NCT number,protocol
3698,2011-004593-29, Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma,09-10-2015,NA,other,protocol
3699,2011-004593-29, Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma,09-10-2015,NA,US NCT number,results
3700,2011-004593-29, Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma,09-10-2015,NA,ISRCTN number,results
3701,2011-004698-98," A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy",20-03-2012,NA,US NCT number,protocol
3702,2011-004698-98," A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy",20-03-2012,Celgene Protocol Number RV-CLL-GCLLSG-0725,other,protocol
3703,2011-004698-98," A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy",20-03-2012,NCT01556776,US NCT number,results
3704,2011-004698-98," A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of lenalidomide (Revlimid®) as maintenance therapy for high-risk patients with chronic lymphocytic leukemia following first-line therapy",20-03-2012,NA,ISRCTN number,results
3705,2011-004787-30, Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,13-07-2012,NA,US NCT number,protocol
3706,2011-004787-30, Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,13-07-2012,NA,other,protocol
3707,2011-004787-30, Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,13-07-2012,NA,US NCT number,results
3708,2011-004787-30, Modification of the visual outcome after optic neuritis in CIS or MS by Gilenya®,13-07-2012,NA,ISRCTN number,results
3709,2011-004847-35, Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first),03-05-2012,NA,US NCT number,protocol
3710,2011-004847-35, Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first),03-05-2012,NA,other,protocol
3711,2011-004847-35, Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first),03-05-2012,NA,US NCT number,results
3712,2011-004847-35, Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first),03-05-2012,NA,ISRCTN number,results
3713,2011-004868-30," AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION AND REGISTRY FOR MB OCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION",24-11-2011,NCT02066220,US NCT number,protocol
3714,2011-004868-30," AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION AND REGISTRY FOR MB OCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION",24-11-2011,RG_12-229NS  University of Birmingham ID ,other,protocol
3715,2011-004868-30," AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION AND REGISTRY FOR MB OCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION",24-11-2011,NA,US NCT number,results
3716,2011-004868-30," AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION AND REGISTRY FOR MB OCURRING IN THE CONTEXT OF GENETIC PREDISPOSITION",24-11-2011,NA,ISRCTN number,results
3717,2011-004944-23, ,05-12-2011,NA,US NCT number,protocol
3718,2011-004944-23, ,05-12-2011,NA,other,protocol
3719,2011-004944-23, ,05-12-2011,NA,US NCT number,results
3720,2011-004944-23, ,05-12-2011,NA,ISRCTN number,results
3721,2011-004953-17," Measurement of epidermal and dermal thickness under therapy with Pimecrolimus 1 % Creme (Elidel® 1 % Creme), Hydrocortisonacetat 1 % Creme (Hydrogalen® Creme),  Betamethasonvalerat 0,1 % Creme (Betagalen® Creme), Methylprednisolonaceponat 0,1 % Creme (Advantan® Creme), Dermatop® Basecreme and without therapy by optical coherencetomography (OCT) and 20-MHZ-ultrasound.",09-12-2011,NA,US NCT number,protocol
3722,2011-004953-17," Measurement of epidermal and dermal thickness under therapy with Pimecrolimus 1 % Creme (Elidel® 1 % Creme), Hydrocortisonacetat 1 % Creme (Hydrogalen® Creme),  Betamethasonvalerat 0,1 % Creme (Betagalen® Creme), Methylprednisolonaceponat 0,1 % Creme (Advantan® Creme), Dermatop® Basecreme and without therapy by optical coherencetomography (OCT) and 20-MHZ-ultrasound.",09-12-2011,NA,other,protocol
3723,2011-004953-17," Measurement of epidermal and dermal thickness under therapy with Pimecrolimus 1 % Creme (Elidel® 1 % Creme), Hydrocortisonacetat 1 % Creme (Hydrogalen® Creme),  Betamethasonvalerat 0,1 % Creme (Betagalen® Creme), Methylprednisolonaceponat 0,1 % Creme (Advantan® Creme), Dermatop® Basecreme and without therapy by optical coherencetomography (OCT) and 20-MHZ-ultrasound.",09-12-2011,NA,US NCT number,results
3724,2011-004953-17," Measurement of epidermal and dermal thickness under therapy with Pimecrolimus 1 % Creme (Elidel® 1 % Creme), Hydrocortisonacetat 1 % Creme (Hydrogalen® Creme),  Betamethasonvalerat 0,1 % Creme (Betagalen® Creme), Methylprednisolonaceponat 0,1 % Creme (Advantan® Creme), Dermatop® Basecreme and without therapy by optical coherencetomography (OCT) and 20-MHZ-ultrasound.",09-12-2011,NA,ISRCTN number,results
3725,2011-005082-21, Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma,19-04-2012,NA,US NCT number,protocol
3726,2011-005082-21, Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma,19-04-2012,NA,other,protocol
3727,2011-005082-21, Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma,19-04-2012,NCT01569204,US NCT number,results
3728,2011-005082-21, Targeted BEACOPP variants in patients with newly diagnosed advanced classical Hodgkin Lymphoma,19-04-2012,NA,ISRCTN number,results
3729,2011-005296-16, Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),21-06-2012,NA,US NCT number,protocol
3730,2011-005296-16, Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),21-06-2012,NA,other,protocol
3731,2011-005296-16, Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),21-06-2012,NA,US NCT number,results
3732,2011-005296-16, Capecitabine and bevacizumab with radiotherapy after 3-6 months chemotherapy for patients with oligometastatic colorectal cancer (OLGA trial),21-06-2012,NA,ISRCTN number,results
3733,2011-005305-73," Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.",03-04-2012,NA,US NCT number,protocol
3734,2011-005305-73," Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.",03-04-2012,NA,other,protocol
3735,2011-005305-73," Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.",03-04-2012,NA,US NCT number,results
3736,2011-005305-73," Effects of clopidogrel vs prasugel vs ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting. A randomised, prospective study.",03-04-2012,NA,ISRCTN number,results
3737,2011-005471-17, Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors,03-01-2012,NA,US NCT number,protocol
3738,2011-005471-17, Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors,03-01-2012,NA,other,protocol
3739,2011-005471-17, Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors,03-01-2012,NCT01729481,US NCT number,results
3740,2011-005471-17, Phase II Study for the Evaluation of the Efficacy of Gemcitabine plus Erlotinib in Rash-positive Patients with metastatic pancreatic cancer and good risk factors,03-01-2012,NA,ISRCTN number,results
3741,2011-005615-87," A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",24-07-2012,NA,US NCT number,protocol
3742,2011-005615-87," A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",24-07-2012,NA,other,protocol
3743,2011-005615-87," A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",24-07-2012,NA,US NCT number,results
3744,2011-005615-87," A multicenter, randomized, double-blind, placebo-controlled 12-week, parallel-group study with a 6 week follow up period to demonstrate efficacy and safety of subcutaneous Omalizumab in patients with urticaria factitia refractory to standard treatment",24-07-2012,NA,ISRCTN number,results
3745,2011-005628-16, FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients,08-05-2012,NA,US NCT number,protocol
3746,2011-005628-16, FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients,08-05-2012,DRKS-Number DRKS00003349,other,protocol
3747,2011-005628-16, FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients,08-05-2012,NA,US NCT number,results
3748,2011-005628-16, FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients,08-05-2012,NA,ISRCTN number,results
3749,2011-005655-13, A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922,10-05-2012,NA,US NCT number,protocol
3750,2011-005655-13, A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922,10-05-2012,NA,other,protocol
3751,2011-005655-13, A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922,10-05-2012,NA,US NCT number,results
3752,2011-005655-13, A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922,10-05-2012,NA,ISRCTN number,results
3753,2011-005797-32," Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",27-11-2012,NA,US NCT number,protocol
3754,2011-005797-32," Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",27-11-2012,DRKS 00004353,other,protocol
3755,2011-005797-32," Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",27-11-2012,NA,US NCT number,results
3756,2011-005797-32," Effentora® for Dyspnoea (EffenDys) - Fentanyl buccal tablet (FBT) for the relief of episodic dyspnoea (ED) in cancer patients: an open label, randomized, morphine-controlled, crossover, phase II trial",27-11-2012,NA,ISRCTN number,results
3757,2011-005807-33, ,20-09-2012,NA,US NCT number,protocol
3758,2011-005807-33, ,20-09-2012,NA,other,protocol
3759,2011-005807-33, ,20-09-2012,NCT01914159,US NCT number,results
3760,2011-005807-33, ,20-09-2012,NA,ISRCTN number,results
3761,2011-005906-32, Efficacy and safety of MRI-based thrombolysis in wake-up,02-05-2012,NCT01525290,US NCT number,protocol
3762,2011-005906-32, Efficacy and safety of MRI-based thrombolysis in wake-up,02-05-2012,NA,other,protocol
3763,2011-005906-32, Efficacy and safety of MRI-based thrombolysis in wake-up,02-05-2012,NCT01525290,US NCT number,results
3764,2011-005906-32, Efficacy and safety of MRI-based thrombolysis in wake-up,02-05-2012,NA,ISRCTN number,results
3765,2011-006204-13," Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study.",27-07-2012,NA,US NCT number,protocol
3766,2011-006204-13," Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study.",27-07-2012,NA,other,protocol
3767,2011-006204-13," Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study.",27-07-2012,NA,US NCT number,results
3768,2011-006204-13," Efficacy and safety of oral prednisone as add-on therapy in the prophylactic treatment of episodic cluster headache: a randomized, placebo controlled parallel study.",27-07-2012,NA,ISRCTN number,results
3769,2011-006310-13, CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer:,17-10-2014,NA,US NCT number,protocol
3770,2011-006310-13, CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer:,17-10-2014,NA,other,protocol
3771,2011-006310-13, CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer:,17-10-2014,NA,US NCT number,results
3772,2011-006310-13, CAO/ARO/AIO-12: Induction chemotherapy before or after preoperative chemoradiotherapy and surgery for locally advanced rectal cancer:,17-10-2014,NA,ISRCTN number,results
3773,2012-000108-13, A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),09-11-2012,NA,US NCT number,protocol
3774,2012-000108-13, A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),09-11-2012,NA,other,protocol
3775,2012-000108-13, A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),09-11-2012,NA,US NCT number,results
3776,2012-000108-13, A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS),09-11-2012,NA,ISRCTN number,results
3777,2012-000188-25, Lormetazepam versus Midazolam used as sedatives for critically ill ,14-03-2013,NCT02022592,US NCT number,protocol
3778,2012-000188-25, Lormetazepam versus Midazolam used as sedatives for critically ill ,14-03-2013,NA,other,protocol
3779,2012-000188-25, Lormetazepam versus Midazolam used as sedatives for critically ill ,14-03-2013,NCT02022592,US NCT number,results
3780,2012-000188-25, Lormetazepam versus Midazolam used as sedatives for critically ill ,14-03-2013,NA,ISRCTN number,results
3781,2012-000391-42," Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline",30-04-2012,NA,US NCT number,protocol
3782,2012-000391-42," Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline",30-04-2012,NA,other,protocol
3783,2012-000391-42," Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline",30-04-2012,NA,US NCT number,results
3784,2012-000391-42," Investigation on the peritoneal tissue concentrations of antibiotics in surgical patients with peritonitis using microdialysis. Example: linezolide, tigecycline",30-04-2012,NA,ISRCTN number,results
3785,2012-000411-91," Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",04-12-2012,NA,US NCT number,protocol
3786,2012-000411-91," Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",04-12-2012,NA,other,protocol
3787,2012-000411-91," Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",04-12-2012,NA,US NCT number,results
3788,2012-000411-91," Monitoring natural killer cells in multiple sclerosis patients treated with fingolimod: a monocentric, prospective, one year, baseline-to-treatment, open-label, single group pilot trial",04-12-2012,NA,ISRCTN number,results
3789,2012-000443-27, Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,19-03-2012,NA,US NCT number,protocol
3790,2012-000443-27, Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,19-03-2012,NA,other,protocol
3791,2012-000443-27, Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,19-03-2012,NA,US NCT number,results
3792,2012-000443-27, Determination of the penetration of antibiotics into epithelial lining fluid during continuous infusion in mechanically ventilated ICU patients: example meropenem,19-03-2012,NA,ISRCTN number,results
3793,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,protocol
3794,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,other,protocol
3795,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,results
3796,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,ISRCTN number,results
3797,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,protocol
3798,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,other,protocol
3799,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,results
3800,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,ISRCTN number,results
3801,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,protocol
3802,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,other,protocol
3803,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,results
3804,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,ISRCTN number,results
3805,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,protocol
3806,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,other,protocol
3807,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,US NCT number,results
3808,2012-000447-27, Open Label Study for the Functional Characterization of Drug Metabolism and Transport in patients before routine visceral surgery,23-04-2012,NA,ISRCTN number,results
3809,2012-000793-30, International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,17-12-2012,NCT01802814,US NCT number,protocol
3810,2012-000793-30, International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,17-12-2012,NA,other,protocol
3811,2012-000793-30, International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,17-12-2012,NA,US NCT number,results
3812,2012-000793-30, International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010,17-12-2012,NA,ISRCTN number,results
3813,2012-000810-12, IntReALL HR 2010,01-02-2016,NA,US NCT number,protocol
3814,2012-000810-12, IntReALL HR 2010,01-02-2016,NA,other,protocol
3815,2012-000810-12, IntReALL HR 2010,01-02-2016,NA,US NCT number,results
3816,2012-000810-12, IntReALL HR 2010,01-02-2016,NA,ISRCTN number,results
3817,2012-000928-18," Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)",28-06-2013,NA,US NCT number,protocol
3818,2012-000928-18," Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)",28-06-2013,NA,other,protocol
3819,2012-000928-18," Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)",28-06-2013,NCT02008721,US NCT number,results
3820,2012-000928-18," Double blind, randomised, prospective placebo controlled parallel group phase III study to investigate the Effect of EGCG supplementation on disease progression of patients with Multiple System Atrophy (MSA)",28-06-2013,NA,ISRCTN number,results
3821,2012-001039-30," BetHäm2012:  A monocenter, single-blind, randomized, 2-armed, placebo-controlled, cross-over study to investigate coagulation markers in patients with haemophilia A after administration of Betain",16-11-2012,NA,US NCT number,protocol
3822,2012-001039-30," BetHäm2012:  A monocenter, single-blind, randomized, 2-armed, placebo-controlled, cross-over study to investigate coagulation markers in patients with haemophilia A after administration of Betain",16-11-2012,NA,other,protocol
3823,2012-001039-30," BetHäm2012:  A monocenter, single-blind, randomized, 2-armed, placebo-controlled, cross-over study to investigate coagulation markers in patients with haemophilia A after administration of Betain",16-11-2012,NA,US NCT number,results
3824,2012-001039-30," BetHäm2012:  A monocenter, single-blind, randomized, 2-armed, placebo-controlled, cross-over study to investigate coagulation markers in patients with haemophilia A after administration of Betain",16-11-2012,NA,ISRCTN number,results
3825,2012-001134-33," Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure ",28-08-2012,NA,US NCT number,protocol
3826,2012-001134-33," Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure ",28-08-2012,NA,other,protocol
3827,2012-001134-33," Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure ",28-08-2012,NA,US NCT number,results
3828,2012-001134-33," Randomized, Double-Blind, Placebo-Controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients with Congestive Heart Failure ",28-08-2012,NA,ISRCTN number,results
3829,2012-001209-26, Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,17-09-2013,NA,US NCT number,protocol
3830,2012-001209-26, Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,17-09-2013,NA,other,protocol
3831,2012-001209-26, Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,17-09-2013,NA,US NCT number,results
3832,2012-001209-26, Efficacy of Tranylcypromine (TCP) in daily doses up to 60mg and lithiumaugmentation (Li.-Aug.) of antidepressants inn the acute treatmet of therapy-resistant Depression. An open randomized study in a Simon-phase-II-design.,17-09-2013,NA,ISRCTN number,results
3833,2012-001352-19, BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections,08-08-2012,NA,US NCT number,protocol
3834,2012-001352-19, BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections,08-08-2012,NA,other,protocol
3835,2012-001352-19, BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections,08-08-2012,NA,US NCT number,results
3836,2012-001352-19, BE-RELACs-Trial: Biomarkers Explaining RELevance of ACute Rejections,08-08-2012,NA,ISRCTN number,results
3837,2012-001419-21," An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection",09-04-2013,NA,US NCT number,protocol
3838,2012-001419-21," An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection",09-04-2013,NA,other,protocol
3839,2012-001419-21," An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection",09-04-2013,NA,US NCT number,results
3840,2012-001419-21," An open label, randomised, non-inferiority trial of pegylated interferon, ribavirin and telaprevir versus pegylated interferon and ribavirin alone in the response guided treatment of acute hepatitis C genotype 1 virus infection in patients with HIV-1 co-infection",09-04-2013,NA,ISRCTN number,results
3841,2012-001582-33, Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,03-07-2012,NA,US NCT number,protocol
3842,2012-001582-33, Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,03-07-2012,NA,other,protocol
3843,2012-001582-33, Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,03-07-2012,NA,US NCT number,results
3844,2012-001582-33, Intraindividual cross-over comparison of Gadobutrol and Gadoterate enhanced combined DSC-MR-Perfusion and MR-Angiography in patients with cerebrovascular disease,03-07-2012,NA,ISRCTN number,results
3845,2012-001583-29," Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects",12-07-2012,NA,US NCT number,protocol
3846,2012-001583-29," Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects",12-07-2012,NA,other,protocol
3847,2012-001583-29," Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects",12-07-2012,NA,US NCT number,results
3848,2012-001583-29," Prospective, open-label, two-arm, parallel-group, single center phase IV clinical trial to evaluate the diagnostic value of a Gadobutrol enhanced dynamic susceptibility perfusion MRI (DSC-MRP) and a non contrast arterial spin labeling perfusion MRI (ASL-MRP) in subjects with minor cognitive impairment or minor Alzheimer's disease compared to age matched mentally healthy subjects",12-07-2012,NA,ISRCTN number,results
3849,2012-001650-26," A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock ",14-08-2012,NA,US NCT number,protocol
3850,2012-001650-26," A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock ",14-08-2012,NA,other,protocol
3851,2012-001650-26," A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock ",14-08-2012,NA,US NCT number,results
3852,2012-001650-26," A randomised, placebo-controlled, double-blind, monocentre study on the application of physostigminsalicylate (Anticholium®) as adjunctive measure in perioperative sepsis/septic shock ",14-08-2012,NA,ISRCTN number,results
3853,2012-001670-28, Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema,14-08-2012,NA,US NCT number,protocol
3854,2012-001670-28, Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema,14-08-2012,NA,other,protocol
3855,2012-001670-28, Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema,14-08-2012,NA,US NCT number,results
3856,2012-001670-28, Angiotensin Converting Enzyme Inhibitor (ACE) Induced Angioedema,14-08-2012,NA,ISRCTN number,results
3857,2012-001725-26, A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector,18-12-2012,NA,US NCT number,protocol
3858,2012-001725-26, A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector,18-12-2012,NA,other,protocol
3859,2012-001725-26, A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector,18-12-2012,NA,US NCT number,results
3860,2012-001725-26, A Phase I/II Gene Therapy trial for X-CGD with a SIN gamma retroviral vector,18-12-2012,NA,ISRCTN number,results
3861,2012-001891-13," Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial ",13-09-2012,NA,US NCT number,protocol
3862,2012-001891-13," Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial ",13-09-2012,NA,other,protocol
3863,2012-001891-13," Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial ",13-09-2012,NCT01788189,US NCT number,results
3864,2012-001891-13," Lenalidomide in conjunction with methotrexate, leucovorin, cytarabine and rituximab for the treatment of relapsed or refractory CD20-positive aggressive lymphomas: an open-label, multicenter phase I/II trial ",13-09-2012,NA,ISRCTN number,results
3865,2012-001947-31, Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial,17-07-2012,NA,US NCT number,protocol
3866,2012-001947-31, Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial,17-07-2012,NA,other,protocol
3867,2012-001947-31, Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial,17-07-2012,NA,US NCT number,results
3868,2012-001947-31, Ofatumumab Induction and Maintenance in Elderly Patients with Poor Risk CLL in the Context of Allogeneic Transplantation: CLLX4 Trial,17-07-2012,NA,ISRCTN number,results
3869,2012-001989-15," A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease.",18-05-2012,NA,US NCT number,protocol
3870,2012-001989-15," A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease.",18-05-2012,NA,other,protocol
3871,2012-001989-15," A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease.",18-05-2012,NA,US NCT number,results
3872,2012-001989-15," A randomised, placebo controlled, double blind, cross-over, single center clinical Study to investigate the effect of heart rate reduction with ivabradine on endothelial function and vascular stiffness in patients with stable coronary heart disease.",18-05-2012,NA,ISRCTN number,results
3873,2012-002154-23, Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML)  when no intensive treatment is possible,11-04-2014,NA,US NCT number,protocol
3874,2012-002154-23, Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML)  when no intensive treatment is possible,11-04-2014,NA,other,protocol
3875,2012-002154-23, Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML)  when no intensive treatment is possible,11-04-2014,NA,US NCT number,results
3876,2012-002154-23, Phase I/II pilot trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in patients with relapsed or refractory acute myeloid leukemia (AML)  when no intensive treatment is possible,11-04-2014,NA,ISRCTN number,results
3877,2012-002278-30, Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,14-06-2012,NA,US NCT number,protocol
3878,2012-002278-30, Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,14-06-2012,NA,other,protocol
3879,2012-002278-30, Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,14-06-2012,NA,US NCT number,results
3880,2012-002278-30, Effects of Linagliptin on Renal Endothelium Function in Patients with Type 2 Diabetes.,14-06-2012,NA,ISRCTN number,results
3881,2012-002431-29, A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis,11-03-2013,NCT01644110,US NCT number,protocol
3882,2012-002431-29, A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis,11-03-2013,NA,other,protocol
3883,2012-002431-29, A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis,11-03-2013,NA,US NCT number,results
3884,2012-002431-29, A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis,11-03-2013,NA,ISRCTN number,results
3885,2012-002685-12, Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells,29-10-2012,NA,US NCT number,protocol
3886,2012-002685-12, Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells,29-10-2012,NA,other,protocol
3887,2012-002685-12, Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells,29-10-2012,NA,US NCT number,results
3888,2012-002685-12, Treatment of steroid resistant severe acute gastrointestinal graft-versus-host disease with in vitro expanded donor-derived regulatory T cells,29-10-2012,NA,ISRCTN number,results
3889,2012-002887-29, Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab ,07-11-2012,NA,US NCT number,protocol
3890,2012-002887-29, Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab ,07-11-2012,NA,other,protocol
3891,2012-002887-29, Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab ,07-11-2012,NA,US NCT number,results
3892,2012-002887-29, Translational therapy in patients with Osteogenesis imperfecta - a pilot trial on treatment with the RANKL-antibody Denosumab ,07-11-2012,NA,ISRCTN number,results
3893,2012-002944-25," EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke",22-07-2014,NCT01833312,US NCT number,protocol
3894,2012-002944-25," EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke",22-07-2014,EuroHYP-1 EuroHYP-1,other,protocol
3895,2012-002944-25," EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke",22-07-2014,NCT01833312,US NCT number,results
3896,2012-002944-25," EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke",22-07-2014,NA,ISRCTN number,results
3897,2012-003023-38," Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous stem cell transplantation – a GERman MAINtenance study (GERMAIN)(GERMAIN)",23-10-2013,NA,US NCT number,protocol
3898,2012-003023-38," Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous stem cell transplantation – a GERman MAINtenance study (GERMAIN)(GERMAIN)",23-10-2013,NA,other,protocol
3899,2012-003023-38," Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous stem cell transplantation – a GERman MAINtenance study (GERMAIN)(GERMAIN)",23-10-2013,NA,US NCT number,results
3900,2012-003023-38," Phase II study of Bortezomib, Melphalan, Prednisone (VMP) followed by Lenalidomide maintenance vs. VMP without maintenance in Myeloma patients not eligible to high-dose chemotherapy and autologous stem cell transplantation – a GERman MAINtenance study (GERMAIN)(GERMAIN)",23-10-2013,NA,ISRCTN number,results
3901,2012-003033-42," Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses for immune response enhancement, measured as response to a preponed single vaccination",26-02-2013,NA,US NCT number,protocol
3902,2012-003033-42," Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses for immune response enhancement, measured as response to a preponed single vaccination",26-02-2013,NA,other,protocol
3903,2012-003033-42," Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses for immune response enhancement, measured as response to a preponed single vaccination",26-02-2013,NA,US NCT number,results
3904,2012-003033-42," Prospective, open-label, multicentre clinical trial, phase I/IIa, to investigate the safety and tolerability of allogeneic B-cell concentrates CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses for immune response enhancement, measured as response to a preponed single vaccination",26-02-2013,NA,ISRCTN number,results
3905,2012-003217-33," Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",13-08-2012,NA,US NCT number,protocol
3906,2012-003217-33," Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",13-08-2012,NA,other,protocol
3907,2012-003217-33," Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",13-08-2012,NA,US NCT number,results
3908,2012-003217-33," Immunological response of a single dose of 100,000 I.U. of cholecalciferol (vitamin D3)",13-08-2012,NA,ISRCTN number,results
3909,2012-003234-16, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study,26-02-2013,NA,US NCT number,protocol
3910,2012-003234-16, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study,26-02-2013,NA,other,protocol
3911,2012-003234-16, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study,26-02-2013,NA,US NCT number,results
3912,2012-003234-16, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD – The ABACOPD Study,26-02-2013,NA,ISRCTN number,results
3913,2012-003281-40," Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study",27-08-2012,NA,US NCT number,protocol
3914,2012-003281-40," Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study",27-08-2012,NA,other,protocol
3915,2012-003281-40," Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study",27-08-2012,NA,US NCT number,results
3916,2012-003281-40," Efficacy of gencydo nasal spray on early nasal response after allergen exposition in patients with grass pollen allergy: a randomized, placebo controlled cross over study",27-08-2012,NA,ISRCTN number,results
3917,2012-003528-19, STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL ,20-09-2012,NA,US NCT number,protocol
3918,2012-003528-19, STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL ,20-09-2012,NA,other,protocol
3919,2012-003528-19, STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL ,20-09-2012,NA,US NCT number,results
3920,2012-003528-19, STEM CELL TRANSPLANTATION FOR ERADICATION OF MINIMAL ,20-09-2012,ISRCTN47877138,ISRCTN number,results
3921,2012-003609-80, European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.,11-06-2013,NA,US NCT number,protocol
3922,2012-003609-80, European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.,11-06-2013,ECASS-4: ExTEND None,other,protocol
3923,2012-003609-80, European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.,11-06-2013,NA,US NCT number,results
3924,2012-003609-80, European Cooperative Acute Stroke Study-4: Extending the time for thrombolysis in emergency neurological deficits.,11-06-2013,NA,ISRCTN number,results
3925,2012-003621-21," Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",06-06-2013,NA,US NCT number,protocol
3926,2012-003621-21," Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",06-06-2013,NA,other,protocol
3927,2012-003621-21," Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",06-06-2013,NA,US NCT number,results
3928,2012-003621-21," Prospective phase IIA multicenter double-blinded randomized placebo-controlled clinical trial evaluating the efficacy and safety of inhaled, aerosolized Tobramycin (TOBI®) b.i.d. in patients with ventilator-associated pneumonia (VAP)",06-06-2013,NA,ISRCTN number,results
3929,2012-003630-16," A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation",24-01-2013,NA,US NCT number,protocol
3930,2012-003630-16," A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation",24-01-2013,NA,other,protocol
3931,2012-003630-16," A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation",24-01-2013,NA,US NCT number,results
3932,2012-003630-16," A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation",24-01-2013,NA,ISRCTN number,results
3933,2012-003669-17," Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).",25-04-2013,NCT01900327,US NCT number,protocol
3934,2012-003669-17," Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).",25-04-2013,NA,other,protocol
3935,2012-003669-17," Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).",25-04-2013,NA,US NCT number,results
3936,2012-003669-17," Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma (NEOPA).",25-04-2013,NA,ISRCTN number,results
3937,2012-003696-18, Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.,01-03-2013,NA,US NCT number,protocol
3938,2012-003696-18, Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.,01-03-2013,DRKS 00004361,other,protocol
3939,2012-003696-18, Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.,01-03-2013,NCT01879839,US NCT number,results
3940,2012-003696-18, Effect of a preinterventional calorie restriction on renal function after contrast agent exposition in patients at risk.,01-03-2013,NA,ISRCTN number,results
3941,2012-003750-89," A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy",21-11-2012,NA,US NCT number,protocol
3942,2012-003750-89," A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy",21-11-2012,NA,other,protocol
3943,2012-003750-89," A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy",21-11-2012,NA,US NCT number,results
3944,2012-003750-89," A placebo-controlled, double blind, randomised trial with crossover-design investigating the effect of oxytocin nasal spray on neuronal processes of empathy",21-11-2012,NA,ISRCTN number,results
3945,2012-003858-81, Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus,22-04-2013,NA,US NCT number,protocol
3946,2012-003858-81, Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus,22-04-2013,NA,other,protocol
3947,2012-003858-81, Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus,22-04-2013,NA,US NCT number,results
3948,2012-003858-81, Effect of Linagliptin therapy on myocardial diastolic function in patients with type 2 diabetes mellitus,22-04-2013,NA,ISRCTN number,results
3949,2012-003859-12, Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,22-04-2013,NCT02077309,US NCT number,protocol
3950,2012-003859-12, Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,22-04-2013,NA,other,protocol
3951,2012-003859-12, Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,22-04-2013,NA,US NCT number,results
3952,2012-003859-12, Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus,22-04-2013,NA,ISRCTN number,results
3953,2012-003882-17," Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",08-04-2013,NA,US NCT number,protocol
3954,2012-003882-17," Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",08-04-2013,NA,other,protocol
3955,2012-003882-17," Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",08-04-2013,NCT02071615,US NCT number,results
3956,2012-003882-17," Effects of modafinil, caffeine and methylphenidate on functional brain activity and cognitive performance in healthy subjects: a randomized, placebo-controlled, double-blind fMRI study.",08-04-2013,NA,ISRCTN number,results
3957,2012-003943-32, Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,31-03-2015,NA,US NCT number,protocol
3958,2012-003943-32, Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,31-03-2015,NA,other,protocol
3959,2012-003943-32, Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,31-03-2015,NA,US NCT number,results
3960,2012-003943-32, Influence of diabetes control on treatment of diabetic macular edema with ranibizumab,31-03-2015,NA,ISRCTN number,results
3961,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NCT02684708,US NCT number,protocol
3962,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,Amendment05 final,other,protocol
3963,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,US NCT number,results
3964,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,ISRCTN number,results
3965,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NCT02684708,US NCT number,protocol
3966,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,Amendment05 final,other,protocol
3967,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,US NCT number,results
3968,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,ISRCTN number,results
3969,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NCT02684708,US NCT number,protocol
3970,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,Amendment05 final,other,protocol
3971,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,US NCT number,results
3972,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,ISRCTN number,results
3973,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NCT02684708,US NCT number,protocol
3974,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,Amendment05 final,other,protocol
3975,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,US NCT number,results
3976,2012-004053-88, EuroNet-Paediatric Hodgkin’s Lymphoma Group ,20-01-2015,NA,ISRCTN number,results
3977,2012-004074-25," Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial",29-07-2013,NA,US NCT number,protocol
3978,2012-004074-25," Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial",29-07-2013,NA,other,protocol
3979,2012-004074-25," Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial",29-07-2013,NA,US NCT number,results
3980,2012-004074-25," Comparison of the efficacy and safety of two different starting dosages of prednisolone in early active rheumatoid arthritis: a randomized, placebo controlled trial",29-07-2013,NA,ISRCTN number,results
3981,2012-004082-41," Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine",14-01-2013,NA,US NCT number,protocol
3982,2012-004082-41," Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine",14-01-2013,NA,other,protocol
3983,2012-004082-41," Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine",14-01-2013,NA,US NCT number,results
3984,2012-004082-41," Monocenter, double blind, randomised, placebo controlled study t evaluate Physostigmin for the Treatment of delirium in perioperative intensive care medicine",14-01-2013,NA,ISRCTN number,results
3985,2012-004111-32," Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",09-11-2012,NA,US NCT number,protocol
3986,2012-004111-32," Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",09-11-2012,NA,other,protocol
3987,2012-004111-32," Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",09-11-2012,NA,US NCT number,results
3988,2012-004111-32," Prospective, open-label, multicentre study on the incidence of Squamous Cell Carcinoma and Actinic Keratoses in solid organ transplant recipients treated with per protocol, cyclic field application of MAL-PDT versus lesion adapted cryotherapy",09-11-2012,NA,ISRCTN number,results
3989,2012-004240-30," Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-specific peptide-stimulated T-cells (CD3+) for the prevention or treatment of reactivation of 'CMV and/or EBV in patients after allogeneic HLA-identical stem cell transplantation",02-12-2013,NA,US NCT number,protocol
3990,2012-004240-30," Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-specific peptide-stimulated T-cells (CD3+) for the prevention or treatment of reactivation of 'CMV and/or EBV in patients after allogeneic HLA-identical stem cell transplantation",02-12-2013,NA,other,protocol
3991,2012-004240-30," Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-specific peptide-stimulated T-cells (CD3+) for the prevention or treatment of reactivation of 'CMV and/or EBV in patients after allogeneic HLA-identical stem cell transplantation",02-12-2013,NA,US NCT number,results
3992,2012-004240-30," Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-specific peptide-stimulated T-cells (CD3+) for the prevention or treatment of reactivation of 'CMV and/or EBV in patients after allogeneic HLA-identical stem cell transplantation",02-12-2013,NA,ISRCTN number,results
3993,2012-004383-22, Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain.,15-01-2013,NA,US NCT number,protocol
3994,2012-004383-22, Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain.,15-01-2013,NA,other,protocol
3995,2012-004383-22, Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain.,15-01-2013,NA,US NCT number,results
3996,2012-004383-22, Perioperative complications in obese and non-obese patients: Prevention and treatment of wound infections and post-operative pain.,15-01-2013,NA,ISRCTN number,results
3997,2012-004442-15," High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety ",17-09-2013,NA,US NCT number,protocol
3998,2012-004442-15," High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety ",17-09-2013,DRKS DRKS00005455,other,protocol
3999,2012-004442-15," High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety ",17-09-2013,NA,US NCT number,results
4000,2012-004442-15," High-dose intravenous silibinin infusions during 10 days as add-on treatment to triple therapy (telaprevir, peginterferon alpha and ribavirin) in cirrhotic GT 1 hepatitis C virus infected patients being null responders to prior dual therapy with peginterferon alpha and ribavirin – a proof-of-concept trial on antiviral efficacy and safety ",17-09-2013,NA,ISRCTN number,results
4001,2012-004585-18," Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. ",07-12-2012,NA,US NCT number,protocol
4002,2012-004585-18," Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. ",07-12-2012,NA,other,protocol
4003,2012-004585-18," Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. ",07-12-2012,NA,US NCT number,results
4004,2012-004585-18," Perioperative administration of Tapentadol – tolerance, safety and effects on postoperative rehabilitation and quality of life. ",07-12-2012,NA,ISRCTN number,results
4005,2012-004807-10, Relapse Escalation treatment trial in Optic Neuritis (RESCON):,26-10-2012,NA,US NCT number,protocol
4006,2012-004807-10, Relapse Escalation treatment trial in Optic Neuritis (RESCON):,26-10-2012,NA,other,protocol
4007,2012-004807-10, Relapse Escalation treatment trial in Optic Neuritis (RESCON):,26-10-2012,NA,US NCT number,results
4008,2012-004807-10, Relapse Escalation treatment trial in Optic Neuritis (RESCON):,26-10-2012,NA,ISRCTN number,results
4009,2012-005002-22, ACEMg mediated hearing preservation ,10-07-2013,NA,US NCT number,protocol
4010,2012-005002-22, ACEMg mediated hearing preservation ,10-07-2013,NA,other,protocol
4011,2012-005002-22, ACEMg mediated hearing preservation ,10-07-2013,NA,US NCT number,results
4012,2012-005002-22, ACEMg mediated hearing preservation ,10-07-2013,NA,ISRCTN number,results
4013,2012-005078-70, Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial),22-08-2013,NA,US NCT number,protocol
4014,2012-005078-70, Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial),22-08-2013,CRCTU Ref No HE3015,other,protocol
4015,2012-005078-70, Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial),22-08-2013,NA,US NCT number,results
4016,2012-005078-70, Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial),22-08-2013,NA,ISRCTN number,results
4017,2012-005254-30," Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers ",18-06-2013,NA,US NCT number,protocol
4018,2012-005254-30," Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers ",18-06-2013,NA,other,protocol
4019,2012-005254-30," Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers ",18-06-2013,NCT02108353,US NCT number,results
4020,2012-005254-30," Multicenter, randomized, double-blind, placebo controlled trial of 2 mg melatonin for circadian phase adjustment and improvement of metabolic control in night shift workers ",18-06-2013,NA,ISRCTN number,results
4021,2012-005312-26, Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,11-01-2013,NA,US NCT number,protocol
4022,2012-005312-26, Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,11-01-2013,NA,other,protocol
4023,2012-005312-26, Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,11-01-2013,NA,US NCT number,results
4024,2012-005312-26, Sustained release 4-aminopyridine (Fampyra®) in cerebellar gait disorder,11-01-2013,NA,ISRCTN number,results
4025,2012-005414-18, Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT,14-10-2013,NA,US NCT number,protocol
4026,2012-005414-18, Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT,14-10-2013,NA,other,protocol
4027,2012-005414-18, Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT,14-10-2013,NA,US NCT number,results
4028,2012-005414-18, Thiotepa- Fludarabine- Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from a different unrelated donor in patients with AML relapsing from prior allogeneic HCT,14-10-2013,NA,ISRCTN number,results
4029,2012-005439-10, Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion,23-07-2013,NA,US NCT number,protocol
4030,2012-005439-10, Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion,23-07-2013,NA,other,protocol
4031,2012-005439-10, Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion,23-07-2013,NCT01968239,US NCT number,results
4032,2012-005439-10, Re-treatment with intravitreal application of ranibizumab guided by morphological macular changes documented by optical coherence tomography (OCT) in patients with macular edema due to branch retinal vein occlusion,23-07-2013,NA,ISRCTN number,results
4033,2012-005569-10," Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma  in BRAF inhibitor non-pretreated and pretreated  subjects with advanced, non-resectable (Stage IIIC) or metastatic  (Stage IV) BRAF V600 mutation-positive melanoma",17-04-2013,NA,US NCT number,protocol
4034,2012-005569-10," Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma  in BRAF inhibitor non-pretreated and pretreated  subjects with advanced, non-resectable (Stage IIIC) or metastatic  (Stage IV) BRAF V600 mutation-positive melanoma",17-04-2013,NA,other,protocol
4035,2012-005569-10," Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma  in BRAF inhibitor non-pretreated and pretreated  subjects with advanced, non-resectable (Stage IIIC) or metastatic  (Stage IV) BRAF V600 mutation-positive melanoma",17-04-2013,NA,US NCT number,results
4036,2012-005569-10," Biopsy- and biology-driven optimization of targeted therapy of metastatic melanoma  in BRAF inhibitor non-pretreated and pretreated  subjects with advanced, non-resectable (Stage IIIC) or metastatic  (Stage IV) BRAF V600 mutation-positive melanoma",17-04-2013,NA,ISRCTN number,results
4037,2012-005617-39, Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy ,17-12-2013,NA,US NCT number,protocol
4038,2012-005617-39, Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy ,17-12-2013,NA,other,protocol
4039,2012-005617-39, Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy ,17-12-2013,NA,US NCT number,results
4040,2012-005617-39, Pharmacokinetics of Tigecycline in Patients Receiving Continuous Renal Replacement Therapy ,17-12-2013,NA,ISRCTN number,results
4041,2012-005652-42, Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,12-06-2013,NA,US NCT number,protocol
4042,2012-005652-42, Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,12-06-2013,NA,other,protocol
4043,2012-005652-42, Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,12-06-2013,NA,US NCT number,results
4044,2012-005652-42, Biomarkers Of The Humoral Immune Response After Conversion To Belatacept In Comparison To Conventional Immunosuppressive Therapy In Renal Transplant Patients,12-06-2013,NA,ISRCTN number,results
4045,2012-005657-24," Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.",30-06-2014,NA,US NCT number,protocol
4046,2012-005657-24," Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.",30-06-2014,NA,other,protocol
4047,2012-005657-24," Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.",30-06-2014,NA,US NCT number,results
4048,2012-005657-24," Personalized marker-driven early switch to aflibercept in patients with metastatic colorectal cancer. A run in marker determination phase followed by a marker-driven randomized part - a multicenter, multinational, two-part, phase II trial.",30-06-2014,NA,ISRCTN number,results
4049,2012-005698-30, Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,29-01-2013,NA,US NCT number,protocol
4050,2012-005698-30, Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,29-01-2013,NA,other,protocol
4051,2012-005698-30, Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,29-01-2013,NA,US NCT number,results
4052,2012-005698-30, Impact of Xenon-anaesthesia on the renal function after partial nephrectomy - PaNeX: Partial Nephrectomy under Xenon,29-01-2013,NA,ISRCTN number,results
4053,2012-005726-30," A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",29-05-2013,NA,US NCT number,protocol
4054,2012-005726-30," A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",29-05-2013,NA,other,protocol
4055,2012-005726-30," A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",29-05-2013,NA,US NCT number,results
4056,2012-005726-30," A multi-center, double-blind placebo-controlled parallel group phase II study of the efficacy and safety of rilonacept in subjects with cold contact urticaria (CCU)",29-05-2013,NA,ISRCTN number,results
4057,2012-005846-39," Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA)",12-03-2014,NA,US NCT number,protocol
4058,2012-005846-39," Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA)",12-03-2014,NA,other,protocol
4059,2012-005846-39," Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA)",12-03-2014,NA,US NCT number,results
4060,2012-005846-39," Phase II, multicenter, open-label, single-arm trial in advanced and relapsed Angiosarcomas, to evaluate the efficacy of pazopanib (Votrient) in combination with standard of care treatment paclitaxel ( Evaluation of Votrient in angiosarcoma - EVA)",12-03-2014,NA,ISRCTN number,results
4061,2013-000030-35, Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial,26-02-2013,NA,US NCT number,protocol
4062,2013-000030-35, Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial,26-02-2013,NA,other,protocol
4063,2013-000030-35, Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial,26-02-2013,NCT01797484,US NCT number,results
4064,2013-000030-35, Reduction of Ischemic Myocardium with Ranolazine-Treatment in patients with acute myocardial Ischemia – RIMINI-Pilot-Trial,26-02-2013,NA,ISRCTN number,results
4065,2013-000043-78," Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation",07-01-2014,NCT02196961,US NCT number,protocol
4066,2013-000043-78," Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation",07-01-2014,NA,other,protocol
4067,2013-000043-78," Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation",07-01-2014,NA,US NCT number,results
4068,2013-000043-78," Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo®; Ipilimumab, Yervoy®) versus observation",07-01-2014,NA,ISRCTN number,results
4069,2013-000077-68," Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5) receiving Imatinib at a dose of 400 to 800 mg daily. An open-label, randomised multicenter phase 3b study to determine the confirmed rate of molecular response ≥ 4 log (MR4) at two years",21-06-2013,NCT02174445,US NCT number,protocol
4070,2013-000077-68," Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5) receiving Imatinib at a dose of 400 to 800 mg daily. An open-label, randomised multicenter phase 3b study to determine the confirmed rate of molecular response ≥ 4 log (MR4) at two years",21-06-2013,DRKS DRKS00006285,other,protocol
4071,2013-000077-68," Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5) receiving Imatinib at a dose of 400 to 800 mg daily. An open-label, randomised multicenter phase 3b study to determine the confirmed rate of molecular response ≥ 4 log (MR4) at two years",21-06-2013,NA,US NCT number,results
4072,2013-000077-68," Imatinib continuation versus Nilotinib 300 mg twice daily in patients with chronic myeloid leukemia (CML) in chronic phase and major molecular response (MMR) without molecular response ≥ 4.5 log (MR4.5) receiving Imatinib at a dose of 400 to 800 mg daily. An open-label, randomised multicenter phase 3b study to determine the confirmed rate of molecular response ≥ 4 log (MR4) at two years",21-06-2013,NA,ISRCTN number,results
4073,2013-000107-17, Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of  4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),05-04-2013,NA,US NCT number,protocol
4074,2013-000107-17, Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of  4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),05-04-2013,NA,other,protocol
4075,2013-000107-17, Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of  4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),05-04-2013,NA,US NCT number,results
4076,2013-000107-17, Pharmacological therapy of episodic ataxia type 2: a placebo-controlled comparison of the efficacy of  4-aminopyridine sustained-release (Fampyra TM) and acetazolamide (Acemit TM),05-04-2013,NA,ISRCTN number,results
4077,2013-000211-24," A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris",08-07-2013,NA,US NCT number,protocol
4078,2013-000211-24," A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris",08-07-2013,NA,other,protocol
4079,2013-000211-24," A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris",08-07-2013,NA,US NCT number,results
4080,2013-000211-24," A multicenter, randomized, placebo-controlled, double-blind proof of concept study to evaluate the efficacy and safety of the human normal immunoglobulin Intratect® 5% for intravenous use as adjuvant therapy in patients with Pemphigus Vulgaris",08-07-2013,NA,ISRCTN number,results
4081,2013-000337-13," Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study",12-02-2013,NCT01864265,US NCT number,protocol
4082,2013-000337-13," Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study",12-02-2013,NA,other,protocol
4083,2013-000337-13," Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study",12-02-2013,NCT01864265,US NCT number,results
4084,2013-000337-13," Prediction of response to Certolizumab Pegol treatment by functional MRI of the brain. A multi-center, randomized double-blind controlled study",12-02-2013,NA,ISRCTN number,results
4085,2013-000338-37," Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",23-09-2014,NA,US NCT number,protocol
4086,2013-000338-37," Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",23-09-2014,NA,other,protocol
4087,2013-000338-37," Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",23-09-2014,NCT02307396,US NCT number,results
4088,2013-000338-37," Evaluation of the necessity of a pharmacological treatment with antipsychotics for the prevention of relapse in long-term stabilized schizophrenic patients: a randomized, single-blind, longitudinal trial",23-09-2014,NA,ISRCTN number,results
4089,2013-000416-24, THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),08-04-2013,NA,US NCT number,protocol
4090,2013-000416-24, THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),08-04-2013,NA,other,protocol
4091,2013-000416-24, THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),08-04-2013,NA,US NCT number,results
4092,2013-000416-24, THE EFFECT OF AZELAIC ACID ON SYMPTOMS OF ACNE IN FEMALE PATIENTS AGE 20-45 WITH MILD TO MODERATE PAPULOPUSTULAR ACNE (ACNE TARDA),08-04-2013,NA,ISRCTN number,results
4093,2013-000506-37," Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide",18-07-2014,NA,US NCT number,protocol
4094,2013-000506-37," Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide",18-07-2014,NA,other,protocol
4095,2013-000506-37," Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide",18-07-2014,NA,US NCT number,results
4096,2013-000506-37," Efficacy of first line Dexamethasone, Rituximab and Cyclophosphamide",18-07-2014,NA,ISRCTN number,results
4097,2013-000522-58," A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia",18-06-2014,NA,US NCT number,protocol
4098,2013-000522-58," A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia",18-06-2014,NA,other,protocol
4099,2013-000522-58," A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia",18-06-2014,NA,US NCT number,results
4100,2013-000522-58," A randomized, double blind, phase II trial of pazopanib versus placebo as maintenance therapy in patients with retroperitoneal and visceral high-risk soft tissue sarcomas following prior- and/or adjuvant doxorubicin / ifosfamide chemotherapy with regional hyperthermia",18-06-2014,NA,ISRCTN number,results
4101,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,US NCT number,protocol
4102,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,ClinicalTrials.gov Identifier NCT01792804,other,protocol
4103,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NCT01792804,US NCT number,results
4104,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,ISRCTN number,results
4105,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,US NCT number,protocol
4106,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,ClinicalTrials.gov Identifier NCT01792804,other,protocol
4107,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NCT01792804,US NCT number,results
4108,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,ISRCTN number,results
4109,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,US NCT number,protocol
4110,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,ClinicalTrials.gov Identifier NCT01792804,other,protocol
4111,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NCT01792804,US NCT number,results
4112,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,ISRCTN number,results
4113,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,US NCT number,protocol
4114,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,ClinicalTrials.gov Identifier NCT01792804,other,protocol
4115,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NCT01792804,US NCT number,results
4116,2013-000577-77, EARLY ORAL SWITCH THERAPY IN LOW-RISK STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTION,27-05-2013,NA,ISRCTN number,results
4117,2013-000823-15, Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,19-11-2013,NA,US NCT number,protocol
4118,2013-000823-15, Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,19-11-2013,NA,other,protocol
4119,2013-000823-15, Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,19-11-2013,NCT02096068,US NCT number,results
4120,2013-000823-15, Neuroprotection with Dexmedetomidine in patients undergoing elective cardiac or abdominal surgery,19-11-2013,NA,ISRCTN number,results
4121,2013-000899-16, Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy,10-09-2013,NA,US NCT number,protocol
4122,2013-000899-16, Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy,10-09-2013,NA,other,protocol
4123,2013-000899-16, Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy,10-09-2013,NA,US NCT number,results
4124,2013-000899-16, Investigation of pharmacokinetics of Linezolid and Meropenem in patients receiving continuous renal replacement therapy,10-09-2013,NA,ISRCTN number,results
4125,2013-000970-31," Randomized, placebo-controlled multicenter trial of lithium plus treatment as",01-10-2013,NA,US NCT number,protocol
4126,2013-000970-31," Randomized, placebo-controlled multicenter trial of lithium plus treatment as",01-10-2013,NA,other,protocol
4127,2013-000970-31," Randomized, placebo-controlled multicenter trial of lithium plus treatment as",01-10-2013,NA,US NCT number,results
4128,2013-000970-31," Randomized, placebo-controlled multicenter trial of lithium plus treatment as",01-10-2013,NA,ISRCTN number,results
4129,2013-000999-15, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,06-06-2013,NCT02085629,US NCT number,protocol
4130,2013-000999-15, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,06-06-2013,NA,other,protocol
4131,2013-000999-15, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,06-06-2013,NCT02085629,US NCT number,results
4132,2013-000999-15, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M reg Trial,06-06-2013,NA,ISRCTN number,results
4133,2013-001062-41, Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy,19-04-2013,NA,US NCT number,protocol
4134,2013-001062-41, Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy,19-04-2013,NA,other,protocol
4135,2013-001062-41, Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy,19-04-2013,NA,US NCT number,results
4136,2013-001062-41, Neoadjuvant chemotherapy with Cabazitaxel in high risk prostate cancer patients prior to radical prostatectomy,19-04-2013,NA,ISRCTN number,results
4137,2013-001081-42, Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,29-07-2014,NA,US NCT number,protocol
4138,2013-001081-42, Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,29-07-2014,NA,other,protocol
4139,2013-001081-42, Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,29-07-2014,NA,US NCT number,results
4140,2013-001081-42, Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection with Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study,29-07-2014,NA,ISRCTN number,results
4141,2013-001269-18, A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).,30-08-2013,NA,US NCT number,protocol
4142,2013-001269-18, A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).,30-08-2013,NA,other,protocol
4143,2013-001269-18, A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).,30-08-2013,NA,US NCT number,results
4144,2013-001269-18, A multicenter phase II study in patients with HER2-negative metastatic breast cancer and persisting HER2-negative circulating tumor cells (CTCs).,30-08-2013,NA,ISRCTN number,results
4145,2013-001294-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,24-04-2014,NA,US NCT number,protocol
4146,2013-001294-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,24-04-2014,NA,other,protocol
4147,2013-001294-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,24-04-2014,NCT02371434,US NCT number,results
4148,2013-001294-24, The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation – Natural regulatory T-cells (nTregs) Trial.,24-04-2014,NA,ISRCTN number,results
4149,2013-001357-26, HIGH DOSE SUPPLEMENTATION OF SELENIUM IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) IMPLANT SURGERY – A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL,01-04-2014,NA,US NCT number,protocol
4150,2013-001357-26, HIGH DOSE SUPPLEMENTATION OF SELENIUM IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) IMPLANT SURGERY – A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL,01-04-2014,NA,other,protocol
4151,2013-001357-26, HIGH DOSE SUPPLEMENTATION OF SELENIUM IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) IMPLANT SURGERY – A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL,01-04-2014,NCT02530788,US NCT number,results
4152,2013-001357-26, HIGH DOSE SUPPLEMENTATION OF SELENIUM IN LEFT VENTRICULAR ASSIST DEVICE (LVAD) IMPLANT SURGERY – A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL,01-04-2014,NA,ISRCTN number,results
4153,2013-001383-31, Hypericum perforatum to improve post-operative Pain Outcome after monosegmental Spinal microdistectomy,17-10-2014,NA,US NCT number,protocol
4154,2013-001383-31, Hypericum perforatum to improve post-operative Pain Outcome after monosegmental Spinal microdistectomy,17-10-2014,NA,other,protocol
4155,2013-001383-31, Hypericum perforatum to improve post-operative Pain Outcome after monosegmental Spinal microdistectomy,17-10-2014,NA,US NCT number,results
4156,2013-001383-31, Hypericum perforatum to improve post-operative Pain Outcome after monosegmental Spinal microdistectomy,17-10-2014,NA,ISRCTN number,results
4157,2013-001546-34," Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single armed, two-cohort, phase II EADO trial NEO-VC",08-07-2014,NA,US NCT number,protocol
4158,2013-001546-34," Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single armed, two-cohort, phase II EADO trial NEO-VC",08-07-2014,NA,other,protocol
4159,2013-001546-34," Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single armed, two-cohort, phase II EADO trial NEO-VC",08-07-2014,NA,US NCT number,results
4160,2013-001546-34," Neoadjuvant treatment with the combination of Vemurafenib, Cobimetinib and Atezolizumab in limited metastasis of malignant melanoma (AJCC stage IIIC/IV) and integrated biomarker study: A single armed, two-cohort, phase II EADO trial NEO-VC",08-07-2014,NA,ISRCTN number,results
4161,2013-001550-98, Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM),19-07-2013,NCT01866449,US NCT number,protocol
4162,2013-001550-98, Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM),19-07-2013,NA,other,protocol
4163,2013-001550-98, Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM),19-07-2013,NA,US NCT number,results
4164,2013-001550-98, Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM),19-07-2013,NA,ISRCTN number,results
4165,2013-001599-40," Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",14-11-2013,NA,US NCT number,protocol
4166,2013-001599-40," Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",14-11-2013,DRKS DRKS00004858,other,protocol
4167,2013-001599-40," Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",14-11-2013,NA,US NCT number,results
4168,2013-001599-40," Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN).",14-11-2013,NA,ISRCTN number,results
4169,2013-001601-85, Aprepitant in histamine-refractory chronic pruritus:,14-11-2013,NA,US NCT number,protocol
4170,2013-001601-85, Aprepitant in histamine-refractory chronic pruritus:,14-11-2013,NA,other,protocol
4171,2013-001601-85, Aprepitant in histamine-refractory chronic pruritus:,14-11-2013,NA,US NCT number,results
4172,2013-001601-85, Aprepitant in histamine-refractory chronic pruritus:,14-11-2013,NA,ISRCTN number,results
4173,2013-001626-26, Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial),30-09-2013,NA,US NCT number,protocol
4174,2013-001626-26, Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial),30-09-2013,NA,other,protocol
4175,2013-001626-26, Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial),30-09-2013,NA,US NCT number,results
4176,2013-001626-26, Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver cirrhosis and ascites (INCA trial),30-09-2013,NA,ISRCTN number,results
4177,2013-001636-22," A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",25-06-2013,NA,US NCT number,protocol
4178,2013-001636-22," A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",25-06-2013,NA,other,protocol
4179,2013-001636-22," A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",25-06-2013,NCT01959451,US NCT number,results
4180,2013-001636-22," A prospective, randomized, parallel-group, open label, non-inferiority, multicenter trial of a 12 month vs. a short-term platelet function testing guided prasugrel therapy in acute coronary syndrome patients undergoing coronary stenting",25-06-2013,NA,ISRCTN number,results
4181,2013-001657-28, Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),18-11-2013,NA,US NCT number,protocol
4182,2013-001657-28, Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),18-11-2013,NA,other,protocol
4183,2013-001657-28, Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),18-11-2013,NA,US NCT number,results
4184,2013-001657-28, Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban: Prospective Management Trial (HoT-PE),18-11-2013,NA,ISRCTN number,results
4185,2013-001770-19," 6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients  versus  a  slower dose tapering and lower  starting dose of  Advagraf",12-05-2014,NA,US NCT number,protocol
4186,2013-001770-19," 6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients  versus  a  slower dose tapering and lower  starting dose of  Advagraf",12-05-2014,NA,other,protocol
4187,2013-001770-19," 6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients  versus  a  slower dose tapering and lower  starting dose of  Advagraf",12-05-2014,NA,US NCT number,results
4188,2013-001770-19," 6 month, multi-center, open-label, prospective, randomized trial, investigating a standard regimen of an advagraf based immunosuppressive regimen in de-novo renal transplant patients  versus  a  slower dose tapering and lower  starting dose of  Advagraf",12-05-2014,NA,ISRCTN number,results
4189,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,protocol
4190,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,other,protocol
4191,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,results
4192,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,ISRCTN number,results
4193,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,protocol
4194,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,other,protocol
4195,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,results
4196,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,ISRCTN number,results
4197,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,protocol
4198,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,other,protocol
4199,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,results
4200,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,ISRCTN number,results
4201,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,protocol
4202,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,other,protocol
4203,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,US NCT number,results
4204,2013-001866-40," The effect of Zinc-D-gluconate on bleeding propensity of the periodontium in patients with chronic parodontitis - a randomised, placebo-controlled, double-blind interventional study",28-10-2014,NA,ISRCTN number,results
4205,2013-001998-24," A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000 IU/kg/d versus placebo for 28 days for preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants.",16-05-2014,NA,US NCT number,protocol
4206,2013-001998-24," A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000 IU/kg/d versus placebo for 28 days for preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants.",16-05-2014,NA,other,protocol
4207,2013-001998-24," A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000 IU/kg/d versus placebo for 28 days for preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants.",16-05-2014,NA,US NCT number,results
4208,2013-001998-24," A prospective, multicenter, double blind, placebo-controlled, two-arm parallel group phase 3 trial to evaluate the effect of early postnatal additional high dose oral vitamin A supplementation of 5000 IU/kg/d versus placebo for 28 days for preventing bronchopulmonary dysplasia (BPD) or death in extremely-low-birth-weight (ELBW) infants.",16-05-2014,NA,ISRCTN number,results
4209,2013-002036-24," A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer",30-01-2014,NA,US NCT number,protocol
4210,2013-002036-24," A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer",30-01-2014,NA,other,protocol
4211,2013-002036-24," A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer",30-01-2014,NA,US NCT number,results
4212,2013-002036-24," A non-randomised, non-comparative monocenter investigator initiated trial to assess the efficacy and safety of Carmustine in patients with BRCA1/2-associated advanced breast and ovarian cancer",30-01-2014,NA,ISRCTN number,results
4213,2013-002132-25, RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial,03-02-2015,NCT02577926,US NCT number,protocol
4214,2013-002132-25, RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial,03-02-2015,NA,other,protocol
4215,2013-002132-25, RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial,03-02-2015,NA,US NCT number,results
4216,2013-002132-25, RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial,03-02-2015,NA,ISRCTN number,results
4217,2013-002272-40," PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME",08-07-2013,NA,US NCT number,protocol
4218,2013-002272-40," PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME",08-07-2013,NA,other,protocol
4219,2013-002272-40," PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME",08-07-2013,NCT01944800,US NCT number,results
4220,2013-002272-40," PROSPECTIVE, RANDOMIZED TRIAL OF TICAGRELOR VERSUS PRASUGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME",08-07-2013,NA,ISRCTN number,results
4221,2013-002386-18, Network connectivity and inhibitory control under atomoxetin challenge - ,10-11-2015,NA,US NCT number,protocol
4222,2013-002386-18, Network connectivity and inhibitory control under atomoxetin challenge - ,10-11-2015,NA,other,protocol
4223,2013-002386-18, Network connectivity and inhibitory control under atomoxetin challenge - ,10-11-2015,NA,US NCT number,results
4224,2013-002386-18, Network connectivity and inhibitory control under atomoxetin challenge - ,10-11-2015,NA,ISRCTN number,results
4225,2013-002409-75," Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",23-08-2013,NA,US NCT number,protocol
4226,2013-002409-75," Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",23-08-2013,NA,other,protocol
4227,2013-002409-75," Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",23-08-2013,NA,US NCT number,results
4228,2013-002409-75," Intra-individual, comparison of the MRI contrast agents gadoxetic acid (Primovist®) versus gadoterate meglumine (Dotarem®) in liver MRI of patients with HCC and underlying cirrhosis",23-08-2013,NA,ISRCTN number,results
4229,2013-002515-10," Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial ",16-05-2014,NCT01962571,US NCT number,protocol
4230,2013-002515-10," Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial ",16-05-2014,DRKS DRKS00005298,other,protocol
4231,2013-002515-10," Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial ",16-05-2014,NCT01962571,US NCT number,results
4232,2013-002515-10," Treatment of Optic Neuritis with Erythropoietin: a randomised, double-blind, placebo-controlled trial ",16-05-2014,NA,ISRCTN number,results
4233,2013-002539-13, Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP),30-12-2013,NA,US NCT number,protocol
4234,2013-002539-13, Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP),30-12-2013,NA,other,protocol
4235,2013-002539-13, Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP),30-12-2013,NA,US NCT number,results
4236,2013-002539-13, Multicenter randomized double masked parallel design exploratory study to assess safety and efficacy of two different doses of intravitreal anti-VEGF treatment with ranibizumab (0.12 mg vs. 0.20 mg) in infants with retinopathy of prematurity (ROP),30-12-2013,NA,ISRCTN number,results
4237,2013-002737-38, A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ,07-02-2014,NA,US NCT number,protocol
4238,2013-002737-38, A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ,07-02-2014,NA,other,protocol
4239,2013-002737-38, A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ,07-02-2014,NCT02183870,US NCT number,results
4240,2013-002737-38, A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations ,07-02-2014,NA,ISRCTN number,results
4241,2013-002825-52," Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.",16-12-2013,NA,US NCT number,protocol
4242,2013-002825-52," Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.",16-12-2013,NA,other,protocol
4243,2013-002825-52," Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.",16-12-2013,NA,US NCT number,results
4244,2013-002825-52," Single-center, open-label, single-arm Phase IIa study in kidney transplant patients with acute T-cell-mediated rejection in renal transplant according to Banff criteria (class IA and IB) without (stage I) or with (stage II) deterioration of graft function for detecting the effectiveness of treatment with canakinumab regarding the regression of infiltrates in the graft biopsy.",16-12-2013,NA,ISRCTN number,results
4245,2013-003048-21, CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR),20-09-2013,NA,US NCT number,protocol
4246,2013-003048-21, CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR),20-09-2013,ClinicalTrials.gov  NCT01931592,other,protocol
4247,2013-003048-21, CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR),20-09-2013,NA,US NCT number,results
4248,2013-003048-21, CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR),20-09-2013,NA,ISRCTN number,results
4249,2013-003117-18, Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),07-04-2014,NCT02013648,US NCT number,protocol
4250,2013-003117-18, Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),07-04-2014,NA,other,protocol
4251,2013-003117-18, Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),07-04-2014,NA,US NCT number,results
4252,2013-003117-18, Randomized Phase III Study of Intensive Chemotherapy with or without Dasatinib (Sprycel™) in Adult Patients with Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML),07-04-2014,NA,ISRCTN number,results
4253,2013-003191-12, Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years ,26-11-2013,NA,US NCT number,protocol
4254,2013-003191-12, Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years ,26-11-2013,ClinicalTrials.gov NCT02140242,other,protocol
4255,2013-003191-12, Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years ,26-11-2013,NA,US NCT number,results
4256,2013-003191-12, Randomized comparison between two dose levels of daunorubicin and between one versus two cycles of in-duction therapy for adult patients with acute myeloid leukemia ≤65 years ,26-11-2013,NA,ISRCTN number,results
4257,2013-003211-22," A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression",04-02-2014,NA,US NCT number,protocol
4258,2013-003211-22," A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression",04-02-2014,NA,other,protocol
4259,2013-003211-22," A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression",04-02-2014,NA,US NCT number,results
4260,2013-003211-22," A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A CLL Patients with Risk of Early Disease Progression",04-02-2014,NA,ISRCTN number,results
4261,2013-003234-32, Pathological changes in the myocardial microvasculature - a MR-based quantification,24-03-2014,NA,US NCT number,protocol
4262,2013-003234-32, Pathological changes in the myocardial microvasculature - a MR-based quantification,24-03-2014,NA,other,protocol
4263,2013-003234-32, Pathological changes in the myocardial microvasculature - a MR-based quantification,24-03-2014,NA,US NCT number,results
4264,2013-003234-32, Pathological changes in the myocardial microvasculature - a MR-based quantification,24-03-2014,NA,ISRCTN number,results
4265,2013-003253-21, B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents,27-12-2016,NA,US NCT number,protocol
4266,2013-003253-21, B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents,27-12-2016,NA,other,protocol
4267,2013-003253-21, B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents,27-12-2016,NA,US NCT number,results
4268,2013-003253-21, B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents,27-12-2016,NA,ISRCTN number,results
4269,2013-003306-45," An  open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery ",11-12-2014,NA,US NCT number,protocol
4270,2013-003306-45," An  open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery ",11-12-2014,NA,other,protocol
4271,2013-003306-45," An  open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery ",11-12-2014,NA,US NCT number,results
4272,2013-003306-45," An  open-label, uncontrolled, single arm phase II trial of BKM120 (Buparlisib) in patients with metastatic melanoma with brain metastases not eligible for surgery or radiosurgery ",11-12-2014,NA,ISRCTN number,results
4273,2013-003352-20," Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospective, controlled monocenter trial",03-05-2016,NA,US NCT number,protocol
4274,2013-003352-20," Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospective, controlled monocenter trial",03-05-2016,NA,other,protocol
4275,2013-003352-20," Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospective, controlled monocenter trial",03-05-2016,NA,US NCT number,results
4276,2013-003352-20," Correlation of functional and structural outcomes with serum antibody profiles in patients with neovascular age-related macular degeneration treated with ranibizumab and healthy subjects: a prospective, controlled monocenter trial",03-05-2016,NA,ISRCTN number,results
4277,2013-003369-33," JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with relapsed or refractory Hodgkin Lymphoma (HL).",10-07-2015,NCT02164500,US NCT number,protocol
4278,2013-003369-33," JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with relapsed or refractory Hodgkin Lymphoma (HL).",10-07-2015,NA,other,protocol
4279,2013-003369-33," JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with relapsed or refractory Hodgkin Lymphoma (HL).",10-07-2015,NCT02164500,US NCT number,results
4280,2013-003369-33," JeRiCHO (JAK-inhibition in recurrent classical Hodgkin Lymphoma): A phase II, open-label, prospective, non-randomized, multicenter clinical trial with the JAK-inhibitor ruxolitinib in patients with relapsed or refractory Hodgkin Lymphoma (HL).",10-07-2015,NA,ISRCTN number,results
4281,2013-003370-27," Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome",24-07-2014,NA,US NCT number,protocol
4282,2013-003370-27," Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome",24-07-2014,NA,other,protocol
4283,2013-003370-27," Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome",24-07-2014,NA,US NCT number,results
4284,2013-003370-27," Functional MRI (fMRI) after challenge and treatment with antidepressants and their relation to the clinical course, to the Hypothalamus-Hypophysis-Adrenocortical Axis and the colon microbiome",24-07-2014,NA,ISRCTN number,results
4285,2013-003421-28, Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia,03-01-2014,NA,US NCT number,protocol
4286,2013-003421-28, Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia,03-01-2014,NA,other,protocol
4287,2013-003421-28, Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia,03-01-2014,NA,US NCT number,results
4288,2013-003421-28, Randomised controlled phase-2 trial to determine the efficacy of adoptive immunotherapy with haploidentical natural killer cells in high-risk acute myeloid leukemia,03-01-2014,NA,ISRCTN number,results
4289,2013-003466-13," Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a phase III-part to evaluate safety and efficacy of nelarabine in T-ALL patients",05-05-2015,NA,US NCT number,protocol
4290,2013-003466-13," Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a phase III-part to evaluate safety and efficacy of nelarabine in T-ALL patients",05-05-2015,NA,other,protocol
4291,2013-003466-13," Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a phase III-part to evaluate safety and efficacy of nelarabine in T-ALL patients",05-05-2015,NA,US NCT number,results
4292,2013-003466-13," Treatment optimization in adult patients with newly diagnosed acute lymphoblastic leukemia or lymphoblastic lymphoma by individualised, targeted and intensified treatment - a phase IV-trial with a phase III-part to evaluate safety and efficacy of nelarabine in T-ALL patients",05-05-2015,NA,ISRCTN number,results
4293,2013-003492-35, Prevention of Silent Cerebral Thromboembolism ,17-03-2015,NCT02067182,US NCT number,protocol
4294,2013-003492-35, Prevention of Silent Cerebral Thromboembolism ,17-03-2015,NA,other,protocol
4295,2013-003492-35, Prevention of Silent Cerebral Thromboembolism ,17-03-2015,NCT02067182,US NCT number,results
4296,2013-003492-35, Prevention of Silent Cerebral Thromboembolism ,17-03-2015,NA,ISRCTN number,results
4297,2013-003542-17," A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",07-04-2014,NA,US NCT number,protocol
4298,2013-003542-17," A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",07-04-2014,NA,other,protocol
4299,2013-003542-17," A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",07-04-2014,NA,US NCT number,results
4300,2013-003542-17," A multi-center, randomized, double blind, dose escalating phase III study on the efficacy, safety and long term outcome of continuous vs. on demand treatment of chronic spontaneous urticaria with rupatadine",07-04-2014,NA,ISRCTN number,results
4301,2013-003601-25," A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",12-11-2013,NA,US NCT number,protocol
4302,2013-003601-25," A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",12-11-2013,NA,other,protocol
4303,2013-003601-25," A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",12-11-2013,NA,US NCT number,results
4304,2013-003601-25," A multicenter, Double-blind, RandOmised, two arm Parallel group trial to determine the effects of torasemide versus furosemide on one marker (PIP) of cardiac fibrosis in patient with Diastolic Heart Failure and diabetes mellitus type II",12-11-2013,NA,ISRCTN number,results
4305,2013-003678-29," Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and",23-01-2014,NA,US NCT number,protocol
4306,2013-003678-29," Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and",23-01-2014,NA,other,protocol
4307,2013-003678-29," Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and",23-01-2014,NCT02046915,US NCT number,results
4308,2013-003678-29," Phase II multicenter, open‐label, single arm clinical Study of Pomalidomide and",23-01-2014,NA,ISRCTN number,results
4309,2013-003689-15," Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease",17-02-2014,NA,US NCT number,protocol
4310,2013-003689-15," Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease",17-02-2014,NA,other,protocol
4311,2013-003689-15," Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease",17-02-2014,NA,US NCT number,results
4312,2013-003689-15," Stop exogenous allergic alveolitis (EAA) in childhood: healthy into adulthood – a randomized, double-blind, placebo-controlled, parallel-group study to evaluate prednisolone treatment and course of disease",17-02-2014,NA,ISRCTN number,results
4313,2013-003714-40," Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group",02-07-2014,NCT02615938,US NCT number,protocol
4314,2013-003714-40," Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group",02-07-2014,NA,other,protocol
4315,2013-003714-40," Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group",02-07-2014,NA,US NCT number,results
4316,2013-003714-40," Hydroxychloroquine in pediatric ILD START randomized controlled in parallel-group, then switch placebo to active drug, and STOP randomized controlled in parallel-group",02-07-2014,NA,ISRCTN number,results
4317,2013-003990-89, Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –,02-02-2015,NCT02191930,US NCT number,protocol
4318,2013-003990-89, Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –,02-02-2015,NA,other,protocol
4319,2013-003990-89, Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –,02-02-2015,NA,US NCT number,results
4320,2013-003990-89, Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –,02-02-2015,NA,ISRCTN number,results
4321,2013-004130-15," Investigator-initiated clinical research trial on the effects of  5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",05-03-2014,NA,US NCT number,protocol
4322,2013-004130-15," Investigator-initiated clinical research trial on the effects of  5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",05-03-2014,NA,other,protocol
4323,2013-004130-15," Investigator-initiated clinical research trial on the effects of  5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",05-03-2014,NA,US NCT number,results
4324,2013-004130-15," Investigator-initiated clinical research trial on the effects of  5% Minoxidil topical foam on gene expression, hair growth and scalp microenvironment in men with androgenetic alopecia",05-03-2014,NA,ISRCTN number,results
4325,2013-004169-14," Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content",05-12-2013,NA,US NCT number,protocol
4326,2013-004169-14," Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content",05-12-2013,NA,other,protocol
4327,2013-004169-14," Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content",05-12-2013,NA,US NCT number,results
4328,2013-004169-14," Randomized, placebo controlled, crossover clinical study to analyse the effect of dapagliflozin on microvascular and macrovascular circulation and total body sodium content",05-12-2013,NA,ISRCTN number,results
4329,2013-004187-56," International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years.",21-11-2016,NA,US NCT number,protocol
4330,2013-004187-56," International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years.",21-11-2016,NA,other,protocol
4331,2013-004187-56," International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years.",21-11-2016,NA,US NCT number,results
4332,2013-004187-56," International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < 18 years.",21-11-2016,NA,ISRCTN number,results
4333,2013-004353-24, Wound Management in Post-Bariatric Surgery,23-01-2014,NA,US NCT number,protocol
4334,2013-004353-24, Wound Management in Post-Bariatric Surgery,23-01-2014,NA,other,protocol
4335,2013-004353-24, Wound Management in Post-Bariatric Surgery,23-01-2014,NA,US NCT number,results
4336,2013-004353-24, Wound Management in Post-Bariatric Surgery,23-01-2014,NA,ISRCTN number,results
4337,2013-004458-34," A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients with BRAF Wildtype Metastatic Melanoma ",15-08-2014,NA,US NCT number,protocol
4338,2013-004458-34," A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients with BRAF Wildtype Metastatic Melanoma ",15-08-2014,NA,other,protocol
4339,2013-004458-34," A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients with BRAF Wildtype Metastatic Melanoma ",15-08-2014,NCT02308553,US NCT number,results
4340,2013-004458-34," A Phase I/II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients with BRAF Wildtype Metastatic Melanoma ",15-08-2014,NA,ISRCTN number,results
4341,2013-004481-34," RANDOMIZED PHASE 2  TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 I.V., GM-CSF) IN PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED HIGH RISK NEUROBLASTOMA",20-08-2014,NA,US NCT number,protocol
4342,2013-004481-34," RANDOMIZED PHASE 2  TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 I.V., GM-CSF) IN PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED HIGH RISK NEUROBLASTOMA",20-08-2014,NA,other,protocol
4343,2013-004481-34," RANDOMIZED PHASE 2  TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 I.V., GM-CSF) IN PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED HIGH RISK NEUROBLASTOMA",20-08-2014,NA,US NCT number,results
4344,2013-004481-34," RANDOMIZED PHASE 2  TRIAL COMPARING EXPERIMENTAL IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 S.C.,GM-CSF) IN RECURRENT HIGH RISK NEUROBLASTOMA PATIENTS WITH STANDARD IMMUNOTHERAPY (ANTI-GD2 ANTIBODY, IL-2 I.V., GM-CSF) IN PATIENTS WITH RECURRENT AND NEWLY DIAGNOSED HIGH RISK NEUROBLASTOMA",20-08-2014,NA,ISRCTN number,results
4345,2013-004604-19, Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheumatoid arthritis (RA) patients,03-06-2014,NA,US NCT number,protocol
4346,2013-004604-19, Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheumatoid arthritis (RA) patients,03-06-2014,NA,other,protocol
4347,2013-004604-19, Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheumatoid arthritis (RA) patients,03-06-2014,NA,US NCT number,results
4348,2013-004604-19, Delayed Gadolinium-enhanced Magnetic resonance Imaging (MRI) of Cartilage - A pilot study to measure the effect of Adalimumab plus Methotrexat (MTX) versus Placebo plus MTX on cartilage in early rheumatoid arthritis (RA) patients,03-06-2014,NA,ISRCTN number,results
4349,2013-004616-21," A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod)",04-02-2014,NA,US NCT number,protocol
4350,2013-004616-21," A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod)",04-02-2014,NA,other,protocol
4351,2013-004616-21," A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod)",04-02-2014,NCT02325440,US NCT number,results
4352,2013-004616-21," A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatment with Natalizumab to Gilenya® (Fingolimod)",04-02-2014,NA,ISRCTN number,results
4353,2013-004644-28, Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection,18-03-2014,NA,US NCT number,protocol
4354,2013-004644-28, Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection,18-03-2014,NA,other,protocol
4355,2013-004644-28, Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection,18-03-2014,NA,US NCT number,results
4356,2013-004644-28, Administration of Rifaximin to improve Liver Regeneration and Outcome following Major Liver Resection,18-03-2014,NA,ISRCTN number,results
4357,2013-004879-13, α-RT; Phase II open-label study to evaluate the efficacy and safety of,28-07-2014,NA,US NCT number,protocol
4358,2013-004879-13, α-RT; Phase II open-label study to evaluate the efficacy and safety of,28-07-2014,NA,other,protocol
4359,2013-004879-13, α-RT; Phase II open-label study to evaluate the efficacy and safety of,28-07-2014,NA,US NCT number,results
4360,2013-004879-13, α-RT; Phase II open-label study to evaluate the efficacy and safety of,28-07-2014,NA,ISRCTN number,results
4361,2013-004881-33, Pharmacovigilance in children and adolescents: ,06-05-2014,NA,US NCT number,protocol
4362,2013-004881-33, Pharmacovigilance in children and adolescents: ,06-05-2014,NA,other,protocol
4363,2013-004881-33, Pharmacovigilance in children and adolescents: ,06-05-2014,NA,US NCT number,results
4364,2013-004881-33, Pharmacovigilance in children and adolescents: ,06-05-2014,NA,ISRCTN number,results
4365,2013-004882-15, A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response,05-05-2014,NA,US NCT number,protocol
4366,2013-004882-15, A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response,05-05-2014,Deutsches Register für Klinische Studien DRKS00006240 ,other,protocol
4367,2013-004882-15, A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response,05-05-2014,NA,US NCT number,results
4368,2013-004882-15, A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response,05-05-2014,NA,ISRCTN number,results
4369,2013-004956-39, Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population,06-05-2014,NA,US NCT number,protocol
4370,2013-004956-39, Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population,06-05-2014,NA,other,protocol
4371,2013-004956-39, Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population,06-05-2014,NA,US NCT number,results
4372,2013-004956-39, Study to evaluate the impact of donor-specific HLA-antibodies on graft function and survival after renal transplantation - Long term follow up of the SMART study population,06-05-2014,NA,ISRCTN number,results
4373,2013-005326-38," A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients with chronic heart failure and reduced ejection fraction",18-11-2014,NA,US NCT number,protocol
4374,2013-005326-38," A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients with chronic heart failure and reduced ejection fraction",18-11-2014,NA,other,protocol
4375,2013-005326-38," A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients with chronic heart failure and reduced ejection fraction",18-11-2014,NA,US NCT number,results
4376,2013-005326-38," A multicenter, randomized, double-blind, placebo-controlled study to demonstrate that digitoxin reduces a composite of overall mortality and hospitalization for worsening heart failure in patients with chronic heart failure and reduced ejection fraction",18-11-2014,NA,ISRCTN number,results
4377,2013-005362-19, Therapy  of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),18-12-2013,NA,US NCT number,protocol
4378,2013-005362-19, Therapy  of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),18-12-2013,NA,other,protocol
4379,2013-005362-19, Therapy  of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),18-12-2013,NA,US NCT number,results
4380,2013-005362-19, Therapy  of antibody-mediated autoimmune diseases by Bortezomib (TAVAB),18-12-2013,NA,ISRCTN number,results
4381,2013-005364-26," Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoint (PROBE) trial to compare the efficacy of Dabigatran (150 mg bid) with Phenprocoumon for the resolution of left atrial appendage thrombus formation in patients with atrial fibrillation",28-04-2014,NA,US NCT number,protocol
4382,2013-005364-26," Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoint (PROBE) trial to compare the efficacy of Dabigatran (150 mg bid) with Phenprocoumon for the resolution of left atrial appendage thrombus formation in patients with atrial fibrillation",28-04-2014,NA,other,protocol
4383,2013-005364-26," Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoint (PROBE) trial to compare the efficacy of Dabigatran (150 mg bid) with Phenprocoumon for the resolution of left atrial appendage thrombus formation in patients with atrial fibrillation",28-04-2014,NA,US NCT number,results
4384,2013-005364-26," Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoint (PROBE) trial to compare the efficacy of Dabigatran (150 mg bid) with Phenprocoumon for the resolution of left atrial appendage thrombus formation in patients with atrial fibrillation",28-04-2014,NA,ISRCTN number,results
4385,2013-005446-11," A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation",25-09-2014,NA,US NCT number,protocol
4386,2013-005446-11," A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation",25-09-2014,NA,other,protocol
4387,2013-005446-11," A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation",25-09-2014,NA,US NCT number,results
4388,2013-005446-11," A prospective phase I/II study to investigate the feasibility, safety and efficacy of IL-15 activated cytokine induced killer (CIK) cells in relapsing patients with acute leukemia or myelodysplastic syndromes after allogeneic stem cell transplantation",25-09-2014,NA,ISRCTN number,results
4389,2013-005485-19," Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (BPV).",18-07-2014,NA,US NCT number,protocol
4390,2013-005485-19," Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (BPV).",18-07-2014,NA,other,protocol
4391,2013-005485-19," Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (BPV).",18-07-2014,NCT02237261,US NCT number,results
4392,2013-005485-19," Bendamustine, Prednisone and Velcade® for first-line treatment of patients with symptomatic multiple myeloma not eligible for high-dose chemotherapy followed by autologous stem cell transplantation (BPV).",18-07-2014,NA,ISRCTN number,results
4393,2013-005503-13, A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation ,12-08-2014,NA,US NCT number,protocol
4394,2013-005503-13, A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation ,12-08-2014,NA,other,protocol
4395,2013-005503-13, A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation ,12-08-2014,NA,US NCT number,results
4396,2013-005503-13, A prospective randomized single blind monocenter phase II study of organ perfusion with Custodiol-N compared with Custodiol solution in living donor kidney transplantation ,12-08-2014,NA,ISRCTN number,results
4397,2014-000097-19," Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",12-01-2016,NA,US NCT number,protocol
4398,2014-000097-19," Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",12-01-2016,NA,other,protocol
4399,2014-000097-19," Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",12-01-2016,NA,US NCT number,results
4400,2014-000097-19," Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinjector application (Fastjekt® Junior) in infants with acute anaphylactic reaction during a food provocation",12-01-2016,NA,ISRCTN number,results
4401,2014-000174-19, Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A ,01-09-2014,NA,US NCT number,protocol
4402,2014-000174-19, Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A ,01-09-2014,NA,other,protocol
4403,2014-000174-19, Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A ,01-09-2014,NA,US NCT number,results
4404,2014-000174-19, Efficacy and Safety of Eltrombopag in Patients with Acquired Moderate Aplastic Anemia (EMAA) who are treated with Ciclosporin A ,01-09-2014,NA,ISRCTN number,results
4405,2014-000180-41, Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.,04-02-2015,NA,US NCT number,protocol
4406,2014-000180-41, Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.,04-02-2015,Eradicate N/A,other,protocol
4407,2014-000180-41, Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.,04-02-2015,NA,US NCT number,results
4408,2014-000180-41, Carriage of 3GCREB in patients at risk for relapsing infection: randomized controlled trial of intestinal decolonization with colistin plus rifaximin.,04-02-2015,NA,ISRCTN number,results
4409,2014-000181-21," Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",23-04-2014,NA,US NCT number,protocol
4410,2014-000181-21," Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",23-04-2014,NA,other,protocol
4411,2014-000181-21," Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",23-04-2014,NA,US NCT number,results
4412,2014-000181-21," Disease activity controlled dose escalating study to assess the efficacy, and safety of treatment with bilastine 20 mg, 40 mg and 80 mg in chronic spontaneous urticaria.",23-04-2014,NA,ISRCTN number,results
4413,2014-000346-30," An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML",20-10-2014,NA,US NCT number,protocol
4414,2014-000346-30," An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML",20-10-2014,NA,other,protocol
4415,2014-000346-30," An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML",20-10-2014,NA,US NCT number,results
4416,2014-000346-30," An open-label, multicenter study of INC424 monotherapy or in combination with azacitidine for patients with post-myeloproliferative disorders (MPD) – AML or with CMML",20-10-2014,NA,ISRCTN number,results
4417,2014-000477-39, Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),17-11-2015,NCT02198482,US NCT number,protocol
4418,2014-000477-39, Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),17-11-2015,NA,other,protocol
4419,2014-000477-39, Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),17-11-2015,NCT02198482,US NCT number,results
4420,2014-000477-39, Dose Finding safety run in Phase followed by a randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),17-11-2015,NA,ISRCTN number,results
4421,2014-000555-93, Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia ,26-05-2014,NA,US NCT number,protocol
4422,2014-000555-93, Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia ,26-05-2014,clinicaltrials.gov NCT02778906,other,protocol
4423,2014-000555-93, Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia ,26-05-2014,NA,US NCT number,results
4424,2014-000555-93, Abatacept reversing subclinical Inflammation as measured by MRI in ACPA positive Arthralgia ,26-05-2014,NA,ISRCTN number,results
4425,2014-000569-35," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)",16-10-2014,NA,US NCT number,protocol
4426,2014-000569-35," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)",16-10-2014,NA,other,protocol
4427,2014-000569-35," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)",16-10-2014,NCT02345863,US NCT number,results
4428,2014-000569-35," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 and ibrutinib (BIG) followed by ibrutinib and GA101 maintenance in CLL patients (CLL2-BIG protocol)",16-10-2014,NA,ISRCTN number,results
4429,2014-000580-40," A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ABT-199 and GA101 maintenance in CLL patients",22-01-2015,NA,US NCT number,protocol
4430,2014-000580-40," A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ABT-199 and GA101 maintenance in CLL patients",22-01-2015,NA,other,protocol
4431,2014-000580-40," A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ABT-199 and GA101 maintenance in CLL patients",22-01-2015,NA,US NCT number,results
4432,2014-000580-40," A prospective, open-label, multicentre phase-II-trial to evaluate the efficacy and safety of a sequential regimen of Bendamustine followed by GA101 (Obinutuzumab) and ABT-199 (Venetoclax) followed by ABT-199 and GA101 maintenance in CLL patients",22-01-2015,NA,ISRCTN number,results
4433,2014-000582-47," A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG)",09-02-2015,NA,US NCT number,protocol
4434,2014-000582-47," A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG)",09-02-2015,NA,other,protocol
4435,2014-000582-47," A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG)",09-02-2015,NA,US NCT number,results
4436,2014-000582-47," A prospective, open-label, multicenter phase-II-trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab) and CAL-101 (idelalisib) followed by CAL-101 and GA101 maintenance in CLL patients (CLL2-BCG-trial of the GCLLSG)",09-02-2015,NA,ISRCTN number,results
4437,2014-000588-42, PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA,29-07-2014,NA,US NCT number,protocol
4438,2014-000588-42, PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA,29-07-2014,NA,other,protocol
4439,2014-000588-42, PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA,29-07-2014,NA,US NCT number,results
4440,2014-000588-42, PHASE II STUDY OF MONOCLONAL ANTIBODY CH14.18/CHO CONTINUOUS INFUSION IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSED NEUROBLASTOMA,29-07-2014,NA,ISRCTN number,results
4441,2014-000590-39," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG)",05-11-2015,NA,US NCT number,protocol
4442,2014-000590-39," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG)",05-11-2015,NA,other,protocol
4443,2014-000590-39," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG)",05-11-2015,NCT02689141,US NCT number,results
4444,2014-000590-39," A prospective, open-label, multicentre phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by ofatumumab and ibrutinib followed by ibrutinib and ofatumumab maintenance in CLL patients (CLL2-BIO-trial of the GCLLSG)",05-11-2015,NA,ISRCTN number,results
4445,2014-000599-24," Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy",02-09-2014,NA,US NCT number,protocol
4446,2014-000599-24," Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy",02-09-2014,Study Code Novartis - IMP supply  CBKM120ZDE02T,other,protocol
4447,2014-000599-24," Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy",02-09-2014,NCT02404844,US NCT number,results
4448,2014-000599-24," Molecularly stratified parallel group phase II trial of the phosphoinositide 3-kinase (PI3K) inhibitor BKM120 in combination with tamoxifen in patients with hormone receptor-positive, HER2-negative inoperable (locally advanced or metastatic) breast cancer with prior exposure to antihormonal therapy",02-09-2014,NA,ISRCTN number,results
4449,2014-000709-10, Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,13-10-2014,NA,US NCT number,protocol
4450,2014-000709-10, Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,13-10-2014,NA,other,protocol
4451,2014-000709-10, Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,13-10-2014,NCT02419378,US NCT number,results
4452,2014-000709-10, Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential,13-10-2014,NA,ISRCTN number,results
4453,2014-000860-16, Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction,17-03-2014,NA,US NCT number,protocol
4454,2014-000860-16, Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction,17-03-2014,NA,other,protocol
4455,2014-000860-16, Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction,17-03-2014,NCT02287129,US NCT number,results
4456,2014-000860-16, Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction,17-03-2014,NA,ISRCTN number,results
4457,2014-000861-32," Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)",02-09-2015,NA,US NCT number,protocol
4458,2014-000861-32," Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)",02-09-2015,DRKS-ID:  DRKS00009822,other,protocol
4459,2014-000861-32," Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)",02-09-2015,NA,US NCT number,results
4460,2014-000861-32," Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF)",02-09-2015,NA,ISRCTN number,results
4461,2014-000924-11, Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.,13-03-2015,NA,US NCT number,protocol
4462,2014-000924-11, Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.,13-03-2015,NA,other,protocol
4463,2014-000924-11, Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.,13-03-2015,NA,US NCT number,results
4464,2014-000924-11, Phase IIA Study on therapy with the NF-kB inhibiting and apoptosis inducing drug dimethylfumarate (DMF) in Patients with Cutaneous T cell lymphoma.,13-03-2015,NA,ISRCTN number,results
4465,2014-000973-38, Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,31-03-2014,NA,US NCT number,protocol
4466,2014-000973-38, Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,31-03-2014,NA,other,protocol
4467,2014-000973-38, Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,31-03-2014,NA,US NCT number,results
4468,2014-000973-38, Xenon-inhalation: elimination of xenon and its effect on erythropoetin-levels in blood of healthy volunteers,31-03-2014,NA,ISRCTN number,results
4469,2014-001148-40, Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,23-04-2014,NA,US NCT number,protocol
4470,2014-001148-40, Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,23-04-2014,NA,other,protocol
4471,2014-001148-40, Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,23-04-2014,NA,US NCT number,results
4472,2014-001148-40, Pharmacodynamic comparison of thienopyridine loading strategies in patients undergoing elective coronary stenting,23-04-2014,NA,ISRCTN number,results
4473,2014-001167-12," A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease",02-02-2015,NA,US NCT number,protocol
4474,2014-001167-12," A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease",02-02-2015,NA,other,protocol
4475,2014-001167-12," A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease",02-02-2015,NCT02523313,US NCT number,results
4476,2014-001167-12," A Phase II Randomized, Double-Blind Trial of Immunotherapy with Nivolumab or Nivolumab plus Ipilimumab versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma with No Evidence of Disease",02-02-2015,NA,ISRCTN number,results
4477,2014-001325-33, Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,20-02-2015,NA,US NCT number,protocol
4478,2014-001325-33, Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,20-02-2015,NA,other,protocol
4479,2014-001325-33, Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,20-02-2015,NCT02540395,US NCT number,results
4480,2014-001325-33, Prospective donor-specific Cellular alloresponse assessment for Immunosuppression Minimization in de novo renal transplantation,20-02-2015,NA,ISRCTN number,results
4481,2014-001363-12, autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,21-10-2015,NA,US NCT number,protocol
4482,2014-001363-12, autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,21-10-2015,NA,other,protocol
4483,2014-001363-12, autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,21-10-2015,NA,US NCT number,results
4484,2014-001363-12, autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction  in Generalized mantle cell Lymphoma – a randomized European MCL Network trial,21-10-2015,NA,ISRCTN number,results
4485,2014-001541-24, Neuroenhancement of Interpersonal Psychotherapy in Major Depression,04-08-2015,NA,US NCT number,protocol
4486,2014-001541-24, Neuroenhancement of Interpersonal Psychotherapy in Major Depression,04-08-2015,NA,other,protocol
4487,2014-001541-24, Neuroenhancement of Interpersonal Psychotherapy in Major Depression,04-08-2015,NA,US NCT number,results
4488,2014-001541-24, Neuroenhancement of Interpersonal Psychotherapy in Major Depression,04-08-2015,NA,ISRCTN number,results
4489,2014-001551-22, Reduction of postoperative wound infections by antiseptica,18-06-2014,NA,US NCT number,protocol
4490,2014-001551-22, Reduction of postoperative wound infections by antiseptica,18-06-2014,NA,other,protocol
4491,2014-001551-22, Reduction of postoperative wound infections by antiseptica,18-06-2014,NA,US NCT number,results
4492,2014-001551-22, Reduction of postoperative wound infections by antiseptica,18-06-2014,NA,ISRCTN number,results
4493,2014-001594-14," Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied twice to the intestinal mucosa as an in-vitro diagnostic in the framework of a confocal laser-endomicroscopic examination of colitis ulcerosa patients with an indication for Adalimumab treatment",22-09-2014,NA,US NCT number,protocol
4494,2014-001594-14," Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied twice to the intestinal mucosa as an in-vitro diagnostic in the framework of a confocal laser-endomicroscopic examination of colitis ulcerosa patients with an indication for Adalimumab treatment",22-09-2014,NA,other,protocol
4495,2014-001594-14," Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied twice to the intestinal mucosa as an in-vitro diagnostic in the framework of a confocal laser-endomicroscopic examination of colitis ulcerosa patients with an indication for Adalimumab treatment",22-09-2014,NA,US NCT number,results
4496,2014-001594-14," Prospective, single-centre, open-label, one-arm clinical trial, phase I/IIa, to assess the safety and tolerability and to investigate the predictive power of FITC-Adalimumab, when topically applied twice to the intestinal mucosa as an in-vitro diagnostic in the framework of a confocal laser-endomicroscopic examination of colitis ulcerosa patients with an indication for Adalimumab treatment",22-09-2014,NA,ISRCTN number,results
4497,2014-001874-32," Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial",16-02-2015,NA,US NCT number,protocol
4498,2014-001874-32," Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial",16-02-2015,NA,other,protocol
4499,2014-001874-32," Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial",16-02-2015,NA,US NCT number,results
4500,2014-001874-32," Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trial",16-02-2015,NA,ISRCTN number,results
4501,2014-001959-24," BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial",27-06-2014,NA,US NCT number,protocol
4502,2014-001959-24," BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial",27-06-2014,NA,other,protocol
4503,2014-001959-24," BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial",27-06-2014,NA,US NCT number,results
4504,2014-001959-24," BoTN: Onabotulinumtoxin A for the treatment of trigeminal neuralgia: Efficacy, safety and neurophysiological alterations under therapy – a prospective, controlled trial",27-06-2014,NA,ISRCTN number,results
4505,2014-001968-35, Add-on spironolactone for the treatment of schizophrenia,23-01-2015,NA,US NCT number,protocol
4506,2014-001968-35, Add-on spironolactone for the treatment of schizophrenia,23-01-2015,NA,other,protocol
4507,2014-001968-35, Add-on spironolactone for the treatment of schizophrenia,23-01-2015,NA,US NCT number,results
4508,2014-001968-35, Add-on spironolactone for the treatment of schizophrenia,23-01-2015,NA,ISRCTN number,results
4509,2014-001991-76," Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study",30-10-2014,NA,US NCT number,protocol
4510,2014-001991-76," Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study",30-10-2014,NA,other,protocol
4511,2014-001991-76," Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study",30-10-2014,NA,US NCT number,results
4512,2014-001991-76," Initial treatment of idiopathic nephrotic syndrome in children with mycophenolate mofetil vs. prednisone: A randomized, controlled, multicenter study",30-10-2014,NA,ISRCTN number,results
4513,2014-002171-29, Intensified Loading with Prasugrel versus Moderate Loading with Clopidogrel in PCI-treated Patients with Biomarker-Negative Angina pectoris.,13-04-2015,NA,US NCT number,protocol
4514,2014-002171-29, Intensified Loading with Prasugrel versus Moderate Loading with Clopidogrel in PCI-treated Patients with Biomarker-Negative Angina pectoris.,13-04-2015,NA,other,protocol
4515,2014-002171-29, Intensified Loading with Prasugrel versus Moderate Loading with Clopidogrel in PCI-treated Patients with Biomarker-Negative Angina pectoris.,13-04-2015,NA,US NCT number,results
4516,2014-002171-29, Intensified Loading with Prasugrel versus Moderate Loading with Clopidogrel in PCI-treated Patients with Biomarker-Negative Angina pectoris.,13-04-2015,NA,ISRCTN number,results
4517,2014-002236-14," Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study",19-08-2015,NA,US NCT number,protocol
4518,2014-002236-14," Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study",19-08-2015,NA,other,protocol
4519,2014-002236-14," Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study",19-08-2015,NA,US NCT number,results
4520,2014-002236-14," Phenprocoumon versus Dabigatran in subjects with atrial fibrillation and left atrial thrombus - a prospective, randomized, controlled, open-label one year follow-up pilot study",19-08-2015,NA,ISRCTN number,results
4521,2014-002249-22," DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.",23-03-2015,NA,US NCT number,protocol
4522,2014-002249-22," DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.",23-03-2015,NA,other,protocol
4523,2014-002249-22," DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.",23-03-2015,NA,US NCT number,results
4524,2014-002249-22," DETECT V/CHEVENDO: A multicenter, randomized phase III study to compare chemo- versus endocrine therapy in combination with dual HER2-targeted therapy of Herceptin® (trastuzumab) and Perjeta® (pertuzumab) plus Kisqali® (ribociclib) in patients with HER2 positive and hormone-receptor positive metastatic breast cancer.",23-03-2015,NA,ISRCTN number,results
4525,2014-002363-15," EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",04-11-2014,NA,US NCT number,protocol
4526,2014-002363-15," EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",04-11-2014,NA,other,protocol
4527,2014-002363-15," EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",04-11-2014,NA,US NCT number,results
4528,2014-002363-15," EVITA Trial: Effect of VItamin D as add-on Therapy for vitamin D insufficient patients with severe Asthma: a randomized, double-blind, placebo-controlled trial.",04-11-2014,NA,ISRCTN number,results
4529,2014-002392-28, Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,04-08-2014,NA,US NCT number,protocol
4530,2014-002392-28, Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,04-08-2014,NA,other,protocol
4531,2014-002392-28, Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,04-08-2014,NCT02507492,US NCT number,results
4532,2014-002392-28, Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity,04-08-2014,NA,ISRCTN number,results
4533,2014-002439-32, A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma ,13-02-2015,NA,US NCT number,protocol
4534,2014-002439-32, A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma ,13-02-2015,NA,other,protocol
4535,2014-002439-32, A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma ,13-02-2015,NA,US NCT number,results
4536,2014-002439-32, A Randomized Phase II Trial of Transarterial Radioembolization with Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolization with Cisplatin (TACE) in Patients with Liver Metastases from Uveal Melanoma ,13-02-2015,NA,ISRCTN number,results
4537,2014-002479-28, GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration,15-04-2015,NA,US NCT number,protocol
4538,2014-002479-28, GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration,15-04-2015,NA,other,protocol
4539,2014-002479-28, GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration,15-04-2015,NA,US NCT number,results
4540,2014-002479-28, GM-CSF Inhalation to improve HOst defense and Pulmonary barrier rEstoration,15-04-2015,NA,ISRCTN number,results
4541,2014-002643-18," REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",03-05-2018,NCT02453867,US NCT number,protocol
4542,2014-002643-18," REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",03-05-2018,Centre for Evidence in Transplantation Approval CET010,other,protocol
4543,2014-002643-18," REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",03-05-2018,NA,US NCT number,results
4544,2014-002643-18," REDUCE - Multicenter, prospective, randomized study investigating the efficacy and safety of a reduced immunosuppressive therapy with tacrolimus once daily in comparison to standard triple immunosuppression in senior renal transplant recipients",03-05-2018,NA,ISRCTN number,results
4545,2014-002702-21," A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients",04-03-2015,NA,US NCT number,protocol
4546,2014-002702-21," A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients",04-03-2015,NA,other,protocol
4547,2014-002702-21," A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients",04-03-2015,NA,US NCT number,results
4548,2014-002702-21," A double- blind, placebo controlled, randomized, multicenter, Phase II study to assess the efficacy of BL-8040 addition to consolidation therapy in AML patients",04-03-2015,NA,ISRCTN number,results
4549,2014-002790-11, Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab ,02-03-2015,NA,US NCT number,protocol
4550,2014-002790-11, Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab ,02-03-2015,NA,other,protocol
4551,2014-002790-11, Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab ,02-03-2015,NA,US NCT number,results
4552,2014-002790-11, Evaluation of additional peripheral panretinal LASER-treatment on recurrences of macular edema due to CRVO undergoing anti-VEGF treatment with ranibizumab ,02-03-2015,NA,ISRCTN number,results
4553,2014-003022-40, Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin,30-10-2014,NA,US NCT number,protocol
4554,2014-003022-40, Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin,30-10-2014,NA,other,protocol
4555,2014-003022-40, Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin,30-10-2014,NA,US NCT number,results
4556,2014-003022-40, Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin,30-10-2014,NA,ISRCTN number,results
4557,2014-003079-40, A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma,16-10-2014,NA,US NCT number,protocol
4558,2014-003079-40, A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma,16-10-2014,NA,other,protocol
4559,2014-003079-40, A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma,16-10-2014,NCT02495922,US NCT number,results
4560,2014-003079-40, A randomized phase III trial on the effect of elotuzumab in VRD induction /consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma,16-10-2014,NA,ISRCTN number,results
4561,2014-003150-13, A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy,29-01-2015,NA,US NCT number,protocol
4562,2014-003150-13, A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy,29-01-2015,NA,other,protocol
4563,2014-003150-13, A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy,29-01-2015,NA,US NCT number,results
4564,2014-003150-13, A randomized placebo-controlled phase 2 study of decitabine with or without eltrombopag in AML patients ≥65 years of age not eligible for intensive chemotherapy,29-01-2015,NA,ISRCTN number,results
4565,2014-003171-39, Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation,17-10-2014,NA,US NCT number,protocol
4566,2014-003171-39, Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation,17-10-2014,NA,other,protocol
4567,2014-003171-39, Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation,17-10-2014,NA,US NCT number,results
4568,2014-003171-39, Transfer of Streptamer-selected multi-antigen specific T cells to prevent infections and relapse and to reduce the risk of Graft-versus-Host Disease after allogeneic stem cell transplantation,17-10-2014,NA,ISRCTN number,results
4569,2014-003313-28," SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)",18-06-2015,NA,US NCT number,protocol
4570,2014-003313-28," SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)",18-06-2015,NA,other,protocol
4571,2014-003313-28," SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)",18-06-2015,NA,US NCT number,results
4572,2014-003313-28," SGLT2 inhibition with empagliflozin in patients with type 2 diabetes mellitus: Influences on left ventricular mass, function, and cardiac lipid content (EMPATROPHY)",18-06-2015,NA,ISRCTN number,results
4573,2014-003457-34," Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",27-07-2018,NA,US NCT number,protocol
4574,2014-003457-34," Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",27-07-2018,NA,other,protocol
4575,2014-003457-34," Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",27-07-2018,NA,US NCT number,results
4576,2014-003457-34," Safety of autologous CardAP-cells in patients with dilatative cardiomyopathy: an open, monocentric, double-arm, 3+3 dose escalation, phase I/II study",27-07-2018,NA,ISRCTN number,results
4577,2014-003481-25," A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis",17-02-2015,NA,US NCT number,protocol
4578,2014-003481-25," A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis",17-02-2015,NA,other,protocol
4579,2014-003481-25," A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis",17-02-2015,NA,US NCT number,results
4580,2014-003481-25," A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis",17-02-2015,NA,ISRCTN number,results
4581,2014-003546-27, Chromoendoscopy versus conventional endoscopy in Patients with polyposis syndrome,02-02-2016,NA,US NCT number,protocol
4582,2014-003546-27, Chromoendoscopy versus conventional endoscopy in Patients with polyposis syndrome,02-02-2016,NA,other,protocol
4583,2014-003546-27, Chromoendoscopy versus conventional endoscopy in Patients with polyposis syndrome,02-02-2016,NA,US NCT number,results
4584,2014-003546-27, Chromoendoscopy versus conventional endoscopy in Patients with polyposis syndrome,02-02-2016,NA,ISRCTN number,results
4585,2014-003561-15, Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation,18-12-2015,NA,US NCT number,protocol
4586,2014-003561-15, Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation,18-12-2015,NA,other,protocol
4587,2014-003561-15, Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation,18-12-2015,NA,US NCT number,results
4588,2014-003561-15, Safety and Tolerance of Immunomodulating Therapy with Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation,18-12-2015,NA,ISRCTN number,results
4589,2014-003581-25," Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial ",15-12-2014,NA,US NCT number,protocol
4590,2014-003581-25," Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial ",15-12-2014,NA,other,protocol
4591,2014-003581-25," Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial ",15-12-2014,NA,US NCT number,results
4592,2014-003581-25," Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial ",15-12-2014,NA,ISRCTN number,results
4593,2014-003582-24," A double blind, randomised, multicentre, active controlled, parallel-group, phase III trial to evaluate the efficacy, safety and pharmacokinetics of intravenous clonidine (hydrochloride) compared to midazolam for sedation in children from birth to less than 18 years of age.",12-02-2015,NA,US NCT number,protocol
4594,2014-003582-24," A double blind, randomised, multicentre, active controlled, parallel-group, phase III trial to evaluate the efficacy, safety and pharmacokinetics of intravenous clonidine (hydrochloride) compared to midazolam for sedation in children from birth to less than 18 years of age.",12-02-2015,NA,other,protocol
4595,2014-003582-24," A double blind, randomised, multicentre, active controlled, parallel-group, phase III trial to evaluate the efficacy, safety and pharmacokinetics of intravenous clonidine (hydrochloride) compared to midazolam for sedation in children from birth to less than 18 years of age.",12-02-2015,NCT02509273,US NCT number,results
4596,2014-003582-24," A double blind, randomised, multicentre, active controlled, parallel-group, phase III trial to evaluate the efficacy, safety and pharmacokinetics of intravenous clonidine (hydrochloride) compared to midazolam for sedation in children from birth to less than 18 years of age.",12-02-2015,NA,ISRCTN number,results
4597,2014-003647-34, Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias ,06-02-2015,NCT02310243,US NCT number,protocol
4598,2014-003647-34, Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias ,06-02-2015,NA,other,protocol
4599,2014-003647-34, Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias ,06-02-2015,NCT02310243,US NCT number,results
4600,2014-003647-34, Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias ,06-02-2015,NA,ISRCTN number,results
4601,2014-003787-21, Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab,15-12-2014,NA,US NCT number,protocol
4602,2014-003787-21, Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab,15-12-2014,NA,other,protocol
4603,2014-003787-21, Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab,15-12-2014,NA,US NCT number,results
4604,2014-003787-21, Randomised study of the efficacy of cetuximab rechallenge in patients with metastatic colorectal cancer (RAS wild-type) responding to first-line treatment with FOLFIRI plus cetuximab,15-12-2014,NA,ISRCTN number,results
4605,2014-003810-96, Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,24-11-2014,NA,US NCT number,protocol
4606,2014-003810-96, Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,24-11-2014,NA,other,protocol
4607,2014-003810-96, Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,24-11-2014,NCT02322502,US NCT number,results
4608,2014-003810-96, Emergence times and airway reactions in general laryngeal mask airway anesthesia: a randomized multicenter controlled trial,24-11-2014,NA,ISRCTN number,results
4609,2014-004013-85, Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody levels,19-11-2015,NA,US NCT number,protocol
4610,2014-004013-85, Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody levels,19-11-2015,NA,other,protocol
4611,2014-004013-85, Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody levels,19-11-2015,NA,US NCT number,results
4612,2014-004013-85, Sequential versus simultaneous vaccination with pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23) in unvaccinated older adults: Immunological memory and antibody levels,19-11-2015,NA,ISRCTN number,results
4613,2014-004036-19, GHSG-AFM13,02-01-2015,NCT02321592,US NCT number,protocol
4614,2014-004036-19, GHSG-AFM13,02-01-2015,NA,other,protocol
4615,2014-004036-19, GHSG-AFM13,02-01-2015,NCT02321592,US NCT number,results
4616,2014-004036-19, GHSG-AFM13,02-01-2015,NA,ISRCTN number,results
4617,2014-004088-19, Postoperative pain treatment after elective cardiac surgery using patient-controlled target-controlled infusion (TCI-PCA) with hydromorphone vs. patient-controlled analgesia (PCA) with morphine,20-11-2014,NA,US NCT number,protocol
4618,2014-004088-19, Postoperative pain treatment after elective cardiac surgery using patient-controlled target-controlled infusion (TCI-PCA) with hydromorphone vs. patient-controlled analgesia (PCA) with morphine,20-11-2014,NA,other,protocol
4619,2014-004088-19, Postoperative pain treatment after elective cardiac surgery using patient-controlled target-controlled infusion (TCI-PCA) with hydromorphone vs. patient-controlled analgesia (PCA) with morphine,20-11-2014,NCT02483221,US NCT number,results
4620,2014-004088-19, Postoperative pain treatment after elective cardiac surgery using patient-controlled target-controlled infusion (TCI-PCA) with hydromorphone vs. patient-controlled analgesia (PCA) with morphine,20-11-2014,NA,ISRCTN number,results
4621,2014-004095-31," A prospective phase II, randomized multi-center trial of  a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)",05-05-2015,NA,US NCT number,protocol
4622,2014-004095-31," A prospective phase II, randomized multi-center trial of  a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)",05-05-2015,NA,other,protocol
4623,2014-004095-31," A prospective phase II, randomized multi-center trial of  a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)",05-05-2015,NA,US NCT number,results
4624,2014-004095-31," A prospective phase II, randomized multi-center trial of  a combined modularized treatment with metronomic low-dose treosulfan, pioglitazone and clarithromycin versus nivolumab in patients with squamous cell lung cancer and non- squamous cell lung cancer, respectively after platin failure (ModuLung)",05-05-2015,NA,ISRCTN number,results
4625,2014-004197-42, A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma ,22-03-2016,NCT02770378,US NCT number,protocol
4626,2014-004197-42, A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma ,22-03-2016,NA,other,protocol
4627,2014-004197-42, A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma ,22-03-2016,NCT02770378,US NCT number,results
4628,2014-004197-42, A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma ,22-03-2016,NA,ISRCTN number,results
4629,2014-004267-20," Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)",18-03-2015,NCT02396628,US NCT number,protocol
4630,2014-004267-20," Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)",18-03-2015,DRKS DRKS00007939,other,protocol
4631,2014-004267-20," Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)",18-03-2015,NA,US NCT number,results
4632,2014-004267-20," Multicenter, randomized Phase 2 Trial to determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) versus BAT in Steroid-refractory acute Graft-versus-Host Disease (aGvHD)",18-03-2015,NA,ISRCTN number,results
4633,2014-004551-32, Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety ,28-08-2015,NA,US NCT number,protocol
4634,2014-004551-32, Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety ,28-08-2015,NA,other,protocol
4635,2014-004551-32, Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety ,28-08-2015,NA,US NCT number,results
4636,2014-004551-32, Daclatasvir plus Sofosbuvir for chronic HCV-infected renal transplant patients – a pilot study of efficacy and safety ,28-08-2015,NA,ISRCTN number,results
4637,2014-004597-42, LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E ,16-03-2016,NA,US NCT number,protocol
4638,2014-004597-42, LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E ,16-03-2016,NA,other,protocol
4639,2014-004597-42, LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E ,16-03-2016,NA,US NCT number,results
4640,2014-004597-42, LGX818 in combination with MEK162 in refractory or relapsed multiple myeloma patients with BRAFV600E ,16-03-2016,NA,ISRCTN number,results
4641,2014-004780-21, GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma,28-04-2015,NA,US NCT number,protocol
4642,2014-004780-21, GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma,28-04-2015,NA,other,protocol
4643,2014-004780-21, GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma,28-04-2015,NA,US NCT number,results
4644,2014-004780-21, GOAL trial: Rescue treatment with the monoclonal anti CD20-antibody Obinutuzumab (GA101) in combination with PixantrOne for the treatment of patients with relapsed Aggressive B-cell Lymphoma,28-04-2015,NA,ISRCTN number,results
4645,2014-004798-17," Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis-Arthritis & Bone Program)",11-03-2015,NA,US NCT number,protocol
4646,2014-004798-17," Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis-Arthritis & Bone Program)",11-03-2015,NA,other,protocol
4647,2014-004798-17," Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis-Arthritis & Bone Program)",11-03-2015,NCT02483234,US NCT number,results
4648,2014-004798-17," Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoriasis-Arthritis & Bone Program)",11-03-2015,NA,ISRCTN number,results
4649,2014-004854-33, Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial).,11-11-2015,NCT02669589,US NCT number,protocol
4650,2014-004854-33, Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial).,11-11-2015,NA,other,protocol
4651,2014-004854-33, Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial).,11-11-2015,NCT02669589,US NCT number,results
4652,2014-004854-33, Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial).,11-11-2015,NA,ISRCTN number,results
4653,2014-004981-52, Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study,17-12-2015,NA,US NCT number,protocol
4654,2014-004981-52, Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study,17-12-2015,AX-CL-OTHER-PI-003916  Celgene number,other,protocol
4655,2014-004981-52, Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study,17-12-2015,NA,US NCT number,results
4656,2014-004981-52, Nab-Paclitaxel (Abraxane®) and Gemcitabine as first line therapy in patients with cholangiocarcinoma ineligible for cisplatin-based chemotherapy – a pilot study,17-12-2015,NA,ISRCTN number,results
4657,2014-005004-21, THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1),21-05-2015,NA,US NCT number,protocol
4658,2014-005004-21, THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1),21-05-2015,NA,other,protocol
4659,2014-005004-21, THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1),21-05-2015,NA,US NCT number,results
4660,2014-005004-21, THOR - Tübingen Choroideremia gene therapy trial open label Phase 2 clinical trial using an adeno-associated viral vector (AAV2) encoding Rab-escort protein 1 (REP1),21-05-2015,NA,ISRCTN number,results
4661,2014-005069-60, R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL,30-12-2014,NA,US NCT number,protocol
4662,2014-005069-60, R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL,30-12-2014,DRKS-Number DRKS00000718,other,protocol
4663,2014-005069-60, R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL,30-12-2014,NA,US NCT number,results
4664,2014-005069-60, R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL,30-12-2014,NA,ISRCTN number,results
4665,2014-005109-19, Apixaban for treatment of embolic stroke of undetermined source,29-06-2015,NA,US NCT number,protocol
4666,2014-005109-19, Apixaban for treatment of embolic stroke of undetermined source,29-06-2015,NA,other,protocol
4667,2014-005109-19, Apixaban for treatment of embolic stroke of undetermined source,29-06-2015,NA,US NCT number,results
4668,2014-005109-19, Apixaban for treatment of embolic stroke of undetermined source,29-06-2015,NA,ISRCTN number,results
4669,2014-005121-13," Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photodamaged skin of the face ",19-02-2015,NA,US NCT number,protocol
4670,2014-005121-13," Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photodamaged skin of the face ",19-02-2015,NA,other,protocol
4671,2014-005121-13," Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photodamaged skin of the face ",19-02-2015,NCT02736760,US NCT number,results
4672,2014-005121-13," Prospective, randomized, controlled, multicenter, two-armed, study comparing daylight photodynamic therapy using MAL with cryosurgery for the treatment and prophylaxis of actinic keratoses in photodamaged skin of the face ",19-02-2015,NA,ISRCTN number,results
4673,2014-005130-55, HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD.,12-01-2016,NCT02661503,US NCT number,protocol
4674,2014-005130-55, HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD.,12-01-2016,NA,other,protocol
4675,2014-005130-55, HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD.,12-01-2016,NA,US NCT number,results
4676,2014-005130-55, HD21 for advanced stages: Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparision of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD.,12-01-2016,NA,ISRCTN number,results
4677,2014-005164-15," A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 ",17-09-2015,NA,US NCT number,protocol
4678,2014-005164-15," A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 ",17-09-2015,NA,other,protocol
4679,2014-005164-15," A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 ",17-09-2015,NA,US NCT number,results
4680,2014-005164-15," A prospective multicenter Phase 2 Study of the Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 ",17-09-2015,NA,ISRCTN number,results
4681,2014-005210-28, Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study),23-12-2015,NA,US NCT number,protocol
4682,2014-005210-28, Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study),23-12-2015,NA,other,protocol
4683,2014-005210-28, Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study),23-12-2015,NA,US NCT number,results
4684,2014-005210-28, Ruxolitinib versus allogeneic stem cell transplantation for patients with myelofibrosis according to donor availability: A prospective phase II trial (MMM 02 study),23-12-2015,NA,ISRCTN number,results
4685,2014-005239-15, Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,03-02-2016,NA,US NCT number,protocol
4686,2014-005239-15, Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,03-02-2016,NA,other,protocol
4687,2014-005239-15, Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,03-02-2016,NCT03062150,US NCT number,results
4688,2014-005239-15, Effects of mineralocorticoid receptor stimulation on cognitive bias and social cognition in patients with major depression and healthy controls: what’s the role of NMDA receptors?,03-02-2016,NA,ISRCTN number,results
4689,2014-005263-33, Intravitreal Aflibercept (Eylea®) for therapy of choroidal ,26-02-2015,NA,US NCT number,protocol
4690,2014-005263-33, Intravitreal Aflibercept (Eylea®) for therapy of choroidal ,26-02-2015,NA,other,protocol
4691,2014-005263-33, Intravitreal Aflibercept (Eylea®) for therapy of choroidal ,26-02-2015,NCT02537054,US NCT number,results
4692,2014-005263-33, Intravitreal Aflibercept (Eylea®) for therapy of choroidal ,26-02-2015,NA,ISRCTN number,results
4693,2014-005287-15, - PRE-POINT-EARLY STUDY -,13-04-2015,NA,US NCT number,protocol
4694,2014-005287-15, - PRE-POINT-EARLY STUDY -,13-04-2015,NA,other,protocol
4695,2014-005287-15, - PRE-POINT-EARLY STUDY -,13-04-2015,NCT02547519,US NCT number,results
4696,2014-005287-15, - PRE-POINT-EARLY STUDY -,13-04-2015,NA,ISRCTN number,results
4697,2014-005344-17," Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",02-01-2015,NA,US NCT number,protocol
4698,2014-005344-17," Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",02-01-2015,NA,other,protocol
4699,2014-005344-17," Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",02-01-2015,NA,US NCT number,results
4700,2014-005344-17," Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study.",02-01-2015,NA,ISRCTN number,results
4701,2014-005440-17," Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain",11-03-2015,NA,US NCT number,protocol
4702,2014-005440-17," Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain",11-03-2015,NA,other,protocol
4703,2014-005440-17," Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain",11-03-2015,NCT02820519,US NCT number,results
4704,2014-005440-17," Tolerability and analgesic efficacy of Loxapine in patients with refractory, chemotherapy-induced neuropathic pain",11-03-2015,NA,ISRCTN number,results
4705,2014-005473-36, Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects,26-01-2015,NA,US NCT number,protocol
4706,2014-005473-36, Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects,26-01-2015,NA,other,protocol
4707,2014-005473-36, Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects,26-01-2015,NA,US NCT number,results
4708,2014-005473-36, Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects,26-01-2015,NA,ISRCTN number,results
4709,2014-005531-13," Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nilotinib or Dasatinib therapy, ""Bosutinib Dose Optimization Study - BODO-Study"" ",21-09-2015,NA,US NCT number,protocol
4710,2014-005531-13," Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nilotinib or Dasatinib therapy, ""Bosutinib Dose Optimization Study - BODO-Study"" ",21-09-2015,NA,other,protocol
4711,2014-005531-13," Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nilotinib or Dasatinib therapy, ""Bosutinib Dose Optimization Study - BODO-Study"" ",21-09-2015,NA,US NCT number,results
4712,2014-005531-13," Multicenter, open-label single arm phase II study testing the tolerability and the efficacy of Bosutinib step-in dosing in Chronic Phase CML patients intolerant or refractory to previous Imatinib, Nilotinib or Dasatinib therapy, ""Bosutinib Dose Optimization Study - BODO-Study"" ",21-09-2015,NA,ISRCTN number,results
4713,2014-005669-54, Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours,03-12-2019,NCT04738162,US NCT number,protocol
4714,2014-005669-54, Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours,03-12-2019,NA,other,protocol
4715,2014-005669-54, Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours,03-12-2019,NA,US NCT number,results
4716,2014-005669-54, Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours,03-12-2019,NA,ISRCTN number,results
4717,2015-000125-36, Daptomycin concentration in drainage fluid and blood samples of ICU patients,21-03-2016,NA,US NCT number,protocol
4718,2015-000125-36, Daptomycin concentration in drainage fluid and blood samples of ICU patients,21-03-2016,NA,other,protocol
4719,2015-000125-36, Daptomycin concentration in drainage fluid and blood samples of ICU patients,21-03-2016,NCT03004066,US NCT number,results
4720,2015-000125-36, Daptomycin concentration in drainage fluid and blood samples of ICU patients,21-03-2016,NA,ISRCTN number,results
4721,2015-000268-32," Prospective, open-label, randomised, single-centre, two-arm, parallel-group, cross-over controlled clinical study, phase 4, to investigate the efficacy of tropicamid 0.5% eyedrops compared to cyclopentolat 0.5% eyedrops for cycloplegia for objective refraction measurement of the eye in 4- to 6-year old children",05-06-2015,NA,US NCT number,protocol
4722,2015-000268-32," Prospective, open-label, randomised, single-centre, two-arm, parallel-group, cross-over controlled clinical study, phase 4, to investigate the efficacy of tropicamid 0.5% eyedrops compared to cyclopentolat 0.5% eyedrops for cycloplegia for objective refraction measurement of the eye in 4- to 6-year old children",05-06-2015,NA,other,protocol
4723,2015-000268-32," Prospective, open-label, randomised, single-centre, two-arm, parallel-group, cross-over controlled clinical study, phase 4, to investigate the efficacy of tropicamid 0.5% eyedrops compared to cyclopentolat 0.5% eyedrops for cycloplegia for objective refraction measurement of the eye in 4- to 6-year old children",05-06-2015,NA,US NCT number,results
4724,2015-000268-32," Prospective, open-label, randomised, single-centre, two-arm, parallel-group, cross-over controlled clinical study, phase 4, to investigate the efficacy of tropicamid 0.5% eyedrops compared to cyclopentolat 0.5% eyedrops for cycloplegia for objective refraction measurement of the eye in 4- to 6-year old children",05-06-2015,NA,ISRCTN number,results
4725,2015-000360-34, DUALIS,07-04-2015,NA,US NCT number,protocol
4726,2015-000360-34, DUALIS,07-04-2015,NA,other,protocol
4727,2015-000360-34, DUALIS,07-04-2015,NCT02486133,US NCT number,results
4728,2015-000360-34, DUALIS,07-04-2015,NA,ISRCTN number,results
4729,2015-000388-15," Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial",09-12-2015,NA,US NCT number,protocol
4730,2015-000388-15," Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial",09-12-2015,NA,other,protocol
4731,2015-000388-15," Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial",09-12-2015,NA,US NCT number,results
4732,2015-000388-15," Prophylactic treatment of vestibular paroxysmia with carbamazepine: a prospective, randomized, placebo-controlled, cross-over, multi-center trial",09-12-2015,NA,ISRCTN number,results
4733,2015-000460-34," Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) ",12-10-2015,NA,US NCT number,protocol
4734,2015-000460-34," Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) ",12-10-2015,NA,other,protocol
4735,2015-000460-34," Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) ",12-10-2015,NA,US NCT number,results
4736,2015-000460-34," Effects of Acetyl-DL-Leucine on cerebellar ataxia - a multinational, multicenter, randomized, double-blind, placebo-controlled, 2-way crossover phase III trial (ALCAT) ",12-10-2015,NA,ISRCTN number,results
4737,2015-000465-31," Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",30-03-2016,NA,US NCT number,protocol
4738,2015-000465-31," Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",30-03-2016,NA,other,protocol
4739,2015-000465-31," Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",30-03-2016,NA,US NCT number,results
4740,2015-000465-31," Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression",30-03-2016,NA,ISRCTN number,results
4741,2015-000488-15, Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD,07-08-2015,NA,US NCT number,protocol
4742,2015-000488-15, Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD,07-08-2015,NA,other,protocol
4743,2015-000488-15, Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD,07-08-2015,NA,US NCT number,results
4744,2015-000488-15, Vigilance regulation as predictor of response to Psychostimulants in adult patients with ADHD,07-08-2015,NA,ISRCTN number,results
4745,2015-000538-31, NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,07-04-2015,NA,US NCT number,protocol
4746,2015-000538-31, NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,07-04-2015,NA,other,protocol
4747,2015-000538-31, NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,07-04-2015,NA,US NCT number,results
4748,2015-000538-31, NEUORIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the knee joint,07-04-2015,NA,ISRCTN number,results
4749,2015-000568-32, Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation,01-11-2016,NA,US NCT number,protocol
4750,2015-000568-32, Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation,01-11-2016,NA,other,protocol
4751,2015-000568-32, Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation,01-11-2016,NCT03153514,US NCT number,results
4752,2015-000568-32, Obinutuzumab containing conditioning regimen for CLL patients and patients with Richter`s transformation requiring an allogeneic stem cell transplantation,01-11-2016,NA,ISRCTN number,results
4753,2015-000686-32," Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: ",17-03-2015,NA,US NCT number,protocol
4754,2015-000686-32," Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: ",17-03-2015,NA,other,protocol
4755,2015-000686-32," Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: ",17-03-2015,NCT03312855,US NCT number,results
4756,2015-000686-32," Revacept, a novel inhibitor of platelet adhesion in patients with stable coronary artery disease undergoing elective percutaneous coronary interventions: ",17-03-2015,NA,ISRCTN number,results
4757,2015-000733-76," A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-blastic leukemia (Blast Successor Trial)",02-03-2016,NA,US NCT number,protocol
4758,2015-000733-76," A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-blastic leukemia (Blast Successor Trial)",02-03-2016,NA,other,protocol
4759,2015-000733-76," A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-blastic leukemia (Blast Successor Trial)",02-03-2016,NA,US NCT number,results
4760,2015-000733-76," A multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor acute lympho-blastic leukemia (Blast Successor Trial)",02-03-2016,NA,ISRCTN number,results
4761,2015-000749-21, Botulinumtoxin A for emotional stabilization in borderline personality disorder,30-12-2015,NA,US NCT number,protocol
4762,2015-000749-21, Botulinumtoxin A for emotional stabilization in borderline personality disorder,30-12-2015,NA,other,protocol
4763,2015-000749-21, Botulinumtoxin A for emotional stabilization in borderline personality disorder,30-12-2015,NA,US NCT number,results
4764,2015-000749-21, Botulinumtoxin A for emotional stabilization in borderline personality disorder,30-12-2015,NA,ISRCTN number,results
4765,2015-000762-65, Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum,25-06-2015,NA,US NCT number,protocol
4766,2015-000762-65, Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum,25-06-2015,NA,other,protocol
4767,2015-000762-65, Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum,25-06-2015,NCT02733094,US NCT number,results
4768,2015-000762-65, Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum,25-06-2015,NA,ISRCTN number,results
4769,2015-000978-35, Statin Treatment of Oxysterol Pathology in SPG5: a Randomized Controlled Trial,19-06-2015,NA,US NCT number,protocol
4770,2015-000978-35, Statin Treatment of Oxysterol Pathology in SPG5: a Randomized Controlled Trial,19-06-2015,NA,other,protocol
4771,2015-000978-35, Statin Treatment of Oxysterol Pathology in SPG5: a Randomized Controlled Trial,19-06-2015,NA,US NCT number,results
4772,2015-000978-35, Statin Treatment of Oxysterol Pathology in SPG5: a Randomized Controlled Trial,19-06-2015,NA,ISRCTN number,results
4773,2015-001151-68," A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia",22-12-2015,NA,US NCT number,protocol
4774,2015-001151-68," A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia",22-12-2015,NA,other,protocol
4775,2015-001151-68," A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia",22-12-2015,NA,US NCT number,results
4776,2015-001151-68," A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracyclines-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia",22-12-2015,NA,ISRCTN number,results
4777,2015-001309-14, Comparison of the efficacy of using a human acellular dermis (Epiflex®) against the surgical standard procedure for closing an open abdomen with respect to avoiding ventral hernia. ,09-11-2015,NA,US NCT number,protocol
4778,2015-001309-14, Comparison of the efficacy of using a human acellular dermis (Epiflex®) against the surgical standard procedure for closing an open abdomen with respect to avoiding ventral hernia. ,09-11-2015,NA,other,protocol
4779,2015-001309-14, Comparison of the efficacy of using a human acellular dermis (Epiflex®) against the surgical standard procedure for closing an open abdomen with respect to avoiding ventral hernia. ,09-11-2015,NA,US NCT number,results
4780,2015-001309-14, Comparison of the efficacy of using a human acellular dermis (Epiflex®) against the surgical standard procedure for closing an open abdomen with respect to avoiding ventral hernia. ,09-11-2015,NA,ISRCTN number,results
4781,2015-001434-16, A method for measuring volume changes of the alveolar ridge during,30-06-2015,NA,US NCT number,protocol
4782,2015-001434-16, A method for measuring volume changes of the alveolar ridge during,30-06-2015,NA,other,protocol
4783,2015-001434-16, A method for measuring volume changes of the alveolar ridge during,30-06-2015,NA,US NCT number,results
4784,2015-001434-16, A method for measuring volume changes of the alveolar ridge during,30-06-2015,NA,ISRCTN number,results
4785,2015-001456-29," A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) ",08-07-2015,NA,US NCT number,protocol
4786,2015-001456-29," A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) ",08-07-2015,NA,other,protocol
4787,2015-001456-29," A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) ",08-07-2015,NA,US NCT number,results
4788,2015-001456-29," A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Treatment Resistant Unipolar Major Depressive Disorder (MDD) ",08-07-2015,NA,ISRCTN number,results
4789,2015-001522-41, Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications ,03-07-2015,NA,US NCT number,protocol
4790,2015-001522-41, Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications ,03-07-2015,NA,other,protocol
4791,2015-001522-41, Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications ,03-07-2015,NA,US NCT number,results
4792,2015-001522-41, Prophylactic application of donor-derived central memory T lymphocytes (TCM) after allogeneic HSCT to prevent infectious complications ,03-07-2015,NA,ISRCTN number,results
4793,2015-001683-20, Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus,03-08-2015,NCT02509286,US NCT number,protocol
4794,2015-001683-20, Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus,03-08-2015,DRKS DRKS00008008 ,other,protocol
4795,2015-001683-20, Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus,03-08-2015,NA,US NCT number,results
4796,2015-001683-20, Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus,03-08-2015,NA,ISRCTN number,results
4797,2015-001820-51," BMC2012, Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa",15-10-2015,NA,US NCT number,protocol
4798,2015-001820-51," BMC2012, Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa",15-10-2015,NA,other,protocol
4799,2015-001820-51," BMC2012, Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa",15-10-2015,NCT02803177,US NCT number,results
4800,2015-001820-51," BMC2012, Cell based therapy by implanted bone marrow-derived mononuclear cells (BMC) for bone augmentation of plate-stabilized proximal humeral fractures - a randomized, open, multicentric study - phase IIa",15-10-2015,NA,ISRCTN number,results
4801,2015-001830-12, Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.,20-07-2015,NA,US NCT number,protocol
4802,2015-001830-12, Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.,20-07-2015,NA,other,protocol
4803,2015-001830-12, Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.,20-07-2015,NCT02596555,US NCT number,results
4804,2015-001830-12, Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism.,20-07-2015,NA,ISRCTN number,results
4805,2015-001868-19," A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study",06-07-2015,NA,US NCT number,protocol
4806,2015-001868-19," A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study",06-07-2015,NA,other,protocol
4807,2015-001868-19," A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study",06-07-2015,NA,US NCT number,results
4808,2015-001868-19," A randomized, double-blind, placebo-controlled, mono-center study to evaluate the effects of mepolizumab on airway physiology in patients with eosinophilic asthma: the MEMORY study",06-07-2015,NA,ISRCTN number,results
4809,2015-002212-32, Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A,27-10-2015,NCT02669680,US NCT number,protocol
4810,2015-002212-32, Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A,27-10-2015,NA,other,protocol
4811,2015-002212-32, Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A,27-10-2015,NCT02669680,US NCT number,results
4812,2015-002212-32, Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A,27-10-2015,NA,ISRCTN number,results
4813,2015-002285-23, Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST),26-09-2016,NA,US NCT number,protocol
4814,2015-002285-23, Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST),26-09-2016,NA,other,protocol
4815,2015-002285-23, Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST),26-09-2016,NA,US NCT number,results
4816,2015-002285-23, Phase 2 trial of ponatinib in patients with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) following failure or intolerance of prior therapy with imatinib (POETIG trial – POnatinib after rEsisTance to Imatinib in GIST),26-09-2016,NA,ISRCTN number,results
4817,2015-002288-41, Open-label pilot Phase I / II study on hyperthermic intraperitoneal chemotherapy ( HIPEC ) after macroscopically complete resection ( R0 / R1 ) of adenocarcinomas of the pancreas ( PanHIPEC ),25-08-2015,NA,US NCT number,protocol
4818,2015-002288-41, Open-label pilot Phase I / II study on hyperthermic intraperitoneal chemotherapy ( HIPEC ) after macroscopically complete resection ( R0 / R1 ) of adenocarcinomas of the pancreas ( PanHIPEC ),25-08-2015,NA,other,protocol
4819,2015-002288-41, Open-label pilot Phase I / II study on hyperthermic intraperitoneal chemotherapy ( HIPEC ) after macroscopically complete resection ( R0 / R1 ) of adenocarcinomas of the pancreas ( PanHIPEC ),25-08-2015,NCT02863471,US NCT number,results
4820,2015-002288-41, Open-label pilot Phase I / II study on hyperthermic intraperitoneal chemotherapy ( HIPEC ) after macroscopically complete resection ( R0 / R1 ) of adenocarcinomas of the pancreas ( PanHIPEC ),25-08-2015,NA,ISRCTN number,results
4821,2015-002465-28, Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation,11-11-2015,NA,US NCT number,protocol
4822,2015-002465-28, Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation,11-11-2015,NA,other,protocol
4823,2015-002465-28, Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation,11-11-2015,NA,US NCT number,results
4824,2015-002465-28, Anti-donor alloreactivity-guided CNI minimization versus unguided standard triple therapy in living-donor kidney transplantation,11-11-2015,NA,ISRCTN number,results
4825,2015-002491-24, Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease,30-03-2016,NA,US NCT number,protocol
4826,2015-002491-24, Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease,30-03-2016,DRKS DRKS00008783,other,protocol
4827,2015-002491-24, Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease,30-03-2016,NA,US NCT number,results
4828,2015-002491-24, Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease,30-03-2016,NA,ISRCTN number,results
4829,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,protocol
4830,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,other,protocol
4831,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,results
4832,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,ISRCTN number,results
4833,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,protocol
4834,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,other,protocol
4835,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,results
4836,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,ISRCTN number,results
4837,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,protocol
4838,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,other,protocol
4839,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,results
4840,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,ISRCTN number,results
4841,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,protocol
4842,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,other,protocol
4843,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,US NCT number,results
4844,2015-002588-40, Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients,10-05-2016,NA,ISRCTN number,results
4845,2015-002602-36, Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT),08-03-2016,NA,US NCT number,protocol
4846,2015-002602-36, Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT),08-03-2016,NA,other,protocol
4847,2015-002602-36, Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT),08-03-2016,NA,US NCT number,results
4848,2015-002602-36, Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT),08-03-2016,NA,ISRCTN number,results
4849,2015-002727-25, Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma,16-03-2017,NA,US NCT number,protocol
4850,2015-002727-25, Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma,16-03-2017,EUDAMED-Number CIV-17-03-018624,other,protocol
4851,2015-002727-25, Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma,16-03-2017,NA,US NCT number,results
4852,2015-002727-25, Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma,16-03-2017,NA,ISRCTN number,results
4853,2015-002752-27, Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20),04-04-2017,NA,US NCT number,protocol
4854,2015-002752-27, Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20),04-04-2017,NA,other,protocol
4855,2015-002752-27, Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20),04-04-2017,NA,US NCT number,results
4856,2015-002752-27, Umbrella protocol for phase I/IIa trials of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed glioblastoma without MGMT promoter methylation: NCT Neuro Master Match - N²M² (NOA-20),04-04-2017,NA,ISRCTN number,results
4857,2015-002831-16, Validation of a test system for development of medications for alcoholism,13-08-2015,NA,US NCT number,protocol
4858,2015-002831-16, Validation of a test system for development of medications for alcoholism,13-08-2015,NA,other,protocol
4859,2015-002831-16, Validation of a test system for development of medications for alcoholism,13-08-2015,NA,US NCT number,results
4860,2015-002831-16, Validation of a test system for development of medications for alcoholism,13-08-2015,NA,ISRCTN number,results
4861,2015-002835-17, Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions,26-11-2015,NA,US NCT number,protocol
4862,2015-002835-17, Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions,26-11-2015,NA,other,protocol
4863,2015-002835-17, Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions,26-11-2015,NA,US NCT number,results
4864,2015-002835-17, Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions,26-11-2015,NA,ISRCTN number,results
4865,2015-002935-16," Single centre, open-label, randomized, controlled, cross over study to evaluate the pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver transplant recipients",16-09-2015,NA,US NCT number,protocol
4866,2015-002935-16," Single centre, open-label, randomized, controlled, cross over study to evaluate the pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver transplant recipients",16-09-2015,NA,other,protocol
4867,2015-002935-16," Single centre, open-label, randomized, controlled, cross over study to evaluate the pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver transplant recipients",16-09-2015,NCT03241043,US NCT number,results
4868,2015-002935-16," Single centre, open-label, randomized, controlled, cross over study to evaluate the pharmacokinetic and bioavailability of Envarsus® in comparison to Advagraf® in de novo liver transplant recipients",16-09-2015,NA,ISRCTN number,results
4869,2015-003028-30, Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes,11-08-2015,NA,US NCT number,protocol
4870,2015-003028-30, Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes,11-08-2015,NA,other,protocol
4871,2015-003028-30, Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes,11-08-2015,NA,US NCT number,results
4872,2015-003028-30, Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes,11-08-2015,NA,ISRCTN number,results
4873,2015-003128-30, Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL),21-12-2015,NCT02626884,US NCT number,protocol
4874,2015-003128-30, Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL),21-12-2015,NA,other,protocol
4875,2015-003128-30, Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL),21-12-2015,NCT02626884,US NCT number,results
4876,2015-003128-30, Phase II trial of the Btk-inhibitor Ibrutinib in patients with relapsed nodular lymphocyte-predominant Hodgkin Lymphoma (NLPHL),21-12-2015,NA,ISRCTN number,results
4877,2015-003171-29, The correlation between vancomycin AUC and trough levels during,04-11-2015,NA,US NCT number,protocol
4878,2015-003171-29, The correlation between vancomycin AUC and trough levels during,04-11-2015,NA,other,protocol
4879,2015-003171-29, The correlation between vancomycin AUC and trough levels during,04-11-2015,NA,US NCT number,results
4880,2015-003171-29, The correlation between vancomycin AUC and trough levels during,04-11-2015,NA,ISRCTN number,results
4881,2015-003369-27, A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) ,18-05-2016,NA,US NCT number,protocol
4882,2015-003369-27, A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) ,18-05-2016,DRKS DRKS00010424,other,protocol
4883,2015-003369-27, A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) ,18-05-2016,NA,US NCT number,results
4884,2015-003369-27, A Phase I-IIa trial on low-dose IL-2 (Aldesleukin) treatment for immunological dysregulation in common variable immunodeficiency (CVID) ,18-05-2016,NA,ISRCTN number,results
4885,2015-003379-31, An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes ,02-09-2016,NA,US NCT number,protocol
4886,2015-003379-31, An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes ,02-09-2016,NA,other,protocol
4887,2015-003379-31, An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes ,02-09-2016,NCT03182322,US NCT number,results
4888,2015-003379-31, An immune efficacy study for primary prevention using intranasal insulin therapy in islet autoantibody negative children at high genetic risk for type 1 diabetes ,02-09-2016,NA,ISRCTN number,results
4889,2015-003395-72," Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind  study (VitD@BPPV)",21-07-2016,NA,US NCT number,protocol
4890,2015-003395-72," Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind  study (VitD@BPPV)",21-07-2016,NA,other,protocol
4891,2015-003395-72," Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind  study (VitD@BPPV)",21-07-2016,NA,US NCT number,results
4892,2015-003395-72," Vitamin D in secondary prevention of benign paroxysmal positional vertigo: a prospective, multicenter, randomized, placebo-controlled, double-blind  study (VitD@BPPV)",21-07-2016,NA,ISRCTN number,results
4893,2015-003429-32," “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",19-08-2016,NA,US NCT number,protocol
4894,2015-003429-32," “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",19-08-2016,NA,other,protocol
4895,2015-003429-32," “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",19-08-2016,NA,US NCT number,results
4896,2015-003429-32," “Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the treatment of elderly patients (age 61-80 years) with CD20+ diffuse large B-cell lymphoma, IPI ≥ 2”",19-08-2016,NA,ISRCTN number,results
4897,2015-003502-16, Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line),22-06-2016,NA,US NCT number,protocol
4898,2015-003502-16, Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line),22-06-2016,NA,other,protocol
4899,2015-003502-16, Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line),22-06-2016,NA,US NCT number,results
4900,2015-003502-16, Treatment optimization for patients with chronic myeloid leukemia (CML) with treatment naïve disease (1st line) and patients with resistance or intolerance against alternative Abl-Kinase Inhibitors (≥2nd line),22-06-2016,NA,ISRCTN number,results
4901,2015-003670-32," A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)",07-04-2016,NA,US NCT number,protocol
4902,2015-003670-32," A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)",07-04-2016,DRKS DRKS00009269,other,protocol
4903,2015-003670-32," A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)",07-04-2016,NA,US NCT number,results
4904,2015-003670-32," A dual-center prospective phase I/II trial to establish safety, tolerability and to obtain first data on efficacy of losartan in children with recessive dystrophic epidermolysis bullosa (RDEB)",07-04-2016,NA,ISRCTN number,results
4905,2015-003920-30, Phase-II study on the value of post-transplant Cyclophosphamide ,21-04-2016,NA,US NCT number,protocol
4906,2015-003920-30, Phase-II study on the value of post-transplant Cyclophosphamide ,21-04-2016,DRKS DRKS00009880,other,protocol
4907,2015-003920-30, Phase-II study on the value of post-transplant Cyclophosphamide ,21-04-2016,NA,US NCT number,results
4908,2015-003920-30, Phase-II study on the value of post-transplant Cyclophosphamide ,21-04-2016,NA,ISRCTN number,results
4909,2015-004028-69," 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study",04-10-2016,NA,US NCT number,protocol
4910,2015-004028-69," 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study",04-10-2016,NA,other,protocol
4911,2015-004028-69," 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study",04-10-2016,NA,US NCT number,results
4912,2015-004028-69," 5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 study",04-10-2016,NA,ISRCTN number,results
4913,2015-004066-28, A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15,22-11-2017,NCT03338348,US NCT number,protocol
4914,2015-004066-28, A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15,22-11-2017,NA,other,protocol
4915,2015-004066-28, A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15,22-11-2017,NCT03338348,US NCT number,results
4916,2015-004066-28, A Phase II Study with a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome with Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15,22-11-2017,NA,ISRCTN number,results
4917,2015-004172-30," Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity ",16-04-2021,NA,US NCT number,protocol
4918,2015-004172-30," Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity ",16-04-2021,NA,other,protocol
4919,2015-004172-30," Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity ",16-04-2021,NA,US NCT number,results
4920,2015-004172-30," Prevention of paclitaxel-related neurological side effects with lithium – a randomized, double-blind, placebo-controlled, explorative proof-of-concept phase II clinical trial to counteract chemotherapy induced neurotoxicity ",16-04-2021,NA,ISRCTN number,results
4921,2015-004184-36," Prospective, randomised, double-blind, placebo-controlled, single centre phase IIa clinical trial to investigate the safety and tolerability as well as the impact of a substitution of sexual hormones with an estrogen-progestin combination over 10 weeks in addition to in-house psychotherapy on neuro-endocrinological parameters, psychopathology and neuro-psychological performance compared to in-house psychotherapy alone in adult females with anorexia nervosa",09-12-2015,NA,US NCT number,protocol
4922,2015-004184-36," Prospective, randomised, double-blind, placebo-controlled, single centre phase IIa clinical trial to investigate the safety and tolerability as well as the impact of a substitution of sexual hormones with an estrogen-progestin combination over 10 weeks in addition to in-house psychotherapy on neuro-endocrinological parameters, psychopathology and neuro-psychological performance compared to in-house psychotherapy alone in adult females with anorexia nervosa",09-12-2015,NA,other,protocol
4923,2015-004184-36," Prospective, randomised, double-blind, placebo-controlled, single centre phase IIa clinical trial to investigate the safety and tolerability as well as the impact of a substitution of sexual hormones with an estrogen-progestin combination over 10 weeks in addition to in-house psychotherapy on neuro-endocrinological parameters, psychopathology and neuro-psychological performance compared to in-house psychotherapy alone in adult females with anorexia nervosa",09-12-2015,NA,US NCT number,results
4924,2015-004184-36," Prospective, randomised, double-blind, placebo-controlled, single centre phase IIa clinical trial to investigate the safety and tolerability as well as the impact of a substitution of sexual hormones with an estrogen-progestin combination over 10 weeks in addition to in-house psychotherapy on neuro-endocrinological parameters, psychopathology and neuro-psychological performance compared to in-house psychotherapy alone in adult females with anorexia nervosa",09-12-2015,NA,ISRCTN number,results
4925,2015-004304-27," Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma",01-03-2016,NA,US NCT number,protocol
4926,2015-004304-27," Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma",01-03-2016,NA,other,protocol
4927,2015-004304-27," Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma",01-03-2016,NA,US NCT number,results
4928,2015-004304-27," Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma",01-03-2016,NA,ISRCTN number,results
4929,2015-004606-41," A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANCE > 50 ML/MIN) PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH TP53 DELETION (17P-) AND/OR MUTATION ",21-04-2016,NA,US NCT number,protocol
4930,2015-004606-41," A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANCE > 50 ML/MIN) PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH TP53 DELETION (17P-) AND/OR MUTATION ",21-04-2016,NA,other,protocol
4931,2015-004606-41," A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANCE > 50 ML/MIN) PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH TP53 DELETION (17P-) AND/OR MUTATION ",21-04-2016,NCT02758665,US NCT number,results
4932,2015-004606-41," A PROSPECTIVE, OPEN-LABEL, MULTICENTRE PHASE-II TRIAL OF IBRUTINIB PLUS VENETOCLAX PLUS OBINUTUZUMAB IN PHYSICALLY FIT (CIRS ≤ 6 & NORMAL CREATININE CLEARANCE) OR UNFIT (CIRS >6 OR CREATININE CLEARANCE > 50 ML/MIN) PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH TP53 DELETION (17P-) AND/OR MUTATION ",21-04-2016,NA,ISRCTN number,results
4933,2015-004731-12, Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment,09-06-2016,NCT02834559,US NCT number,protocol
4934,2015-004731-12, Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment,09-06-2016,NA,other,protocol
4935,2015-004731-12, Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment,09-06-2016,NA,US NCT number,results
4936,2015-004731-12, Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients with Retinal Detachment,09-06-2016,NA,ISRCTN number,results
4937,2015-004849-11, Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5),04-07-2016,NA,US NCT number,protocol
4938,2015-004849-11, Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5),04-07-2016,NA,other,protocol
4939,2015-004849-11, Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5),04-07-2016,NA,US NCT number,results
4940,2015-004849-11, Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5),04-07-2016,NA,ISRCTN number,results
4941,2015-004936-36," A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation",30-09-2016,NA,US NCT number,protocol
4942,2015-004936-36," A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation",30-09-2016,ClinicalTrials.gov  NCTO2950051,other,protocol
4943,2015-004936-36," A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation",30-09-2016,NA,US NCT number,results
4944,2015-004936-36," A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) versus  obinutuzumab plus ibrutinib plus venetoclax (GIVe) in fit pa-tients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation",30-09-2016,NA,ISRCTN number,results
4945,2015-004998-33, Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI 2nd or 3rd time,07-03-2016,NCT02917720,US NCT number,protocol
4946,2015-004998-33, Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI 2nd or 3rd time,07-03-2016,NA,other,protocol
4947,2015-004998-33, Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI 2nd or 3rd time,07-03-2016,NA,US NCT number,results
4948,2015-004998-33, Multicenter prospective trial after first or second unsuccessful treatment discontinuation in chronic myeloid leukemia estimating the efficacy of nilotinib in inducing the persistence of molecular remission after stopping TKI 2nd or 3rd time,07-03-2016,NA,ISRCTN number,results
4949,2015-005071-25, Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,27-11-2015,NA,US NCT number,protocol
4950,2015-005071-25, Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,27-11-2015,NA,other,protocol
4951,2015-005071-25, Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,27-11-2015,NA,US NCT number,results
4952,2015-005071-25, Pharmacodynamic comparison of different oral P2Y12-receptor inhibitor loading strategies for transitioning from cangrelor in patients undergoing coronary stenting,27-11-2015,NA,ISRCTN number,results
4953,2015-005097-37," A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma",21-03-2016,NA,US NCT number,protocol
4954,2015-005097-37," A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma",21-03-2016,NA,other,protocol
4955,2015-005097-37," A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma",21-03-2016,NA,US NCT number,results
4956,2015-005097-37," A phase II, multicenter, open-label, randomized-controlled trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy with an anti- PD-L1 antibody atezolizumab for the treatment in patients with unresectable or metastatic BRAF V600 mutant melanoma",21-03-2016,NA,ISRCTN number,results
4957,2015-005219-34, Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy,20-03-2017,NA,US NCT number,protocol
4958,2015-005219-34, Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy,20-03-2017,Deutsches Register Klinische Studien DRKS00009451,other,protocol
4959,2015-005219-34, Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy,20-03-2017,NA,US NCT number,results
4960,2015-005219-34, Parenteral Nutrition during neoadjuvant chemotherapy for patients with advanced cancer of the GE-junction/esophagus/stomach/pancreas or rectum for reduction of postoperative morbiditiy,20-03-2017,NA,ISRCTN number,results
4961,2015-005281-29, Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia,15-01-2016,NA,US NCT number,protocol
4962,2015-005281-29, Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia,15-01-2016,NA,other,protocol
4963,2015-005281-29, Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia,15-01-2016,NA,US NCT number,results
4964,2015-005281-29, Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF in children with relapsed acute lymphoblastic leukemia,15-01-2016,NA,ISRCTN number,results
4965,2015-005346-58, Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),05-08-2016,NA,US NCT number,protocol
4966,2015-005346-58, Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),05-08-2016,NA,other,protocol
4967,2015-005346-58, Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),05-08-2016,NCT04114188,US NCT number,results
4968,2015-005346-58, Tacrolimus after rATG and infliximab induction immunosuppression (RIMINI),05-08-2016,NA,ISRCTN number,results
4969,2015-005416-15, An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome,24-03-2016,NA,US NCT number,protocol
4970,2015-005416-15, An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome,24-03-2016,DRKS DRKS00010085,other,protocol
4971,2015-005416-15, An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome,24-03-2016,NA,US NCT number,results
4972,2015-005416-15, An open label phase II study of Sirolimus in patients with segmental overgrowth syndrome,24-03-2016,NA,ISRCTN number,results
4973,2015-005566-33, APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF),04-02-2016,NA,US NCT number,protocol
4974,2015-005566-33, APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF),04-02-2016,NA,other,protocol
4975,2015-005566-33, APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF),04-02-2016,NCT02789917,US NCT number,results
4976,2015-005566-33, APixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF),04-02-2016,NA,ISRCTN number,results
4977,2015-005740-34, Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus,29-09-2016,NA,US NCT number,protocol
4978,2015-005740-34, Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus,29-09-2016,NA,other,protocol
4979,2015-005740-34, Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus,29-09-2016,NA,US NCT number,results
4980,2015-005740-34, Effectiveness of Dapagliflozin + Saxagliptin to revert from a standard basalbolus,29-09-2016,NA,ISRCTN number,results
4981,2015-005744-34," Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency",28-09-2018,NA,US NCT number,protocol
4982,2015-005744-34," Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency",28-09-2018,NA,other,protocol
4983,2015-005744-34," Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency",28-09-2018,NA,US NCT number,results
4984,2015-005744-34," Randomized, Double-Blinded, Controlled Trial of Intravenous Iron in Patients With Cardiovascular Disease and Concomitant Iron Deficiency",28-09-2018,NA,ISRCTN number,results
4985,2015-005757-12," Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance,",02-05-2017,NA,US NCT number,protocol
4986,2015-005757-12," Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance,",02-05-2017,NA,other,protocol
4987,2015-005757-12," Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance,",02-05-2017,NA,US NCT number,results
4988,2015-005757-12," Effect of IV iron (ferric carboxymaltose, Ferinject) on exercise tolerance,",02-05-2017,NA,ISRCTN number,results
4989,2015-005817-61, iVAC-CLL01: Patient-individualized peptide vaccination,13-04-2016,NCT02802943,US NCT number,protocol
4990,2015-005817-61, iVAC-CLL01: Patient-individualized peptide vaccination,13-04-2016,NA,other,protocol
4991,2015-005817-61, iVAC-CLL01: Patient-individualized peptide vaccination,13-04-2016,NA,US NCT number,results
4992,2015-005817-61, iVAC-CLL01: Patient-individualized peptide vaccination,13-04-2016,NA,ISRCTN number,results
4993,2016-000048-32, Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder ,10-10-2017,NA,US NCT number,protocol
4994,2016-000048-32, Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder ,10-10-2017,NA,other,protocol
4995,2016-000048-32, Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder ,10-10-2017,NA,US NCT number,results
4996,2016-000048-32, Evaluation of the Therapeutic Effects of Testosterone on Pain Perception in case of Chronic Pain Disorder ,10-10-2017,NA,ISRCTN number,results
4997,2016-000068-40, Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,12-09-2016,NA,US NCT number,protocol
4998,2016-000068-40, Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,12-09-2016,NA,other,protocol
4999,2016-000068-40, Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,12-09-2016,NA,US NCT number,results
5000,2016-000068-40, Intravenous iron in patients with systolic heart failure and iron deficiency to improve morbidity & mortality,12-09-2016,NA,ISRCTN number,results
5001,2016-000136-17," Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock",08-04-2016,NA,US NCT number,protocol
5002,2016-000136-17," Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock",08-04-2016,NA,other,protocol
5003,2016-000136-17," Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock",08-04-2016,NA,US NCT number,results
5004,2016-000136-17," Prospective, randomized, multicenter clinical trial on the impact of Therapeutic Drug Monitoring (TDM) of piperacillin on organ functions and survival in the treatment of severe sepsis or septic shock",08-04-2016,NA,ISRCTN number,results
5005,2016-000172-19, Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes,21-11-2016,NA,US NCT number,protocol
5006,2016-000172-19, Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes,21-11-2016,NA,other,protocol
5007,2016-000172-19, Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes,21-11-2016,NCT03132181,US NCT number,results
5008,2016-000172-19, Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients with Type 2 Diabetes,21-11-2016,NA,ISRCTN number,results
5009,2016-000214-30, Empagliflozin and its effect on heart failure in type 2 diabetes,30-05-2016,NA,US NCT number,protocol
5010,2016-000214-30, Empagliflozin and its effect on heart failure in type 2 diabetes,30-05-2016,DRKS 00009894,other,protocol
5011,2016-000214-30, Empagliflozin and its effect on heart failure in type 2 diabetes,30-05-2016,NA,US NCT number,results
5012,2016-000214-30, Empagliflozin and its effect on heart failure in type 2 diabetes,30-05-2016,NA,ISRCTN number,results
5013,2016-000222-19, Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiority (Phase III),30-01-2017,NA,US NCT number,protocol
5014,2016-000222-19, Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiority (Phase III),30-01-2017,NA,other,protocol
5015,2016-000222-19, Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiority (Phase III),30-01-2017,NA,US NCT number,results
5016,2016-000222-19, Effect of ALlopurinol in addition to hypothermia for hypoxic-ischemic Brain Injury on Neurocognitive Outcome – a blinded randomized placebo-controlled parallel group multicenter trial for superiority (Phase III),30-01-2017,NA,ISRCTN number,results
5017,2016-000284-17, Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).,16-08-2016,NA,US NCT number,protocol
5018,2016-000284-17, Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).,16-08-2016,NA,other,protocol
5019,2016-000284-17, Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).,16-08-2016,NA,US NCT number,results
5020,2016-000284-17, Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).,16-08-2016,NA,ISRCTN number,results
5021,2016-000421-39," Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy (AMLSG 26-16 / AML-ViVA)",30-11-2016,NCT02942758,US NCT number,protocol
5022,2016-000421-39," Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy (AMLSG 26-16 / AML-ViVA)",30-11-2016,NA,other,protocol
5023,2016-000421-39," Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy (AMLSG 26-16 / AML-ViVA)",30-11-2016,NA,US NCT number,results
5024,2016-000421-39," Randomized Phase II trial with safety run-in phase evaluating low-dose azacitidine, all-trans retinoic acid and pioglitazone versus standard dose azacitidine in patients >=60 years with acute myeloid leukemia (AML) who are refractory to standard induction chemotherapy (AMLSG 26-16 / AML-ViVA)",30-11-2016,NA,ISRCTN number,results
5025,2016-000432-17," A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients",12-09-2016,NA,US NCT number,protocol
5026,2016-000432-17," A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients",12-09-2016,NA,other,protocol
5027,2016-000432-17," A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients",12-09-2016,NA,US NCT number,results
5028,2016-000432-17," A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary diagnosed high-risk multiple myeloma paTients",12-09-2016,NA,ISRCTN number,results
5029,2016-000433-51," DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial",11-07-2016,NA,US NCT number,protocol
5030,2016-000433-51," DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial",11-07-2016,NA,other,protocol
5031,2016-000433-51," DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial",11-07-2016,NA,US NCT number,results
5032,2016-000433-51," DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial",11-07-2016,NA,ISRCTN number,results
5033,2016-000477-21, Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial,10-01-2017,NA,US NCT number,protocol
5034,2016-000477-21, Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial,10-01-2017,NA,other,protocol
5035,2016-000477-21, Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial,10-01-2017,NCT03151603,US NCT number,results
5036,2016-000477-21, Reducing antibiotic use for uncomplicated urinary tract infection in gen-eral practice by treatment with Uva ursi - a comparative effectiveness trial,10-01-2017,NA,ISRCTN number,results
5037,2016-000564-42, A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS),20-02-2017,NCT03087201,US NCT number,protocol
5038,2016-000564-42, A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS),20-02-2017,NA,other,protocol
5039,2016-000564-42, A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS),20-02-2017,NA,US NCT number,results
5040,2016-000564-42, A randomized multi-centre double-blind placebo controlled trial to demonstrate the efficacy and safety of nabiximols in the treatment of adults with chronic tic disorders (CANNA-TICS),20-02-2017,NA,ISRCTN number,results
5041,2016-000573-20, Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction,26-04-2016,NA,US NCT number,protocol
5042,2016-000573-20, Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction,26-04-2016,NA,other,protocol
5043,2016-000573-20, Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction,26-04-2016,NA,US NCT number,results
5044,2016-000573-20, Effects of MUTAFLOR® on exercise-induced gastro-intestinal dysfunction,26-04-2016,NA,ISRCTN number,results
5045,2016-000615-33, Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),06-07-2016,NCT02758782,US NCT number,protocol
5046,2016-000615-33, Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),06-07-2016,NA,other,protocol
5047,2016-000615-33, Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),06-07-2016,NCT02758782,US NCT number,results
5048,2016-000615-33, Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on progression of structural damage in the spine over two years in patients with ankylosing spondylitis: a randomized controlled multicentre trial (CONSUL),06-07-2016,NA,ISRCTN number,results
5049,2016-000706-12," A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma",01-11-2016,NCT03075423,US NCT number,protocol
5050,2016-000706-12," A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma",01-11-2016,SUNNIFORECAST SUNNIFORECAST,other,protocol
5051,2016-000706-12," A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma",01-11-2016,NA,US NCT number,results
5052,2016-000706-12," A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Standard of Care in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma",01-11-2016,NA,ISRCTN number,results
5053,2016-000755-27, FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA,07-07-2016,NCT03492775,US NCT number,protocol
5054,2016-000755-27, FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA,07-07-2016,NA,other,protocol
5055,2016-000755-27, FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA,07-07-2016,NA,US NCT number,results
5056,2016-000755-27, FIRST LINE THERAPY OF ADVANCED STAGE FOLLICULAR LYMPHOMA,07-07-2016,NA,ISRCTN number,results
5057,2016-000825-38, SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial),29-07-2016,NCT02985242,US NCT number,protocol
5058,2016-000825-38, SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial),29-07-2016,NA,other,protocol
5059,2016-000825-38, SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial),29-07-2016,NA,US NCT number,results
5060,2016-000825-38, SGLT2-inhibition with Empagliflozin reduces progression of diabetic retinopathy in patients with high risk of diabetic macular edema (The SUPER-Trial),29-07-2016,NA,ISRCTN number,results
5061,2016-001030-94," Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory therapy-a randomized phase III, multicenter trial with post-study follow-up.",14-12-2016,NCT03117816,US NCT number,protocol
5062,2016-001030-94," Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory therapy-a randomized phase III, multicenter trial with post-study follow-up.",14-12-2016,NA,other,protocol
5063,2016-001030-94," Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory therapy-a randomized phase III, multicenter trial with post-study follow-up.",14-12-2016,NA,US NCT number,results
5064,2016-001030-94," Efficacy and safety of pegylated-proline-interferon alpha 2B (AOP2014) in maintaining deep molecular remissions in patients with chronic myeloid leukemia (CML) who discontinue ABL-kinase inhibitory therapy-a randomized phase III, multicenter trial with post-study follow-up.",14-12-2016,NA,ISRCTN number,results
5065,2016-001166-29, A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),12-08-2019,NA,US NCT number,protocol
5066,2016-001166-29, A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),12-08-2019,NA,other,protocol
5067,2016-001166-29, A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),12-08-2019,NA,US NCT number,results
5068,2016-001166-29, A randomised controlled trial to compare ocrelizumab or alemtuzumab with autologous hematopoietic stem cell transplantation (aHSCT) in high inflammatory multiple sclerosis (COAST),12-08-2019,NA,ISRCTN number,results
5069,2016-001264-11," A phase IV, single-center, randomized, double-blind, placebo-controlled, parallel group study on the effects of empagliflozin on left ventricular diastolic function compared to usual care in individuals with type 2 diabetes",09-06-2016,NA,US NCT number,protocol
5070,2016-001264-11," A phase IV, single-center, randomized, double-blind, placebo-controlled, parallel group study on the effects of empagliflozin on left ventricular diastolic function compared to usual care in individuals with type 2 diabetes",09-06-2016,NA,other,protocol
5071,2016-001264-11," A phase IV, single-center, randomized, double-blind, placebo-controlled, parallel group study on the effects of empagliflozin on left ventricular diastolic function compared to usual care in individuals with type 2 diabetes",09-06-2016,NA,US NCT number,results
5072,2016-001264-11," A phase IV, single-center, randomized, double-blind, placebo-controlled, parallel group study on the effects of empagliflozin on left ventricular diastolic function compared to usual care in individuals with type 2 diabetes",09-06-2016,NA,ISRCTN number,results
5073,2016-001313-24, SUbstition of PERioperative Albumin Deficiency Disorders,05-09-2016,NA,US NCT number,protocol
5074,2016-001313-24, SUbstition of PERioperative Albumin Deficiency Disorders,05-09-2016,NA,other,protocol
5075,2016-001313-24, SUbstition of PERioperative Albumin Deficiency Disorders,05-09-2016,NA,US NCT number,results
5076,2016-001313-24, SUbstition of PERioperative Albumin Deficiency Disorders,05-09-2016,NA,ISRCTN number,results
5077,2016-001378-13," A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.",13-10-2016,NA,US NCT number,protocol
5078,2016-001378-13," A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.",13-10-2016,NA,other,protocol
5079,2016-001378-13," A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.",13-10-2016,NA,US NCT number,results
5080,2016-001378-13," A randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxine treatment for cervical dystonia.",13-10-2016,NA,ISRCTN number,results
5081,2016-001554-18, English: Are Antipsychotics Neurotoxic or Neuroprotective? A Randomised Multicentre Longitudinal Study for Comparison of Two Therapy Strategies for the Treatment of Schizophrenia.,24-06-2016,NA,US NCT number,protocol
5082,2016-001554-18, English: Are Antipsychotics Neurotoxic or Neuroprotective? A Randomised Multicentre Longitudinal Study for Comparison of Two Therapy Strategies for the Treatment of Schizophrenia.,24-06-2016,NA,other,protocol
5083,2016-001554-18, English: Are Antipsychotics Neurotoxic or Neuroprotective? A Randomised Multicentre Longitudinal Study for Comparison of Two Therapy Strategies for the Treatment of Schizophrenia.,24-06-2016,NA,US NCT number,results
5084,2016-001554-18, English: Are Antipsychotics Neurotoxic or Neuroprotective? A Randomised Multicentre Longitudinal Study for Comparison of Two Therapy Strategies for the Treatment of Schizophrenia.,24-06-2016,NA,ISRCTN number,results
5085,2016-001611-20, Pathophysiology-based therapy of epileptic encephalopathies,26-09-2016,NA,US NCT number,protocol
5086,2016-001611-20, Pathophysiology-based therapy of epileptic encephalopathies,26-09-2016,NA,other,protocol
5087,2016-001611-20, Pathophysiology-based therapy of epileptic encephalopathies,26-09-2016,NA,US NCT number,results
5088,2016-001611-20, Pathophysiology-based therapy of epileptic encephalopathies,26-09-2016,NA,ISRCTN number,results
5089,2016-001628-72, Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients,07-04-2017,NA,US NCT number,protocol
5090,2016-001628-72, Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients,07-04-2017,DRKS 00011932,other,protocol
5091,2016-001628-72, Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients,07-04-2017,NA,US NCT number,results
5092,2016-001628-72, Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients,07-04-2017,NA,ISRCTN number,results
5093,2016-001777-33, EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,06-06-2016,NA,US NCT number,protocol
5094,2016-001777-33, EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,06-06-2016,NA,other,protocol
5095,2016-001777-33, EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,06-06-2016,NCT02758964,US NCT number,results
5096,2016-001777-33, EVALUATION OF CEREBRAL THROMBOEMBOLISM AFTER TAVR,06-06-2016,NA,ISRCTN number,results
5097,2016-001784-36, Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin,08-04-2019,NA,US NCT number,protocol
5098,2016-001784-36, Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin,08-04-2019,NA,other,protocol
5099,2016-001784-36, Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin,08-04-2019,NA,US NCT number,results
5100,2016-001784-36, Multicentre prospective trial for extracranial malignant germ cell tumours including a randomized comparison of Carboplatin and Cisplatin,08-04-2019,NA,ISRCTN number,results
5101,2016-001788-34," Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients",01-06-2017,NA,US NCT number,protocol
5102,2016-001788-34," Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients",01-06-2017,NA,other,protocol
5103,2016-001788-34," Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients",01-06-2017,NA,US NCT number,results
5104,2016-001788-34," Prospective, randomized study concerning personalized medicine with Pentaglobin® after interventional infectious source control in peritonitis patients",01-06-2017,NA,ISRCTN number,results
5105,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,protocol
5106,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,other,protocol
5107,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,results
5108,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,ISRCTN number,results
5109,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,protocol
5110,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,other,protocol
5111,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,results
5112,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,ISRCTN number,results
5113,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,protocol
5114,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,other,protocol
5115,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,results
5116,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,ISRCTN number,results
5117,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,protocol
5118,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,other,protocol
5119,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,US NCT number,results
5120,2016-001935-12, AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia,19-02-2018,NA,ISRCTN number,results
5121,2016-002059-89, Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro,12-06-2017,NA,US NCT number,protocol
5122,2016-002059-89, Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro,12-06-2017,NA,other,protocol
5123,2016-002059-89, Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro,12-06-2017,NA,US NCT number,results
5124,2016-002059-89, Therapy of Nodal Follicular Non-Hodgkin Lymphoma (WHO grade 1/2) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro,12-06-2017,NA,ISRCTN number,results
5125,2016-002163-34, Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC),14-06-2017,NA,US NCT number,protocol
5126,2016-002163-34, Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC),14-06-2017,NA,other,protocol
5127,2016-002163-34, Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC),14-06-2017,NA,US NCT number,results
5128,2016-002163-34, Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC),14-06-2017,NA,ISRCTN number,results
5129,2016-002272-27," Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma",09-01-2017,NCT03366272,US NCT number,protocol
5130,2016-002272-27," Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma",09-01-2017,NA,other,protocol
5131,2016-002272-27," Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma",09-01-2017,NA,US NCT number,results
5132,2016-002272-27," Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy with Aggressive Non-Hodgkin Lymphoma in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxaliplatin plus Rituximab in case of B-cell lymphoma",09-01-2017,NA,ISRCTN number,results
5133,2016-002351-16," An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema",01-12-2016,NA,US NCT number,protocol
5134,2016-002351-16," An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema",01-12-2016,NA,other,protocol
5135,2016-002351-16," An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema",01-12-2016,NA,US NCT number,results
5136,2016-002351-16," An investigator-initiated, randomized, double-blind, placebo controlled study of Apremilast to demonstrate efficacy in subjects with nummular eczema",01-12-2016,NA,ISRCTN number,results
5137,2016-002370-12, PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,21-07-2016,NA,US NCT number,protocol
5138,2016-002370-12, PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,21-07-2016,NA,other,protocol
5139,2016-002370-12, PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,21-07-2016,NA,US NCT number,results
5140,2016-002370-12, PROOF OF CONCEPT STUDY OF HYQVIA IN PATIENTS WITH IMMUNOGLOBULIN DEFICIENCY AND RECURRENT INFECTIONS WITH CHRONIC FATIGUE SYNDROME,21-07-2016,NA,ISRCTN number,results
5141,2016-002388-33, Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy,15-08-2016,NA,US NCT number,protocol
5142,2016-002388-33, Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy,15-08-2016,NA,other,protocol
5143,2016-002388-33, Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy,15-08-2016,NA,US NCT number,results
5144,2016-002388-33, Therapeutic drug monitoring (TDM) for personalized antibiotic treatment with piperacillin-tazobactam (PipTaz) in patients with febrile neutropenia after myelo-suppressive cytostatic chemotherapy,15-08-2016,NA,ISRCTN number,results
5145,2016-002550-20, Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial,30-09-2016,NA,US NCT number,protocol
5146,2016-002550-20, Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial,30-09-2016,NA,other,protocol
5147,2016-002550-20, Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial,30-09-2016,NA,US NCT number,results
5148,2016-002550-20, Allogeneic microbiota-reconstitution (AMR) for the Treatment of patients with diarrhea-predominant irritable bowel Syndrome (IBS-D) - the AMIRA trial,30-09-2016,NA,ISRCTN number,results
5149,2016-002557-38, Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell,09-10-2017,NA,US NCT number,protocol
5150,2016-002557-38, Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell,09-10-2017,NA,other,protocol
5151,2016-002557-38, Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell,09-10-2017,NA,US NCT number,results
5152,2016-002557-38, Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell,09-10-2017,NA,ISRCTN number,results
5153,2016-002626-37," Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial",28-11-2016,NA,US NCT number,protocol
5154,2016-002626-37," Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial",28-11-2016,NA,other,protocol
5155,2016-002626-37," Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial",28-11-2016,NA,US NCT number,results
5156,2016-002626-37," Nivolumab and AVD in earlystage unfavorable classical Hodgkin lymphoma - A GHSG randomized, multicenter phase II trial",28-11-2016,NA,ISRCTN number,results
5157,2016-002735-16," Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) ",04-10-2016,NA,US NCT number,protocol
5158,2016-002735-16," Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) ",04-10-2016,Short title STAR-V7,other,protocol
5159,2016-002735-16," Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) ",04-10-2016,NA,US NCT number,results
5160,2016-002735-16," Correlation between common clinical outcome parameters, CTC-changes and ARV7-status (androgen receptor splice variant 7) in patients with mCRPC treated with first line abiraterone acetat (Zytiga®) ",04-10-2016,NA,ISRCTN number,results
5161,2016-002920-10, TREAT-SVDs:,04-08-2016,NCT03082014,US NCT number,protocol
5162,2016-002920-10, TREAT-SVDs:,04-08-2016,Oxford Research Ethics Committee B 17/SC/0338,other,protocol
5163,2016-002920-10, TREAT-SVDs:,04-08-2016,NA,US NCT number,results
5164,2016-002920-10, TREAT-SVDs:,04-08-2016,NA,ISRCTN number,results
5165,2016-002941-49, Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study,22-07-2016,NA,US NCT number,protocol
5166,2016-002941-49, Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study,22-07-2016,NA,other,protocol
5167,2016-002941-49, Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study,22-07-2016,NA,US NCT number,results
5168,2016-002941-49, Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study,22-07-2016,NA,ISRCTN number,results
5169,2016-003168-37," Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study",29-11-2018,NA,US NCT number,protocol
5170,2016-003168-37," Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study",29-11-2018,NA,other,protocol
5171,2016-003168-37," Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study",29-11-2018,NA,US NCT number,results
5172,2016-003168-37," Therapeutic Iloprost for the treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial): a prospective, randomized, multicenter phase II study",29-11-2018,NA,ISRCTN number,results
5173,2016-003175-22, Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP--,13-11-2017,NA,US NCT number,protocol
5174,2016-003175-22, Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP--,13-11-2017,NA,other,protocol
5175,2016-003175-22, Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP--,13-11-2017,NA,US NCT number,results
5176,2016-003175-22, Two-arm randomized phase II trial to assess the feasibility and efficacy of a treatment with Durvalumab a PDL1-Inhibitor plus Tremelimumab a CTLA-4- Inhibitor in combination with radiotherapy and a treatment with Durvalumab in combination with radiotherapy as first-line therapy for patients with non-resectable locally advanced HPV negative HNSCC- A COMPARISON WITH A HISTORICAL CONTROL GROUP--,13-11-2017,NA,ISRCTN number,results
5177,2016-003223-30, Prophylactic treatment of hemiplegic migraine with Lamotrigine,20-02-2017,NA,US NCT number,protocol
5178,2016-003223-30, Prophylactic treatment of hemiplegic migraine with Lamotrigine,20-02-2017,NA,other,protocol
5179,2016-003223-30, Prophylactic treatment of hemiplegic migraine with Lamotrigine,20-02-2017,NA,US NCT number,results
5180,2016-003223-30, Prophylactic treatment of hemiplegic migraine with Lamotrigine,20-02-2017,NA,ISRCTN number,results
5181,2016-003334-25, A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition,15-11-2016,NCT03083691,US NCT number,protocol
5182,2016-003334-25, A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition,15-11-2016,NA,other,protocol
5183,2016-003334-25, A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition,15-11-2016,NA,US NCT number,results
5184,2016-003334-25, A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in relapsed lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition,15-11-2016,NA,ISRCTN number,results
5185,2016-003360-39, Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis,11-04-2017,NA,US NCT number,protocol
5186,2016-003360-39, Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis,11-04-2017,DRKS00011660 Deutsches Register Klinischer Studien,other,protocol
5187,2016-003360-39, Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis,11-04-2017,NA,US NCT number,results
5188,2016-003360-39, Safety and efficacy of Abatacept in patients with treatment-resistant sarcoidosis,11-04-2017,NA,ISRCTN number,results
5189,2016-003477-18, A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes,12-01-2017,NA,US NCT number,protocol
5190,2016-003477-18, A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes,12-01-2017,NA,other,protocol
5191,2016-003477-18, A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes,12-01-2017,NCT03227484,US NCT number,results
5192,2016-003477-18, A double-blind randomized study to determine the effect of empagliflozin versus placebo on brain insulin sensitivity in patients with prediabetes,12-01-2017,NA,ISRCTN number,results
5193,2016-003551-30, Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia,27-02-2017,NA,US NCT number,protocol
5194,2016-003551-30, Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia,27-02-2017,NA,other,protocol
5195,2016-003551-30, Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia,27-02-2017,NA,US NCT number,results
5196,2016-003551-30, Modeling of the impact of a PCSK9 inhibition on lipoproteins in patients with dyslipidemia,27-02-2017,NA,ISRCTN number,results
5197,2016-003568-38, German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV ,13-10-2016,NA,US NCT number,protocol
5198,2016-003568-38, German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV ,13-10-2016,NA,other,protocol
5199,2016-003568-38, German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV ,13-10-2016,NA,US NCT number,results
5200,2016-003568-38, German Treatment Optimization Study for Children with De Novo and Relapsed Langerhans cell Histiocytosis (LCH) as Part of the International Study LCH-IV ,13-10-2016,NA,ISRCTN number,results
5201,2016-003684-19, Xenon-anesthesia on patients undergoing major liver-resection: randomized controlled trial,27-11-2017,NA,US NCT number,protocol
5202,2016-003684-19, Xenon-anesthesia on patients undergoing major liver-resection: randomized controlled trial,27-11-2017,NA,other,protocol
5203,2016-003684-19, Xenon-anesthesia on patients undergoing major liver-resection: randomized controlled trial,27-11-2017,NA,US NCT number,results
5204,2016-003684-19, Xenon-anesthesia on patients undergoing major liver-resection: randomized controlled trial,27-11-2017,NA,ISRCTN number,results
5205,2016-003705-34, PIGMENT – PDE6A gene therapy for retinitis pigmentosa,26-11-2018,NA,US NCT number,protocol
5206,2016-003705-34, PIGMENT – PDE6A gene therapy for retinitis pigmentosa,26-11-2018,NA,other,protocol
5207,2016-003705-34, PIGMENT – PDE6A gene therapy for retinitis pigmentosa,26-11-2018,NA,US NCT number,results
5208,2016-003705-34, PIGMENT – PDE6A gene therapy for retinitis pigmentosa,26-11-2018,NA,ISRCTN number,results
5209,2016-003738-25," A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)",05-10-2017,NA,US NCT number,protocol
5210,2016-003738-25," A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)",05-10-2017,NA,other,protocol
5211,2016-003738-25," A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)",05-10-2017,NA,US NCT number,results
5212,2016-003738-25," A 28-week, multi-center randomized, double-blind, placebo-controlled study to evaluate the potential of Dapagliflozin plus Exenatide in combination with high-dose intensive insulin therapy compared to Placebo in obese insulin-resistant patients with Type 2 Diabetes mellitus (Proof-of-concept study)",05-10-2017,NA,ISRCTN number,results
5213,2016-003802-14, Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,14-10-2016,NA,US NCT number,protocol
5214,2016-003802-14, Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,14-10-2016,NA,other,protocol
5215,2016-003802-14, Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,14-10-2016,NA,US NCT number,results
5216,2016-003802-14, Skin penetration of anti-inflammatory compounds in lesional compared to non-lesional skin of psoriasis patients,14-10-2016,NA,ISRCTN number,results
5217,2016-003828-23," A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)		",31-01-2017,NA,US NCT number,protocol
5218,2016-003828-23," A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)		",31-01-2017,NA,other,protocol
5219,2016-003828-23," A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)		",31-01-2017,NCT03046381,US NCT number,results
5220,2016-003828-23," A pilot open-label study to assess the efficacy and safety of tocilizumab (TCZ) in patients with active Schnitzler’s syndrome (SchS)		",31-01-2017,NA,ISRCTN number,results
5221,2016-003902-14, Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study,03-02-2017,NA,US NCT number,protocol
5222,2016-003902-14, Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study,03-02-2017,NA,other,protocol
5223,2016-003902-14, Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study,03-02-2017,NA,US NCT number,results
5224,2016-003902-14, Intravenous Fish Oil based Lipid Emulsion as Pharmaconutrient Strategy in High-Risk Cardiac Surgery Patients: a Phase II Dosing Study,03-02-2017,NA,ISRCTN number,results
5225,2016-003947-12, Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells,02-02-2017,NA,US NCT number,protocol
5226,2016-003947-12, Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells,02-02-2017,NA,other,protocol
5227,2016-003947-12, Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells,02-02-2017,NA,US NCT number,results
5228,2016-003947-12, Treatment of steroid-resistant chronic graft-versus-host-disease with donor-derived regulatory T cells,02-02-2017,NA,ISRCTN number,results
5229,2016-004147-37, Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency:,24-11-2016,NA,US NCT number,protocol
5230,2016-004147-37, Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency:,24-11-2016,NA,other,protocol
5231,2016-004147-37, Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency:,24-11-2016,NA,US NCT number,results
5232,2016-004147-37, Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency:,24-11-2016,NA,ISRCTN number,results
5233,2016-004373-40," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after chemotherapy",15-05-2017,NA,US NCT number,protocol
5234,2016-004373-40," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after chemotherapy",15-05-2017,Merck trial code  MS100070_0075,other,protocol
5235,2016-004373-40," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after chemotherapy",15-05-2017,NA,US NCT number,results
5236,2016-004373-40," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of avelumab in patients with advanced, metastatic high grade neuroendocrine carcinomas NEC G3 (WHO 2010) progressive after chemotherapy",15-05-2017,NA,ISRCTN number,results
5237,2016-004396-51, Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial),13-02-2017,NA,US NCT number,protocol
5238,2016-004396-51, Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial),13-02-2017,German Clinical Trial Register (DRKS) DRKS-ID: DRKS00011374,other,protocol
5239,2016-004396-51, Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial),13-02-2017,NA,US NCT number,results
5240,2016-004396-51, Pentaerithrityl tetranitrate (PETN) for secondary prevention of intrauterine growth restriction (PETN Trial),13-02-2017,NA,ISRCTN number,results
5241,2016-004446-29," Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients",21-03-2017,NA,US NCT number,protocol
5242,2016-004446-29," Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients",21-03-2017,NA,other,protocol
5243,2016-004446-29," Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients",21-03-2017,NA,US NCT number,results
5244,2016-004446-29," Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients",21-03-2017,NA,ISRCTN number,results
5245,2016-004488-38, Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with chronic diabetic macular edema,18-08-2017,NA,US NCT number,protocol
5246,2016-004488-38, Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with chronic diabetic macular edema,18-08-2017,NA,other,protocol
5247,2016-004488-38, Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with chronic diabetic macular edema,18-08-2017,NA,US NCT number,results
5248,2016-004488-38, Iluvit – An investigator initiated monocentric pilot study to investigate inflammation parameters and growth factors in the vitreous during a cortisone long-term therapy with Iluvien® in patients with chronic diabetic macular edema,18-08-2017,NA,ISRCTN number,results
5249,2016-004505-13," Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE ",21-08-2017,NA,US NCT number,protocol
5250,2016-004505-13," Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE ",21-08-2017,NA,other,protocol
5251,2016-004505-13," Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE ",21-08-2017,NCT03446209,US NCT number,results
5252,2016-004505-13," Tocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE ",21-08-2017,NA,ISRCTN number,results
5253,2016-004555-79, Impact of preoperative midazolam on outcome of elderly patients: a multicenter randomised controlled trial,11-04-2017,NCT03052660,US NCT number,protocol
5254,2016-004555-79, Impact of preoperative midazolam on outcome of elderly patients: a multicenter randomised controlled trial,11-04-2017,NA,other,protocol
5255,2016-004555-79, Impact of preoperative midazolam on outcome of elderly patients: a multicenter randomised controlled trial,11-04-2017,NCT03052660,US NCT number,results
5256,2016-004555-79, Impact of preoperative midazolam on outcome of elderly patients: a multicenter randomised controlled trial,11-04-2017,NA,ISRCTN number,results
5257,2016-004614-10, An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma,16-01-2017,NA,US NCT number,protocol
5258,2016-004614-10, An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma,16-01-2017,NA,other,protocol
5259,2016-004614-10, An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma,16-01-2017,NA,US NCT number,results
5260,2016-004614-10, An open label phase II study to evaluate safety and efficacy of combined treatment with ipilimumab and nivolumab in patients with four and more symptomatic brain metastases of melanoma,16-01-2017,NA,ISRCTN number,results
5261,2016-004660-19, CDK4/6 inhibition in locally advanced/metastatic chordoma ,30-08-2017,NCT03110744,US NCT number,protocol
5262,2016-004660-19, CDK4/6 inhibition in locally advanced/metastatic chordoma ,30-08-2017,NA,other,protocol
5263,2016-004660-19, CDK4/6 inhibition in locally advanced/metastatic chordoma ,30-08-2017,NA,US NCT number,results
5264,2016-004660-19, CDK4/6 inhibition in locally advanced/metastatic chordoma ,30-08-2017,NA,ISRCTN number,results
5265,2016-004730-18, The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT),30-06-2017,NA,US NCT number,protocol
5266,2016-004730-18, The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT),30-06-2017,NA,other,protocol
5267,2016-004730-18, The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT),30-06-2017,NA,US NCT number,results
5268,2016-004730-18, The influence of Timolol Nasal Spray on Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT),30-06-2017,NA,ISRCTN number,results
5269,2016-004758-13, Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy,25-09-2017,NA,US NCT number,protocol
5270,2016-004758-13, Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy,25-09-2017,NA,other,protocol
5271,2016-004758-13, Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy,25-09-2017,NA,US NCT number,results
5272,2016-004758-13, Multicenter randomized controlled study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy,25-09-2017,NA,ISRCTN number,results
5273,2016-004786-80," A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.",30-06-2017,NA,US NCT number,protocol
5274,2016-004786-80," A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.",30-06-2017,NA,other,protocol
5275,2016-004786-80," A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.",30-06-2017,NA,US NCT number,results
5276,2016-004786-80," A phase IIa, randomized, placebo-controlled, double-blind, cross-over study to evaluate safety and efficacy of subcutanous administration of anakinra in patients with cystic fibrosis.",30-06-2017,NA,ISRCTN number,results
5277,2016-004787-20," An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery (NadiHN)",05-07-2017,NA,US NCT number,protocol
5278,2016-004787-20," An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery (NadiHN)",05-07-2017,NA,other,protocol
5279,2016-004787-20," An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery (NadiHN)",05-07-2017,NA,US NCT number,results
5280,2016-004787-20," An Open Label, Randomized Phase 2 Clinical Trial of Nivolumab investigating Effiacy and safety of Nivolumab given once prior to, concurrent to the radiotherapy (RT) and as maintenance therapy over 12 months in patients with advanced resectable HNSCC after surgery (NadiHN)",05-07-2017,NA,ISRCTN number,results
5281,2016-004808-60, Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector -  A unicenter Phase I /II clinical trial,25-07-2017,NCT03676504,US NCT number,protocol
5282,2016-004808-60, Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector -  A unicenter Phase I /II clinical trial,25-07-2017,NA,other,protocol
5283,2016-004808-60, Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector -  A unicenter Phase I /II clinical trial,25-07-2017,NA,US NCT number,results
5284,2016-004808-60, Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector -  A unicenter Phase I /II clinical trial,25-07-2017,NA,ISRCTN number,results
5285,2016-004825-17, A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,09-11-2017,NA,US NCT number,protocol
5286,2016-004825-17, A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,09-11-2017,NA,other,protocol
5287,2016-004825-17, A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,09-11-2017,NA,US NCT number,results
5288,2016-004825-17, A Proof-of-concept study to investigate the Efficacy of Telbivudine Over Placebo in patients with Parvovirus-associated Inflammatory Cardiomyopathy,09-11-2017,NA,ISRCTN number,results
5289,2016-004836-39, An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL).,17-05-2017,NA,US NCT number,protocol
5290,2016-004836-39, An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL).,17-05-2017,NA,other,protocol
5291,2016-004836-39, An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL).,17-05-2017,NA,US NCT number,results
5292,2016-004836-39, An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy In patients aged 56 years and older with Acute Lymphoblastic leukemia (ALL).,17-05-2017,NA,ISRCTN number,results
5293,2016-005022-10, Improvement of synaptic plasticity and cognitive function in RAS pathway disorders,09-11-2017,NA,US NCT number,protocol
5294,2016-005022-10, Improvement of synaptic plasticity and cognitive function in RAS pathway disorders,09-11-2017,NA,other,protocol
5295,2016-005022-10, Improvement of synaptic plasticity and cognitive function in RAS pathway disorders,09-11-2017,NA,US NCT number,results
5296,2016-005022-10, Improvement of synaptic plasticity and cognitive function in RAS pathway disorders,09-11-2017,NA,ISRCTN number,results
5297,2016-005100-26," A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia",07-07-2017,NA,US NCT number,protocol
5298,2016-005100-26," A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia",07-07-2017,NA,other,protocol
5299,2016-005100-26," A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia",07-07-2017,NA,US NCT number,results
5300,2016-005100-26," A pilot Study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency in patients with pulmonary hypertension and iron deficiency anemia",07-07-2017,NA,ISRCTN number,results
5301,2016-005101-39, A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol,15-05-2018,NA,US NCT number,protocol
5302,2016-005101-39, A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol,15-05-2018,NA,other,protocol
5303,2016-005101-39, A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol,15-05-2018,NA,US NCT number,results
5304,2016-005101-39, A phase IV study to explore the safety of ORal IrON supplementation with ferric maltol,15-05-2018,NA,ISRCTN number,results
5305,2017-000058-21, Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,28-08-2017,NCT03463317,US NCT number,protocol
5306,2017-000058-21, Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,28-08-2017,NA,other,protocol
5307,2017-000058-21, Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,28-08-2017,NA,US NCT number,results
5308,2017-000058-21, Left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding compared to medical therapy: a prospective randomized clinical trial,28-08-2017,NA,ISRCTN number,results
5309,2017-000152-26, Intraoperative wound irrigation to prevent surgical site infection after,26-04-2017,NA,US NCT number,protocol
5310,2017-000152-26, Intraoperative wound irrigation to prevent surgical site infection after,26-04-2017,NA,other,protocol
5311,2017-000152-26, Intraoperative wound irrigation to prevent surgical site infection after,26-04-2017,NA,US NCT number,results
5312,2017-000152-26, Intraoperative wound irrigation to prevent surgical site infection after,26-04-2017,NA,ISRCTN number,results
5313,2017-000304-14," Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma",17-02-2017,NA,US NCT number,protocol
5314,2017-000304-14," Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma",17-02-2017,NA,other,protocol
5315,2017-000304-14," Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma",17-02-2017,NA,US NCT number,results
5316,2017-000304-14," Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma",17-02-2017,NA,ISRCTN number,results
5317,2017-000394-36, Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients,02-08-2017,NCT03415906,US NCT number,protocol
5318,2017-000394-36, Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients,02-08-2017,NA,other,protocol
5319,2017-000394-36, Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients,02-08-2017,NA,US NCT number,results
5320,2017-000394-36, Influences of angiotensin-neprilysin inhibition with Sacubitril/Valsartan (ENTRESTO®) on centrally generated sympathetic activity in heart failure patients,02-08-2017,NA,ISRCTN number,results
5321,2017-000403-24, HepNet pilot trial: Multicenter trial for the treatment of chronic hepatitis E with sofosbuvir (SofE),08-09-2017,NCT03282474,US NCT number,protocol
5322,2017-000403-24, HepNet pilot trial: Multicenter trial for the treatment of chronic hepatitis E with sofosbuvir (SofE),08-09-2017,NA,other,protocol
5323,2017-000403-24, HepNet pilot trial: Multicenter trial for the treatment of chronic hepatitis E with sofosbuvir (SofE),08-09-2017,NCT03282474,US NCT number,results
5324,2017-000403-24, HepNet pilot trial: Multicenter trial for the treatment of chronic hepatitis E with sofosbuvir (SofE),08-09-2017,NA,ISRCTN number,results
5325,2017-000435-13," Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.",16-10-2017,NA,US NCT number,protocol
5326,2017-000435-13," Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.",16-10-2017,NA,other,protocol
5327,2017-000435-13," Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.",16-10-2017,NA,US NCT number,results
5328,2017-000435-13," Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.",16-10-2017,NA,ISRCTN number,results
5329,2017-000514-35, Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U),03-04-2018,NCT03063541,US NCT number,protocol
5330,2017-000514-35, Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U),03-04-2018,NA,other,protocol
5331,2017-000514-35, Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U),03-04-2018,NA,US NCT number,results
5332,2017-000514-35, Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U),03-04-2018,NA,ISRCTN number,results
5333,2017-000635-13, Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption,22-02-2018,NA,US NCT number,protocol
5334,2017-000635-13, Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption,22-02-2018,NA,other,protocol
5335,2017-000635-13, Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption,22-02-2018,NA,US NCT number,results
5336,2017-000635-13, Escalating therapy in steroid-refractory relapses of multiple sclerosis – comparison of methylprednisolone to immunoadsorption,22-02-2018,NA,ISRCTN number,results
5337,2017-000697-11, SPIRonolactone In the Treatment of Heart Failure -,08-12-2017,NA,US NCT number,protocol
5338,2017-000697-11, SPIRonolactone In the Treatment of Heart Failure -,08-12-2017,NA,other,protocol
5339,2017-000697-11, SPIRonolactone In the Treatment of Heart Failure -,08-12-2017,NA,US NCT number,results
5340,2017-000697-11, SPIRonolactone In the Treatment of Heart Failure -,08-12-2017,NA,ISRCTN number,results
5341,2017-000764-15," European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS",06-07-2017,NA,US NCT number,protocol
5342,2017-000764-15," European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS",06-07-2017,NA,other,protocol
5343,2017-000764-15," European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS",06-07-2017,NA,US NCT number,results
5344,2017-000764-15," European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS",06-07-2017,NA,ISRCTN number,results
5345,2017-000768-13, An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases ,14-08-2017,NA,US NCT number,protocol
5346,2017-000768-13, An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases ,14-08-2017,NA,other,protocol
5347,2017-000768-13, An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases ,14-08-2017,NA,US NCT number,results
5348,2017-000768-13, An open-label phase II multicenter study of vemurafenib (Zelboraf®) plus cobimetinib (Cotellic®) after radiosurgery in patients with active BRAF-V600-mutant melanoma brain metastases ,14-08-2017,NA,ISRCTN number,results
5349,2017-000868-15, Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.,14-06-2017,NA,US NCT number,protocol
5350,2017-000868-15, Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.,14-06-2017,Internal project no. P001151,other,protocol
5351,2017-000868-15, Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.,14-06-2017,NA,US NCT number,results
5352,2017-000868-15, Stereotactic Cisternal Lavage in Patients with Aneurysmal Subarachnoid Hemorrhage with Urokinase and Nimodipine for the Prevention of Secondary Brain Injury. A Randomized Controlled Trial.,14-06-2017,NA,ISRCTN number,results
5353,2017-001083-38, Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial,20-11-2017,NA,US NCT number,protocol
5354,2017-001083-38, Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial,20-11-2017,NA,other,protocol
5355,2017-001083-38, Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial,20-11-2017,NA,US NCT number,results
5356,2017-001083-38, Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial,20-11-2017,NA,ISRCTN number,results
5357,2017-001207-68, A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors,03-01-2018,NA,US NCT number,protocol
5358,2017-001207-68, A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors,03-01-2018,German Clinical Trial Register DRKS00014689,other,protocol
5359,2017-001207-68, A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors,03-01-2018,NA,US NCT number,results
5360,2017-001207-68, A multicenter single-arm pilot study of ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors,03-01-2018,NA,ISRCTN number,results
5361,2017-001262-25," A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",06-08-2018,NA,US NCT number,protocol
5362,2017-001262-25," A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",06-08-2018,NA,other,protocol
5363,2017-001262-25," A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",06-08-2018,NA,US NCT number,results
5364,2017-001262-25," A randomized, double-blind, placebo-controlled, proof-of-concept, multicenter, 16-week treatment study with a 16 week follow-up period to assess the exploratory efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with cholinergic urticaria despite H1-antihistamine treatment.",06-08-2018,NA,ISRCTN number,results
5365,2017-001355-31, Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile:,03-07-2018,NA,US NCT number,protocol
5366,2017-001355-31, Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile:,03-07-2018,NA,other,protocol
5367,2017-001355-31, Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile:,03-07-2018,NA,US NCT number,results
5368,2017-001355-31, Penumbral Rescue by Normobaric O=O Administration in Patients with Ischemic Stroke and Target Mismatch ProFile:,03-07-2018,NA,ISRCTN number,results
5369,2017-001357-14," Randomized, doubleblind, 4-arms, monocentric,  interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.",27-07-2017,NA,US NCT number,protocol
5370,2017-001357-14," Randomized, doubleblind, 4-arms, monocentric,  interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.",27-07-2017,NA,other,protocol
5371,2017-001357-14," Randomized, doubleblind, 4-arms, monocentric,  interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.",27-07-2017,NA,US NCT number,results
5372,2017-001357-14," Randomized, doubleblind, 4-arms, monocentric,  interventinal Study for enhancing the efficacy of tDCS across from single intervention or Placebo by nicotinergic stimulation in schizophrenia.",27-07-2017,NA,ISRCTN number,results
5373,2017-001479-22, Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial),04-07-2017,NCT03021525,US NCT number,protocol
5374,2017-001479-22, Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial),04-07-2017,NA,other,protocol
5375,2017-001479-22, Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial),04-07-2017,NA,US NCT number,results
5376,2017-001479-22, Individualized perioperative hemodynamic goal-directed therapy in major abdominal surgery (iPEGASUS-trial),04-07-2017,NA,ISRCTN number,results
5377,2017-001604-30," Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",29-09-2017,NA,US NCT number,protocol
5378,2017-001604-30," Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",29-09-2017,NA,other,protocol
5379,2017-001604-30," Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",29-09-2017,NCT03444103,US NCT number,results
5380,2017-001604-30," Safety, Tolerability and Efficacy of anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection after Kidney Transplantation - A Pilot Trial",29-09-2017,NA,ISRCTN number,results
5381,2017-001616-11," Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide",29-12-2017,NA,US NCT number,protocol
5382,2017-001616-11," Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide",29-12-2017,NA,other,protocol
5383,2017-001616-11," Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide",29-12-2017,NA,US NCT number,results
5384,2017-001616-11," Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma and Subsequent Maintenance with Elotuzumab and Lenalidomide versus Single-Agent Lenalidomide",29-12-2017,NA,ISRCTN number,results
5385,2017-001691-39, LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma ,06-12-2018,NA,US NCT number,protocol
5386,2017-001691-39, LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma ,06-12-2018,NA,other,protocol
5387,2017-001691-39, LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma ,06-12-2018,NA,US NCT number,results
5388,2017-001691-39, LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma ,06-12-2018,NA,ISRCTN number,results
5389,2017-001755-31, Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies,22-03-2018,NCT03127215,US NCT number,protocol
5390,2017-001755-31, Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies,22-03-2018,NA,other,protocol
5391,2017-001755-31, Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies,22-03-2018,NA,US NCT number,results
5392,2017-001755-31, Randomized Phase-II Study of Trabectedin/Olaparib Compared to Physician’s Choice in Subjects with Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies,22-03-2018,NA,ISRCTN number,results
5393,2017-002122-20, Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE),22-01-2018,NA,US NCT number,protocol
5394,2017-002122-20, Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE),22-01-2018,NA,other,protocol
5395,2017-002122-20, Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE),22-01-2018,NA,US NCT number,results
5396,2017-002122-20, Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma (IMPORTANCE),22-01-2018,NA,ISRCTN number,results
5397,2017-002163-17," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.",20-11-2017,NCT03761511,US NCT number,protocol
5398,2017-002163-17," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.",20-11-2017,NA,other,protocol
5399,2017-002163-17," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.",20-11-2017,NA,US NCT number,results
5400,2017-002163-17," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.",20-11-2017,NA,ISRCTN number,results
5401,2017-002194-18, Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT),10-01-2018,NA,US NCT number,protocol
5402,2017-002194-18, Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT),10-01-2018,NA,other,protocol
5403,2017-002194-18, Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT),10-01-2018,NA,US NCT number,results
5404,2017-002194-18, Phase 1/2 Trial to determine the Response Rate of Nivolumab in Acute Myeloid Leukemia (AML) relapse after Allogeneic Hematopoietic Cell Transplantation (allo-HCT),10-01-2018,NA,ISRCTN number,results
5405,2017-002314-31," Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplantation",03-05-2018,NA,US NCT number,protocol
5406,2017-002314-31," Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplantation",03-05-2018,NA,other,protocol
5407,2017-002314-31," Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplantation",03-05-2018,NA,US NCT number,results
5408,2017-002314-31," Phase 2 Study Evaluating the Safety, Tolerability and Efficacy of Allogeneic Donor Lymphocyte Infusions Combined with Blinatumomab in Patients with Treatment-Resistant Mixed Chimerism or Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplantation",03-05-2018,NA,ISRCTN number,results
5409,2017-002331-41, Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized,10-04-2019,NA,US NCT number,protocol
5410,2017-002331-41, Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized,10-04-2019,NA,other,protocol
5411,2017-002331-41, Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized,10-04-2019,NA,US NCT number,results
5412,2017-002331-41, Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients with Acute Leukemia with Identical GVHD Prophylaxis – A Randomized,10-04-2019,NA,ISRCTN number,results
5413,2017-002468-41," A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations",13-12-2017,NCT03645980,US NCT number,protocol
5414,2017-002468-41," A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations",13-12-2017,NA,other,protocol
5415,2017-002468-41," A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations",13-12-2017,NA,US NCT number,results
5416,2017-002468-41," A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations",13-12-2017,NA,ISRCTN number,results
5417,2017-002490-19, Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis in patients with moderate to advanced Fuchs endothelial corneal dystrophy (FECD),30-06-2017,NA,US NCT number,protocol
5418,2017-002490-19, Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis in patients with moderate to advanced Fuchs endothelial corneal dystrophy (FECD),30-06-2017,NA,other,protocol
5419,2017-002490-19, Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis in patients with moderate to advanced Fuchs endothelial corneal dystrophy (FECD),30-06-2017,NA,US NCT number,results
5420,2017-002490-19, Prospective single-centre randomized observer-blind placebo-controlled parallel-group phase IIa clinical trial to investigate the safety and efficacy of ripasudil 0.4% eye drops after descemetorhexis in patients with moderate to advanced Fuchs endothelial corneal dystrophy (FECD),30-06-2017,NA,ISRCTN number,results
5421,2017-002546-74, Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk,01-03-2018,NCT03480672,US NCT number,protocol
5422,2017-002546-74, Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk,01-03-2018,NA,other,protocol
5423,2017-002546-74, Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk,01-03-2018,NA,US NCT number,results
5424,2017-002546-74, Postoperative adjuvant radiochemotherapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk,01-03-2018,NA,ISRCTN number,results
5425,2017-002588-17, Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents,26-06-2019,NA,US NCT number,protocol
5426,2017-002588-17, Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents,26-06-2019,NA,other,protocol
5427,2017-002588-17, Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents,26-06-2019,NA,US NCT number,results
5428,2017-002588-17, Safety and effects on visual function of 0.01% Atropin eye drops for myopia inhibition in children and adolescents,26-06-2019,NA,ISRCTN number,results
5429,2017-002695-45, Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure),22-12-2017,NA,US NCT number,protocol
5430,2017-002695-45, Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure),22-12-2017,NA,other,protocol
5431,2017-002695-45, Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure),22-12-2017,NA,US NCT number,results
5432,2017-002695-45, Effect of Empagliflozin on Cardiac Output in Patients with Acute Heart Failure (EMPA Acute Heart Failure),22-12-2017,NA,ISRCTN number,results
5433,2017-002723-16, Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial,23-11-2017,NA,US NCT number,protocol
5434,2017-002723-16, Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial,23-11-2017,NA,other,protocol
5435,2017-002723-16, Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial,23-11-2017,NA,US NCT number,results
5436,2017-002723-16, Evaluation of the potential anti-malarial effect of ivermectin: a controlled human malaria infection trial,23-11-2017,NA,ISRCTN number,results
5437,2017-002793-39, Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB,11-12-2017,NA,US NCT number,protocol
5438,2017-002793-39, Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB,11-12-2017,NA,other,protocol
5439,2017-002793-39, Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB,11-12-2017,NA,US NCT number,results
5440,2017-002793-39, Abatacept Bone Effects in Psoriatic Arthritis with Bone Biomarker – ABEPSA_BB,11-12-2017,NA,ISRCTN number,results
5441,2017-002853-13," Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab",17-10-2017,NA,US NCT number,protocol
5442,2017-002853-13," Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab",17-10-2017,NA,other,protocol
5443,2017-002853-13," Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab",17-10-2017,NA,US NCT number,results
5444,2017-002853-13," Phase II trial for the treatment of older patients with newly diagnosed CD19 positive, Ph/BCR-ABL negative B-precursor acute lymphoblastic leukemia with sequential dose reduced chemotherapy and Blinatumomab",17-10-2017,NA,ISRCTN number,results
5445,2017-003051-35," Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN)",30-05-2018,NA,US NCT number,protocol
5446,2017-003051-35," Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN)",30-05-2018,NA,other,protocol
5447,2017-003051-35," Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN)",30-05-2018,NA,US NCT number,results
5448,2017-003051-35," Efficacy of BELImumab for therapy-resistant SKIN manifestations in patients with lupus erythematosus (LE): A phase III, multicenter, randomized, double-blind, placebo-controlled, 24-week trial (BELI-SKIN)",30-05-2018,NA,ISRCTN number,results
5449,2017-003057-42, Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group,24-10-2017,NA,US NCT number,protocol
5450,2017-003057-42, Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group,24-10-2017,NA,other,protocol
5451,2017-003057-42, Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group,24-10-2017,NA,US NCT number,results
5452,2017-003057-42, Organ preservation in locally advanced rectal cancer by radiochemotherapy followed by consolidation chemotherapy. A prospective phase II pilot trial of the German Rectal Cancer Study Group,24-10-2017,NA,ISRCTN number,results
5453,2017-003088-36, GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial),20-10-2017,NA,US NCT number,protocol
5454,2017-003088-36, GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial),20-10-2017,NA,other,protocol
5455,2017-003088-36, GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial),20-10-2017,NA,US NCT number,results
5456,2017-003088-36, GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial),20-10-2017,NA,ISRCTN number,results
5457,2017-003133-28," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 (venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG protocol)",21-08-2018,NA,US NCT number,protocol
5458,2017-003133-28," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 (venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG protocol)",21-08-2018,NA,other,protocol
5459,2017-003133-28," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 (venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG protocol)",21-08-2018,NA,US NCT number,results
5460,2017-003133-28," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine followed by GA101 (obinutuzumab), acalabrutinib (ACP-196) and ABT-199 (venetoclax) in patients with relapsed/refractory CLL (CLL2-BAAG protocol)",21-08-2018,NA,ISRCTN number,results
5461,2017-003149-56, OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA,10-01-2018,NCT03322865,US NCT number,protocol
5462,2017-003149-56, OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA,10-01-2018,NA,other,protocol
5463,2017-003149-56, OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA,10-01-2018,NA,US NCT number,results
5464,2017-003149-56, OBINUTUZUMAB in MARGINAL ZONE LYMPHOMA,10-01-2018,NA,ISRCTN number,results
5465,2017-003150-16, Copanlisib and Rituximab in Marginal Zone Lymphoma Patients,20-06-2018,NA,US NCT number,protocol
5466,2017-003150-16, Copanlisib and Rituximab in Marginal Zone Lymphoma Patients,20-06-2018,NA,other,protocol
5467,2017-003150-16, Copanlisib and Rituximab in Marginal Zone Lymphoma Patients,20-06-2018,NA,US NCT number,results
5468,2017-003150-16, Copanlisib and Rituximab in Marginal Zone Lymphoma Patients,20-06-2018,NA,ISRCTN number,results
5469,2017-003221-15," PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM",11-10-2018,NA,US NCT number,protocol
5470,2017-003221-15," PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM",11-10-2018,NA,other,protocol
5471,2017-003221-15," PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM",11-10-2018,NA,US NCT number,results
5472,2017-003221-15," PROSPEKTIV RANDOMISIERTE, MULTIZENTRISCHE STUDIE ZUM",11-10-2018,NA,ISRCTN number,results
5473,2017-003226-33, First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8),29-03-2018,NA,US NCT number,protocol
5474,2017-003226-33, First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8),29-03-2018,NA,other,protocol
5475,2017-003226-33, First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8),29-03-2018,NA,US NCT number,results
5476,2017-003226-33, First-line treatment of locally advanced HNSCC with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T cell infiltration (CheckRad-CD8),29-03-2018,NA,ISRCTN number,results
5477,2017-003240-20, Velphoro and impact on the oral cavity and gut microbiome,14-09-2017,NA,US NCT number,protocol
5478,2017-003240-20, Velphoro and impact on the oral cavity and gut microbiome,14-09-2017,NA,other,protocol
5479,2017-003240-20, Velphoro and impact on the oral cavity and gut microbiome,14-09-2017,NA,US NCT number,results
5480,2017-003240-20, Velphoro and impact on the oral cavity and gut microbiome,14-09-2017,NA,ISRCTN number,results
5481,2017-003256-22," Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma",15-11-2017,NA,US NCT number,protocol
5482,2017-003256-22," Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma",15-11-2017,NA,other,protocol
5483,2017-003256-22," Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma",15-11-2017,NA,US NCT number,results
5484,2017-003256-22," Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma",15-11-2017,NA,ISRCTN number,results
5485,2017-003311-19, Phase IIa proof-of-principle study for the ,18-09-2017,NA,US NCT number,protocol
5486,2017-003311-19, Phase IIa proof-of-principle study for the ,18-09-2017,NA,other,protocol
5487,2017-003311-19, Phase IIa proof-of-principle study for the ,18-09-2017,NA,US NCT number,results
5488,2017-003311-19, Phase IIa proof-of-principle study for the ,18-09-2017,NA,ISRCTN number,results
5489,2017-003334-82, Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - ,02-01-2019,NCT03480334,US NCT number,protocol
5490,2017-003334-82, Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - ,02-01-2019,NA,other,protocol
5491,2017-003334-82, Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - ,02-01-2019,NA,US NCT number,results
5492,2017-003334-82, Abscopal Effect of Radiotherapy and Nivolumab in anti-PD1 Pretreated Relapsed or Refractory classical Hodgkin Lymphoma - ,02-01-2019,NA,ISRCTN number,results
5493,2017-003387-12," Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study",25-10-2017,NA,US NCT number,protocol
5494,2017-003387-12," Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study",25-10-2017,NA,other,protocol
5495,2017-003387-12," Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study",25-10-2017,NA,US NCT number,results
5496,2017-003387-12," Dopamine action on metabolism depending on genetic heterogeneity – a randomized, placebo-controlled double blind study",25-10-2017,NA,ISRCTN number,results
5497,2017-003496-54, A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH),16-08-2018,NA,US NCT number,protocol
5498,2017-003496-54, A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH),16-08-2018,NA,other,protocol
5499,2017-003496-54, A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH),16-08-2018,NA,US NCT number,results
5500,2017-003496-54, A multicenter randomized phase II study to determine the optimal first-line chemotherapy regimen in patients with metastatic pancreatic cancer (FOOTPATH),16-08-2018,NA,ISRCTN number,results
5501,2017-003556-23," A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade",04-04-2018,NA,US NCT number,protocol
5502,2017-003556-23," A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade",04-04-2018,NA,other,protocol
5503,2017-003556-23," A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade",04-04-2018,NA,US NCT number,results
5504,2017-003556-23," A Phase 2, single arm study on dacarbazine (DTIC) followed by immunotherapy re-challenge in unresectable or metastatic melanoma with primary resistance to PD-1/PD-L1 or PD-1 + CTLA4 Blockade",04-04-2018,NA,ISRCTN number,results
5505,2017-003676-31, Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS,25-04-2018,NA,US NCT number,protocol
5506,2017-003676-31, Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS,25-04-2018,NA,other,protocol
5507,2017-003676-31, Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS,25-04-2018,NA,US NCT number,results
5508,2017-003676-31, Inhibition of Rho Kinase (ROCK) with Fasudil as disease-modifying treatment for ALS,25-04-2018,NA,ISRCTN number,results
5509,2017-003688-37, Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension ,02-05-2018,NA,US NCT number,protocol
5510,2017-003688-37, Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension ,02-05-2018,NA,other,protocol
5511,2017-003688-37, Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension ,02-05-2018,NA,US NCT number,results
5512,2017-003688-37, Phosphodiesterase-5 inhibition in patients with heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension ,02-05-2018,NA,ISRCTN number,results
5513,2017-003813-24," A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",02-05-2018,NA,US NCT number,protocol
5514,2017-003813-24," A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",02-05-2018,NA,other,protocol
5515,2017-003813-24," A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",02-05-2018,NA,US NCT number,results
5516,2017-003813-24," A phase I/IIa, prospective, mono-center, randomized, open labeled, controlled study to assess the safety and efficacy of applying Iloprost locally in the fracture site to promote bone healing in patients with proximal humeral fracture",02-05-2018,NA,ISRCTN number,results
5517,2017-004110-25, MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse,16-08-2018,NA,US NCT number,protocol
5518,2017-004110-25, MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse,16-08-2018,NA,other,protocol
5519,2017-004110-25, MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse,16-08-2018,NA,US NCT number,results
5520,2017-004110-25, MRD-guided treatment with pembrolizumab and azacitidine in NPM1mut AML patients with an imminent hematological relapse,16-08-2018,NA,ISRCTN number,results
5521,2017-004129-33," Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.",07-05-2018,NA,US NCT number,protocol
5522,2017-004129-33," Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.",07-05-2018,NA,other,protocol
5523,2017-004129-33," Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.",07-05-2018,NA,US NCT number,results
5524,2017-004129-33," Randomized, double-blind, placebo controlled, parallel-group, prospective clinical study to analyse the effect of evolocumab on vascular function.",07-05-2018,NA,ISRCTN number,results
5525,2017-004130-28, Occurence of Oronasal Fistulas (ONF) using a fibrin sealant patch in primary palatoplasty,13-03-2018,NA,US NCT number,protocol
5526,2017-004130-28, Occurence of Oronasal Fistulas (ONF) using a fibrin sealant patch in primary palatoplasty,13-03-2018,NA,other,protocol
5527,2017-004130-28, Occurence of Oronasal Fistulas (ONF) using a fibrin sealant patch in primary palatoplasty,13-03-2018,NA,US NCT number,results
5528,2017-004130-28, Occurence of Oronasal Fistulas (ONF) using a fibrin sealant patch in primary palatoplasty,13-03-2018,NA,ISRCTN number,results
5529,2017-004149-26, Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,21-03-2018,NA,US NCT number,protocol
5530,2017-004149-26, Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,21-03-2018,NA,other,protocol
5531,2017-004149-26, Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,21-03-2018,NA,US NCT number,results
5532,2017-004149-26, Effect of Metformin and Empagliflozin in insulin resistant patients with heart failure with reduced ejection fraction,21-03-2018,NA,ISRCTN number,results
5533,2017-004219-37," A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",29-07-2020,NA,US NCT number,protocol
5534,2017-004219-37," A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",29-07-2020,NA,other,protocol
5535,2017-004219-37," A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",29-07-2020,NA,US NCT number,results
5536,2017-004219-37," A randomized, prospective, multicenter, controlled and double-blinded Phase II Clinical Trial to evaluate the influence of inhaled Aviptadil on Cough and Quality of Life in Sarcoidosis patients",29-07-2020,NA,ISRCTN number,results
5537,2017-004362-95," Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia",05-02-2019,NCT03620903,US NCT number,protocol
5538,2017-004362-95," Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia",05-02-2019,NA,other,protocol
5539,2017-004362-95," Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia",05-02-2019,NA,US NCT number,results
5540,2017-004362-95," Efficacy of first line Bortezomib, Rituximab, Ibrutinib (B-RI) for patients with treatment naive Waldenström’s Macroglobulinemia",05-02-2019,NA,ISRCTN number,results
5541,2017-004458-41," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",09-07-2018,NA,US NCT number,protocol
5542,2017-004458-41," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",09-07-2018,NA,other,protocol
5543,2017-004458-41," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",09-07-2018,NA,US NCT number,results
5544,2017-004458-41," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 16-week treatment study with a 16 week follow-up period to assess the efficacy and safety of Dupilumab (anti-IL4Ra) in adult patients with chronic spontaneous urticaria despite H1-antihistamine treatment.",09-07-2018,NA,ISRCTN number,results
5545,2017-004570-34," Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatinib and Pembrolizumab",06-07-2018,NA,US NCT number,protocol
5546,2017-004570-34," Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatinib and Pembrolizumab",06-07-2018,Deutsches Register Klinischer Studien DRKS00013336,other,protocol
5547,2017-004570-34," Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatinib and Pembrolizumab",06-07-2018,NA,US NCT number,results
5548,2017-004570-34," Phase II, Open-label, Study in Patients with anaplastic (ATC) or poorly differentiated thyroid carcinomas (PDTC) to investigate the Clinical Efficacy and Safety of the Combination Therapy of Lenvatinib and Pembrolizumab",06-07-2018,NA,ISRCTN number,results
5549,2017-004729-34," Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study",25-01-2019,NA,US NCT number,protocol
5550,2017-004729-34," Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study",25-01-2019,NA,other,protocol
5551,2017-004729-34," Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study",25-01-2019,NA,US NCT number,results
5552,2017-004729-34," Effects of transdermal estrogen on Bone Mass in adolescent female patients with Anorexia nervosa (AN) – a placebo-controlled, double-blind, randomized, interventional study",25-01-2019,NA,ISRCTN number,results
5553,2017-004768-37, A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma,28-05-2018,NCT03617731,US NCT number,protocol
5554,2017-004768-37, A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma,28-05-2018,NA,other,protocol
5555,2017-004768-37, A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma,28-05-2018,NA,US NCT number,results
5556,2017-004768-37, A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) induction and lenalidomide maintenance in patients with newly diagnosed multiple myeloma,28-05-2018,NA,ISRCTN number,results
5557,2017-004883-37, Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients ,09-09-2020,NA,US NCT number,protocol
5558,2017-004883-37, Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients ,09-09-2020,NA,other,protocol
5559,2017-004883-37, Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients ,09-09-2020,NA,US NCT number,results
5560,2017-004883-37, Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients ,09-09-2020,NA,ISRCTN number,results
5561,2017-004889-10," Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study",12-04-2018,NA,US NCT number,protocol
5562,2017-004889-10," Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study",12-04-2018,NA,other,protocol
5563,2017-004889-10," Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study",12-04-2018,NA,US NCT number,results
5564,2017-004889-10," Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study",12-04-2018,NA,ISRCTN number,results
5565,2017-005032-42, Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease,10-02-2020,NA,US NCT number,protocol
5566,2017-005032-42, Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease,10-02-2020,NA,other,protocol
5567,2017-005032-42, Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease,10-02-2020,NA,US NCT number,results
5568,2017-005032-42, Effect of Liraglutide on the Metabolic Profile in Patients with Type 2 Diabetes and Cardiovascular Disease,10-02-2020,NA,ISRCTN number,results
5569,2017-005121-21, Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib,17-09-2018,NA,US NCT number,protocol
5570,2017-005121-21, Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib,17-09-2018,NA,other,protocol
5571,2017-005121-21, Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib,17-09-2018,NA,US NCT number,results
5572,2017-005121-21, Exploring the theragnostic value of osimertinib in EGFR-mutated lung cancer (THEROS) - A multicentric phase II study in patients with TKI-resistant EGFR-mutated lung cancer exhibiting early metabolic response to osimertinib,17-09-2018,NA,ISRCTN number,results
5573,2017-005151-83, INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,09-07-2018,NA,US NCT number,protocol
5574,2017-005151-83, INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,09-07-2018,NA,other,protocol
5575,2017-005151-83, INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,09-07-2018,NA,US NCT number,results
5576,2017-005151-83, INDUCTION AND MAINTENANCE OF MUCOSAL HEALING IN CROHN’S DISEASE WITH USTEKINUMAB IN CLINICAL PRACTICE,09-07-2018,NA,ISRCTN number,results
5577,2017-005158-12, TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach,16-08-2018,NA,US NCT number,protocol
5578,2017-005158-12, TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach,16-08-2018,NA,other,protocol
5579,2017-005158-12, TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach,16-08-2018,NA,US NCT number,results
5580,2017-005158-12, TEAM-Trial: Targeting Epigenetic therapy resistance in AML with Bortezomib: A multi-centre matched threshold crossing phase II approach,16-08-2018,NA,ISRCTN number,results
5581,2018-000017-20, Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) ,16-05-2018,NA,US NCT number,protocol
5582,2018-000017-20, Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) ,16-05-2018,NA,other,protocol
5583,2018-000017-20, Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) ,16-05-2018,NA,US NCT number,results
5584,2018-000017-20, Antiplatelet effect of acetylsalicylic acid in patients after cardiac surgery: Impact of dipyrone (metamizole) ,16-05-2018,NA,ISRCTN number,results
5585,2018-000112-21, Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer ,22-06-2018,NA,US NCT number,protocol
5586,2018-000112-21, Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer ,22-06-2018,NA,other,protocol
5587,2018-000112-21, Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer ,22-06-2018,NA,US NCT number,results
5588,2018-000112-21, Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer ,22-06-2018,NA,ISRCTN number,results
5589,2018-000127-14, INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies,01-02-2019,NA,US NCT number,protocol
5590,2018-000127-14, INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies,01-02-2019,BMS Trial Code CA209-9JH ,other,protocol
5591,2018-000127-14, INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies,01-02-2019,NA,US NCT number,results
5592,2018-000127-14, INFORM2 exploratory multinational phase I/II combination study of Nivolumab and Entinostat in children and adolescents with refractory high-risk malignancies,01-02-2019,NA,ISRCTN number,results
5593,2018-000187-28, Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,04-08-2020,NA,US NCT number,protocol
5594,2018-000187-28, Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,04-08-2020,NA,other,protocol
5595,2018-000187-28, Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,04-08-2020,NA,US NCT number,results
5596,2018-000187-28, Pembrolizumab in Marginal Zone Lymphoma - a multicenter open label single-arm phase II study,04-08-2020,NA,ISRCTN number,results
5597,2018-000254-21, Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck,02-11-2020,NA,US NCT number,protocol
5598,2018-000254-21, Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck,02-11-2020,NA,other,protocol
5599,2018-000254-21, Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck,02-11-2020,NA,US NCT number,results
5600,2018-000254-21, Window of opportunity study of preoperative immunotherapy with atezolizumab (Tecentriq®) or FAP-interleukin 2v (IL2v) (RO6874281) in local squamous cell carcinoma of the head and neck,02-11-2020,NA,ISRCTN number,results
5601,2018-000257-45, A phase Ib/II single-arm study evaluating the safety and efficacy of,18-03-2021,NA,US NCT number,protocol
5602,2018-000257-45, A phase Ib/II single-arm study evaluating the safety and efficacy of,18-03-2021,NA,other,protocol
5603,2018-000257-45, A phase Ib/II single-arm study evaluating the safety and efficacy of,18-03-2021,NA,US NCT number,results
5604,2018-000257-45, A phase Ib/II single-arm study evaluating the safety and efficacy of,18-03-2021,NA,ISRCTN number,results
5605,2018-000335-27, Early PsA on treatment strategy,09-07-2018,NA,US NCT number,protocol
5606,2018-000335-27, Early PsA on treatment strategy,09-07-2018,NA,other,protocol
5607,2018-000335-27, Early PsA on treatment strategy,09-07-2018,NA,US NCT number,results
5608,2018-000335-27, Early PsA on treatment strategy,09-07-2018,NA,ISRCTN number,results
5609,2018-000342-19," Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer's disease or in patients with mild Alzheimer's disease",20-08-2018,NA,US NCT number,protocol
5610,2018-000342-19," Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer's disease or in patients with mild Alzheimer's disease",20-08-2018,NA,other,protocol
5611,2018-000342-19," Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer's disease or in patients with mild Alzheimer's disease",20-08-2018,NA,US NCT number,results
5612,2018-000342-19," Prospective, randomized, double-blind clinical trial phase II for the anti-inflammatory effects of Curazink (zinc histidine) for 8 weeks in elderly patients with mild cognitive impairment in Alzheimer's disease or in patients with mild Alzheimer's disease",20-08-2018,NA,ISRCTN number,results
5613,2018-000383-28, Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG),04-07-2018,NA,US NCT number,protocol
5614,2018-000383-28, Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG),04-07-2018,NA,other,protocol
5615,2018-000383-28, Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG),04-07-2018,NA,US NCT number,results
5616,2018-000383-28, Perioperative immunotherapy vs. chemo-immunotherapy stratified by early response evaluation in patients with advanced gastric cancer (GC) and adenocarcinoma of the esophago-gastric junction (AEG),04-07-2018,NA,ISRCTN number,results
5617,2018-000399-13, A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced  NSCLC harbouring FGFR genetic alterations after relapse of standard therapy,18-10-2018,NA,US NCT number,protocol
5618,2018-000399-13, A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced  NSCLC harbouring FGFR genetic alterations after relapse of standard therapy,18-10-2018,NA,other,protocol
5619,2018-000399-13, A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced  NSCLC harbouring FGFR genetic alterations after relapse of standard therapy,18-10-2018,NA,US NCT number,results
5620,2018-000399-13, A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced  NSCLC harbouring FGFR genetic alterations after relapse of standard therapy,18-10-2018,NA,ISRCTN number,results
5621,2018-000415-25, PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL,21-06-2018,NA,US NCT number,protocol
5622,2018-000415-25, PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL,21-06-2018,German Clinical Trials Register DRKS00014054,other,protocol
5623,2018-000415-25, PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL,21-06-2018,NA,US NCT number,results
5624,2018-000415-25, PANCREATIC RESECTION WITH PERIOPERATIVE OFF-LABEL STUDY OF PROPRANOLOL AND ETODOLAC – A PHASE II RANDOMIZED TRIAL,21-06-2018,NA,ISRCTN number,results
5625,2018-000453-41, Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety and efficacy,07-03-2018,NCT03168516,US NCT number,protocol
5626,2018-000453-41, Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety and efficacy,07-03-2018,NA,other,protocol
5627,2018-000453-41, Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety and efficacy,07-03-2018,NA,US NCT number,results
5628,2018-000453-41, Effects of closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C) on outcome of extremely preterm infants – a randomized controlled parallel group multicenter trial for safety and efficacy,07-03-2018,NA,ISRCTN number,results
5629,2018-000492-32," Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections ",19-09-2018,NA,US NCT number,protocol
5630,2018-000492-32," Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections ",19-09-2018,NA,other,protocol
5631,2018-000492-32," Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections ",19-09-2018,NA,US NCT number,results
5632,2018-000492-32," Effects of antibiotics on micobiota, pulmonary immune response and incidence of ventilator-associated infections ",19-09-2018,NA,ISRCTN number,results
5633,2018-000578-31, Impact of benralizumab treatment on circulating,05-04-2018,NA,US NCT number,protocol
5634,2018-000578-31, Impact of benralizumab treatment on circulating,05-04-2018,NA,other,protocol
5635,2018-000578-31, Impact of benralizumab treatment on circulating,05-04-2018,NA,US NCT number,results
5636,2018-000578-31, Impact of benralizumab treatment on circulating,05-04-2018,NA,ISRCTN number,results
5637,2018-000853-29, Treatment of chemo-refractory viral infections after allogeneic,24-06-2019,NCT04832607,US NCT number,protocol
5638,2018-000853-29, Treatment of chemo-refractory viral infections after allogeneic,24-06-2019,DRKS 00018985,other,protocol
5639,2018-000853-29, Treatment of chemo-refractory viral infections after allogeneic,24-06-2019,NA,US NCT number,results
5640,2018-000853-29, Treatment of chemo-refractory viral infections after allogeneic,24-06-2019,NA,ISRCTN number,results
5641,2018-000873-59, Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma,12-06-2018,NA,US NCT number,protocol
5642,2018-000873-59, Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma,12-06-2018,NA,other,protocol
5643,2018-000873-59, Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma,12-06-2018,NA,US NCT number,results
5644,2018-000873-59, Consolidation Therapy with Brentuximab Vedotin after Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma,12-06-2018,NA,ISRCTN number,results
5645,2018-000876-14," ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients",08-10-2019,NA,US NCT number,protocol
5646,2018-000876-14," ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients",08-10-2019,NA,other,protocol
5647,2018-000876-14," ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients",08-10-2019,NA,US NCT number,results
5648,2018-000876-14," ACO/ARO/AIO-18.1: Short-course radiotherapy versus chemoradiotherapy, followed by consolidation chemotherapy, and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients",08-10-2019,NA,ISRCTN number,results
5649,2018-001356-35, ACO/ARO/AIO-18.2,04-05-2020,NA,US NCT number,protocol
5650,2018-001356-35, ACO/ARO/AIO-18.2,04-05-2020,NA,other,protocol
5651,2018-001356-35, ACO/ARO/AIO-18.2,04-05-2020,NA,US NCT number,results
5652,2018-001356-35, ACO/ARO/AIO-18.2,04-05-2020,NA,ISRCTN number,results
5653,2018-001386-16, Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA),29-01-2019,NA,US NCT number,protocol
5654,2018-001386-16, Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA),29-01-2019,NA,other,protocol
5655,2018-001386-16, Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA),29-01-2019,NA,US NCT number,results
5656,2018-001386-16, Investigation of the efficacy of acamprosate and calcium in comparison to placebo as validation of a behavioural test for alcohol dependence (TEMACA),29-01-2019,NA,ISRCTN number,results
5657,2018-001433-41, Phase II Studie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion,02-01-2019,NA,US NCT number,protocol
5658,2018-001433-41, Phase II Studie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion,02-01-2019,NA,other,protocol
5659,2018-001433-41, Phase II Studie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion,02-01-2019,NA,US NCT number,results
5660,2018-001433-41, Phase II Studie zur Verminderung der Peritonealkarzinose-Inzidenz nach kurativer Gastrektomie eines Magenkarzinoms oder Adenokarzinoms des gastroösophagealen Übergangs durch hypertherme intraperitoneale Chemoperfusion,02-01-2019,NA,ISRCTN number,results
5661,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,protocol
5662,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,other,protocol
5663,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,results
5664,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,ISRCTN number,results
5665,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,protocol
5666,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,other,protocol
5667,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,results
5668,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,ISRCTN number,results
5669,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,protocol
5670,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,other,protocol
5671,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,results
5672,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,ISRCTN number,results
5673,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,protocol
5674,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,other,protocol
5675,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,US NCT number,results
5676,2018-001664-38, A proof of concept and assessment of maximal effect study with low dose Fenfluramine as add-on therapy in Myoclonic Astatic Epilepsy (Doose-Syndrome),02-04-2019,NA,ISRCTN number,results
5677,2018-001728-20, - RACE  -,02-01-2020,NA,US NCT number,protocol
5678,2018-001728-20, - RACE  -,02-01-2020,NA,other,protocol
5679,2018-001728-20, - RACE  -,02-01-2020,NA,US NCT number,results
5680,2018-001728-20, - RACE  -,02-01-2020,NA,ISRCTN number,results
5681,2018-001802-27," A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.",13-12-2018,NCT03612232,US NCT number,protocol
5682,2018-001802-27," A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.",13-12-2018,NA,other,protocol
5683,2018-001802-27," A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.",13-12-2018,NA,US NCT number,results
5684,2018-001802-27," A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma.",13-12-2018,NA,ISRCTN number,results
5685,2018-001823-38," A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder",27-06-2018,NCT03529890,US NCT number,protocol
5686,2018-001823-38," A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder",27-06-2018,NA,other,protocol
5687,2018-001823-38," A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder",27-06-2018,NA,US NCT number,results
5688,2018-001823-38," A prospective, single arm, multicenter, phase II-trial to assess safety and efficacy of preoperative RAdiation therapy before radical CystEctomy combined with ImmunoTherapy in locally advanced urothelial carcinoma of the bladder",27-06-2018,NA,ISRCTN number,results
5689,2018-001874-89, Randomised controlled multicentre study of albumin replacement therapy in septic shock ,19-11-2018,NA,US NCT number,protocol
5690,2018-001874-89, Randomised controlled multicentre study of albumin replacement therapy in septic shock ,19-11-2018,ZKSJ0112_ARISS ZKSJ0112,other,protocol
5691,2018-001874-89, Randomised controlled multicentre study of albumin replacement therapy in septic shock ,19-11-2018,NA,US NCT number,results
5692,2018-001874-89, Randomised controlled multicentre study of albumin replacement therapy in septic shock ,19-11-2018,NA,ISRCTN number,results
5693,2018-002010-12, Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance  in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study,02-01-2019,NA,US NCT number,protocol
5694,2018-002010-12, Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance  in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study,02-01-2019,NA,other,protocol
5695,2018-002010-12, Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance  in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study,02-01-2019,NA,US NCT number,results
5696,2018-002010-12, Avelumab added to FOLFIRI plus Cetuximab followed by Avelumab maintenance  in patients with previously untreated RAS/BRAF wild-type metastatic colorectal cancer - The phase II FIRE-6-Avelumab study,02-01-2019,NA,ISRCTN number,results
5697,2018-002256-33, Frontline Asciminib combination in chronic phase CML,26-03-2019,NCT03906292,US NCT number,protocol
5698,2018-002256-33, Frontline Asciminib combination in chronic phase CML,26-03-2019,NA,other,protocol
5699,2018-002256-33, Frontline Asciminib combination in chronic phase CML,26-03-2019,NA,US NCT number,results
5700,2018-002256-33, Frontline Asciminib combination in chronic phase CML,26-03-2019,NA,ISRCTN number,results
5701,2018-002492-17," A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of patients with Richter Transformation.",10-07-2019,NA,US NCT number,protocol
5702,2018-002492-17," A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of patients with Richter Transformation.",10-07-2019,NA,other,protocol
5703,2018-002492-17," A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of patients with Richter Transformation.",10-07-2019,NA,US NCT number,results
5704,2018-002492-17," A prospective, open-label, multicentre Phase-II-Trial to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK Inhibitor, plus tislelizumab (BGB-A317), a PD-1 Inhibitor, for treatment of patients with Richter Transformation.",10-07-2019,NA,ISRCTN number,results
5705,2018-002606-31," Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority",30-01-2019,NA,US NCT number,protocol
5706,2018-002606-31," Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority",30-01-2019,NA,other,protocol
5707,2018-002606-31," Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority",30-01-2019,NA,US NCT number,results
5708,2018-002606-31," Sublingual versus intravenous Fentanyl in patients with acute trauma - a randomized, double-blind, double-dummy study to demonstrate non-inferiority",30-01-2019,NA,ISRCTN number,results
5709,2018-002652-33, A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor,04-02-2020,NA,US NCT number,protocol
5710,2018-002652-33, A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor,04-02-2020,NA,other,protocol
5711,2018-002652-33, A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor,04-02-2020,NA,US NCT number,results
5712,2018-002652-33, A phase 2 trial to assess haploidentical Alpha/ß T-depleted stem cell transplantation in patients with sickle cell disease with no available sibling donor,04-02-2020,NA,ISRCTN number,results
5713,2018-002675-17, Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD,13-08-2019,NCT03989713,US NCT number,protocol
5714,2018-002675-17, Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD,13-08-2019,Trial Code HeLeNe- 18-03,other,protocol
5715,2018-002675-17, Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD,13-08-2019,NA,US NCT number,results
5716,2018-002675-17, Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD,13-08-2019,NA,ISRCTN number,results
5717,2018-002678-34, Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18,01-04-2019,NA,US NCT number,protocol
5718,2018-002678-34, Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18,01-04-2019,NA,other,protocol
5719,2018-002678-34, Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18,01-04-2019,NA,US NCT number,results
5720,2018-002678-34, Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics - AMLSG 30-18,01-04-2019,NA,ISRCTN number,results
5721,2018-002824-17," Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock",08-11-2018,NA,US NCT number,protocol
5722,2018-002824-17," Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock",08-11-2018,NA,other,protocol
5723,2018-002824-17," Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock",08-11-2018,NCT03989531,US NCT number,results
5724,2018-002824-17," Placebo-controlled, double-blind, randomized trial to assess the efficacy and safety of Adrecizumab in subjects with cardiogenic shock",08-11-2018,NA,ISRCTN number,results
5725,2018-002849-11, Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation,27-12-2018,NA,US NCT number,protocol
5726,2018-002849-11, Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation,27-12-2018,NA,other,protocol
5727,2018-002849-11, Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation,27-12-2018,NA,US NCT number,results
5728,2018-002849-11, Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation,27-12-2018,NA,ISRCTN number,results
5729,2018-002936-26, Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma ,17-12-2018,NA,US NCT number,protocol
5730,2018-002936-26, Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma ,17-12-2018,NA,other,protocol
5731,2018-002936-26, Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma ,17-12-2018,NA,US NCT number,results
5732,2018-002936-26, Efficacy and safety of Trifluridine/Tipiracil in combination with Irinotecan as a second line therapy in patients with Cholangiocarcinoma ,17-12-2018,NA,ISRCTN number,results
5733,2018-002938-20, Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,03-12-2018,NA,US NCT number,protocol
5734,2018-002938-20, Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,03-12-2018,NA,other,protocol
5735,2018-002938-20, Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,03-12-2018,NA,US NCT number,results
5736,2018-002938-20, Avelumab + Paclitaxel/ Ramucirumab as second line treatment in gastro-esophageal adenocarcinoma: a phase II trial of the AIO,03-12-2018,NA,ISRCTN number,results
5737,2018-002939-21, An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients,04-10-2019,NA,US NCT number,protocol
5738,2018-002939-21, An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients,04-10-2019,NA,other,protocol
5739,2018-002939-21, An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients,04-10-2019,NA,US NCT number,results
5740,2018-002939-21, An Open-Label Phase II Study of Relatlimab (BMS-986016) with Nivolumab (BMS- 936558) in Combination with 5-Azacytidine for the Treatment of Patients with Refractory/Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older Acute Myeloid Leukemia Patients,04-10-2019,NA,ISRCTN number,results
5741,2018-002947-27," Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",07-03-2019,NA,US NCT number,protocol
5742,2018-002947-27," Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",07-03-2019,NA,other,protocol
5743,2018-002947-27," Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",07-03-2019,NA,US NCT number,results
5744,2018-002947-27," Simvastatin add-on to Escitalopram in patients with comorbid obesity and major depression: A multicenter, randomized, double-blind, placebo-controlled trial",07-03-2019,NA,ISRCTN number,results
5745,2018-002979-17, Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation,07-11-2018,NA,US NCT number,protocol
5746,2018-002979-17, Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation,07-11-2018,NA,other,protocol
5747,2018-002979-17, Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation,07-11-2018,NA,US NCT number,results
5748,2018-002979-17, Use of doxapram as a new antiarrhythmic drug for a specific therapy of atrial fibrillation,07-11-2018,NA,ISRCTN number,results
5749,2018-003025-28, Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax  ,29-01-2019,NA,US NCT number,protocol
5750,2018-003025-28, Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax  ,29-01-2019,NA,other,protocol
5751,2018-003025-28, Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax  ,29-01-2019,NA,US NCT number,results
5752,2018-003025-28, Phase-I/II trial for relapsed or refractory AML patients combining cytarabine and mitoxantrone with venetoclax  ,29-01-2019,NA,ISRCTN number,results
5753,2018-003048-22, A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition,01-04-2019,NA,US NCT number,protocol
5754,2018-003048-22, A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition,01-04-2019,Deutsches Register Klinische Studien  DRKS00015218,other,protocol
5755,2018-003048-22, A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition,01-04-2019,NA,US NCT number,results
5756,2018-003048-22, A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibition,01-04-2019,NA,ISRCTN number,results
5757,2018-003270-27," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-netoclax (ABT-199) in patients with relapsed/refractory CLL (CLL2-BZAG protocol)",12-12-2019,NA,US NCT number,protocol
5758,2018-003270-27," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-netoclax (ABT-199) in patients with relapsed/refractory CLL (CLL2-BZAG protocol)",12-12-2019,NA,other,protocol
5759,2018-003270-27," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-netoclax (ABT-199) in patients with relapsed/refractory CLL (CLL2-BZAG protocol)",12-12-2019,NA,US NCT number,results
5760,2018-003270-27," A prospective, open-label, multicenter phase-II trial to evaluate the efficacy and safety of a sequential regimen of bendamustine fol-lowed by obinutuzumab (GA101), zanubrutinib (BGB-3111) and ve-netoclax (ABT-199) in patients with relapsed/refractory CLL (CLL2-BZAG protocol)",12-12-2019,NA,ISRCTN number,results
5761,2018-003321-29, Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics,01-07-2019,NA,US NCT number,protocol
5762,2018-003321-29, Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics,01-07-2019,NA,other,protocol
5763,2018-003321-29, Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics,01-07-2019,NA,US NCT number,results
5764,2018-003321-29, Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics,01-07-2019,NA,ISRCTN number,results
5765,2018-003474-27, Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study,23-01-2019,NCT03818308,US NCT number,protocol
5766,2018-003474-27, Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study,23-01-2019,NA,other,protocol
5767,2018-003474-27, Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study,23-01-2019,NCT03818308,US NCT number,results
5768,2018-003474-27, Multicenter trial for the treatment of acute Hepatitis C for 8 weeks with Sofosbuvir/Velpatasvir fix dose combination - The HepNet Acute HCV-V study,23-01-2019,NA,ISRCTN number,results
5769,2018-003526-88, Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia,05-08-2020,NCT04263480,US NCT number,protocol
5770,2018-003526-88, Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia,05-08-2020,CZAR-1 CZAR-1,other,protocol
5771,2018-003526-88, Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia,05-08-2020,NA,US NCT number,results
5772,2018-003526-88, Efficacy and safety of Carfilzomib in combination with Ibrutinib vs. Ibrutinib alone in Waldenström’s Macroglobulinemia,05-08-2020,NA,ISRCTN number,results
5773,2018-003557-21, Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes,17-10-2018,NA,US NCT number,protocol
5774,2018-003557-21, Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes,17-10-2018,NA,other,protocol
5775,2018-003557-21, Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes,17-10-2018,NA,US NCT number,results
5776,2018-003557-21, Effect of insulin glargine and lixisenatide versus insulin glargine on brain insulin sensitivity in patients with type 2 diabetes,17-10-2018,NA,ISRCTN number,results
5777,2018-003560-31, A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL),26-07-2019,NA,US NCT number,protocol
5778,2018-003560-31, A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL),26-07-2019,NA,other,protocol
5779,2018-003560-31, A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL),26-07-2019,NA,US NCT number,results
5780,2018-003560-31, A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL),26-07-2019,NA,ISRCTN number,results
5781,2018-003691-12, Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) ,01-08-2019,NA,US NCT number,protocol
5782,2018-003691-12, Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) ,01-08-2019,NA,other,protocol
5783,2018-003691-12, Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) ,01-08-2019,NA,US NCT number,results
5784,2018-003691-12, Circulating tumour DNA based decision for adjuvant treatment in colon cancer stage II evaluation (CIRCULATE) ,01-08-2019,NA,ISRCTN number,results
5785,2018-003692-35, Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure,14-02-2019,NA,US NCT number,protocol
5786,2018-003692-35, Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure,14-02-2019,ZKS Protocol Code ZKSJ0109_EMPAG-HF,other,protocol
5787,2018-003692-35, Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure,14-02-2019,NA,US NCT number,results
5788,2018-003692-35, Effects of empagliflozin on diuresis and renal function in patients with acute decompensated heart failure,14-02-2019,NA,ISRCTN number,results
5789,2018-003703-19, The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial,20-05-2019,NA,US NCT number,protocol
5790,2018-003703-19, The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial,20-05-2019,NA,other,protocol
5791,2018-003703-19, The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial,20-05-2019,NA,US NCT number,results
5792,2018-003703-19, The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Randomized Trial,20-05-2019,NA,ISRCTN number,results
5793,2018-003877-91, Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in adult subjects with active ACPA-positive Rheumatoid Arthritis failing Methotrexate,26-02-2019,NA,US NCT number,protocol
5794,2018-003877-91, Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in adult subjects with active ACPA-positive Rheumatoid Arthritis failing Methotrexate,26-02-2019,NA,other,protocol
5795,2018-003877-91, Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in adult subjects with active ACPA-positive Rheumatoid Arthritis failing Methotrexate,26-02-2019,NA,US NCT number,results
5796,2018-003877-91, Sequential B cell/T cell therapy to re-induce humoral immune tolerance in ACPA-positive Rheumatoid Arthritis (TOLERA): a prospective randomized controlled open-label single-centre clinical trial in adult subjects with active ACPA-positive Rheumatoid Arthritis failing Methotrexate,26-02-2019,NA,ISRCTN number,results
5797,2018-004038-13, A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free,13-02-2020,NA,US NCT number,protocol
5798,2018-004038-13, A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free,13-02-2020,NA,other,protocol
5799,2018-004038-13, A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free,13-02-2020,NA,US NCT number,results
5800,2018-004038-13, A Prospective Multicenter Phase 2 Study of the Chemotherapy-Free,13-02-2020,NA,ISRCTN number,results
5801,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,protocol
5802,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,DRKS DRKS00021108,other,protocol
5803,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,results
5804,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,ISRCTN number,results
5805,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,protocol
5806,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,DRKS DRKS00021108,other,protocol
5807,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,results
5808,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,ISRCTN number,results
5809,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,protocol
5810,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,DRKS DRKS00021108,other,protocol
5811,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,results
5812,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,ISRCTN number,results
5813,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,protocol
5814,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,DRKS DRKS00021108,other,protocol
5815,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,US NCT number,results
5816,2018-004043-23, Cognitive function after liver transplantation comparing Tacrolimus formulations ,15-04-2020,NA,ISRCTN number,results
5817,2018-004136-30," An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical ",14-03-2019,NA,US NCT number,protocol
5818,2018-004136-30," An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical ",14-03-2019,NA,other,protocol
5819,2018-004136-30," An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical ",14-03-2019,NA,US NCT number,results
5820,2018-004136-30," An Open-Label, Pilot Study to assess the effect of Lanadelumab on the clinical ",14-03-2019,NA,ISRCTN number,results
5821,2018-004254-22, Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - ,25-06-2019,NA,US NCT number,protocol
5822,2018-004254-22, Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - ,25-06-2019,NA,other,protocol
5823,2018-004254-22, Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - ,25-06-2019,NA,US NCT number,results
5824,2018-004254-22, Efficacy of Tofacitinib in Reduction of Inflammation Detected on MRI in Patients with Psoriatic ArthritiS PresenTing with Axial InvOlvement - ,25-06-2019,NA,ISRCTN number,results
5825,2018-004329-10," A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy",21-02-2020,NA,US NCT number,protocol
5826,2018-004329-10," A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy",21-02-2020,NA,other,protocol
5827,2018-004329-10," A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy",21-02-2020,NA,US NCT number,results
5828,2018-004329-10," A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy",21-02-2020,NA,ISRCTN number,results
5829,2018-004451-20," A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",09-04-2019,NA,US NCT number,protocol
5830,2018-004451-20," A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",09-04-2019,NA,other,protocol
5831,2018-004451-20," A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",09-04-2019,NA,US NCT number,results
5832,2018-004451-20," A  multicenter,  open  label,  single-arm  pilot  study  to  evaluate  the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)",09-04-2019,NA,ISRCTN number,results
5833,2018-004523-36, Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany,02-01-2019,NA,US NCT number,protocol
5834,2018-004523-36, Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany,02-01-2019,NA,other,protocol
5835,2018-004523-36, Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany,02-01-2019,NA,US NCT number,results
5836,2018-004523-36, Safety and protective efficacy of a simplified Plasmodium falciparum sporozoite Chemoprophylaxis Vaccine (PfSPZ-CVac) regimen in healthy malaria-naïve adults in Germany,02-01-2019,NA,ISRCTN number,results
5837,2018-004557-24, Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,18-06-2019,NA,US NCT number,protocol
5838,2018-004557-24, Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,18-06-2019,NA,other,protocol
5839,2018-004557-24, Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,18-06-2019,NA,US NCT number,results
5840,2018-004557-24, Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis,18-06-2019,NA,ISRCTN number,results
5841,2018-004562-33," A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)",22-07-2019,NA,US NCT number,protocol
5842,2018-004562-33," A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)",22-07-2019,NA,other,protocol
5843,2018-004562-33," A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)",22-07-2019,NA,US NCT number,results
5844,2018-004562-33," A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy (CheCUP)",22-07-2019,NA,ISRCTN number,results
5845,2018-004564-59, WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION,15-05-2019,NA,US NCT number,protocol
5846,2018-004564-59, WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION,15-05-2019,DRKS DRKS00016363,other,protocol
5847,2018-004564-59, WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION,15-05-2019,NA,US NCT number,results
5848,2018-004564-59, WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION,15-05-2019,NA,ISRCTN number,results
5849,2018-004734-15, EBIO – Enthesitis biopsy study,06-05-2019,NA,US NCT number,protocol
5850,2018-004734-15, EBIO – Enthesitis biopsy study,06-05-2019,NA,other,protocol
5851,2018-004734-15, EBIO – Enthesitis biopsy study,06-05-2019,NA,US NCT number,results
5852,2018-004734-15, EBIO – Enthesitis biopsy study,06-05-2019,NA,ISRCTN number,results
5853,2018-005027-16, Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial,15-05-2020,NA,US NCT number,protocol
5854,2018-005027-16, Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial,15-05-2020,NA,other,protocol
5855,2018-005027-16, Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial,15-05-2020,NA,US NCT number,results
5856,2018-005027-16, Improvement of functional Outcome for patients with newly diagnosed grade II or III glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial,15-05-2020,NA,ISRCTN number,results
5857,2019-000058-77, Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC,29-08-2019,NA,US NCT number,protocol
5858,2019-000058-77, Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC,29-08-2019,NA,other,protocol
5859,2019-000058-77, Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC,29-08-2019,NA,US NCT number,results
5860,2019-000058-77, Prospective Phase-II Trial of induction chemotherapy and chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed by surgery or definitive chemoradiation boost and consolidation durvalumab in resectable stage III NSCLC,29-08-2019,NA,ISRCTN number,results
5861,2019-000136-26, Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation,28-10-2019,NA,US NCT number,protocol
5862,2019-000136-26, Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation,28-10-2019,NA,other,protocol
5863,2019-000136-26, Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation,28-10-2019,NA,US NCT number,results
5864,2019-000136-26, Midostaurin in MRD positive acute myeloid leukemia after allogeneic stem cell transplantation,28-10-2019,NA,ISRCTN number,results
5865,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,protocol
5866,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,other,protocol
5867,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,results
5868,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,ISRCTN number,results
5869,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,protocol
5870,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,other,protocol
5871,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,results
5872,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,ISRCTN number,results
5873,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,protocol
5874,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,other,protocol
5875,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,results
5876,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,ISRCTN number,results
5877,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,protocol
5878,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,other,protocol
5879,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,US NCT number,results
5880,2019-000598-22, Effects of Tralokinumab treatment of atopic dermatitis on skin barrier function (TraSki),01-04-2020,NA,ISRCTN number,results
5881,2019-000885-39, Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure,04-06-2020,NCT04396899,US NCT number,protocol
5882,2019-000885-39, Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure,04-06-2020,NA,other,protocol
5883,2019-000885-39, Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure,04-06-2020,NA,US NCT number,results
5884,2019-000885-39, Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure,04-06-2020,NA,ISRCTN number,results
5885,2019-000894-22, Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease,02-10-2019,NA,US NCT number,protocol
5886,2019-000894-22, Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease,02-10-2019,NA,other,protocol
5887,2019-000894-22, Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease,02-10-2019,NA,US NCT number,results
5888,2019-000894-22, Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease,02-10-2019,NA,ISRCTN number,results
5889,2019-000914-12," Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors",16-01-2020,NA,US NCT number,protocol
5890,2019-000914-12," Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors",16-01-2020,NA,other,protocol
5891,2019-000914-12," Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors",16-01-2020,NA,US NCT number,results
5892,2019-000914-12," Gazyvaro Targeting Tumor Promoting, Regulatory B-cells in Solid Tumors",16-01-2020,NA,ISRCTN number,results
5893,2019-000922-23, Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC),31-01-2020,NA,US NCT number,protocol
5894,2019-000922-23, Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC),31-01-2020,NA,other,protocol
5895,2019-000922-23, Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC),31-01-2020,NA,US NCT number,results
5896,2019-000922-23, Transarterial chemoembolization (TACE) with Irinotecan and Mitomycin C versus TACE with Doxorubicin in patients with Hepatocellular carcinoma not amenable to curative treatment - IRITACE- a randomized multicenter phase 2 trial. A trial of the German Alliance for Liver Cancer (GALC),31-01-2020,NA,ISRCTN number,results
5897,2019-000972-40, Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency,07-02-2020,NA,US NCT number,protocol
5898,2019-000972-40, Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency,07-02-2020,DRKS DRKS00017736,other,protocol
5899,2019-000972-40, Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency,07-02-2020,NA,US NCT number,results
5900,2019-000972-40, Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiency,07-02-2020,NA,ISRCTN number,results
5901,2019-001075-36," A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -",13-02-2020,NA,US NCT number,protocol
5902,2019-001075-36," A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -",13-02-2020,NA,other,protocol
5903,2019-001075-36," A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -",13-02-2020,NA,US NCT number,results
5904,2019-001075-36," A phase II study to evaluate the safety, tolerability and efficacy of Cabozantinib in patients with hepatocellular carcinoma (HCC) and impaired liver function (Child-Pugh score B7-8) - CABOCHILD -",13-02-2020,NA,ISRCTN number,results
5905,2019-001086-32, ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study,11-09-2019,NA,US NCT number,protocol
5906,2019-001086-32, ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study,11-09-2019,NA,other,protocol
5907,2019-001086-32, ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study,11-09-2019,NA,US NCT number,results
5908,2019-001086-32, ADVANCE-CSX Pilot – Antioxidant Treatment with Vitamin C in Cardiac Surgery Patients – a Clinical Pilot Study,11-09-2019,NA,ISRCTN number,results
5909,2019-001235-31, Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to,11-11-2019,NA,US NCT number,protocol
5910,2019-001235-31, Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to,11-11-2019,NA,other,protocol
5911,2019-001235-31, Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to,11-11-2019,NA,US NCT number,results
5912,2019-001235-31, Factor XII-associated cold autoinflammatory syndrome (FACAS) linked to,11-11-2019,NA,ISRCTN number,results
5913,2019-001264-30," A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma",20-08-2019,NCT04499339,US NCT number,protocol
5914,2019-001264-30," A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma",20-08-2019,NA,other,protocol
5915,2019-001264-30," A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma",20-08-2019,NA,US NCT number,results
5916,2019-001264-30," A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma",20-08-2019,NA,ISRCTN number,results
5917,2019-001324-35, Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE),20-09-2019,NCT04016025,US NCT number,protocol
5918,2019-001324-35, Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE),20-09-2019,NA,other,protocol
5919,2019-001324-35, Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE),20-09-2019,NA,US NCT number,results
5920,2019-001324-35, Randomized single-blind study on the adherence to treatment with topical methylprednisolone aceponate (Advantan®) in different vehicles (AD-HERE),20-09-2019,NA,ISRCTN number,results
5921,2019-001416-30, IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS  following allogeneic blood stem cell transplantation,23-03-2020,NA,US NCT number,protocol
5922,2019-001416-30, IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS  following allogeneic blood stem cell transplantation,23-03-2020,Celgene Protocol Code AG221-CL-AML-PI-13299,other,protocol
5923,2019-001416-30, IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS  following allogeneic blood stem cell transplantation,23-03-2020,NA,US NCT number,results
5924,2019-001416-30, IDH2-Post-Allo-Trial: Enasidenib as consolidation or salvage therapy for patients with IDH2 mutated AML or MDS  following allogeneic blood stem cell transplantation,23-03-2020,NA,ISRCTN number,results
5925,2019-001692-37, Pharmacologic treatment augmentation in chronic depression,19-07-2019,NA,US NCT number,protocol
5926,2019-001692-37, Pharmacologic treatment augmentation in chronic depression,19-07-2019,NA,other,protocol
5927,2019-001692-37, Pharmacologic treatment augmentation in chronic depression,19-07-2019,NA,US NCT number,results
5928,2019-001692-37, Pharmacologic treatment augmentation in chronic depression,19-07-2019,NA,ISRCTN number,results
5929,2019-001725-27," A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses.",29-05-2019,NA,US NCT number,protocol
5930,2019-001725-27," A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses.",29-05-2019,DRKS DRKS00017468,other,protocol
5931,2019-001725-27," A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses.",29-05-2019,NA,US NCT number,results
5932,2019-001725-27," A randomized, open, three-arm comparative study of modern methods of postoperative pain therapy in patients with knee endoprostheses.",29-05-2019,NA,ISRCTN number,results
5933,2019-001759-38," Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects",09-09-2019,NA,US NCT number,protocol
5934,2019-001759-38," Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects",09-09-2019,NA,other,protocol
5935,2019-001759-38," Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects",09-09-2019,NA,US NCT number,results
5936,2019-001759-38," Pharmacokinetics of a microdosed cocktail containing rivaroxaban, apixaban and edoxaban in children with congenital heart defects",09-09-2019,NA,ISRCTN number,results
5937,2019-001770-29, Viral load guided Immunosuppression after Lung Transplantation ,28-05-2019,NA,US NCT number,protocol
5938,2019-001770-29, Viral load guided Immunosuppression after Lung Transplantation ,28-05-2019,NA,other,protocol
5939,2019-001770-29, Viral load guided Immunosuppression after Lung Transplantation ,28-05-2019,NA,US NCT number,results
5940,2019-001770-29, Viral load guided Immunosuppression after Lung Transplantation ,28-05-2019,NA,ISRCTN number,results
5941,2019-002036-90," A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma",02-10-2019,NCT04200755,US NCT number,protocol
5942,2019-002036-90," A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma",02-10-2019,NA,other,protocol
5943,2019-002036-90," A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma",02-10-2019,NA,US NCT number,results
5944,2019-002036-90," A randomized, placebo-controlled phase IIa clinical trial to evaluate the efficacy and safety of subcutaneous Dupilumab in localized scleroderma",02-10-2019,NA,ISRCTN number,results
5945,2019-002197-31," AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting.",16-09-2019,NCT04413201,US NCT number,protocol
5946,2019-002197-31," AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting.",16-09-2019,DRKS DRKS00020509,other,protocol
5947,2019-002197-31," AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting.",16-09-2019,NA,US NCT number,results
5948,2019-002197-31," AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compared to osimertinib in patients with EGFRmutated/T790M Mutation negative non-squamous NSCLC in the first-line setting.",16-09-2019,NA,ISRCTN number,results
5949,2019-002317-19, Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial,23-01-2020,NA,US NCT number,protocol
5950,2019-002317-19, Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial,23-01-2020,NA,other,protocol
5951,2019-002317-19, Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial,23-01-2020,NA,US NCT number,results
5952,2019-002317-19, Prophylactic nimodipine treatment for hearing preservation after vestibular schwannoma surgery: a randomized multi-center phase III trial,23-01-2020,NA,ISRCTN number,results
5953,2019-002373-59," A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).",21-07-2020,NA,US NCT number,protocol
5954,2019-002373-59," A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).",21-07-2020,NA,other,protocol
5955,2019-002373-59," A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).",21-07-2020,NA,US NCT number,results
5956,2019-002373-59," A prospective, multicenter phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients with relapsed/refractory transformed or Aggressive Lymphoma (GOAL II).",21-07-2020,NA,ISRCTN number,results
5957,2019-002430-36," A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)",12-12-2019,NCT04224636,US NCT number,protocol
5958,2019-002430-36," A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)",12-12-2019,NA,other,protocol
5959,2019-002430-36," A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)",12-12-2019,NA,US NCT number,results
5960,2019-002430-36," A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on 24-months survival rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND)",12-12-2019,NA,ISRCTN number,results
5961,2019-002461-35," Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy  (PREBOTPilot)",17-07-2019,NA,US NCT number,protocol
5962,2019-002461-35," Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy  (PREBOTPilot)",17-07-2019,NA,other,protocol
5963,2019-002461-35," Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy  (PREBOTPilot)",17-07-2019,NA,US NCT number,results
5964,2019-002461-35," Monocenter, randomized, controlled, open-label, phase-II clinical trial of PREoperative endoscopic injection of BOTulinum toxin in the sphincter of Oddi to reduce postoperative pancreatic fistula after distal pancreatectomy  (PREBOTPilot)",17-07-2019,NA,ISRCTN number,results
5965,2019-002478-29, Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung),31-07-2019,NA,US NCT number,protocol
5966,2019-002478-29, Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung),31-07-2019,NA,other,protocol
5967,2019-002478-29, Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung),31-07-2019,NA,US NCT number,results
5968,2019-002478-29, Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung),31-07-2019,NA,ISRCTN number,results
5969,2019-002607-18," Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome",14-11-2019,NA,US NCT number,protocol
5970,2019-002607-18," Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome",14-11-2019,NA,other,protocol
5971,2019-002607-18," Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome",14-11-2019,NA,US NCT number,results
5972,2019-002607-18," Randomized, controlled interventional trial to investigate the efficacy of amiloride for the treatment of edema in human nephrotic syndrome",14-11-2019,NA,ISRCTN number,results
5973,2019-002734-37," Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)",13-10-2020,NCT04617457,US NCT number,protocol
5974,2019-002734-37," Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)",13-10-2020,NA,other,protocol
5975,2019-002734-37," Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)",13-10-2020,NA,US NCT number,results
5976,2019-002734-37," Open-Label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy with Liposomal Irinotecan Combined with Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients with Hepatic Oligometastatic Adenocarcinoma of the Pancreas (HOLIPANC)",13-10-2020,NA,ISRCTN number,results
5977,2019-002833-12," Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity troponin values",04-10-2019,NA,US NCT number,protocol
5978,2019-002833-12," Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity troponin values",04-10-2019,NA,other,protocol
5979,2019-002833-12," Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity troponin values",04-10-2019,NA,US NCT number,results
5980,2019-002833-12," Investigator-initiated, placebo-controlled, randomized trial to assess the efficacy and safety of platelet inhibition and/ or lipid lowering in non-ACS-patients with elevated high-sensitivity troponin values",04-10-2019,NA,ISRCTN number,results
5981,2019-002930-35, Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma,27-08-2020,NA,US NCT number,protocol
5982,2019-002930-35, Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma,27-08-2020,ClinicalTrials.gov NCT04161118,other,protocol
5983,2019-002930-35, Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma,27-08-2020,NA,US NCT number,results
5984,2019-002930-35, Phase II trial of TisaGenlecleucel in Elderly Patients with First-Relapsed or Primary Refractory Agressive B-cell Non-Hodgkin Lymphoma,27-08-2020,NA,ISRCTN number,results
5985,2019-003100-13, Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention,01-04-2020,NA,US NCT number,protocol
5986,2019-003100-13, Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention,01-04-2020,NA,other,protocol
5987,2019-003100-13, Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention,01-04-2020,NA,US NCT number,results
5988,2019-003100-13, Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention,01-04-2020,NA,ISRCTN number,results
5989,2019-003162-41," An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema",10-08-2020,NA,US NCT number,protocol
5990,2019-003162-41," An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema",10-08-2020,NA,other,protocol
5991,2019-003162-41," An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema",10-08-2020,NA,US NCT number,results
5992,2019-003162-41," An investigator-initiated, multi-center, randomized, double-blind, placebo controlled study of Dupilumab to demonstrate efficacy in subjects with nummular eczema",10-08-2020,NA,ISRCTN number,results
5993,2019-003190-26, An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER,12-10-2020,NA,US NCT number,protocol
5994,2019-003190-26, An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER,12-10-2020,NA,other,protocol
5995,2019-003190-26, An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER,12-10-2020,NA,US NCT number,results
5996,2019-003190-26, An investigator-sponsored Phase 3b Open-label Study of Anti-FGF23 Antibody Burosumab (KRN23) in Adult Patients with X-linked Hypophosphatemia (XLH) in GERmany - BurGER,12-10-2020,NA,ISRCTN number,results
5997,2019-003662-40," Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)   ",22-10-2019,NA,US NCT number,protocol
5998,2019-003662-40," Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)   ",22-10-2019,NA,other,protocol
5999,2019-003662-40," Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)   ",22-10-2019,NA,US NCT number,results
6000,2019-003662-40," Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and safety of the adalimumab biosimilar Amgevita in subjects with moderate to severe active chronic inflammatory bowel diesease (Crohn's disease and ulcerative colitis)   ",22-10-2019,NA,ISRCTN number,results
6001,2019-003710-13," A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation",30-06-2021,NA,US NCT number,protocol
6002,2019-003710-13," A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation",30-06-2021,NA,other,protocol
6003,2019-003710-13," A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation",30-06-2021,NA,US NCT number,results
6004,2019-003710-13," A multi-center interventional study to assess pharmacokinetics, effectiveness and tolerability of prolonged-release Tacrolimus after Paediatric Kidney Transplantation",30-06-2021,NA,ISRCTN number,results
6005,2019-003854-99," A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)",22-10-2020,NCT04608318,US NCT number,protocol
6006,2019-003854-99," A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)",22-10-2020,NA,other,protocol
6007,2019-003854-99," A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)",22-10-2020,NA,US NCT number,results
6008,2019-003854-99," A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab versus fixed-duration Venetoclax plus Ibrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)",22-10-2020,NA,ISRCTN number,results
6009,2019-003856-35, Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA),20-08-2020,NA,US NCT number,protocol
6010,2019-003856-35, Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA),20-08-2020,NA,other,protocol
6011,2019-003856-35, Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA),20-08-2020,NA,US NCT number,results
6012,2019-003856-35, Daratumumab for first line treatment of transplant-ineligible myeloma patients followed by daratumumab re-treatment at first relapse (GMMG-DADA),20-08-2020,NA,ISRCTN number,results
6013,2019-003863-23, Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia,28-11-2019,NA,US NCT number,protocol
6014,2019-003863-23, Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia,28-11-2019,NA,other,protocol
6015,2019-003863-23, Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia,28-11-2019,NA,US NCT number,results
6016,2019-003863-23, Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia,28-11-2019,NA,ISRCTN number,results
6017,2019-003913-32, Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in adult patients with newly diagnosed AML,22-07-2020,NCT04093505,US NCT number,protocol
6018,2019-003913-32, Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in adult patients with newly diagnosed AML,22-07-2020,NA,other,protocol
6019,2019-003913-32, Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in adult patients with newly diagnosed AML,22-07-2020,NA,US NCT number,results
6020,2019-003913-32, Randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare intensive postremission therapy double blinded with or without glasdegib in adult patients with newly diagnosed AML,22-07-2020,NA,ISRCTN number,results
6021,2019-004118-33," A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured",16-06-2020,NCT02187120,US NCT number,protocol
6022,2019-004118-33," A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured",16-06-2020,NA,other,protocol
6023,2019-004118-33," A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured",16-06-2020,NA,US NCT number,results
6024,2019-004118-33," A multi-centre randomised, double-blind, placebo-controlled trial of pre-hospital treatment with tranexamic acid for severely injured",16-06-2020,NA,ISRCTN number,results
6025,2019-004126-13, Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors,04-06-2020,NCT04767906,US NCT number,protocol
6026,2019-004126-13, Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors,04-06-2020,NA,other,protocol
6027,2019-004126-13, Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors,04-06-2020,NA,US NCT number,results
6028,2019-004126-13, Cabozantinib treatment in a phase II study for patients with hepatocellular carcinoma (HCC) refractory to PD-1 or PD-L1 inhibitors,04-06-2020,NA,ISRCTN number,results
6029,2019-004223-20," Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",30-03-2021,NA,US NCT number,protocol
6030,2019-004223-20," Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",30-03-2021,NA,other,protocol
6031,2019-004223-20," Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",30-03-2021,NA,US NCT number,results
6032,2019-004223-20," Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer: FIRE 8; AIO-KRK/YMO-0519",30-03-2021,NA,ISRCTN number,results
6033,2019-004491-19," A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia",03-06-2020,NA,US NCT number,protocol
6034,2019-004491-19," A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia",03-06-2020,NA,other,protocol
6035,2019-004491-19," A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia",03-06-2020,NA,US NCT number,results
6036,2019-004491-19," A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia",03-06-2020,NA,ISRCTN number,results
6037,2019-004512-58, Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation,06-03-2020,NA,US NCT number,protocol
6038,2019-004512-58, Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation,06-03-2020,NA,other,protocol
6039,2019-004512-58, Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation,06-03-2020,NA,US NCT number,results
6040,2019-004512-58, Comparison of Fluorescein-INtra-VItal microscopy Versus conventional frozen section diagnosis for intraOperative histopathological evaluation,06-03-2020,NA,ISRCTN number,results
6041,2019-004536-37, Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial,16-06-2020,NA,US NCT number,protocol
6042,2019-004536-37, Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial,16-06-2020,NA,other,protocol
6043,2019-004536-37, Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial,16-06-2020,NA,US NCT number,results
6044,2019-004536-37, Treatment of MDS/AML patients with an impending hematological relapse with azacitidine alone or in combination with pevonedistat - a randomized phase 2 trial,16-06-2020,NA,ISRCTN number,results
6045,2019-004739-22, Efficacy of ruxolitinib cream in Prurigo nodularis patients: ,09-10-2020,NA,US NCT number,protocol
6046,2019-004739-22, Efficacy of ruxolitinib cream in Prurigo nodularis patients: ,09-10-2020,NA,other,protocol
6047,2019-004739-22, Efficacy of ruxolitinib cream in Prurigo nodularis patients: ,09-10-2020,NA,US NCT number,results
6048,2019-004739-22, Efficacy of ruxolitinib cream in Prurigo nodularis patients: ,09-10-2020,NA,ISRCTN number,results
6049,2019-004757-88, Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment,19-05-2021,NA,US NCT number,protocol
6050,2019-004757-88, Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment,19-05-2021,NA,other,protocol
6051,2019-004757-88, Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment,19-05-2021,NA,US NCT number,results
6052,2019-004757-88, Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line treatment,19-05-2021,NA,ISRCTN number,results
6053,2019-004946-13, Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile ,04-05-2020,NA,US NCT number,protocol
6054,2019-004946-13, Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile ,04-05-2020,NA,other,protocol
6055,2019-004946-13, Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile ,04-05-2020,NA,US NCT number,results
6056,2019-004946-13, Conversion to extended-release MeltDose® tacrolimus after kidney transplantation - impact on glucose metabolism and lipid profile ,04-05-2020,NA,ISRCTN number,results
6057,2019-005008-16," Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial",04-08-2020,NA,US NCT number,protocol
6058,2019-005008-16," Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial",04-08-2020,DRKS-ID DRKS00021290,other,protocol
6059,2019-005008-16," Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial",04-08-2020,NA,US NCT number,results
6060,2019-005008-16," Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial",04-08-2020,NA,ISRCTN number,results
6061,2020-000382-16," Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination   with bortezomib-dexamethasone as a quadruplet in relapsed / refractory multiple myeloma (RRMM) patients",04-11-2020,NA,US NCT number,protocol
6062,2020-000382-16," Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination   with bortezomib-dexamethasone as a quadruplet in relapsed / refractory multiple myeloma (RRMM) patients",04-11-2020,DRKS DRKS00020561 ,other,protocol
6063,2020-000382-16," Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination   with bortezomib-dexamethasone as a quadruplet in relapsed / refractory multiple myeloma (RRMM) patients",04-11-2020,NA,US NCT number,results
6064,2020-000382-16," Efficacy of daratumumab (Dara) retreatment using a histone deacetylase-inhibitor (HDACi: panobinostat) as a Dara-longevity-inducing, epigenetic agent in combination   with bortezomib-dexamethasone as a quadruplet in relapsed / refractory multiple myeloma (RRMM) patients",04-11-2020,NA,ISRCTN number,results
6065,2020-000388-21," Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB ",29-10-2020,NA,US NCT number,protocol
6066,2020-000388-21," Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB ",29-10-2020,NA,other,protocol
6067,2020-000388-21," Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB ",29-10-2020,NA,US NCT number,results
6068,2020-000388-21," Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB ",29-10-2020,NA,ISRCTN number,results
6069,2020-000529-19," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia",22-07-2020,NA,US NCT number,protocol
6070,2020-000529-19," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia",22-07-2020,NA,other,protocol
6071,2020-000529-19," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia",22-07-2020,NA,US NCT number,results
6072,2020-000529-19," A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSS-OVER STUDY FOR EVALUATION OF THE EFFICIENCY AND SAFETY OF TIOTROPIUM INHALATION SOLUTION (5 µG) VIA RESPIMAT® INHALER once a day for 24 weeks for children (6 to 12 years) with bronchopulmonary dysplasia",22-07-2020,NA,ISRCTN number,results
6073,2020-000624-20, Core decompression versus core decompression followed by infusion of Iloprost in the,26-04-2021,NA,US NCT number,protocol
6074,2020-000624-20, Core decompression versus core decompression followed by infusion of Iloprost in the,26-04-2021,NA,other,protocol
6075,2020-000624-20, Core decompression versus core decompression followed by infusion of Iloprost in the,26-04-2021,NA,US NCT number,results
6076,2020-000624-20, Core decompression versus core decompression followed by infusion of Iloprost in the,26-04-2021,NA,ISRCTN number,results
6077,2020-000681-42, Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion,29-04-2020,NA,US NCT number,protocol
6078,2020-000681-42, Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion,29-04-2020,NA,other,protocol
6079,2020-000681-42, Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion,29-04-2020,NA,US NCT number,results
6080,2020-000681-42, Long-term need of ranibizumab injections with or without early targeted peripheral laser photocoagulation for treatment of macular edema due to central retinal vein occlusion,29-04-2020,NA,ISRCTN number,results
6081,2020-000693-18, Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial):,25-11-2020,NA,US NCT number,protocol
6082,2020-000693-18, Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial):,25-11-2020,NA,other,protocol
6083,2020-000693-18, Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial):,25-11-2020,NA,US NCT number,results
6084,2020-000693-18, Breaking the big Five Barriers of Brain Metastasis (Break B5-BM NSCLC Trial):,25-11-2020,NA,ISRCTN number,results
6085,2020-000784-23, The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect),22-07-2020,NA,US NCT number,protocol
6086,2020-000784-23, The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect),22-07-2020,NA,other,protocol
6087,2020-000784-23, The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect),22-07-2020,NA,US NCT number,results
6088,2020-000784-23, The effects of esketamine and treatment expectation in acute major depressive disorder: a pharmacological fMRI-study (Expect),22-07-2020,NA,ISRCTN number,results
6089,2020-000796-20," Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients (EnGraft)",04-05-2020,NA,US NCT number,protocol
6090,2020-000796-20," Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients (EnGraft)",04-05-2020,NA,other,protocol
6091,2020-000796-20," Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients (EnGraft)",04-05-2020,NA,US NCT number,results
6092,2020-000796-20," Multicentre, open-label, randomised, two-arm, parallel-group, superiority study to assess bioavailability and practicability of Envarsus® compared with Advagraf® in de novo liver transplant recipients (EnGraft)",04-05-2020,NA,ISRCTN number,results
6093,2020-001050-22, A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer,07-09-2020,NCT04602533,US NCT number,protocol
6094,2020-001050-22, A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer,07-09-2020,For.UM Mainz 19-00778,other,protocol
6095,2020-001050-22, A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer,07-09-2020,NA,US NCT number,results
6096,2020-001050-22, A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin / Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer,07-09-2020,NA,ISRCTN number,results
6097,2020-001224-33, Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19,24-03-2020,NCT04342221,US NCT number,protocol
6098,2020-001224-33, Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19,24-03-2020,NA,other,protocol
6099,2020-001224-33, Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19,24-03-2020,NA,US NCT number,results
6100,2020-001224-33, Randomized controlled trial of hydroxychloroquine versus placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19,24-03-2020,NA,ISRCTN number,results
6101,2020-001318-39, Skin perception after intradermal application of IncobotulinumtoxinA,09-03-2021,NA,US NCT number,protocol
6102,2020-001318-39, Skin perception after intradermal application of IncobotulinumtoxinA,09-03-2021,NA,other,protocol
6103,2020-001318-39, Skin perception after intradermal application of IncobotulinumtoxinA,09-03-2021,NA,US NCT number,results
6104,2020-001318-39, Skin perception after intradermal application of IncobotulinumtoxinA,09-03-2021,NA,ISRCTN number,results
6105,2020-001336-10," Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM8101) to improve proGNosis and outcomES in covid-19 Trial",30-12-2021,NA,US NCT number,protocol
6106,2020-001336-10," Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM8101) to improve proGNosis and outcomES in covid-19 Trial",30-12-2021,NA,other,protocol
6107,2020-001336-10," Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM8101) to improve proGNosis and outcomES in covid-19 Trial",30-12-2021,NA,US NCT number,results
6108,2020-001336-10," Multicenter, randomized, double-blind, biomarker-guided, phase II trial with Adrecizumab (HAM 8101) to improve proGNosis and outcomES in patients with moderate to severe covid-19 - Adrecizumab (HAM8101) to improve proGNosis and outcomES in covid-19 Trial",30-12-2021,NA,ISRCTN number,results
6109,2020-001397-30, APOS study- Antibiotic Prophylaxis for preventing infectious complications in Orthognathic Surgery,12-11-2020,NA,US NCT number,protocol
6110,2020-001397-30, APOS study- Antibiotic Prophylaxis for preventing infectious complications in Orthognathic Surgery,12-11-2020,NA,other,protocol
6111,2020-001397-30, APOS study- Antibiotic Prophylaxis for preventing infectious complications in Orthognathic Surgery,12-11-2020,NA,US NCT number,results
6112,2020-001397-30, APOS study- Antibiotic Prophylaxis for preventing infectious complications in Orthognathic Surgery,12-11-2020,NA,ISRCTN number,results
6113,2020-001408-41," A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia",07-04-2020,NA,US NCT number,protocol
6114,2020-001408-41," A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia",07-04-2020,DRKS  DRKS00021238,other,protocol
6115,2020-001408-41," A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia",07-04-2020,NA,US NCT number,results
6116,2020-001408-41," A prospective, randomized, double blinded placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia",07-04-2020,NA,ISRCTN number,results
6117,2020-001416-15, Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study,21-01-2021,NA,US NCT number,protocol
6118,2020-001416-15, Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study,21-01-2021,NA,other,protocol
6119,2020-001416-15, Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study,21-01-2021,NA,US NCT number,results
6120,2020-001416-15, Pharmacokinetics of Ceftazidime-Avibactam in Bile Fluid – an in-vivo Study,21-01-2021,NA,ISRCTN number,results
6121,2020-001481-11, Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation ,16-04-2020,NCT04338958,US NCT number,protocol
6122,2020-001481-11, Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation ,16-04-2020,Manufacturer code CINC424A0DE01T,other,protocol
6123,2020-001481-11, Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation ,16-04-2020,NA,US NCT number,results
6124,2020-001481-11, Front line treatment with Ruxolitinib in stage II/III Covid-19 patients with defined Hyperinflammation ,16-04-2020,NA,ISRCTN number,results
6125,2020-001482-37, Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients,20-04-2020,NA,US NCT number,protocol
6126,2020-001482-37, Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients,20-04-2020,NA,other,protocol
6127,2020-001482-37, Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients,20-04-2020,NA,US NCT number,results
6128,2020-001482-37, Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 Patients,20-04-2020,NA,ISRCTN number,results
6129,2020-001493-29, Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,14-04-2020,NA,US NCT number,protocol
6130,2020-001493-29, Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,14-04-2020,NA,other,protocol
6131,2020-001493-29, Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,14-04-2020,NA,US NCT number,results
6132,2020-001493-29, Charité trial of Cenicriviroc (CVC) treatment for COVID-19 patients,14-04-2020,NA,ISRCTN number,results
6133,2020-001512-26, Hydroxychloroquine for the treatment of mild COVID-19 disease,01-04-2020,NCT04340544,US NCT number,protocol
6134,2020-001512-26, Hydroxychloroquine for the treatment of mild COVID-19 disease,01-04-2020,NA,other,protocol
6135,2020-001512-26, Hydroxychloroquine for the treatment of mild COVID-19 disease,01-04-2020,NA,US NCT number,results
6136,2020-001512-26, Hydroxychloroquine for the treatment of mild COVID-19 disease,01-04-2020,NA,ISRCTN number,results
6137,2020-001575-33, Low-dose AtropIne for Myopia control in children ,12-02-2021,NCT03865160,US NCT number,protocol
6138,2020-001575-33, Low-dose AtropIne for Myopia control in children ,12-02-2021,DRKS DRKS00023337,other,protocol
6139,2020-001575-33, Low-dose AtropIne for Myopia control in children ,12-02-2021,NA,US NCT number,results
6140,2020-001575-33, Low-dose AtropIne for Myopia control in children ,12-02-2021,NA,ISRCTN number,results
6141,2020-001632-10, A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease,20-04-2020,NA,US NCT number,protocol
6142,2020-001632-10, A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease,20-04-2020,EudraCT-N° 2020-001632-10,other,protocol
6143,2020-001632-10, A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease,20-04-2020,NA,US NCT number,results
6144,2020-001632-10, A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease,20-04-2020,NA,ISRCTN number,results
6145,2020-001654-21, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia  ,05-05-2020,NA,US NCT number,protocol
6146,2020-001654-21, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia  ,05-05-2020,NA,other,protocol
6147,2020-001654-21, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia  ,05-05-2020,NA,US NCT number,results
6148,2020-001654-21, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Inhalation to prevent ARDS in COVID-19 pneumonia  ,05-05-2020,NA,ISRCTN number,results
6149,2020-001732-10, Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil),27-04-2020,NA,US NCT number,protocol
6150,2020-001732-10, Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil),27-04-2020,NA,other,protocol
6151,2020-001732-10, Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil),27-04-2020,NA,US NCT number,results
6152,2020-001732-10, Ruxolitinib for treatment of Covid-19 induced lung injury ARDS (RuXoCoil),27-04-2020,NA,ISRCTN number,results
6153,2020-001899-14," A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis",28-07-2020,NA,US NCT number,protocol
6154,2020-001899-14," A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis",28-07-2020,NA,other,protocol
6155,2020-001899-14," A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis",28-07-2020,NA,US NCT number,results
6156,2020-001899-14," A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis",28-07-2020,NA,ISRCTN number,results
6157,2020-001936-86," A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19",20-08-2020,NA,US NCT number,protocol
6158,2020-001936-86," A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19",20-08-2020,NA,other,protocol
6159,2020-001936-86," A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19",20-08-2020,NA,US NCT number,results
6160,2020-001936-86," A prospective, randomized, open label Phase 2 clinical trial to evaluate superiority of anti-SARS-CoV-2 convalescent plasma versus standard-of-care in hospitalized patients with mild COVID-19",20-08-2020,NA,ISRCTN number,results
6161,2020-002122-82, Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID-19,07-05-2020,NCT04712344,US NCT number,protocol
6162,2020-002122-82, Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID-19,07-05-2020,NA,other,protocol
6163,2020-002122-82, Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID-19,07-05-2020,NA,US NCT number,results
6164,2020-002122-82, Prospective open-label randomized controlled phase 2b clinical study in parallel groups for the assessment of efficacy and safety of immune therapy with COVID-19 convalescent plasma plus standard treatment vs. standard treatment alone of subjects with severe COVID-19,07-05-2020,NA,ISRCTN number,results
6165,2020-002142-17," CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients",26-07-2021,NCT04883749,US NCT number,protocol
6166,2020-002142-17," CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients",26-07-2021,NA,other,protocol
6167,2020-002142-17," CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients",26-07-2021,NA,US NCT number,results
6168,2020-002142-17," CLL-Frail – A prospective, multicenter phase II trial of acalabrutinib in very old (≥80y) or frail CLL-Patients",26-07-2021,NA,ISRCTN number,results
6169,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,protocol
6170,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,other,protocol
6171,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,results
6172,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,ISRCTN number,results
6173,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,protocol
6174,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,other,protocol
6175,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,results
6176,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,ISRCTN number,results
6177,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,protocol
6178,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,other,protocol
6179,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,results
6180,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,ISRCTN number,results
6181,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,protocol
6182,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,other,protocol
6183,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,US NCT number,results
6184,2020-002238-34, Open label extension study for monitoring long-term safety in patients with Myoclonic Astatic Epilepsy (Doose-Syndrome) receiving Fenfluramine as add-on therapy,04-12-2020,NA,ISRCTN number,results
6185,2020-002282-33, Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),29-05-2020,NA,US NCT number,protocol
6186,2020-002282-33, Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),29-05-2020,NA,other,protocol
6187,2020-002282-33, Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),29-05-2020,NA,US NCT number,results
6188,2020-002282-33, Effect of anticoagulation therapy on clinical outcomes in COVID-19 (COVID-PREVENT),29-05-2020,NA,ISRCTN number,results
6189,2020-002502-75, P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults,26-06-2020,NA,US NCT number,protocol
6190,2020-002502-75, P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults,26-06-2020,NA,other,protocol
6191,2020-002502-75, P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults,26-06-2020,NA,US NCT number,results
6192,2020-002502-75, P-pVAC-SARS-CoV-2: Phase I single-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults,26-06-2020,NA,ISRCTN number,results
6193,2020-002504-39, Hamburg Edoxaban foR anticoagulation in COvid-19 study,14-08-2020,NA,US NCT number,protocol
6194,2020-002504-39, Hamburg Edoxaban foR anticoagulation in COvid-19 study,14-08-2020,NA,other,protocol
6195,2020-002504-39, Hamburg Edoxaban foR anticoagulation in COvid-19 study,14-08-2020,NA,US NCT number,results
6196,2020-002504-39, Hamburg Edoxaban foR anticoagulation in COvid-19 study,14-08-2020,NA,ISRCTN number,results
6197,2020-002510-40," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",08-10-2020,NA,US NCT number,protocol
6198,2020-002510-40," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",08-10-2020,NA,other,protocol
6199,2020-002510-40," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",08-10-2020,NA,US NCT number,results
6200,2020-002510-40," A multicenter, randomized, double-blind, placebo-controlled, phase 2, 12-week treatment study followed by a 12 week open label phase and a 12-week follow-up period to assess the efficacy and safety of avdoralimab (IPH5401) C5aR blocking antibody in adult patients with chronic spontaneous urticaria resistant to H1-antihistamine treatment.",08-10-2020,NA,ISRCTN number,results
6201,2020-002541-41," A phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3.",26-11-2020,NA,US NCT number,protocol
6202,2020-002541-41," A phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3.",26-11-2020,NA,other,protocol
6203,2020-002541-41," A phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3.",26-11-2020,NA,US NCT number,results
6204,2020-002541-41," A phase II trial of Cabozantinib in patients with advanced, low proliferative NEN G3.",26-11-2020,NA,ISRCTN number,results
6205,2020-002622-87, A phase II trial of belimumab in combination with,02-06-2021,NA,US NCT number,protocol
6206,2020-002622-87, A phase II trial of belimumab in combination with,02-06-2021,NA,other,protocol
6207,2020-002622-87, A phase II trial of belimumab in combination with,02-06-2021,NA,US NCT number,results
6208,2020-002622-87, A phase II trial of belimumab in combination with,02-06-2021,NA,ISRCTN number,results
6209,2020-002683-31," A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung",03-03-2021,NA,US NCT number,protocol
6210,2020-002683-31," A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung",03-03-2021,NA,other,protocol
6211,2020-002683-31," A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung",03-03-2021,NA,US NCT number,results
6212,2020-002683-31," A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung",03-03-2021,NA,ISRCTN number,results
6213,2020-002788-80," An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH)",08-06-2020,NA,US NCT number,protocol
6214,2020-002788-80," An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH)",08-06-2020,NA,other,protocol
6215,2020-002788-80," An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH)",08-06-2020,NA,US NCT number,results
6216,2020-002788-80," An explorative study to assess the safety, tolerability, and efficacy of AZD4831 in the treatment of pulmonary arterial hypertension (PAH)",08-06-2020,NA,ISRCTN number,results
6217,2020-003503-34, A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,10-11-2020,NCT04631666,US NCT number,protocol
6218,2020-003503-34, A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,10-11-2020,NA,other,protocol
6219,2020-003503-34, A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,10-11-2020,NCT04631666,US NCT number,results
6220,2020-003503-34, A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,10-11-2020,NA,ISRCTN number,results
6221,2020-003925-42," A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients",31-05-2021,NA,US NCT number,protocol
6222,2020-003925-42," A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients",31-05-2021,NA,other,protocol
6223,2020-003925-42," A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients",31-05-2021,NA,US NCT number,results
6224,2020-003925-42," A randomized open-label phase II study on the effect of durvalumab and tremelimumab combined with personalized SIRT (p-SIRT), standard-dose SIRT (sd-SIRT) or immunotherapy followed by on-demand loco-regional SIRT (od-SIRT) in non-resectable hepatocellular carcinoma (HCC) patients",31-05-2021,NA,ISRCTN number,results
6225,2020-003986-20," A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)",15-03-2021,NA,US NCT number,protocol
6226,2020-003986-20," A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)",15-03-2021,NA,other,protocol
6227,2020-003986-20," A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)",15-03-2021,NA,US NCT number,results
6228,2020-003986-20," A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS)",15-03-2021,NA,ISRCTN number,results
6229,2020-004102-63," AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",12-11-2020,NA,US NCT number,protocol
6230,2020-004102-63," AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",12-11-2020,NA,other,protocol
6231,2020-004102-63," AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",12-11-2020,NA,US NCT number,results
6232,2020-004102-63," AN OPEN LABEL, PHASE I/II STUDY TO INVESTIGATE THE USE OF VORAXAZE™ AS INTENDED INTERVENTION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMA AND WITH IMPAIRED RENAL FUNCTION BEING TREATED WITH HIGH-DOSE METHOTREXATE",12-11-2020,NA,ISRCTN number,results
6233,2020-004360-26," A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)",24-06-2021,NA,US NCT number,protocol
6234,2020-004360-26," A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)",24-06-2021,Sponsor Number Uni-Koeln-4441 ,other,protocol
6235,2020-004360-26," A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)",24-06-2021,NA,US NCT number,results
6236,2020-004360-26," A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS WITH HIGH RISK (17P-DELETION, TP53- MUTATION OR COMPLEX KARYOTYPE) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)",24-06-2021,NA,ISRCTN number,results
6237,2020-004399-16," Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",23-02-2021,NA,US NCT number,protocol
6238,2020-004399-16," Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",23-02-2021,NA,other,protocol
6239,2020-004399-16," Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",23-02-2021,NA,US NCT number,results
6240,2020-004399-16," Efficacy of erenumab in chronic cluster headache: A 10-week double-blind, randomized, placebo-controlled, multicentric trial",23-02-2021,NA,ISRCTN number,results
6241,2020-004448-27, A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,18-11-2020,NCT04631705,US NCT number,protocol
6242,2020-004448-27, A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,18-11-2020,NA,other,protocol
6243,2020-004448-27, A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,18-11-2020,NCT04631705,US NCT number,results
6244,2020-004448-27, A Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals,18-11-2020,NA,ISRCTN number,results
6245,2020-004695-18, Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals,15-10-2020,NA,US NCT number,protocol
6246,2020-004695-18, Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals,15-10-2020,NA,other,protocol
6247,2020-004695-18, Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals,15-10-2020,NA,US NCT number,results
6248,2020-004695-18, Reconvalescent plasma/Camostat mesylate early in Sars-CoV-2 Q-PCR positive high risk individuals,15-10-2020,NA,ISRCTN number,results
6249,2020-004748-27, Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention,20-01-2022,NA,US NCT number,protocol
6250,2020-004748-27, Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention,20-01-2022,NA,other,protocol
6251,2020-004748-27, Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention,20-01-2022,NA,US NCT number,results
6252,2020-004748-27, Escalated single platelet inhibition for one month plus direct oral anticoagulation in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention,20-01-2022,NA,ISRCTN number,results
6253,2020-004906-79, An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature,21-07-2021,NA,US NCT number,protocol
6254,2020-004906-79, An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature,21-07-2021,AIO-PAK-0121/ass AIO,other,protocol
6255,2020-004906-79, An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature,21-07-2021,NA,US NCT number,results
6256,2020-004906-79, An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature,21-07-2021,NA,ISRCTN number,results
6257,2020-005518-16, U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing,24-03-2021,NA,US NCT number,protocol
6258,2020-005518-16, U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing,24-03-2021,NA,other,protocol
6259,2020-005518-16, U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing,24-03-2021,NA,US NCT number,results
6260,2020-005518-16, U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing,24-03-2021,NA,ISRCTN number,results
6261,2020-005858-21, PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS),10-06-2021,NA,US NCT number,protocol
6262,2020-005858-21, PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS),10-06-2021,NA,other,protocol
6263,2020-005858-21, PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS),10-06-2021,NA,US NCT number,results
6264,2020-005858-21, PHASE III STUDY COMPARING TRABECTEDIN (T) VERSUS T PLUS tTF-NGR TO ENTRAP T INSIDE THE TUMOR IN PATIENTS WITH METASTATIC AND/OR REFRACTORY SOFT TISSUE SARCOMA (STS),10-06-2021,NA,ISRCTN number,results
6265,2020-005910-17, Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab,10-02-2021,NA,US NCT number,protocol
6266,2020-005910-17, Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab,10-02-2021,NA,other,protocol
6267,2020-005910-17, Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab,10-02-2021,NA,US NCT number,results
6268,2020-005910-17, Phase 2 multicenter study investigating the tolerability and efficacy of UV1 vaccine in patients with recurrent or metastatic PD-L1 positive (CPS≥1) head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab,10-02-2021,NA,ISRCTN number,results
6269,2020-006001-35, Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection ,01-07-2021,NA,US NCT number,protocol
6270,2020-006001-35, Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection ,01-07-2021,German Clinical Trials Register DRKS00024061,other,protocol
6271,2020-006001-35, Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection ,01-07-2021,NA,US NCT number,results
6272,2020-006001-35, Randomized controlled trial of PREoperative injection of BOTulinum toxin into the sphincter of Oddi to reduce bile leakage after hepatic resection ,01-07-2021,NA,ISRCTN number,results
6273,2020-006144-18, Post-resection/ablation chemotherapy ,29-04-2021,NA,US NCT number,protocol
6274,2020-006144-18, Post-resection/ablation chemotherapy ,29-04-2021,AIO Number AIO-KRK-0419,other,protocol
6275,2020-006144-18, Post-resection/ablation chemotherapy ,29-04-2021,NA,US NCT number,results
6276,2020-006144-18, Post-resection/ablation chemotherapy ,29-04-2021,NA,ISRCTN number,results
6277,2021-000130-33," A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)",16-09-2022,NA,US NCT number,protocol
6278,2021-000130-33," A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)",16-09-2022,NA,other,protocol
6279,2021-000130-33," A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)",16-09-2022,NA,US NCT number,results
6280,2021-000130-33," A pilot study to explore safety, tolerability and efficacy of ORal IrON supplementation with ferric maltol in treating iron deficiency and anaemia in patients with Heart Failure (ORION-HF)",16-09-2022,NA,ISRCTN number,results
6281,2021-000133-13, Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder,06-01-2022,NA,US NCT number,protocol
6282,2021-000133-13, Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder,06-01-2022,DRKS DRKS00024066,other,protocol
6283,2021-000133-13, Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder,06-01-2022,NA,US NCT number,results
6284,2021-000133-13, Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder,06-01-2022,NA,ISRCTN number,results
6285,2021-000148-23, 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial,09-03-2021,NA,US NCT number,protocol
6286,2021-000148-23, 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial,09-03-2021,NA,other,protocol
6287,2021-000148-23, 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial,09-03-2021,NA,US NCT number,results
6288,2021-000148-23, 68Ga-FAPI-46 PET for imaging of FAP expressing cancer: A single-center prospective interventional single-arm clinical Trial,09-03-2021,NA,ISRCTN number,results
6289,2021-000183-29, Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase II proof-of-concept trial,21-07-2021,NA,US NCT number,protocol
6290,2021-000183-29, Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase II proof-of-concept trial,21-07-2021,NA,other,protocol
6291,2021-000183-29, Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase II proof-of-concept trial,21-07-2021,NA,US NCT number,results
6292,2021-000183-29, Early Reperfusion Therapy with Intravenous Alteplase for Recovery of VISION in Acute Central Retinal Artery Occlusion (REVISION) - A double-blind randomized placebo-controlled phase II proof-of-concept trial,21-07-2021,NA,ISRCTN number,results
6293,2021-000190-81, A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study,21-09-2021,NA,US NCT number,protocol
6294,2021-000190-81, A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study,21-09-2021,Boehringer Ingelheim Trial-Number: 0205-0546,other,protocol
6295,2021-000190-81, A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study,21-09-2021,NA,US NCT number,results
6296,2021-000190-81, A prospective multicenter placebo-controlled trial to study the efficacy and safety of Tiotropium in preventing severe asthma exacerbations in partial and uncontrolled preschool asthma. TIPP-Study,21-09-2021,NA,ISRCTN number,results
6297,2021-000271-36," Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial",15-06-2021,NA,US NCT number,protocol
6298,2021-000271-36," Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial",15-06-2021,NA,other,protocol
6299,2021-000271-36," Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial",15-06-2021,NA,US NCT number,results
6300,2021-000271-36," Guselkumab in Patients with Oral Lichen Planus - An open label, parallel, randomized, multi- center, phase II trial",15-06-2021,NA,ISRCTN number,results
6301,2021-000319-21, Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),01-07-2021,NA,US NCT number,protocol
6302,2021-000319-21, Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),01-07-2021,NA,other,protocol
6303,2021-000319-21, Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),01-07-2021,NA,US NCT number,results
6304,2021-000319-21, Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibility Study (ClonDoTrial),01-07-2021,NA,ISRCTN number,results
6305,2021-000362-15, Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody,16-12-2021,NCT05045664,US NCT number,protocol
6306,2021-000362-15, Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody,16-12-2021,NA,other,protocol
6307,2021-000362-15, Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody,16-12-2021,NA,US NCT number,results
6308,2021-000362-15, Early Stage Follicular Lymphoma and Radiotherapy PLUS anti-CD20 Antibody,16-12-2021,NA,ISRCTN number,results
6309,2021-000417-16, A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19,01-04-2021,NCT04762186,US NCT number,protocol
6310,2021-000417-16, A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19,01-04-2021,NA,other,protocol
6311,2021-000417-16, A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19,01-04-2021,NA,US NCT number,results
6312,2021-000417-16, A Phase I / randomized Phase II trial to analyse safety and efficacy of human SARS-CoV 2 specific T lymphocyte transfer in patients with COVID-19 in need of treatment or at risk of severe COVID-19,01-04-2021,NA,ISRCTN number,results
6313,2021-000548-23," A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults",18-05-2021,NA,US NCT number,protocol
6314,2021-000548-23," A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults",18-05-2021,NA,other,protocol
6315,2021-000548-23," A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults",18-05-2021,NA,US NCT number,results
6316,2021-000548-23," A multi-center, phase Ib trial to assess the safety, tolerability and immunogenicity of the candidate vaccine MVA-SARS-2-ST in adults",18-05-2021,NA,ISRCTN number,results
6317,2021-000613-16, CCR1 antagonist treatment in patients hospitalized with COVID-19,08-09-2021,NA,US NCT number,protocol
6318,2021-000613-16, CCR1 antagonist treatment in patients hospitalized with COVID-19,08-09-2021,NA,other,protocol
6319,2021-000613-16, CCR1 antagonist treatment in patients hospitalized with COVID-19,08-09-2021,NA,US NCT number,results
6320,2021-000613-16, CCR1 antagonist treatment in patients hospitalized with COVID-19,08-09-2021,NA,ISRCTN number,results
6321,2021-000708-39, Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy,17-05-2021,NA,US NCT number,protocol
6322,2021-000708-39, Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy,17-05-2021,NA,other,protocol
6323,2021-000708-39, Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy,17-05-2021,NA,US NCT number,results
6324,2021-000708-39, Phase I/II trial of meclofenamate in progressive MGMT-methylated glioblastoma under temozolomide second-line therapy,17-05-2021,NA,ISRCTN number,results
6325,2021-000732-54, FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage,09-07-2021,NA,US NCT number,protocol
6326,2021-000732-54, FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage,09-07-2021,NA,other,protocol
6327,2021-000732-54, FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage,09-07-2021,NA,US NCT number,results
6328,2021-000732-54, FINISHER - Fight Inflammation to Improve outcome after aneurysmal Subarachnoid Hemorrhage,09-07-2021,NA,ISRCTN number,results
6329,2021-000962-14," A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",19-04-2021,NA,US NCT number,protocol
6330,2021-000962-14," A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",19-04-2021,NA,other,protocol
6331,2021-000962-14," A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",19-04-2021,NA,US NCT number,results
6332,2021-000962-14," A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus",19-04-2021,NA,ISRCTN number,results
6333,2021-000986-34," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3).",01-09-2021,NA,US NCT number,protocol
6334,2021-000986-34," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3).",01-09-2021,Ipsen trial code ADE60000075,other,protocol
6335,2021-000986-34," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3).",01-09-2021,NA,US NCT number,results
6336,2021-000986-34," A phase II, open-label, multicenter trial to investigate the clinical activity and safety of Cabozantinib in combination with avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3).",01-09-2021,NA,ISRCTN number,results
6337,2021-001005-67, Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy),23-09-2021,NA,US NCT number,protocol
6338,2021-001005-67, Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy),23-09-2021,NA,other,protocol
6339,2021-001005-67, Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy),23-09-2021,NA,US NCT number,results
6340,2021-001005-67, Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy),23-09-2021,NA,ISRCTN number,results
6341,2021-001070-38, B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency,24-03-2021,NA,US NCT number,protocol
6342,2021-001070-38, B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency,24-03-2021,NA,other,protocol
6343,2021-001070-38, B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency,24-03-2021,NA,US NCT number,results
6344,2021-001070-38, B-pVAC-SARS-CoV-2: Phase I/II multi-center safety and immungenicity trial of multi-peptide vaccination to prevent COVID-19 infection in adults with B-cell/antibody deficiency,24-03-2021,NA,ISRCTN number,results
6345,2021-001291-42, Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer,22-04-2022,NA,US NCT number,protocol
6346,2021-001291-42, Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer,22-04-2022,NA,other,protocol
6347,2021-001291-42, Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer,22-04-2022,NA,US NCT number,results
6348,2021-001291-42, Radiotherapy in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer,22-04-2022,NA,ISRCTN number,results
6349,2021-001384-25," An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",16-06-2021,NCT05182385,US NCT number,protocol
6350,2021-001384-25," An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",16-06-2021,NA,other,protocol
6351,2021-001384-25," An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",16-06-2021,NA,US NCT number,results
6352,2021-001384-25," An open label, phase I/II study of Venetoclax in addition to Blinatumomab immunotherapy in adult patients with relapsed/refractory B cell precursor acute lymphoblastic leukemia (BCP-ALL)",16-06-2021,NA,ISRCTN number,results
6353,2021-001508-13," Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)",05-05-2021,NA,US NCT number,protocol
6354,2021-001508-13," Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)",05-05-2021,NA,other,protocol
6355,2021-001508-13," Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)",05-05-2021,NA,US NCT number,results
6356,2021-001508-13," Randomized, controlled, double-blind trial to investigate the effect of colchicin on the endothelial function in patients with CHIP mutations and chronic heart failure with reduced left ventricular function (CHIP-HF)",05-05-2021,NA,ISRCTN number,results
6357,2021-001512-28, Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,13-04-2021,NA,US NCT number,protocol
6358,2021-001512-28, Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,13-04-2021,NA,other,protocol
6359,2021-001512-28, Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,13-04-2021,NA,US NCT number,results
6360,2021-001512-28, Immunogenicity of COVID-19 vaccines in medical staff and special risk populations,13-04-2021,NA,ISRCTN number,results
6361,2021-002073-26, Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy,10-02-2022,NA,US NCT number,protocol
6362,2021-002073-26, Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy,10-02-2022,DRKS DRKS00025078,other,protocol
6363,2021-002073-26, Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy,10-02-2022,NA,US NCT number,results
6364,2021-002073-26, Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy,10-02-2022,NA,ISRCTN number,results
6365,2021-002098-25," A randomized, controlled, multicenter, open label phase II clinical study",19-05-2021,NA,US NCT number,protocol
6366,2021-002098-25," A randomized, controlled, multicenter, open label phase II clinical study",19-05-2021,NA,other,protocol
6367,2021-002098-25," A randomized, controlled, multicenter, open label phase II clinical study",19-05-2021,NA,US NCT number,results
6368,2021-002098-25," A randomized, controlled, multicenter, open label phase II clinical study",19-05-2021,NA,ISRCTN number,results
6369,2021-002245-15, A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,30-04-2021,NA,US NCT number,protocol
6370,2021-002245-15, A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,30-04-2021,NA,other,protocol
6371,2021-002245-15, A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,30-04-2021,NA,US NCT number,results
6372,2021-002245-15, A low-interventional study to investigate the efficacy and safety of SARS-CoV-2 vaccines in patients with rheumatic diseases.,30-04-2021,NA,ISRCTN number,results
6373,2021-002300-12, Epirubicin for the Treatment of Sepsis & Septic Shock,12-07-2021,NA,US NCT number,protocol
6374,2021-002300-12, Epirubicin for the Treatment of Sepsis & Septic Shock,12-07-2021,NA,other,protocol
6375,2021-002300-12, Epirubicin for the Treatment of Sepsis & Septic Shock,12-07-2021,NA,US NCT number,results
6376,2021-002300-12, Epirubicin for the Treatment of Sepsis & Septic Shock,12-07-2021,NA,ISRCTN number,results
6377,2021-002335-33," Inhaled ColiFin® in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial",19-11-2021,NA,US NCT number,protocol
6378,2021-002335-33," Inhaled ColiFin® in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial",19-11-2021,NA,other,protocol
6379,2021-002335-33," Inhaled ColiFin® in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial",19-11-2021,NA,US NCT number,results
6380,2021-002335-33," Inhaled ColiFin® in adult bronchiectasis patients with early asymptomatic Pseudomonas aeruginosa infection– an open-label, proof of concept - randomized controlled trial",19-11-2021,NA,ISRCTN number,results
6381,2021-003088-87, Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery ,16-09-2021,NA,US NCT number,protocol
6382,2021-003088-87, Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery ,16-09-2021,NA,other,protocol
6383,2021-003088-87, Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery ,16-09-2021,NA,US NCT number,results
6384,2021-003088-87, Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery ,16-09-2021,NA,ISRCTN number,results
6385,2021-003523-16, A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer ,02-09-2021,NA,US NCT number,protocol
6386,2021-003523-16, A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer ,02-09-2021,NA,other,protocol
6387,2021-003523-16, A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer ,02-09-2021,NA,US NCT number,results
6388,2021-003523-16, A feasibility trial investigating inductive Apalutamide therapy combined with radical prostatectomy in patients with locally advanced T4 high risk prostate cancer ,02-09-2021,NA,ISRCTN number,results
6389,2021-003650-23," Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis",15-02-2022,NA,US NCT number,protocol
6390,2021-003650-23," Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis",15-02-2022,German Clinical Trials Register DRKS00030348,other,protocol
6391,2021-003650-23," Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis",15-02-2022,NA,US NCT number,results
6392,2021-003650-23," Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis",15-02-2022,NA,ISRCTN number,results
6393,2021-004328-13, Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET ,27-10-2021,NA,US NCT number,protocol
6394,2021-004328-13, Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET ,27-10-2021,NA,other,protocol
6395,2021-004328-13, Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET ,27-10-2021,NA,US NCT number,results
6396,2021-004328-13, Early detection of side effects in patients with metastatic melanoma receiving immune checkpoint inhibitor therapy by investigation of the CD8+ immune infiltrate using [89Zr]Zr-Df-IAB22M2C-PET ,27-10-2021,NA,ISRCTN number,results
6397,2021-004526-29," A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SARS-COV-2 (EU-COVAT-1 AGED)",06-09-2021,NA,US NCT number,protocol
6398,2021-004526-29," A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SARS-COV-2 (EU-COVAT-1 AGED)",06-09-2021,NA,other,protocol
6399,2021-004526-29," A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SARS-COV-2 (EU-COVAT-1 AGED)",06-09-2021,NA,US NCT number,results
6400,2021-004526-29," A MULTINATIONAL, PHASE 2, RANDOMISED, ADAPTIVE PROTOCOL TO EVALUATE IMMUNOGENICITY AND REACTOGENICITY OF DIFFERENT COVID-19 VACCINES ADMINISTRATION IN OLDER ADULTS (≥75) ALREADY VACCINATED AGAINST SARS-COV-2 (EU-COVAT-1 AGED)",06-09-2021,NA,ISRCTN number,results
6401,2021-004631-92, Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma,06-05-2022,NA,US NCT number,protocol
6402,2021-004631-92, Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma,06-05-2022,NA,other,protocol
6403,2021-004631-92, Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma,06-05-2022,NA,US NCT number,results
6404,2021-004631-92, Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma,06-05-2022,NA,ISRCTN number,results
6405,2021-004789-36," Randomized, controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients",30-03-2022,NA,US NCT number,protocol
6406,2021-004789-36," Randomized, controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients",30-03-2022,NA,other,protocol
6407,2021-004789-36," Randomized, controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients",30-03-2022,NA,US NCT number,results
6408,2021-004789-36," Randomized, controlled trial of the use of intranasal midazolam for the treatment of terminal agitation in palliative care patients",30-03-2022,NA,ISRCTN number,results
6409,2021-005362-18, Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B,29-11-2021,NA,US NCT number,protocol
6410,2021-005362-18, Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B,29-11-2021,NA,other,protocol
6411,2021-005362-18, Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B,29-11-2021,NA,US NCT number,results
6412,2021-005362-18, Hepatitis B immunoglobulins to induce HBsAg clearance in patients with chronic hepatitis B,29-11-2021,NA,ISRCTN number,results
6413,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,protocol
6414,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,other,protocol
6415,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,results
6416,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,ISRCTN number,results
6417,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,protocol
6418,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,other,protocol
6419,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,results
6420,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,ISRCTN number,results
6421,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,protocol
6422,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,other,protocol
6423,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,results
6424,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,ISRCTN number,results
6425,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,protocol
6426,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,other,protocol
6427,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,US NCT number,results
6428,2021-005495-19, A randomized controlled trial in preterm infants comparing prophylactic with selective “Less Invasive Surfactant Administration” (PRO-LISA),19-10-2021,NA,ISRCTN number,results
6429,2021-005875-38," A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)",02-05-2022,NA,US NCT number,protocol
6430,2021-005875-38," A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)",02-05-2022,NA,other,protocol
6431,2021-005875-38," A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)",02-05-2022,NA,US NCT number,results
6432,2021-005875-38," A multicenter, randomized, double-blind, placebo-controlled TRial evaluating Immunosuppressive treatment in patients with chronic virus-Negative Inflammatory cardiomyopaThY (TRINITY trial)",02-05-2022,NA,ISRCTN number,results
6433,2021-005949-33," Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa)",02-03-2022,NA,US NCT number,protocol
6434,2021-005949-33," Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa)",02-03-2022,NA,other,protocol
6435,2021-005949-33," Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa)",02-03-2022,NA,US NCT number,results
6436,2021-005949-33," Prospective, single-arm trial of neoadjuvant nivolumab plus ipilimumab in patients with localized renal cell carcinoma who are at a high risk of relapse after radical nephrectomy (NEONIRenCa)",02-03-2022,NA,ISRCTN number,results
6437,2021-006031-25, Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),05-04-2022,NA,US NCT number,protocol
6438,2021-006031-25, Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),05-04-2022,NA,other,protocol
6439,2021-006031-25, Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),05-04-2022,NA,US NCT number,results
6440,2021-006031-25, Treatment of patients with Lichen planus with the JAK-Inhibitor Upadacitinib (Rinvoq®) – a mono-centered double-blinded placebo controlled randomized pilot study (investigator-initiated trial),05-04-2022,NA,ISRCTN number,results
6441,2021-006176-16, Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),04-04-2022,NA,US NCT number,protocol
6442,2021-006176-16, Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),04-04-2022,NA,other,protocol
6443,2021-006176-16, Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),04-04-2022,NA,US NCT number,results
6444,2021-006176-16, Definition of neuroimaging and laboratory biomarkers as possible predictors for treatment response to Galcanezumab in high-frequency episodic migraine (PREDICT),04-04-2022,NA,ISRCTN number,results
6445,2021-006562-20, JAK Inhibition in PReclinical Arthritis,08-08-2022,NA,US NCT number,protocol
6446,2021-006562-20, JAK Inhibition in PReclinical Arthritis,08-08-2022,NA,other,protocol
6447,2021-006562-20, JAK Inhibition in PReclinical Arthritis,08-08-2022,NA,US NCT number,results
6448,2021-006562-20, JAK Inhibition in PReclinical Arthritis,08-08-2022,NA,ISRCTN number,results
6449,2021-006895-17, Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients,19-07-2022,NA,US NCT number,protocol
6450,2021-006895-17, Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients,19-07-2022,NA,other,protocol
6451,2021-006895-17, Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients,19-07-2022,NA,US NCT number,results
6452,2021-006895-17, Phase Ia/IIb study of PHD inhibitor molidustat in combination with IDH1 inhibitor ivosidenib in IDH1-mutated relapsed/refractory AML or MDS/AML patients,19-07-2022,NA,ISRCTN number,results
6453,2022-000557-88," A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia",30-06-2022,NCT05366218,US NCT number,protocol
6454,2022-000557-88," A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia",30-06-2022,NA,other,protocol
6455,2022-000557-88," A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia",30-06-2022,NA,US NCT number,results
6456,2022-000557-88," A Prospective Phase I/II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab (MOR00208) in Pediatric Patients with Relapsed or Refractory Acute B Lineage Leukemia",30-06-2022,NA,ISRCTN number,results
6457,2022-000608-36," Prospective, randomized, controlled, open, multicenter clinical trial on the efficacy and safety of materno-fetal hyperoxygenation (MFHO) during the third trimester of pregnancy to treat underdeveloped left ventricular structures of the fetus",15-03-2022,NA,US NCT number,protocol
6458,2022-000608-36," Prospective, randomized, controlled, open, multicenter clinical trial on the efficacy and safety of materno-fetal hyperoxygenation (MFHO) during the third trimester of pregnancy to treat underdeveloped left ventricular structures of the fetus",15-03-2022,NA,other,protocol
6459,2022-000608-36," Prospective, randomized, controlled, open, multicenter clinical trial on the efficacy and safety of materno-fetal hyperoxygenation (MFHO) during the third trimester of pregnancy to treat underdeveloped left ventricular structures of the fetus",15-03-2022,NA,US NCT number,results
6460,2022-000608-36," Prospective, randomized, controlled, open, multicenter clinical trial on the efficacy and safety of materno-fetal hyperoxygenation (MFHO) during the third trimester of pregnancy to treat underdeveloped left ventricular structures of the fetus",15-03-2022,NA,ISRCTN number,results
6461,2022-000706-10, Pilot study on Administration of Tildrakizumab in patients with Hidradenitis Suppurativa.,20-05-2022,NA,US NCT number,protocol
6462,2022-000706-10, Pilot study on Administration of Tildrakizumab in patients with Hidradenitis Suppurativa.,20-05-2022,NA,other,protocol
6463,2022-000706-10, Pilot study on Administration of Tildrakizumab in patients with Hidradenitis Suppurativa.,20-05-2022,NA,US NCT number,results
6464,2022-000706-10, Pilot study on Administration of Tildrakizumab in patients with Hidradenitis Suppurativa.,20-05-2022,NA,ISRCTN number,results
6465,2022-001041-20," Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care",06-07-2022,NA,US NCT number,protocol
6466,2022-001041-20," Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care",06-07-2022,NA,other,protocol
6467,2022-001041-20," Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care",06-07-2022,NA,US NCT number,results
6468,2022-001041-20," Prednisolone and vitamin B1, B6, and B12 in patients with Post-COVID-19-Syndrome (PC19S) – a randomized controlled trial in primary care",06-07-2022,NA,ISRCTN number,results
6469,2022-001080-27, A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation ,12-04-2022,NA,US NCT number,protocol
6470,2022-001080-27, A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation ,12-04-2022,NA,other,protocol
6471,2022-001080-27, A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation ,12-04-2022,NA,US NCT number,results
6472,2022-001080-27, A multi-center phase I/II trial of memory T cell donor lymphocyte infusions after transplantation of CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for hematopoietic cell transplantation ,12-04-2022,NA,ISRCTN number,results
6473,2022-001186-12," A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma",08-07-2022,NA,US NCT number,protocol
6474,2022-001186-12," A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma",08-07-2022,NA,other,protocol
6475,2022-001186-12," A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma",08-07-2022,NA,US NCT number,results
6476,2022-001186-12," A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as Induction Therapy and Teclistamab in Combination with Daratumumab and Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma",08-07-2022,NA,ISRCTN number,results
